{"c4544948ac508d9b1b6a98d5a18885af20a45b97": [["Consequently, he and others developed innovative biosecurity systems to eliminate and exclude pathogens (Allen, 1999) .", [["innovative biosecurity systems", "PROBLEM", 38, 68], ["pathogens", "PROBLEM", 94, 103]]], ["In 1958, Foster reported on the Cesarean-originated barrier-sustained (COBS) process for the large-scale production of specific pathogen-free (SPF) laboratory rodents (Foster, 1958) .", [["the Cesarean", "TREATMENT", 28, 40], ["sustained (COBS) process", "PROBLEM", 60, 84], ["specific pathogen", "PROBLEM", 119, 136]]], ["To eliminate horizontally transmitted pathogens, a hysterectomy was performed on a near-term dam from a contaminated or conventionally housed colony.", [["colony", "ANATOMY", 142, 148], ["horizontally transmitted pathogens", "PROBLEM", 13, 47], ["a hysterectomy", "TREATMENT", 49, 63], ["a near-term dam", "TREATMENT", 81, 96], ["a contaminated or conventionally housed colony", "PROBLEM", 102, 148], ["pathogens", "OBSERVATION", 38, 47], ["hysterectomy", "OBSERVATION", 51, 63]]], ["The gravid uterus was pulled through a disinfectant solution into a sterile flexible film isolator where the pups were removed from the uterus and suckled on axenic (i.e., germ-free) foster dams.", [["uterus", "ANATOMY", 11, 17], ["pups", "ANATOMY", 109, 113], ["uterus", "ANATOMY", 136, 142], ["germ", "ANATOMY", 172, 176], ["uterus", "ORGAN", 11, 17], ["pups", "ORGANISM", 109, 113], ["uterus", "ORGAN", 136, 142], ["dams", "ORGANISM", 190, 194], ["a disinfectant solution", "TREATMENT", 37, 60], ["a sterile flexible film isolator", "TREATMENT", 66, 98], ["gravid uterus", "ANATOMY", 4, 17], ["uterus", "ANATOMY", 136, 142]]], ["After being mated to expand their number and associated with a cocktail of nonpathogenic bacteria to normalize their physiology and prime their immune system, rederived rodents were transferred to so-called barrier rooms for large-scale production.", [["immune system", "ANATOMICAL_SYSTEM", 144, 157], ["rodents", "ORGANISM", 169, 176], ["nonpathogenic bacteria", "PROBLEM", 75, 97], ["large-scale production", "PROBLEM", 225, 247]]], ["The room-level barrier to adventitious infection entailed disinfection of the room, equipment and supplies, limiting access to trained and properly gowned personnel, and the application of new technologies such as high-efficiency particulate air (HEPA) filtration of incoming air (Dubos and Schaedler, 1960; Foster, 1980; Schaedler and Orcutt, 1983; Trexler and Orcutt, 1999) .", [["infection", "DISEASE", 39, 48], ["adventitious infection", "PROBLEM", 26, 48], ["new technologies", "TREATMENT", 189, 205], ["high-efficiency particulate air (HEPA) filtration", "TREATMENT", 214, 263], ["adventitious", "OBSERVATION_MODIFIER", 26, 38], ["infection", "OBSERVATION", 39, 48], ["air", "OBSERVATION", 276, 279]]], ["The axenic and associated rodents mentioned in the COBS process are collectively classified as gnotobiotic to indicate that they have a completely known microflora.", [["The axenic", "PROBLEM", 0, 10], ["the COBS process", "PROBLEM", 47, 63], ["a completely known microflora", "PROBLEM", 134, 163], ["axenic", "OBSERVATION_MODIFIER", 4, 10]]], ["By contrast, barrierreared rodent colonies are not gnotobiotic because they are housed in uncovered cages and thus acquire a complex microflora from the environment, supplies, personnel, and other sources.", [["colonies", "ANATOMY", 34, 42], ["barrierreared rodent colonies", "CELL_LINE", 13, 42], ["rodent", "SPECIES", 27, 33], ["barrierreared rodent colonies", "PROBLEM", 13, 42], ["gnotobiotic", "PROBLEM", 51, 62]]], ["Instead, they are described as SPF to indicate that according to laboratory testing, they are free from infection with a defined list of infectious agents, commonly known as an 'exclusion' list.", [["infection", "DISEASE", 104, 113], ["laboratory testing", "TEST", 65, 83], ["infection", "PROBLEM", 104, 113], ["infectious agents", "TREATMENT", 137, 154], ["infection", "OBSERVATION", 104, 113]]]], "PMC7300441": [["Coronavirus disease 2019 (COVID\u201019), also informally called the new coronavirus, is a severe acute respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) virus, part of the Coronaviridae family (Gorbalenya, Baker, & Baric, 2020).", [["respiratory", "ANATOMY", 99, 110], ["Coronavirus disease", "DISEASE", 0, 19], ["COVID\u201019", "CHEMICAL", 26, 34], ["coronavirus", "DISEASE", 68, 79], ["respiratory disease", "DISEASE", 99, 118], ["acute respiratory syndrome coronavirus", "DISEASE", 140, 178], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 133, 180], ["SARS\u2010CoV\u20102", "ORGANISM", 182, 192], ["coronavirus", "SPECIES", 68, 79], ["Coronavirus disease 2019 (COVID\u201019", "SPECIES", 0, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 133, 178], ["SARS\u2010CoV\u20102) virus", "SPECIES", 182, 199], ["Coronavirus disease", "PROBLEM", 0, 19], ["the new coronavirus", "PROBLEM", 60, 79], ["a severe acute respiratory disease", "PROBLEM", 84, 118], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 129, 178], ["virus", "PROBLEM", 194, 199], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory disease", "OBSERVATION", 99, 118], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory syndrome", "OBSERVATION", 146, 166]]], ["Although research into the origins of COVID\u201019 is still being conducted, the first reports of infection in humans occurred in December 2019 in Wuhan, southern China, coming from infected animals sold in a popular market.", [["infection", "DISEASE", 94, 103], ["humans", "ORGANISM", 107, 113], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["infection", "PROBLEM", 94, 103], ["infection", "OBSERVATION", 94, 103], ["infected", "OBSERVATION", 178, 186]]], ["Although debate continues about the zoonotic origin of the virus, it is currently thought that naturally infected bats (Zhou, Yang, & Wang, 2020) and pangolins (Zhang, Wu, & Zhang, 2020) transmitted the virus to people, and it then gained the capacity for human\u2013human transmission (Andersen, Rambaut, Lipkin, Holmes, & Garry, 2020; Guo, Cao, & Hong, 2020).", [["bats", "ORGANISM", 114, 118], ["people", "ORGANISM", 212, 218], ["people", "SPECIES", 212, 218], ["the virus", "PROBLEM", 55, 64], ["naturally infected bats", "PROBLEM", 95, 118], ["virus", "OBSERVATION", 59, 64]]]], "65403d5ea32844858b65f544384590b0509fb85e": [["IntroductionA novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has recently emerged from Wuhan in China and spread into a worldwide pandemic into 216 counties with a total of 17 million confirmed cases and 668,910 deaths (as of July 30, 2020) [1] .", [["acute respiratory syndrome coronavirus", "DISEASE", 27, 65], ["SARS", "DISEASE", 67, 71], ["deaths", "DISEASE", 230, 236], ["SARS-CoV-2", "ORGANISM", 67, 77], ["severe acute respiratory syndrome coronavirus", "SPECIES", 20, 65], ["SARS-CoV-2", "SPECIES", 67, 77], ["IntroductionA novel severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 65], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["respiratory syndrome coronavirus", "OBSERVATION", 33, 65]]], ["As with the previous SARS and MERS coronavirus epidemics, SARS-CoV-2 causes respiratory tract infections with variable symptoms ranging from mild flu-like symptoms in children to severe pneumonia, even death for older population with underlying medical conditions such as diabetes, heart, lung, or kidney disease [2] .", [["respiratory tract", "ANATOMY", 76, 93], ["heart", "ANATOMY", 282, 287], ["lung", "ANATOMY", 289, 293], ["kidney", "ANATOMY", 298, 304], ["SARS", "DISEASE", 21, 25], ["coronavirus", "DISEASE", 35, 46], ["SARS", "DISEASE", 58, 62], ["respiratory tract infections", "DISEASE", 76, 104], ["flu-like symptoms", "DISEASE", 146, 163], ["pneumonia", "DISEASE", 186, 195], ["death", "DISEASE", 202, 207], ["diabetes", "DISEASE", 272, 280], ["heart, lung, or kidney disease", "DISEASE", 282, 312], ["MERS coronavirus", "ORGANISM", 30, 46], ["SARS-CoV-2", "ORGANISM", 58, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["children", "ORGANISM", 167, 175], ["heart", "ORGAN", 282, 287], ["lung", "ORGAN", 289, 293], ["kidney", "ORGAN", 298, 304], ["children", "SPECIES", 167, 175], ["MERS coronavirus", "SPECIES", 30, 46], ["SARS-CoV-2", "SPECIES", 58, 68], ["the previous SARS", "PROBLEM", 8, 25], ["MERS coronavirus epidemics", "PROBLEM", 30, 56], ["SARS", "PROBLEM", 58, 62], ["respiratory tract infections", "PROBLEM", 76, 104], ["variable symptoms", "PROBLEM", 110, 127], ["mild flu-like symptoms", "PROBLEM", 141, 163], ["severe pneumonia", "PROBLEM", 179, 195], ["underlying medical conditions", "PROBLEM", 234, 263], ["diabetes", "PROBLEM", 272, 280], ["heart, lung", "PROBLEM", 282, 293], ["kidney disease", "PROBLEM", 298, 312], ["respiratory tract", "ANATOMY", 76, 93], ["mild", "OBSERVATION_MODIFIER", 141, 145], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["pneumonia", "OBSERVATION", 186, 195], ["heart", "ANATOMY", 282, 287], ["lung", "ANATOMY", 289, 293], ["kidney", "ANATOMY", 298, 304]]], ["In spite of current limited understanding of respiratory viral transmission mechanisms, it has been generally accepted that exhaled bioaerosol particles are an important transmission vector [3, 4] .", [["respiratory viral transmission", "DISEASE", 45, 75], ["exhaled bioaerosol particles", "TREATMENT", 124, 152]]], ["Respiratory viral transmission routes include: large droplets generated by infected person's cough and impacting susceptible individuals and fomites, fine particle aerosols generated during physiological breathing and exhalation, touching contaminated surfaces followed by hand to facial mucosa contact, and potentially via fecal to oral or nasal transmission [2] [3] [4] .", [["hand", "ANATOMY", 273, 277], ["facial mucosa", "ANATOMY", 281, 294], ["oral", "ANATOMY", 333, 337], ["nasal", "ANATOMY", 341, 346], ["cough", "DISEASE", 93, 98], ["hand", "ORGANISM_SUBDIVISION", 273, 277], ["mucosa", "MULTI-TISSUE_STRUCTURE", 288, 294], ["fecal", "ORGANISM_SUBDIVISION", 324, 329], ["oral", "ORGANISM_SUBDIVISION", 333, 337], ["person", "SPECIES", 84, 90], ["large droplets", "PROBLEM", 47, 61], ["infected person's cough", "PROBLEM", 75, 98], ["impacting susceptible individuals and fomites", "PROBLEM", 103, 148], ["facial mucosa", "ANATOMY", 281, 294]]], ["Although the relative importance between these modes of infection is highly variable with many unknown, we may guess that the final respiratory virus inoculation step occurs via nasal inhalation of virions from the surrounding air or from contaminated face.", [["nasal", "ANATOMY", 178, 183], ["infection", "DISEASE", 56, 65], ["nasal", "ORGANISM_SUBDIVISION", 178, 183], ["infection", "PROBLEM", 56, 65], ["the final respiratory virus inoculation step", "PROBLEM", 122, 166], ["nasal inhalation of virions", "PROBLEM", 178, 205], ["infection", "OBSERVATION", 56, 65], ["air", "OBSERVATION", 227, 230]]], ["How virions are transmitted from the contaminated face to respiratory mucosa remains unknown.", [["virions", "ANATOMY", 4, 11], ["face", "ANATOMY", 50, 54], ["respiratory mucosa", "ANATOMY", 58, 76], ["respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 58, 76], ["How virions", "PROBLEM", 0, 11], ["virions", "OBSERVATION", 4, 11], ["respiratory mucosa", "ANATOMY", 58, 76]]], ["Moreover, it is not known what is the facial area from where the virus can enter the nose during normal breathing.", [["facial area", "ANATOMY", 38, 49], ["nose", "ANATOMY", 85, 89], ["nose", "ORGAN", 85, 89], ["the virus", "PROBLEM", 61, 70], ["facial", "ANATOMY", 38, 44], ["area", "ANATOMY_MODIFIER", 45, 49], ["virus", "OBSERVATION", 65, 70], ["nose", "ANATOMY", 85, 89], ["normal breathing", "OBSERVATION", 97, 113]]], ["This note attempts to explain the face to nose viral transmission process in a quantitate way using principles of fundamental physics.Transmission of Viral BioaerosolsNormal mouth or nose breathing continuously emits large number of small airborne droplets (less than 1\u00b5m in size) which, due to buoyancy and convention, can float in the surrounding air for long periods of time and translocate to long distances.", [["mouth", "ANATOMY", 174, 179], ["nose", "ANATOMY", 183, 187], ["Viral", "ORGANISM", 150, 155], ["mouth", "ORGANISM_SUBDIVISION", 174, 179], ["nose", "ORGAN", 183, 187], ["the face to nose viral transmission process", "PROBLEM", 30, 73], ["Viral Bioaerosols", "PROBLEM", 150, 167], ["nose breathing", "PROBLEM", 183, 197], ["small airborne droplets", "PROBLEM", 233, 256], ["Viral Bioaerosols", "OBSERVATION", 150, 167], ["mouth", "ANATOMY", 174, 179], ["nose", "ANATOMY", 183, 187], ["large", "OBSERVATION_MODIFIER", 217, 222], ["number", "OBSERVATION_MODIFIER", 223, 229], ["small", "OBSERVATION_MODIFIER", 233, 238], ["airborne droplets", "OBSERVATION", 239, 256]]], ["[5] On the other hand, coughing and sneezing last only a fraction of a second but creates a high-speed aerosol jets (~20m/sec and 60m/sec, respectively) carrying huge number of droplets with sizes varying from submicron to few millimeters [6] .", [["coughing", "DISEASE", 23, 31], ["sneezing", "DISEASE", 36, 44], ["coughing", "PROBLEM", 23, 31], ["sneezing", "PROBLEM", 36, 44], ["coughing", "OBSERVATION", 23, 31], ["sizes", "OBSERVATION_MODIFIER", 191, 196]]], ["The ejected droplets can impact other humans or settle on fomites at a distance between 1 to 2 meters from the emitting person.", [["droplets", "ANATOMY", 12, 20], ["humans", "ORGANISM", 38, 44], ["humans", "SPECIES", 38, 44], ["person", "SPECIES", 120, 126], ["humans", "SPECIES", 38, 44], ["The ejected droplets", "PROBLEM", 0, 20], ["ejected droplets", "OBSERVATION", 4, 20]]], ["The exhaled respiratory droplets contain a variety of biomolecules, mucins, as well as trapped viral payloads.", [["respiratory droplets", "ANATOMY", 12, 32], ["mucins", "GENE_OR_GENE_PRODUCT", 68, 74], ["The exhaled respiratory droplets", "PROBLEM", 0, 32], ["mucins", "TREATMENT", 68, 74], ["trapped viral payloads", "PROBLEM", 87, 109], ["exhaled", "OBSERVATION", 4, 11], ["respiratory droplets", "OBSERVATION", 12, 32], ["viral payloads", "OBSERVATION", 95, 109]]], ["Given the dimension of the coronavirus of ~120nm, each cough or sneeze droplet can project huge number of viral particles on the surrounding targets, including facial areas of susceptible individuals.", [["facial areas", "ANATOMY", 160, 172], ["cough", "DISEASE", 55, 60], ["coronavirus", "ORGANISM", 27, 38], ["the coronavirus", "PROBLEM", 23, 38], ["each cough or sneeze droplet", "PROBLEM", 50, 78], ["viral particles", "PROBLEM", 106, 121], ["susceptible individuals", "PROBLEM", 176, 199], ["coronavirus", "OBSERVATION", 27, 38], ["120nm", "OBSERVATION_MODIFIER", 43, 48], ["huge", "OBSERVATION_MODIFIER", 91, 95], ["number", "OBSERVATION_MODIFIER", 96, 102], ["viral particles", "OBSERVATION", 106, 121], ["facial", "ANATOMY", 160, 166], ["susceptible individuals", "OBSERVATION", 176, 199]]], ["Because viruses can survive on fomites for a prolonged period of time [7] [8] [9] the susceptible individuals can also contaminate their hands and then deposit the viral particles on their faces.", [["individuals", "ORGANISM", 98, 109], ["viruses", "PROBLEM", 8, 15], ["the susceptible individuals", "PROBLEM", 82, 109], ["viral particles", "OBSERVATION", 164, 179]]], ["In fact, hands are considered a major vector for the transmission of healthcare associated infections [10, 11] .", [["infections", "DISEASE", 91, 101], ["hands", "ORGANISM_SUBDIVISION", 9, 14], ["healthcare associated infections", "PROBLEM", 69, 101], ["hands", "ANATOMY", 9, 14]]], ["If there are no viral aerosols in the air surrounding the susceptible person the only viral source is located on the subject's face previously contaminated by his hands.Contaminated Human Face in the Viral Transmission PathRecent human behavioral observation studies reported that on average participants touched their faces between 17.8 and 23 times per hour [12, 13] .", [["hands", "ORGANISM_SUBDIVISION", 163, 168], ["Human", "ORGANISM", 182, 187], ["human", "ORGANISM", 230, 235], ["person", "SPECIES", 70, 76], ["Human", "SPECIES", 182, 187], ["human", "SPECIES", 230, 235], ["participants", "SPECIES", 292, 304], ["human", "SPECIES", 230, 235], ["viral aerosols", "PROBLEM", 16, 30], ["observation studies", "TEST", 247, 266], ["no", "UNCERTAINTY", 13, 15], ["viral", "OBSERVATION_MODIFIER", 16, 21], ["aerosols", "OBSERVATION", 22, 30], ["air", "OBSERVATION", 38, 41], ["viral source", "OBSERVATION", 86, 98], ["hands", "ANATOMY", 163, 168]]], ["Of all face touches, approximately 42-44% involved contact with the proximity of a mucous membrane.", [["mucous membrane", "ANATOMY", 83, 98], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 83, 98], ["all", "ANATOMY_MODIFIER", 3, 6], ["face", "ANATOMY", 7, 11], ["mucous membrane", "ANATOMY", 83, 98]]], ["The relative percentage of facial mucosal touches are: 36% mouth, 31% nose, 27% eyes, and 6% face touches involving combination of the above [12] .", [["facial mucosal", "ANATOMY", 27, 41], ["mouth", "ANATOMY", 59, 64], ["nose", "ANATOMY", 70, 74], ["eyes", "ANATOMY", 80, 84], ["facial mucosal", "ORGAN", 27, 41], ["mouth", "ORGANISM_SUBDIVISION", 59, 64], ["nose", "ORGAN", 70, 74], ["eyes", "ORGAN", 80, 84], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["facial mucosal", "ANATOMY", 27, 41]]], ["Figure 1 shows the spatial distribution of the frequency of face touched areas.", [["spatial", "OBSERVATION_MODIFIER", 19, 26], ["distribution", "OBSERVATION_MODIFIER", 27, 39], ["face", "ANATOMY", 60, 64], ["touched", "OBSERVATION", 65, 72]]], ["Enveloped viruses, such as influenza and coronavirus, may find human facial regions a favorable environment for survival, probably better than on others body parts, including hands, due to more oily, warmer and humid conditions on the face around the nose.", [["facial", "ANATOMY", 69, 75], ["body parts", "ANATOMY", 153, 163], ["nose", "ANATOMY", 251, 255], ["influenza and coronavirus", "DISEASE", 27, 52], ["coronavirus", "ORGANISM", 41, 52], ["human", "ORGANISM", 63, 68], ["body", "ORGANISM_SUBDIVISION", 153, 157], ["hands", "ORGANISM_SUBDIVISION", 175, 180], ["face", "ORGANISM_SUBDIVISION", 235, 239], ["nose", "ORGANISM_SUBDIVISION", 251, 255], ["influenza and coronavirus", "SPECIES", 27, 52], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Enveloped viruses", "PROBLEM", 0, 17], ["influenza", "PROBLEM", 27, 36], ["coronavirus", "PROBLEM", 41, 52], ["warmer", "TREATMENT", 200, 206], ["viruses", "OBSERVATION", 10, 17], ["hands", "ANATOMY", 175, 180], ["nose", "ANATOMY", 251, 255]]], ["At the same time the viral particles in the proximity to nostrils will also experience periodic reciprocal inhale/exhale convective flows generated by the physiological respiration process.Simulation of Face to Nose Viral Transmission.The goal of our simulations is to determine the spatial distribution of wall shear stresses on the human face around the nose.", [["nostrils", "ANATOMY", 57, 65], ["wall", "ANATOMY", 307, 311], ["face", "ANATOMY", 340, 344], ["nose", "ANATOMY", 356, 360], ["human", "ORGANISM", 334, 339], ["face", "ORGANISM_SUBDIVISION", 340, 344], ["nose", "ORGAN", 356, 360], ["human", "SPECIES", 334, 339], ["human", "SPECIES", 334, 339], ["the viral particles", "PROBLEM", 17, 36], ["periodic reciprocal inhale/exhale convective flows", "PROBLEM", 87, 137], ["the physiological respiration process", "PROBLEM", 151, 188], ["wall shear stresses", "PROBLEM", 307, 326], ["viral particles", "OBSERVATION", 21, 36], ["nostrils", "ANATOMY", 57, 65], ["exhale", "OBSERVATION", 114, 120], ["convective flows", "OBSERVATION", 121, 137], ["physiological respiration", "OBSERVATION", 155, 180], ["Face", "ANATOMY", 203, 207], ["Nose", "ANATOMY", 211, 215], ["Viral", "OBSERVATION", 216, 221], ["wall shear stresses", "OBSERVATION", 307, 326], ["nose", "ANATOMY", 356, 360]]], ["High shear stress may be responsible of the viral particle resuspension from the face into the air and subsequent inhalation.", [["High shear stress", "PROBLEM", 0, 17], ["the viral particle resuspension", "TREATMENT", 40, 71], ["subsequent inhalation", "TREATMENT", 103, 124], ["shear stress", "OBSERVATION", 5, 17], ["may be responsible", "UNCERTAINTY", 18, 36], ["viral", "OBSERVATION", 44, 49], ["particle resuspension", "OBSERVATION", 50, 71], ["air", "OBSERVATION", 95, 98]]], ["We An octree mesh of ~150,000 control volumes was constructed around the human face, nose and in the nostrils.", [["face", "ANATOMY", 79, 83], ["nose", "ANATOMY", 85, 89], ["nostrils", "ANATOMY", 101, 109], ["human", "ORGANISM", 73, 78], ["face", "ORGANISM_SUBDIVISION", 79, 83], ["nose", "ORGANISM_SUBDIVISION", 85, 89], ["nostrils", "ORGAN", 101, 109], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["An octree mesh", "TREATMENT", 3, 17], ["octree", "OBSERVATION_MODIFIER", 6, 12], ["mesh", "OBSERVATION", 13, 17], ["human face", "ANATOMY", 73, 83], ["nose", "ANATOMY", 85, 89], ["nostrils", "ANATOMY", 101, 109]]], ["All free boundaries of the box were described using extrapolated pressure boundary conditions.", [["the box", "TREATMENT", 23, 30], ["extrapolated pressure boundary conditions", "TREATMENT", 52, 93], ["free", "OBSERVATION_MODIFIER", 4, 8], ["boundaries", "OBSERVATION_MODIFIER", 9, 19]]], ["The transient laminar air flow is simulated by solving 3D Navier-Stokes and mass continuity equations using CoBi tools [14, 15] .", [["The transient laminar air flow", "PROBLEM", 0, 30], ["mass continuity equations", "PROBLEM", 76, 101], ["CoBi tools", "TEST", 108, 118], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["laminar", "OBSERVATION_MODIFIER", 14, 21], ["air flow", "OBSERVATION", 22, 30], ["mass", "OBSERVATION", 76, 80]]], ["The goal is to determine the spatial distribution of wall shear stresses on the human face around the nose.", [["wall", "ANATOMY", 53, 57], ["face", "ANATOMY", 86, 90], ["nose", "ANATOMY", 102, 106], ["human", "ORGANISM", 80, 85], ["face", "ORGANISM_SUBDIVISION", 86, 90], ["nose", "ORGAN", 102, 106], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["wall shear stresses", "PROBLEM", 53, 72], ["wall shear stresses", "OBSERVATION", 53, 72], ["nose", "ANATOMY", 102, 106]]], ["It has been well documented that wall shear stress is directly related to particle re-suspension form a surface into the flow stream [16, 17] .", [["wall", "ANATOMY", 33, 37], ["surface", "ANATOMY", 104, 111], ["wall shear stress", "PROBLEM", 33, 50], ["wall", "OBSERVATION_MODIFIER", 33, 37], ["shear", "OBSERVATION_MODIFIER", 38, 43], ["stress", "OBSERVATION", 44, 50], ["particle re-suspension", "OBSERVATION", 74, 96]]], ["The facial area from where the viral particle can resuspend depends on the virion particle and facial skin physical status.", [["facial area", "ANATOMY", 4, 15], ["facial skin", "ANATOMY", 95, 106], ["facial area", "MULTI-TISSUE_STRUCTURE", 4, 15], ["skin", "ORGAN", 102, 106], ["the viral particle", "PROBLEM", 27, 45], ["the virion particle", "TREATMENT", 71, 90], ["facial", "ANATOMY", 4, 10], ["viral particle", "OBSERVATION", 31, 45], ["facial", "ANATOMY_MODIFIER", 95, 101], ["skin", "ANATOMY", 102, 106]]], ["Once resuspended from the skin into the air in the nasal vicinity the small virion particle will almost certainly enter through the nostrils into the lungs.", [["skin", "ANATOMY", 26, 30], ["nasal", "ANATOMY", 51, 56], ["nostrils", "ANATOMY", 132, 140], ["lungs", "ANATOMY", 150, 155], ["skin", "ORGAN", 26, 30], ["air", "ORGAN", 40, 43], ["nostrils", "ORGAN", 132, 140], ["lungs", "ORGAN", 150, 155], ["the small virion particle", "TREATMENT", 66, 91], ["skin", "ANATOMY", 26, 30], ["air", "OBSERVATION", 40, 43], ["nasal", "ANATOMY", 51, 56], ["vicinity", "ANATOMY_MODIFIER", 57, 65], ["small", "OBSERVATION_MODIFIER", 70, 75], ["virion particle", "OBSERVATION", 76, 91], ["lungs", "ANATOMY", 150, 155]]], ["Virus size nanoparticles, some containing virion agglomerates, can penetrate deep into the lung and deposit in the alveolar sacks.", [["lung", "ANATOMY", 91, 95], ["alveolar", "ANATOMY", 115, 123], ["Virus", "ORGANISM", 0, 5], ["lung", "ORGAN", 91, 95], ["alveolar sacks", "MULTI-TISSUE_STRUCTURE", 115, 129], ["Virus size nanoparticles", "PROBLEM", 0, 24], ["some containing virion agglomerates", "PROBLEM", 26, 61], ["size", "OBSERVATION_MODIFIER", 6, 10], ["nanoparticles", "OBSERVATION", 11, 24], ["virion agglomerates", "OBSERVATION", 42, 61], ["deep", "ANATOMY_MODIFIER", 77, 81], ["lung", "ANATOMY", 91, 95], ["deposit", "OBSERVATION_MODIFIER", 100, 107], ["alveolar", "ANATOMY_MODIFIER", 115, 123]]], ["Quantitative prediction of the viral particle resuspension region is theoretically possible but would require experimental data for model calibration.ConclusionsThe results presented here indicate that part of the human face close to the nostrils could be a source of viral self-inoculation.", [["nostrils", "ANATOMY", 238, 246], ["human", "ORGANISM", 214, 219], ["nostrils", "ORGAN", 238, 246], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 214, 219], ["the viral particle resuspension region", "TREATMENT", 27, 65], ["model calibration", "TREATMENT", 132, 149], ["viral self-inoculation", "PROBLEM", 268, 290], ["viral", "OBSERVATION", 31, 36], ["particle resuspension", "OBSERVATION", 37, 58], ["nostrils", "ANATOMY", 238, 246]]], ["The amount of inhaled viral load depends on the accumulated facial surface coverage of particles and on the breathing flow rate.", [["facial surface", "ANATOMY", 60, 74], ["facial surface", "TISSUE", 60, 74], ["inhaled viral load", "PROBLEM", 14, 32], ["the accumulated facial surface coverage of particles", "TREATMENT", 44, 96], ["the breathing flow rate", "TEST", 104, 127], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["inhaled viral load", "OBSERVATION", 14, 32], ["facial", "ANATOMY", 60, 66], ["surface", "OBSERVATION_MODIFIER", 67, 74], ["particles", "OBSERVATION_MODIFIER", 87, 96]]], ["We believe that similar to hand washing, periodic cleaning of the facial area, shown in Figure 2b could prevent viral self-infection.ConclusionsIt is plausible that virion nuclei suspended in droplets on the face cannot resuspend.", [["hand", "ANATOMY", 27, 31], ["facial area", "ANATOMY", 66, 77], ["nuclei", "ANATOMY", 172, 178], ["viral self-infection", "DISEASE", 112, 132], ["hand washing", "TREATMENT", 27, 39], ["periodic cleaning of the facial area", "TREATMENT", 41, 77], ["viral self-infection", "PROBLEM", 112, 132], ["facial", "ANATOMY", 66, 72], ["infection", "OBSERVATION", 123, 132], ["virion", "OBSERVATION", 165, 171], ["nuclei suspended", "OBSERVATION", 172, 188]]], ["Hence, another more practical protection practice may involve periodic facial misting with water.", [["facial", "ANATOMY", 71, 77], ["practical protection practice", "TREATMENT", 20, 49], ["facial", "ANATOMY", 71, 77]]], ["To verify theses hypotheses further experimental and computational studies are warranted.FundingThe authors received no financial support for the research, authorship, and/or publication of this article.Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["computational studies", "TEST", 53, 74], ["financial support", "TREATMENT", 120, 137]]]], "PMC7091997": [["Physical descriptionDomestic or European ferrets are carnivorous mammals related to weasels, minks, otters and skunks.", [["ferrets", "ORGANISM", 41, 48], ["ferrets", "SPECIES", 41, 48]]], ["They have long bodies, short legs and thick fur with various color patterns.", [["legs", "ANATOMY", 29, 33], ["legs", "ORGANISM_SUBDIVISION", 29, 33], ["fur", "GENE_OR_GENE_PRODUCT", 44, 47], ["short legs and thick fur with various color patterns", "PROBLEM", 23, 75], ["short", "OBSERVATION_MODIFIER", 23, 28], ["legs", "ANATOMY", 29, 33]]], ["The natural pattern, called sable or fitch, features a yellowish coat with dark patches over the limbs and tail, a facial mask and dark brown eyes.", [["yellowish coat", "ANATOMY", 55, 69], ["limbs", "ANATOMY", 97, 102], ["tail", "ANATOMY", 107, 111], ["facial", "ANATOMY", 115, 121], ["brown eyes", "ANATOMY", 136, 146], ["limbs", "ORGANISM_SUBDIVISION", 97, 102], ["tail", "ORGANISM_SUBDIVISION", 107, 111], ["eyes", "ORGAN", 142, 146], ["a yellowish coat with dark patches over the limbs and tail", "PROBLEM", 53, 111], ["dark brown eyes", "PROBLEM", 131, 146], ["natural pattern", "OBSERVATION", 4, 19], ["yellowish coat", "OBSERVATION", 55, 69], ["dark patches", "OBSERVATION", 75, 87], ["limbs", "ANATOMY", 97, 102], ["tail", "ANATOMY", 107, 111], ["facial mask", "ANATOMY", 115, 126], ["dark", "OBSERVATION", 131, 135], ["brown eyes", "OBSERVATION", 136, 146]]], ["Ferrets have anal scent glands and sebaceous glands but lack sweat glands and hence are particularly susceptible to heat1.", [["Ferrets", "ANATOMY", 0, 7], ["anal scent glands", "ANATOMY", 13, 30], ["sebaceous glands", "ANATOMY", 35, 51], ["sweat glands", "ANATOMY", 61, 73], ["anal scent glands", "ORGAN", 13, 30], ["sebaceous glands", "ORGAN", 35, 51], ["sweat glands", "ORGAN", 61, 73], ["sebaceous glands", "PROBLEM", 35, 51], ["lack sweat glands", "PROBLEM", 56, 73], ["anal", "ANATOMY_MODIFIER", 13, 17], ["scent glands", "ANATOMY", 18, 30], ["sebaceous glands", "ANATOMY", 35, 51]]], ["Adult males weigh \u223c2 kg, whereas females are smaller at \u223c1 kg.", [["smaller", "OBSERVATION_MODIFIER", 45, 52]]], ["Ferrets live for roughly 6\u20138 years.Research r\u00e9sum\u00e9Ferrets have been used as research models since the early 1900s (ref.", [["Research r\u00e9sum\u00e9Ferrets", "TREATMENT", 35, 57]]], ["They are hardy animals that thrive in the lab, provided that their social behaviors, diet and other habits, such as their inclination to burrow and hide, are accommodated.Research r\u00e9sum\u00e9Despite a relatively small representation in the laboratory, ferrets have a distinct niche in biomedical research.", [["ferrets", "ORGANISM", 247, 254], ["ferrets", "SPECIES", 247, 254], ["ferrets", "SPECIES", 247, 254], ["relatively", "OBSERVATION_MODIFIER", 196, 206], ["small", "OBSERVATION_MODIFIER", 207, 212], ["distinct", "OBSERVATION_MODIFIER", 262, 270], ["niche", "OBSERVATION_MODIFIER", 271, 276]]], ["Their tracheal and lung anatomies, which, like their narrow, elongated bodies and short legs, are adapted for burrowing, afford decreased airway resistance and a relatively large lung capacity that facilitate respiratory research.", [["tracheal", "ANATOMY", 6, 14], ["lung", "ANATOMY", 19, 23], ["bodies", "ANATOMY", 71, 77], ["legs", "ANATOMY", 88, 92], ["airway", "ANATOMY", 138, 144], ["lung", "ANATOMY", 179, 183], ["tracheal", "MULTI-TISSUE_STRUCTURE", 6, 14], ["lung", "ORGAN", 19, 23], ["legs", "ORGANISM_SUBDIVISION", 88, 92], ["airway", "MULTI-TISSUE_STRUCTURE", 138, 144], ["lung", "ORGAN", 179, 183], ["Their tracheal and lung anatomies", "PROBLEM", 0, 33], ["their narrow, elongated bodies and short legs", "PROBLEM", 47, 92], ["burrowing", "PROBLEM", 110, 119], ["decreased airway resistance", "PROBLEM", 128, 155], ["a relatively large lung capacity", "PROBLEM", 160, 192], ["tracheal", "ANATOMY", 6, 14], ["lung", "ANATOMY", 19, 23], ["anatomies", "OBSERVATION", 24, 33], ["narrow", "OBSERVATION_MODIFIER", 53, 59], ["elongated", "OBSERVATION_MODIFIER", 61, 70], ["bodies", "OBSERVATION_MODIFIER", 71, 77], ["short", "OBSERVATION_MODIFIER", 82, 87], ["legs", "ANATOMY", 88, 92], ["airway resistance", "OBSERVATION", 138, 155], ["relatively", "OBSERVATION_MODIFIER", 162, 172], ["large", "OBSERVATION_MODIFIER", 173, 178], ["lung", "ANATOMY", 179, 183], ["capacity", "OBSERVATION", 184, 192], ["respiratory research", "OBSERVATION", 209, 229]]], ["Because lung morphology is similar between ferrets and humans, ferrets are used in the study of cystic fibrosis3.Research r\u00e9sum\u00e9In addition to having similar respiratory anatomy, ferrets are also susceptible to respiratory diseases that affect humans (notably, influenza and severe acute respiratory syndrome (SARS)-associated corona virus) and often show clinical signs similar to those observed in humans.", [["lung", "ANATOMY", 8, 12], ["cystic fibrosis3", "ANATOMY", 96, 112], ["respiratory", "ANATOMY", 158, 169], ["respiratory", "ANATOMY", 211, 222], ["cystic fibrosis3", "DISEASE", 96, 112], ["respiratory diseases", "DISEASE", 211, 231], ["influenza", "DISEASE", 261, 270], ["acute respiratory syndrome", "DISEASE", 282, 308], ["SARS", "DISEASE", 310, 314], ["lung", "ORGAN", 8, 12], ["ferrets", "ORGANISM", 43, 50], ["humans", "ORGANISM", 55, 61], ["ferrets", "ORGANISM", 63, 70], ["cystic fibrosis3", "CANCER", 96, 112], ["ferrets", "ORGANISM", 179, 186], ["humans", "ORGANISM", 244, 250], ["corona virus", "ORGANISM", 327, 339], ["humans", "ORGANISM", 400, 406], ["ferrets", "SPECIES", 43, 50], ["humans", "SPECIES", 55, 61], ["ferrets", "SPECIES", 63, 70], ["humans", "SPECIES", 244, 250], ["humans", "SPECIES", 400, 406], ["ferrets", "SPECIES", 43, 50], ["humans", "SPECIES", 55, 61], ["ferrets", "SPECIES", 63, 70], ["humans", "SPECIES", 244, 250], ["humans", "SPECIES", 400, 406], ["the study", "TEST", 83, 92], ["cystic fibrosis3", "PROBLEM", 96, 112], ["similar respiratory anatomy", "PROBLEM", 150, 177], ["respiratory diseases", "PROBLEM", 211, 231], ["influenza", "PROBLEM", 261, 270], ["severe acute respiratory syndrome", "PROBLEM", 275, 308], ["SARS", "PROBLEM", 310, 314], ["corona virus", "PROBLEM", 327, 339], ["clinical signs", "PROBLEM", 356, 370], ["lung", "ANATOMY", 8, 12], ["morphology", "OBSERVATION", 13, 23], ["cystic", "OBSERVATION_MODIFIER", 96, 102], ["fibrosis3", "OBSERVATION", 103, 112], ["respiratory anatomy", "OBSERVATION", 158, 177], ["respiratory diseases", "OBSERVATION", 211, 231], ["severe", "OBSERVATION_MODIFIER", 275, 281], ["acute", "OBSERVATION_MODIFIER", 282, 287], ["respiratory syndrome", "OBSERVATION", 288, 308]]], ["Influenza research has become especially important in recent years owing to the emergence of highly pathogenic strains of influenza that are global health threats.", [["Influenza", "DISEASE", 0, 9], ["influenza", "DISEASE", 122, 131], ["Influenza", "PROBLEM", 0, 9], ["influenza", "PROBLEM", 122, 131]]], ["Ferrets are the model of choice for developing influenza vaccines and therapeutics4.Research r\u00e9sum\u00e9Ferrets are also used to model human gastrointestinal disease, again because of their anatomical and physiological similarities to humans, as well as the fact that both species host Helicobacter organisms that cause gastritis.", [["gastrointestinal", "ANATOMY", 136, 152], ["gastrointestinal disease", "DISEASE", 136, 160], ["gastritis", "DISEASE", 315, 324], ["human", "ORGANISM", 130, 135], ["gastrointestinal", "ORGANISM_SUBDIVISION", 136, 152], ["humans", "ORGANISM", 230, 236], ["Helicobacter organisms", "ORGANISM", 281, 303], ["gastritis", "PATHOLOGICAL_FORMATION", 315, 324], ["human", "SPECIES", 130, 135], ["humans", "SPECIES", 230, 236], ["human", "SPECIES", 130, 135], ["humans", "SPECIES", 230, 236], ["developing influenza vaccines", "TREATMENT", 36, 65], ["therapeutics4", "TREATMENT", 70, 83], ["Research r\u00e9sum\u00e9Ferrets", "TREATMENT", 84, 106], ["model human gastrointestinal disease", "PROBLEM", 124, 160], ["both species host Helicobacter organisms", "PROBLEM", 263, 303], ["gastritis", "PROBLEM", 315, 324], ["influenza", "OBSERVATION", 47, 56], ["gastrointestinal", "ANATOMY", 136, 152], ["disease", "OBSERVATION", 153, 160], ["gastritis", "OBSERVATION", 315, 324]]], ["A ferret model for peptic ulcer disease has aided studies of the epidemiology of this disease as well as its pathogenesis and treatment2.", [["peptic ulcer", "ANATOMY", 19, 31], ["peptic ulcer disease", "DISEASE", 19, 39], ["ferret", "ORGANISM", 2, 8], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 19, 31], ["A ferret model", "TREATMENT", 0, 14], ["peptic ulcer disease", "PROBLEM", 19, 39], ["this disease", "PROBLEM", 81, 93], ["treatment2", "TREATMENT", 126, 136], ["peptic", "OBSERVATION_MODIFIER", 19, 25], ["ulcer", "OBSERVATION", 26, 31], ["disease", "OBSERVATION", 86, 93]]], ["Ferrets have also been used to study the emetic potential of drugs5 and to develop anti-emetic medications6, such as those given to cancer patients.Regulatory coverageDespite their importance in biomedical research, ferrets are not specifically mentioned in the US Animal Welfare Act and Regulations7 or in many of the commonly used recommendations and guidelines for laboratory animal care.", [["cancer", "ANATOMY", 132, 138], ["cancer", "DISEASE", 132, 138], ["Ferrets", "SIMPLE_CHEMICAL", 0, 7], ["drugs5", "SIMPLE_CHEMICAL", 61, 67], ["cancer", "CANCER", 132, 138], ["patients", "ORGANISM", 139, 147], ["ferrets", "ORGANISM", 216, 223], ["patients", "SPECIES", 139, 147], ["drugs5", "TREATMENT", 61, 67], ["anti-emetic medications6", "TREATMENT", 83, 107], ["laboratory animal care", "TREATMENT", 368, 390]]], ["They are covered as 'other animals' under Subpart F of the Animal Welfare Act, which lists only general information on facilities and husbandry and does not include specific requirements for cage size, feed composition or temperature, among other parameters.", [["cage size", "TREATMENT", 191, 200]]], ["The ferret is also covered under the Public Health Service Policy on Humane Care and Use of Laboratory Animals8.", [["ferret", "ORGANISM", 4, 10], ["ferret", "SPECIES", 4, 10], ["ferret", "SPECIES", 4, 10]]], ["Ferrets are not specifically addressed in the most recent edition of the Guide for the Care and Use of Laboratory Animals9, but the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes does include a section dedicated to husbandry and housing requirements for ferrets10.", [["ferrets", "ORGANISM", 320, 327], ["ferrets", "SPECIES", 320, 327], ["ferrets", "SPECIES", 320, 327], ["the Protection of Vertebrate Animals", "TREATMENT", 156, 192]]]], "PMC3623550": [["IntroductionType 2 diabetes mellitus (T2DM) is the most common type of diabetes mellitus, which is characterized by insulin resistance and combined with relatively reduced insulin secretion.1 It is a chronic metabolic disease that affects the body\u2019s ability to turn food into energy.", [["body", "ANATOMY", 243, 247], ["Type 2 diabetes mellitus", "DISEASE", 12, 36], ["T2DM", "DISEASE", 38, 42], ["diabetes mellitus", "DISEASE", 71, 88], ["metabolic disease", "DISEASE", 208, 225], ["insulin", "GENE_OR_GENE_PRODUCT", 116, 123], ["insulin", "GENE_OR_GENE_PRODUCT", 172, 179], ["body", "ORGANISM_SUBDIVISION", 243, 247], ["Type 2 diabetes mellitus", "PROBLEM", 12, 36], ["T2DM", "PROBLEM", 38, 42], ["diabetes mellitus", "PROBLEM", 71, 88], ["insulin resistance", "PROBLEM", 116, 134], ["relatively reduced insulin secretion", "PROBLEM", 153, 189], ["a chronic metabolic disease", "PROBLEM", 198, 225], ["diabetes mellitus", "OBSERVATION", 19, 36], ["most common", "OBSERVATION_MODIFIER", 51, 62], ["diabetes mellitus", "OBSERVATION", 71, 88], ["insulin resistance", "OBSERVATION", 116, 134], ["reduced", "OBSERVATION_MODIFIER", 164, 171], ["insulin secretion", "OBSERVATION", 172, 189], ["chronic", "OBSERVATION_MODIFIER", 200, 207], ["metabolic disease", "OBSERVATION", 208, 225]]], ["People developing T2DM may suffer from blindness, renal failure, coronary artery disease, and so forth.2 Because of its dramatic increase worldwide, T2DM has reached an epidemic scale that is anticipated to affect over 360 million people by 2030.3,4IntroductionBelonging to the nuclear hormone receptor family, peroxisome proliferator-activated receptors (PPARs) are the ligand-activated transcription factors.5,6 PPARs, particularly the subtypes PPAR\u03b1 and PPAR\u03b3, played a central role in regulating the expression of genes involved in the control of lipid and lipoprotein metabolism, glucose homeostasis, and inflammatory processes.", [["renal", "ANATOMY", 50, 55], ["coronary artery", "ANATOMY", 65, 80], ["T2DM", "DISEASE", 18, 22], ["blindness", "DISEASE", 39, 48], ["renal failure", "DISEASE", 50, 63], ["coronary artery disease", "DISEASE", 65, 88], ["T2DM", "DISEASE", 149, 153], ["glucose", "CHEMICAL", 585, 592], ["People", "ORGANISM", 0, 6], ["renal", "ORGAN", 50, 55], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 65, 80], ["people", "ORGANISM", 231, 237], ["nuclear hormone receptor", "GENE_OR_GENE_PRODUCT", 278, 302], ["peroxisome proliferator-activated receptors", "GENE_OR_GENE_PRODUCT", 311, 354], ["PPARs", "GENE_OR_GENE_PRODUCT", 356, 361], ["PPARs", "GENE_OR_GENE_PRODUCT", 414, 419], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 447, 452], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 457, 462], ["lipid", "SIMPLE_CHEMICAL", 551, 556], ["lipoprotein", "SIMPLE_CHEMICAL", 561, 572], ["glucose", "SIMPLE_CHEMICAL", 585, 592], ["nuclear hormone receptor family", "PROTEIN", 278, 309], ["peroxisome proliferator-activated receptors", "PROTEIN", 311, 354], ["PPARs", "PROTEIN", 356, 361], ["ligand-activated transcription factors", "PROTEIN", 371, 409], ["5,6 PPARs", "PROTEIN", 410, 419], ["PPAR\u03b1", "PROTEIN", 447, 452], ["PPAR\u03b3", "PROTEIN", 457, 462], ["People", "SPECIES", 0, 6], ["people", "SPECIES", 231, 237], ["T2DM", "PROBLEM", 18, 22], ["blindness", "PROBLEM", 39, 48], ["renal failure", "PROBLEM", 50, 63], ["coronary artery disease", "PROBLEM", 65, 88], ["T2DM", "PROBLEM", 149, 153], ["an epidemic scale", "PROBLEM", 166, 183], ["lipid and lipoprotein metabolism", "TEST", 551, 583], ["glucose homeostasis", "TEST", 585, 604], ["inflammatory processes", "PROBLEM", 610, 632], ["T2DM", "OBSERVATION", 18, 22], ["blindness", "OBSERVATION", 39, 48], ["renal", "ANATOMY", 50, 55], ["failure", "OBSERVATION", 56, 63], ["coronary artery", "ANATOMY", 65, 80], ["disease", "OBSERVATION", 81, 88], ["dramatic", "OBSERVATION_MODIFIER", 120, 128], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["worldwide", "OBSERVATION_MODIFIER", 138, 147], ["glucose homeostasis", "OBSERVATION", 585, 604], ["inflammatory", "OBSERVATION_MODIFIER", 610, 622]]], ["Accordingly, activating these receptors has become a promising therapeutic strategy for designing drugs against T2DM.7IntroductionThe activated PPAR\u03b1 receptors have a beneficial effect on lipid metabolism by regulating genes on fatty acid and cholesterol metabolism.8 PPAR\u03b1 agonists belong to the class of lipid-lowering drugs (such as fenofibrate and gemfibrozil), and are widely prescribed to reduce triglycerides.9 The PPAR\u03b3 receptors, the most widely studied subtype of PPARs, are located in adipocytes, muscles, and macrophages, where they have a direct influence on T2DM, dyslipidemia, atherosclerosis, and cardiovascular diseases.10,11 Thiazolidinediones are a class of PPAR\u03b3 agonists used in clinical practice to reduce plasma glucose level in type 2 diabetic patients, or to regulate glucose homeostasis by increasing insulin sensitivity and glucose disposal.12IntroductionUnfortunately, if the drug were used alone, the undesirable side effects such as weight gain, edema, and anemia would be caused;13 therefore, it is an urgent and challenging task to develop new dual agonists.", [["adipocytes", "ANATOMY", 496, 506], ["muscles", "ANATOMY", 508, 515], ["macrophages", "ANATOMY", 521, 532], ["cardiovascular", "ANATOMY", 613, 627], ["plasma", "ANATOMY", 728, 734], ["T2DM", "DISEASE", 112, 116], ["fatty acid", "CHEMICAL", 228, 238], ["cholesterol", "CHEMICAL", 243, 254], ["fenofibrate", "CHEMICAL", 336, 347], ["gemfibrozil", "CHEMICAL", 352, 363], ["T2DM", "DISEASE", 572, 576], ["dyslipidemia", "DISEASE", 578, 590], ["atherosclerosis", "DISEASE", 592, 607], ["cardiovascular diseases", "DISEASE", 613, 636], ["Thiazolidinediones", "CHEMICAL", 643, 661], ["glucose", "CHEMICAL", 735, 742], ["diabetic", "DISEASE", 759, 767], ["glucose", "CHEMICAL", 793, 800], ["glucose", "CHEMICAL", 851, 858], ["weight gain", "DISEASE", 963, 974], ["edema", "DISEASE", 976, 981], ["anemia", "DISEASE", 987, 993], ["fatty acid", "CHEMICAL", 228, 238], ["cholesterol", "CHEMICAL", 243, 254], ["fenofibrate", "CHEMICAL", 336, 347], ["gemfibrozil", "CHEMICAL", 352, 363], ["triglycerides", "CHEMICAL", 402, 415], ["Thiazolidinediones", "CHEMICAL", 643, 661], ["glucose", "CHEMICAL", 735, 742], ["glucose", "CHEMICAL", 793, 800], ["glucose", "CHEMICAL", 851, 858], ["PPAR\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 144, 159], ["lipid", "SIMPLE_CHEMICAL", 188, 193], ["fatty acid", "SIMPLE_CHEMICAL", 228, 238], ["cholesterol", "SIMPLE_CHEMICAL", 243, 254], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 268, 273], ["lipid", "SIMPLE_CHEMICAL", 306, 311], ["fenofibrate", "SIMPLE_CHEMICAL", 336, 347], ["gemfibrozil", "SIMPLE_CHEMICAL", 352, 363], ["triglycerides", "SIMPLE_CHEMICAL", 402, 415], ["PPAR\u03b3 receptors", "GENE_OR_GENE_PRODUCT", 422, 437], ["PPARs", "GENE_OR_GENE_PRODUCT", 474, 479], ["adipocytes", "CELL", 496, 506], ["muscles", "ORGAN", 508, 515], ["macrophages", "CELL", 521, 532], ["cardiovascular", "ANATOMICAL_SYSTEM", 613, 627], ["Thiazolidinediones", "SIMPLE_CHEMICAL", 643, 661], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 677, 682], ["plasma", "ORGANISM_SUBSTANCE", 728, 734], ["glucose", "SIMPLE_CHEMICAL", 735, 742], ["patients", "ORGANISM", 768, 776], ["glucose", "SIMPLE_CHEMICAL", 793, 800], ["insulin", "GENE_OR_GENE_PRODUCT", 827, 834], ["glucose", "SIMPLE_CHEMICAL", 851, 858], ["edema", "PATHOLOGICAL_FORMATION", 976, 981], ["PPAR\u03b1 receptors", "PROTEIN", 144, 159], ["PPAR\u03b3 receptors", "PROTEIN", 422, 437], ["PPARs", "PROTEIN", 474, 479], ["adipocytes", "CELL_TYPE", 496, 506], ["macrophages", "CELL_TYPE", 521, 532], ["patients", "SPECIES", 768, 776], ["designing drugs", "TREATMENT", 88, 103], ["T2DM", "PROBLEM", 112, 116], ["The activated PPAR\u03b1 receptors", "TREATMENT", 130, 159], ["lipid metabolism", "TREATMENT", 188, 204], ["fatty acid", "TEST", 228, 238], ["agonists", "TREATMENT", 274, 282], ["lipid-lowering drugs", "TREATMENT", 306, 326], ["fenofibrate", "TREATMENT", 336, 347], ["gemfibrozil", "TREATMENT", 352, 363], ["triglycerides", "TEST", 402, 415], ["The PPAR\u03b3 receptors", "TREATMENT", 418, 437], ["T2DM", "PROBLEM", 572, 576], ["dyslipidemia", "PROBLEM", 578, 590], ["atherosclerosis", "PROBLEM", 592, 607], ["cardiovascular diseases", "PROBLEM", 613, 636], ["Thiazolidinediones", "TREATMENT", 643, 661], ["PPAR\u03b3 agonists", "TREATMENT", 677, 691], ["plasma glucose level", "TEST", 728, 748], ["glucose homeostasis", "TEST", 793, 812], ["increasing insulin sensitivity", "TREATMENT", 816, 846], ["glucose disposal", "TREATMENT", 851, 867], ["the undesirable side effects", "PROBLEM", 926, 954], ["weight gain", "PROBLEM", 963, 974], ["edema", "PROBLEM", 976, 981], ["anemia", "PROBLEM", 987, 993], ["new dual agonists", "TREATMENT", 1072, 1089], ["most widely", "OBSERVATION_MODIFIER", 443, 454], ["PPARs", "OBSERVATION", 474, 479], ["adipocytes", "ANATOMY", 496, 506], ["muscles", "ANATOMY", 508, 515], ["macrophages", "OBSERVATION", 521, 532], ["dyslipidemia", "OBSERVATION", 578, 590], ["atherosclerosis", "OBSERVATION", 592, 607], ["cardiovascular diseases", "OBSERVATION", 613, 636], ["edema", "OBSERVATION", 976, 981], ["anemia", "OBSERVATION", 987, 993]]], ["In this regard, the novel PPAR\u03b1/PPAR\u03b3 dual agonist, formed by combining the lipid benefit of PPAR\u03b1 agonists (such as fibrates) with the glycemic advantages of the PPAR\u03b3 agonists (such as thiazolidinediones), has drawn considerable attention.14 In developing the dual agonists, a critical problem surrounds how to identify the selectivity ratio of the receptor subtype,15 because it may provide useful insights for finding the new drug candidates.", [["thiazolidinediones", "CHEMICAL", 187, 205], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 32, 37], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 93, 98], ["fibrates", "SIMPLE_CHEMICAL", 117, 125], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 163, 168], ["thiazolidinediones", "SIMPLE_CHEMICAL", 187, 205], ["PPAR\u03b1", "PROTEIN", 26, 31], ["PPAR\u03b1 agonists", "TREATMENT", 93, 107], ["fibrates", "TREATMENT", 117, 125], ["the PPAR\u03b3 agonists", "TREATMENT", 159, 177], ["thiazolidinediones", "TREATMENT", 187, 205]]], ["There is more information available about designing potential dual treatments for treating T2DM.16IntroductionMany studies have indicated that computational approaches, such as structural bioinformatics,17 molecular docking,18 pharmacophore modeling,19 Quantitative Structure\u2013Activity Relationship (QSAR) techniques,20\u201324 and a series of user-friendly web server predictors developed recently, such as G-protein-coupled receptors-grey incident degree analysis (GPCR-GIA) and G-protein-coupled receptors -2-layer predictor (GPCR-2L) for identifying G protein-coupled receptors and their types,25,26 iLoc-Euk and iLoc-Hum for predicting subcellular localization of eukaryotic and human proteins,27,28 NR-2L for identifying nuclear receptors and their subfamilies,29 ProtIdent for identifying proteases and their types,30 and HIVcleave for predicting human immunodeficiency virus protease cleavage sites in proteins,31,32 can provide timely and very useful information, as well as insights for drug development.", [["subcellular", "ANATOMY", 635, 646], ["nuclear", "ANATOMY", 721, 728], ["T2DM", "DISEASE", 91, 95], ["human immunodeficiency virus", "DISEASE", 848, 876], ["G-protein", "GENE_OR_GENE_PRODUCT", 402, 411], ["GPCR-GIA", "GENE_OR_GENE_PRODUCT", 461, 469], ["G-protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 475, 502], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 548, 575], ["iLoc-Euk", "GENE_OR_GENE_PRODUCT", 598, 606], ["iLoc-Hum", "GENE_OR_GENE_PRODUCT", 611, 619], ["human", "ORGANISM", 678, 683], ["NR-2L", "GENE_OR_GENE_PRODUCT", 699, 704], ["nuclear", "CELLULAR_COMPONENT", 721, 728], ["HIVcleave", "GENE_OR_GENE_PRODUCT", 823, 832], ["human immunodeficiency virus", "ORGANISM", 848, 876], ["G-protein-coupled receptors", "PROTEIN", 402, 429], ["GPCR", "PROTEIN", 461, 465], ["GIA", "PROTEIN", 466, 469], ["G-protein-coupled receptors -2", "PROTEIN", 475, 505], ["GPCR", "PROTEIN", 523, 527], ["G protein-coupled receptors", "PROTEIN", 548, 575], ["iLoc", "PROTEIN", 598, 602], ["Euk", "PROTEIN", 603, 606], ["iLoc", "PROTEIN", 611, 615], ["Hum", "PROTEIN", 616, 619], ["eukaryotic and human proteins", "PROTEIN", 663, 692], ["27,28 NR-2L", "PROTEIN", 693, 704], ["nuclear receptors", "PROTEIN", 721, 738], ["ProtIdent", "PROTEIN", 764, 773], ["proteases", "PROTEIN", 790, 799], ["HIVcleave", "PROTEIN", 823, 832], ["human immunodeficiency virus protease cleavage sites", "DNA", 848, 900], ["human", "SPECIES", 678, 683], ["human", "SPECIES", 848, 853], ["immunodeficiency virus", "SPECIES", 854, 876], ["human", "SPECIES", 678, 683], ["human immunodeficiency virus", "SPECIES", 848, 876], ["potential dual treatments", "TREATMENT", 52, 77], ["T2DM", "PROBLEM", 91, 95], ["Many studies", "TEST", 110, 122], ["pharmacophore modeling", "TEST", 227, 249], ["G-protein", "TEST", 402, 411], ["GPCR", "TEST", 461, 465], ["GIA", "TEST", 466, 469], ["G", "TEST", 475, 476], ["protein", "TEST", 477, 484], ["receptors", "TEST", 493, 502], ["GPCR", "TEST", 523, 527], ["G protein", "TEST", 548, 557], ["iLoc", "TEST", 598, 602], ["human proteins", "TEST", 678, 692], ["NR", "TEST", 699, 701], ["nuclear receptors", "TEST", 721, 738], ["proteases", "TEST", 790, 799], ["HIVcleave", "TREATMENT", 823, 832], ["predicting human immunodeficiency virus protease cleavage sites", "TREATMENT", 837, 900]]], ["In addition to the aforementioned approaches, the Virtual Screening technique and Core Hopping technique are also very useful.33\u201336 The former can be used to screen for novel molecular scaffolds,37,38 while the latter can be used to generate new lead compounds with improved core properties.37,38IntroductionEncouraged by the aforementioned successful studies, the present study was initiated in an attempt to screen the fragment database in hopes to find a new antidiabetic compound.", [["33\u201336", "CHEMICAL", 126, 131], ["the Virtual Screening technique", "TEST", 46, 77], ["Core Hopping technique", "TREATMENT", 82, 104], ["novel molecular scaffolds", "TREATMENT", 169, 194], ["new lead compounds", "PROBLEM", 242, 260], ["the present study", "TEST", 361, 378], ["the fragment database", "PROBLEM", 417, 438], ["a new antidiabetic compound", "PROBLEM", 456, 483]]], ["Meanwhile, the techniques of the core hopping associated with the glide docking and molecular dynamic simulation were utilized to analyze the binding interactions between the agonist and PPARs.39,40 The absorption, distribution, metabolism, and excretion (ADME) predictions were also used to evaluate whether the new agonist found to date possesses great potential to become a promising drug candidate for treating diabetes mellitus.41,42Protein structures and databases ::: Materials and methodsWe downloaded the crystal structures of PPAR\u03b1 (1k71.pdb) and PPAR\u03b3 (1k74.pdb) from the Protein Data Bank,43,44 and used them as receptors for the current modeling.", [["diabetes mellitus", "DISEASE", 415, 432], ["PPARs", "GENE_OR_GENE_PRODUCT", 187, 192], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 536, 541], ["1k71.pdb", "GENE_OR_GENE_PRODUCT", 543, 551], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 557, 562], ["PPARs", "PROTEIN", 187, 192], ["PPAR\u03b1", "PROTEIN", 536, 541], ["1k71.pdb", "PROTEIN", 543, 551], ["PPAR\u03b3", "PROTEIN", 557, 562], ["1k74", "PROTEIN", 564, 568], ["pdb", "PROTEIN", 569, 572], ["the glide docking", "TREATMENT", 62, 79], ["excretion (ADME) predictions", "TEST", 245, 273], ["diabetes mellitus", "PROBLEM", 415, 432], ["PPAR", "TEST", 536, 540], ["PPAR", "TEST", 557, 561]]], ["The reasons behind the selection of the two proteins are: (1) the two proteins contain the same ligand, GW409544, which is used to easily identify the binding site for comparison; (2) the resolutions of the two crystal structures are quite similar with one (1k7l.pdb) having 2.50 \u00c5 and the other (1k74.pdb) having 2.30 \u00c5; (3) the source organism of both structures was humans.43Protein structures and databases ::: Materials and methodsThe protein-ligand binding site was identified by the SiteMap tool embedded in the Schrodinger Suite 2009 (Schr\u00f6dinger, LLC), as described previously.45\u201347 The binding site encompassed the ligand GW409544, which was observed in the crystal structures of both PPAR\u03b1 (1k7l) and PPAR\u03b3 (1k74).", [["GW409544", "CHEMICAL", 104, 112], ["GW409544", "CHEMICAL", 104, 112], ["GW409544", "CHEMICAL", 632, 640], ["GW409544", "SIMPLE_CHEMICAL", 104, 112], ["humans", "ORGANISM", 369, 375], ["GW409544", "SIMPLE_CHEMICAL", 632, 640], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 695, 700], ["1k7l", "GENE_OR_GENE_PRODUCT", 702, 706], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 712, 717], ["1k74", "GENE_OR_GENE_PRODUCT", 719, 723], ["protein-ligand binding site", "DNA", 440, 467], ["binding site", "DNA", 596, 608], ["PPAR\u03b1", "PROTEIN", 695, 700], ["1k7l", "PROTEIN", 702, 706], ["PPAR\u03b3", "PROTEIN", 712, 717], ["1k74", "PROTEIN", 719, 723], ["humans", "SPECIES", 369, 375], ["humans", "SPECIES", 369, 375], ["the two crystal structures", "PROBLEM", 203, 229], ["The protein-ligand binding site", "PROBLEM", 436, 467], ["The binding site", "PROBLEM", 592, 608], ["LLC", "ANATOMY", 556, 559], ["ligand", "OBSERVATION_MODIFIER", 625, 631], ["both PPAR", "ANATOMY", 690, 699]]], ["The binding site of PPARs is composed of three arms: arm 1, arm 2, and arm 3, as marked in the panels A and B of Figure 1.", [["PPARs", "GENE_OR_GENE_PRODUCT", 20, 25], ["PPARs", "PROTEIN", 20, 25], ["arm 1, arm 2, and arm 3", "DNA", 53, 76], ["PPARs", "ANATOMY", 20, 25], ["arm", "ANATOMY", 53, 56], ["arm", "ANATOMY", 60, 63], ["arm", "ANATOMY", 71, 74], ["marked", "OBSERVATION_MODIFIER", 81, 87]]], ["These three segments play an important role in the interactions between the receptor and ligand.Protein structures and databases ::: Materials and methodsSeveral hydrophobic interactions between the three \u201carms\u201d and the Y-shaped ligand were deemed as the key points for designing the new PPARs agonist.48Protein structures and databases ::: Materials and methodsArm 1 has a predominately polar character and includes the AF2-helix (shown as the purple ribbon in Figure 1), which is responsible for the function of transcriptional activation.", [["PPARs", "GENE_OR_GENE_PRODUCT", 288, 293], ["PPARs", "PROTEIN", 288, 293], ["AF2", "PROTEIN", 421, 424], ["purple ribbon", "PROTEIN", 445, 458], ["Figure 1", "PROTEIN", 462, 470], ["the new PPARs agonist", "TREATMENT", 280, 301], ["Several", "OBSERVATION_MODIFIER", 154, 161], ["hydrophobic", "OBSERVATION_MODIFIER", 162, 173], ["predominately polar", "OBSERVATION_MODIFIER", 374, 393], ["purple", "OBSERVATION_MODIFIER", 445, 451], ["transcriptional activation", "OBSERVATION", 514, 540]]], ["The vital conformation of AF2-helix could generate a charge clamp formed by the network hydrogen bonds, thus significantly reducing the mobility of AF2 and regulating gene expression.7 The hydrophobic tail of the agonist interacts with either arm 2 or arm 3 to improve binding affinity.7Protein structures and databases ::: Materials and methodsThe lead compounds and the fragment databases derived from ZINC (Shoichet Laboratory, Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA) were used for virtual screening and core hopping searching,49 as described below, respectively.Virtual screening ::: Materials and methodsZINC (Shoichet Library, Department of Pharmaceutical Chemistry, University California) was a free database of commercially available compounds and contained over 13 million purchasable compounds in three-dimensional formats.49 The lead compound (or \u201clead-now\u201d) database, one subdatabase of the ZINC, was chosen for virtual screening to find the optimal molecular scaffold by the Glide5 docking program (Schr\u00f6dinger, LLC),35,36 which was interfaced with Schr\u00f6dinger Suite 2009 (Schr\u00f6dinger, LLC).", [["hydrogen", "CHEMICAL", 88, 96], ["AF2", "GENE_OR_GENE_PRODUCT", 148, 151], ["AF2", "PROTEIN", 26, 29], ["AF2", "PROTEIN", 148, 151], ["hydrophobic tail", "PROTEIN", 189, 205], ["arm 2 or arm 3", "DNA", 243, 257], ["ZINC", "PROTEIN", 953, 957], ["a charge clamp", "TREATMENT", 51, 65], ["The lead compounds", "PROBLEM", 345, 363], ["the fragment databases", "PROBLEM", 368, 390], ["virtual screening", "TEST", 535, 552], ["core hopping searching", "TEST", 557, 579], ["the ZINC", "TREATMENT", 949, 957], ["virtual screening", "TEST", 974, 991], ["hydrogen bonds", "OBSERVATION", 88, 102], ["hydrophobic", "OBSERVATION_MODIFIER", 189, 200], ["tail", "OBSERVATION_MODIFIER", 201, 205], ["arm", "ANATOMY", 252, 255], ["compounds", "OBSERVATION_MODIFIER", 354, 363], ["fragment", "OBSERVATION_MODIFIER", 372, 380], ["LLC", "ANATOMY", 1075, 1078], ["LLC", "ANATOMY", 1149, 1152]]], ["The preparation and refinement protocols for the protein receptor and all compound structures were performed on the Protein Preparation Wizard and LigPrep modules embedded in the Schr\u00f6dinger Suite (2009; Schr\u00f6dinger, LLC),35 respectively.", [["protein receptor", "PROTEIN", 49, 65], ["Protein Preparation Wizard and LigPrep modules", "DNA", 116, 162], ["refinement protocols", "TREATMENT", 20, 40], ["the protein receptor", "TREATMENT", 45, 65], ["the Protein Preparation", "TREATMENT", 112, 135], ["LigPrep modules", "TREATMENT", 147, 162], ["LLC", "ANATOMY", 217, 220]]], ["For protein preparation, the process included assigning bond orders, adding hydrogen, treating metals, treating disulfides, deleting waters, alleviating potential steric hindrance, adjusting bond order, and assigning the formal charges by protein minimization with the OPLS2005 force field;50 the constrained refinement value of RMSD (root mean square deviation) for the protein was limited to 0.3 \u00c5.", [["hydrogen", "CHEMICAL", 76, 84], ["metals", "CHEMICAL", 95, 101], ["hydrogen", "CHEMICAL", 76, 84], ["disulfides", "CHEMICAL", 112, 122], ["hydrogen", "SIMPLE_CHEMICAL", 76, 84], ["protein preparation", "TREATMENT", 4, 23], ["hydrogen, treating metals", "TREATMENT", 76, 101], ["disulfides", "TREATMENT", 112, 122], ["potential steric hindrance", "TREATMENT", 153, 179], ["the protein", "TEST", 367, 378], ["steric hindrance", "OBSERVATION", 163, 179]]], ["Meanwhile, for the compounds of the databases, the preparation consisted of generating possible states by ionization at a target pH of 7.0 \u00b1 2.0, desalting, retaining specified chiralities from the three-dimensional structure, and completing geometry minimization with the OPLS2005 force field.50 When the above steps were accomplished, all the investigated compounds were docked into the receptor pocket through the rigid docking model with a high throughput virtual screening scoring function to estimate the binding affinities.39,40Molecular docking with core hopping method ::: Materials and methodsMany useful insights for drug design could be gained by conducting molecular docking studies.17,18,51\u201353 In this study, a new docking algorithm called \u201ccore hopping\u201d was employed.35,36 Core hopping offers function of being able to perform both the fragment-based replacing and molecular docking,36 which makes it a very powerful and cutting-edge technique for de novo drug design because it allows for rapidly screening novel cores to help overcome unwanted properties by generating new lead compounds with improved core properties, as demonstrated by a series of previous studies.37,38Molecular docking with core hopping method ::: Materials and methodsThe procedures of the core hopping computation can be briefly described as follows.", [["17,18,51\u201353", "CHEMICAL", 696, 707], ["a target pH", "TEST", 120, 131], ["geometry minimization", "TREATMENT", 242, 263], ["the OPLS2005 force field", "TREATMENT", 269, 293], ["drug design", "TREATMENT", 628, 639], ["this study", "TEST", 711, 721], ["rapidly screening novel cores", "TREATMENT", 1005, 1034], ["previous studies", "TEST", 1167, 1183], ["the core hopping computation", "TREATMENT", 1275, 1303], ["fragment", "OBSERVATION", 851, 859]]], ["The first step was to define the possible points to which the cores were attached; this could be done by using the program \u201cDefine Combinations\u201d from the Combinatorial Screening panel in Schrodinger 2009 (Schr\u00f6dinger, LLC).", [["LLC", "ANATOMY", 218, 221]]], ["The third step was the cores preparation; this could be done by operating the \u201cProtocore Preparation\u201d module to find the cores attached to the scaffold and using the fragment database derived from ZINC.49Molecular docking with core hopping method ::: Materials and methodsThe fourth step was to align and dock the entire molecular structure built up by the core and scaffold.", [["the cores", "PROBLEM", 117, 126], ["the scaffold", "TREATMENT", 139, 151], ["ZINC", "TREATMENT", 197, 201]]], ["After all the above four steps were accomplished, all the investigated compounds were redocked into the receptor pocket via the rigid protein docking model with the Stand-Precision scoring function to estimate the binding affinities.39,40Molecular dynamics simulations ::: Materials and methodsMany marvelous biological functions in proteins and deoxyribonucleic acid (DNA) and their profound dynamic mechanisms, such as switching between active and inactive states,54,55 cooperative effects,56 allosteric transition,57\u201359 intercalation of drugs into DNA,60 and assembly of microtubules,61 can be revealed by studying their internal motions.62 Likewise, to really understand the interaction mechanism of a receptor with its ligand, we should consider not only the static structures concerned, but also the dynamic information obtained by simulating their internal motions or dynamic processes.63,64Molecular dynamics simulations ::: Materials and methodsTo examine whether the designed agonist remains bound by an explicit solvent from a dynamic point of view, the molecular dynamic simulation was performed with the periodic boundary conditions using the GROMACS 4.0 package under GROMACS 96-53a6 force fields for proteins.65 The topology files and charges for the ligand atoms were generated by the Dundee PRODRG2.5 Server (beta).66 Before starting the simulations, the systems were solvated in explicit water with a flexible simple point charge model in a cubic box, under the condition that the surface of the protein was covered with a water shell of 1.0 nm (nanometer or 10\u22129 of a meter).", [["microtubules", "ANATOMY", 574, 586], ["surface", "ANATOMY", 1499, 1506], ["deoxyribonucleic acid", "CHEMICAL", 346, 367], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 346, 367], ["DNA", "CELLULAR_COMPONENT", 369, 372], ["DNA", "CELLULAR_COMPONENT", 551, 554], ["microtubules", "CELLULAR_COMPONENT", 574, 586], ["beta", "GENE_OR_GENE_PRODUCT", 1326, 1330], ["surface", "CELLULAR_COMPONENT", 1499, 1506], ["methods", "TREATMENT", 287, 294], ["deoxyribonucleic acid (DNA", "PROBLEM", 346, 372], ["their profound dynamic mechanisms", "PROBLEM", 378, 411], ["intercalation of drugs", "TREATMENT", 523, 545], ["the GROMACS", "TREATMENT", 1152, 1163], ["GROMACS", "TEST", 1182, 1189], ["a flexible simple point charge model", "TREATMENT", 1417, 1453], ["a cubic box", "TREATMENT", 1457, 1468], ["a water shell", "TREATMENT", 1539, 1552], ["profound", "OBSERVATION_MODIFIER", 384, 392], ["dynamic mechanisms", "OBSERVATION", 393, 411]]], ["The minimum number of sodium and chloride ions needed to balance the system charge was placed randomly in the solvated system.", [["sodium", "CHEMICAL", 22, 28], ["chloride", "CHEMICAL", 33, 41], ["sodium", "CHEMICAL", 22, 28], ["chloride", "CHEMICAL", 33, 41], ["sodium", "SIMPLE_CHEMICAL", 22, 28], ["chloride ions", "SIMPLE_CHEMICAL", 33, 46], ["sodium and chloride ions", "TREATMENT", 22, 46], ["the system charge", "TREATMENT", 65, 82], ["minimum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Subsequently, the energy minimization was performed for the complex system by using the steepest descent method.67,68 Then, the 10 ns (or 10\u22129 of a second) MD simulations were carried out with a time step of 2 fs (femtosecond, or 10\u221215 of a second).", [["the energy minimization", "TREATMENT", 14, 37], ["the steepest descent method", "TREATMENT", 84, 111]]], ["The Particle Mesh Ewald algorithm was used to calculate the electrostatic interactions.69 All simulations were run under the periodic boundary condition with the Normal Pressure and Temperature (NPT) ensemble by using Berenson\u2019s coupling algorithm for keeping the temperature at 310 K and the pressure at 1 atm.", [["The Particle Mesh Ewald algorithm", "TREATMENT", 0, 33], ["the temperature", "TEST", 260, 275], ["the pressure", "TEST", 289, 301], ["Particle Mesh", "OBSERVATION", 4, 17], ["electrostatic interactions", "OBSERVATION", 60, 86], ["Pressure", "OBSERVATION_MODIFIER", 169, 177]]], ["All bonds are constrained by using the Linear Constraint Solver algorithm.70ADME prediction ::: Materials and methodsADME is a very useful program to eliminate unfavorable compounds with undesired properties in the early stage of drug development via evaluating the proposed structural refinements prior to expensive synthesis.27,42,71 Incorporating ADME predictions as a part of the drug development process can generate lead compounds that are more likely to exhibit satisfactory ADME performances during clinical trials.ADME prediction ::: Materials and methodsThe program of QikProp embedded in Schr\u00f6dinger 2009 (Schr\u00f6dinger, LLC) is a quick, accurate, and easy-to-use program for predicting the ADME properties of the compounds.41,72,73 The QikProp program adopted here was featured by having the functions predict a total of 44 properties of compounds, including the principal descriptors and physiochemical properties.ADME prediction ::: Materials and methodsAll the investigated compounds need not be neutralized before using QikProp because it will be automatically done in QikProp.", [["QikProp", "SIMPLE_CHEMICAL", 1034, 1041], ["QikProp", "SIMPLE_CHEMICAL", 1083, 1090], ["the Linear Constraint Solver algorithm", "TREATMENT", 35, 73], ["unfavorable compounds", "PROBLEM", 160, 181], ["expensive synthesis", "TREATMENT", 307, 326], ["The QikProp program", "TREATMENT", 742, 761], ["QikProp", "TREATMENT", 1034, 1041], ["bonds", "OBSERVATION_MODIFIER", 4, 9], ["LLC", "ANATOMY", 630, 633]]], ["The normal mode of prediction of QikProp was used in this study.", [["QikProp", "SIMPLE_CHEMICAL", 33, 40], ["QikProp", "PROTEIN", 33, 40], ["QikProp", "TREATMENT", 33, 40], ["this study", "TEST", 53, 63], ["normal", "OBSERVATION", 4, 10]]], ["The property analysis for the molecular weight \u2013 partition coefficient (QP logP o/w) \u2013 predicted aqueous solubility (QP logS); in addition, apparent PMDCK permeability (QPP MDCK) was computed in the QikProp program to evaluate whether the compounds hold the potential to become drug candidates.74Virtual screening and core hopping ::: Results and discussionThe detailed procedure of discovering the desired dual agonists is shown in Figure 2.", [["PMDCK", "SIMPLE_CHEMICAL", 149, 154], ["PMDCK", "PROTEIN", 149, 154], ["The property analysis", "TEST", 0, 21], ["the molecular weight", "TEST", 26, 46], ["QP logP", "TEST", 72, 79], ["the compounds", "PROBLEM", 235, 248], ["Virtual screening", "TEST", 296, 313], ["The detailed procedure", "TREATMENT", 357, 379]]], ["The lead-now database from ZINC was screened by utilizing the Glide5 software for its optimal performance targeting the PPAR receptors (PPAR\u03b1:1k7l and PPAR\u03b3:1k74).35,36,49 The top hit, ZINC36728034 (see Figure 2) was selected as the optimal lead compound for further modification according to the well known structures of ragaglitazar and GW409544, as shown in Figure 2.43,75 Consequently, the phenyl group rendered by red color in ZINC36728034 (see Figure 2) is modified into an acidic group colored with blue, as shown in Comp#0 (Figure 2).", [["ZINC36728034", "CHEMICAL", 185, 197], ["ragaglitazar", "CHEMICAL", 322, 334], ["GW409544", "CHEMICAL", 339, 347], ["phenyl", "CHEMICAL", 394, 400], ["ZINC36728034", "CHEMICAL", 432, 444], ["ZINC36728034", "CHEMICAL", 185, 197], ["ragaglitazar", "CHEMICAL", 322, 334], ["GW409544", "CHEMICAL", 339, 347], ["phenyl", "CHEMICAL", 394, 400], ["ZINC36728034", "CHEMICAL", 432, 444], ["ZINC", "SIMPLE_CHEMICAL", 27, 31], ["PPAR receptors", "GENE_OR_GENE_PRODUCT", 120, 134], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 136, 141], ["1k7l", "GENE_OR_GENE_PRODUCT", 142, 146], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 151, 156], ["1k74", "GENE_OR_GENE_PRODUCT", 157, 161], ["ragaglitazar", "SIMPLE_CHEMICAL", 322, 334], ["GW409544", "SIMPLE_CHEMICAL", 339, 347], ["phenyl", "SIMPLE_CHEMICAL", 394, 400], ["ZINC36728034", "SIMPLE_CHEMICAL", 432, 444], ["PPAR receptors", "PROTEIN", 120, 134], ["PPAR\u03b1", "PROTEIN", 136, 141], ["1k7l", "PROTEIN", 142, 146], ["PPAR\u03b3:1k74", "PROTEIN", 151, 161], ["further modification", "TREATMENT", 259, 279], ["red color", "TEST", 419, 428], ["top", "OBSERVATION_MODIFIER", 176, 179], ["hit", "OBSERVATION", 180, 183]]], ["The functional acidic group also exits in the following structures muraglitazar,76 faraglitazar,77 GW6471,78 GW7845,77 CHEMBL166572,79 and so on.", [["muraglitazar", "CHEMICAL", 67, 79], ["faraglitazar", "CHEMICAL", 83, 95], ["GW6471,78 GW7845,77 CHEMBL166572,79", "CHEMICAL", 99, 134], ["muraglitazar", "CHEMICAL", 67, 79], ["faraglitazar", "CHEMICAL", 83, 95], ["muraglitazar", "SIMPLE_CHEMICAL", 67, 79], ["muraglitazar", "TEST", 67, 79], ["faraglitazar", "TEST", 83, 95], ["GW", "TEST", 109, 111], ["CHEMBL", "TEST", 119, 125], ["acidic", "OBSERVATION_MODIFIER", 15, 21]]], ["The new molecule Comp#0 was designed with the intention so it has stronger affinity than ZINC36728034.", [["ZINC36728034", "CHEMICAL", 89, 101], ["ZINC36728034", "CHEMICAL", 89, 101], ["ZINC", "TEST", 89, 93], ["new", "OBSERVATION_MODIFIER", 4, 7], ["molecule", "OBSERVATION_MODIFIER", 8, 16], ["Comp", "OBSERVATION", 17, 21]]], ["Subsequently, the core hopping method was used to search the fragment database for the desired chemical groups to replace the amide group (ie, the R0 group) (Figure 2).", [["amide", "CHEMICAL", 126, 131], ["the core hopping method", "TREATMENT", 14, 37], ["the amide group", "TREATMENT", 122, 137]]], ["Doing this was to help lengthen the Comp#0 structure so as to make it better fit the roomy space in arm 2 (see Figure 1).", [["arm", "ANATOMY", 100, 103]]], ["As a result, the amide group (ie, R0 group) of Comp#0 in Figure 2 was replaced by each of the best ten R groups (ie, the R1 to R10, as marked on the right side of Figure 2).", [["amide", "CHEMICAL", 17, 22], ["amide", "SIMPLE_CHEMICAL", 17, 22], ["the amide group (ie, R0 group)", "TREATMENT", 13, 43], ["marked", "OBSERVATION_MODIFIER", 135, 141], ["right", "ANATOMY_MODIFIER", 149, 154]]], ["Subsequently, they were used to generate the whole molecules (ie, Comp#1 to Comp#10) through the core hopping approach (see Figure 2).", [["the core hopping approach", "TREATMENT", 93, 118]]], ["The ten compounds displayed the same chiral center (S) of the \u03b1 carbon atom of the acidic group with the ragaglitazar and the GW409544 (see Figure 2), and the other compounds of Comp#5 to Comp#10 with the other preferred chiral centers in R groups allowed them to match the active pocket.Virtual screening and core hopping ::: Results and discussionThe above strategy of this study is very similar that in to our previous paper;38 however, the starting point at which the study was carried out is very different.", [["ragaglitazar", "CHEMICAL", 105, 117], ["GW409544", "CHEMICAL", 126, 134], ["\u03b1 carbon", "CHEMICAL", 62, 70], ["ragaglitazar", "CHEMICAL", 105, 117], ["GW409544", "CHEMICAL", 126, 134], ["\u03b1 carbon atom", "SIMPLE_CHEMICAL", 62, 75], ["ragaglitazar", "SIMPLE_CHEMICAL", 105, 117], ["GW409544", "SIMPLE_CHEMICAL", 126, 134], ["Comp#10", "SIMPLE_CHEMICAL", 188, 195], ["R groups", "SIMPLE_CHEMICAL", 239, 247], ["chiral centers in R groups", "TREATMENT", 221, 247], ["the active pocket", "PROBLEM", 270, 287], ["Virtual screening", "TEST", 288, 305], ["this study", "TEST", 371, 381], ["the study", "TEST", 468, 477], ["active", "OBSERVATION_MODIFIER", 274, 280], ["pocket", "OBSERVATION", 281, 287]]], ["This current study used virtual screening as the first operation to find the novel scaffold against PPARs; we also used a previous study for this same purpose,80 and we then developed new compounds with the core hopping method, while the previous study mainly modified the well known ligand GW409544 though the use of two steps of the core hopping method.38 At first glance, the current study is quite similar to a previous study,38 for we used the same protein targets, fragment database, core hopping method, and molecular dynamics modeling, but the detailed approaches are completely different.", [["GW409544", "CHEMICAL", 291, 299], ["GW409544", "CHEMICAL", 291, 299], ["PPARs", "GENE_OR_GENE_PRODUCT", 100, 105], ["GW409544", "SIMPLE_CHEMICAL", 291, 299], ["PPARs", "PROTEIN", 100, 105], ["This current study", "TEST", 0, 18], ["virtual screening", "TEST", 24, 41], ["the first operation", "TREATMENT", 45, 64], ["a previous study", "TEST", 120, 136], ["the previous study", "TEST", 234, 252], ["the core hopping method", "TREATMENT", 331, 354], ["the current study", "TEST", 375, 392], ["a previous study", "TEST", 413, 429], ["fragment database", "TEST", 471, 488], ["core hopping method", "TEST", 490, 509], ["new", "OBSERVATION_MODIFIER", 184, 187], ["compounds", "OBSERVATION_MODIFIER", 188, 197]]], ["Therefore, it will be necessary to combine both studies that use the core hopping method for novel drug development in order to provide more comprehensive information.Modeling of PPAR agonist complex ::: Results and discussionThe best ten potential lead compounds or candidates obtained via the above step were redocked into the two receptors, PPAR\u03b1 (1k71) and PPAR\u03b3 (1k74), respectively.", [["PPAR agonist", "GENE_OR_GENE_PRODUCT", 179, 191], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 344, 349], ["1k71", "GENE_OR_GENE_PRODUCT", 351, 355], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 361, 366], ["PPAR agonist complex", "PROTEIN", 179, 199], ["PPAR\u03b1", "PROTEIN", 344, 349], ["1k71", "PROTEIN", 351, 355], ["PPAR\u03b3", "PROTEIN", 361, 366], ["the core hopping method", "TREATMENT", 65, 88], ["novel drug development", "TREATMENT", 93, 115], ["PPAR", "ANATOMY", 179, 183]]], ["As shown in the panels A and B of Figure 1, the best docked poses of the ten compounds are superposed together in the active pockets of the two receptors, PPAR\u03b1 (1k71) and PPAR\u03b3 (1k74), respectively.", [["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 155, 160], ["1k71", "GENE_OR_GENE_PRODUCT", 162, 166], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 172, 177], ["1k74", "GENE_OR_GENE_PRODUCT", 179, 183], ["PPAR\u03b1", "PROTEIN", 155, 160], ["1k71", "PROTEIN", 162, 166], ["PPAR\u03b3", "PROTEIN", 172, 177], ["1k74", "PROTEIN", 179, 183], ["active", "OBSERVATION_MODIFIER", 118, 124], ["pockets", "OBSERVATION_MODIFIER", 125, 132], ["PPAR", "ANATOMY", 172, 176]]], ["From the docking simulation results, it can be seen that all the compounds form good steric complementarity with the hydrophobic pocket of each receptor and produce strong van der Waals contacts and hydrophobic interactions.", [["the hydrophobic pocket of each receptor", "TREATMENT", 113, 152]]], ["As shown in the black in panels C and D of Figure 1, ragaglitazar (a novel dual agonist for PPAR\u03b1 and PPAR\u03b3 that also includes the important polar acidic head group in its structure) was chosen as a positive control for its high affinity with the PPAR\u03b1 and PPAR\u03b3 receptors in the previous research.75,81\u201383Modeling of PPAR agonist complex ::: Results and discussionListed in Table 1 are the top ten compounds (ie, Comp#1 to Comp#10) that are much stronger than ragaglitazar and Comp#0 in binding to the two PPAR\u03b1 (1k71) and PPAR\u03b3 (1k74) receptors, and these are ranked roughly according to their docking scores to the receptors.", [["head", "ANATOMY", 154, 158], ["ragaglitazar", "CHEMICAL", 53, 65], ["ragaglitazar", "CHEMICAL", 461, 473], ["ragaglitazar", "CHEMICAL", 53, 65], ["ragaglitazar", "CHEMICAL", 461, 473], ["ragaglitazar", "SIMPLE_CHEMICAL", 53, 65], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 92, 97], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 102, 107], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 247, 252], ["PPAR\u03b3 receptors", "GENE_OR_GENE_PRODUCT", 257, 272], ["PPAR agonist", "GENE_OR_GENE_PRODUCT", 318, 330], ["ragaglitazar", "SIMPLE_CHEMICAL", 461, 473], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 507, 512], ["1k71", "GENE_OR_GENE_PRODUCT", 514, 518], ["PPAR\u03b3 (1k74) receptors", "GENE_OR_GENE_PRODUCT", 524, 546], ["PPAR\u03b1", "PROTEIN", 92, 97], ["PPAR\u03b3", "PROTEIN", 102, 107], ["PPAR\u03b1", "PROTEIN", 247, 252], ["PPAR\u03b3 receptors", "PROTEIN", 257, 272], ["PPAR agonist complex", "PROTEIN", 318, 338], ["PPAR\u03b1", "PROTEIN", 507, 512], ["1k71", "PROTEIN", 514, 518], ["PPAR\u03b3 (1k74) receptors", "PROTEIN", 524, 546], ["the black in panels", "TEST", 12, 31], ["a novel dual agonist", "TREATMENT", 67, 87], ["a positive control", "TREATMENT", 197, 215], ["the PPAR\u03b1", "TREATMENT", 243, 252], ["PPAR\u03b3 receptors", "TREATMENT", 257, 272]]], ["The best docked conformations of Comp#1 (carbon atoms colored in gray) and ragaglitazar (carbon atoms colored in black) are aligned together in panels C and D of Figure 1.", [["ragaglitazar", "CHEMICAL", 75, 87], ["carbon atoms", "CHEMICAL", 89, 101], ["carbon", "CHEMICAL", 41, 47], ["ragaglitazar", "CHEMICAL", 75, 87], ["carbon", "CHEMICAL", 89, 95], ["Comp#1", "GENE_OR_GENE_PRODUCT", 33, 39], ["carbon atoms", "SIMPLE_CHEMICAL", 41, 53], ["ragaglitazar", "SIMPLE_CHEMICAL", 75, 87], ["carbon atoms", "SIMPLE_CHEMICAL", 89, 101], ["Comp#1 (carbon atoms colored in gray)", "TREATMENT", 33, 70], ["ragaglitazar (carbon atoms colored", "TREATMENT", 75, 109]]], ["The results of receptor\u2013ligand interactions obtained from the docking simulation had proved that the key residues for the binding interactions between Comp#1 and the receptor were fully consistent with the previous reports.43,71,84 The conservative H-bonding network formed by the polar acidic head group in both ragaglitazar and Comp#1 to the four key residues of PPAR\u03b1 (or PPAR\u03b3), such as Ser280 (or Ser289), Tyr314 (or His323), Tyr464 (or Tyr473), and His440 (or His449) were observed in our docking simulation.", [["43,71,84", "CHEMICAL", 223, 231], ["H", "CHEMICAL", 249, 250], ["ragaglitazar", "CHEMICAL", 313, 325], ["H", "CHEMICAL", 249, 250], ["ragaglitazar", "CHEMICAL", 313, 325], ["Ser280", "CHEMICAL", 391, 397], ["Ser289", "CHEMICAL", 402, 408], ["Tyr314", "CHEMICAL", 411, 417], ["His323", "CHEMICAL", 422, 428], ["Tyr464", "CHEMICAL", 431, 437], ["Tyr473", "CHEMICAL", 442, 448], ["His440", "CHEMICAL", 455, 461], ["His", "CHEMICAL", 466, 469], ["receptor\u2013ligand", "SIMPLE_CHEMICAL", 15, 30], ["Comp#1", "GENE_OR_GENE_PRODUCT", 151, 157], ["ragaglitazar", "SIMPLE_CHEMICAL", 313, 325], ["Comp#1", "GENE_OR_GENE_PRODUCT", 330, 336], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 365, 370], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 375, 380], ["Ser280", "GENE_OR_GENE_PRODUCT", 391, 397], ["Ser289", "GENE_OR_GENE_PRODUCT", 402, 408], ["Tyr314", "GENE_OR_GENE_PRODUCT", 411, 417], ["His323", "AMINO_ACID", 422, 428], ["Tyr464", "GENE_OR_GENE_PRODUCT", 431, 437], ["Tyr473", "AMINO_ACID", 442, 448], ["His440", "AMINO_ACID", 455, 461], ["Comp#1", "PROTEIN", 151, 157], ["H-bonding network", "PROTEIN", 249, 266], ["polar acidic head group", "PROTEIN", 281, 304], ["PPAR\u03b1", "PROTEIN", 365, 370], ["PPAR\u03b3", "PROTEIN", 375, 380], ["Ser280", "PROTEIN", 391, 397], ["Ser289", "PROTEIN", 402, 408], ["the docking simulation", "TEST", 58, 80], ["The conservative H-bonding network", "TREATMENT", 232, 266]]], ["It is noteworthy that Comp#1 has three oxygen atoms to serve as the polar acidic head, which allows Comp#1 to have more opportunities to interact with the AF2-helix.", [["head", "ANATOMY", 81, 85], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 39, 45], ["Comp#1", "GENE_OR_GENE_PRODUCT", 22, 28], ["oxygen atoms", "SIMPLE_CHEMICAL", 39, 51], ["Comp#1", "GENE_OR_GENE_PRODUCT", 100, 106], ["polar acidic head", "PROTEIN", 68, 85], ["Comp#1", "PROTEIN", 100, 106], ["AF2", "PROTEIN", 155, 158], ["three oxygen atoms", "TREATMENT", 33, 51]]], ["In addition, one more H-bond formed between the oxygen atom of the R1 group and Ala333 residue only in the PPAR\u03b1 (1k7l) receptor was observed in this study.", [["oxygen", "CHEMICAL", 48, 54], ["H", "CHEMICAL", 22, 23], ["oxygen", "CHEMICAL", 48, 54], ["Ala333", "CHEMICAL", 80, 86], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["Ala333", "AMINO_ACID", 80, 86], ["PPAR\u03b1 (1k7l) receptor", "GENE_OR_GENE_PRODUCT", 107, 128], ["PPAR\u03b1", "PROTEIN", 107, 112], ["1k7l) receptor", "PROTEIN", 114, 128], ["Ala333 residue", "PROBLEM", 80, 94], ["this study", "TEST", 145, 155], ["oxygen atom", "OBSERVATION", 48, 59], ["PPAR", "ANATOMY", 107, 111]]], ["The H-bonding networks made a major contribution in stabilizing the active conformation of AF2-helix in arm I1, which is extraordinarily important for the regulation of gene expression.7 The hydrophobic part of Comp#1 derived from ZINC36728034 played an important role in complementing the hydrophobic arm 1 formed by the hydrophobic residues, as shown by the light green surface (see panels C and D of Figure 1).", [["ZINC36728034", "CHEMICAL", 231, 243], ["H", "CHEMICAL", 4, 5], ["ZINC36728034", "CHEMICAL", 231, 243], ["arm I1", "GENE_OR_GENE_PRODUCT", 104, 110], ["Comp#1", "GENE_OR_GENE_PRODUCT", 211, 217], ["ZINC36728034", "GENE_OR_GENE_PRODUCT", 231, 243], ["H-bonding networks", "PROTEIN", 4, 22], ["AF2", "PROTEIN", 91, 94], ["arm I1", "PROTEIN", 104, 110], ["hydrophobic arm 1", "PROTEIN", 290, 307], ["the hydrophobic residues", "PROBLEM", 318, 342], ["active", "OBSERVATION_MODIFIER", 68, 74], ["arm", "ANATOMY", 104, 107], ["hydrophobic", "OBSERVATION_MODIFIER", 191, 202], ["hydrophobic residues", "OBSERVATION", 322, 342]]], ["Compared with ragaglitazar, the Comp#1 compound has an extra hydrophobic part, making it more fitted to the hydrophobic arm 1, and hence resulting in a much better binding affinity than ragaglitazar, as clearly indicated by the docking scores shown in Table 1.", [["ragaglitazar", "CHEMICAL", 14, 26], ["ragaglitazar", "CHEMICAL", 186, 198], ["ragaglitazar", "CHEMICAL", 14, 26], ["ragaglitazar", "CHEMICAL", 186, 198], ["ragaglitazar", "SIMPLE_CHEMICAL", 14, 26], ["ragaglitazar", "SIMPLE_CHEMICAL", 186, 198], ["hydrophobic arm 1", "PROTEIN", 108, 125], ["extra hydrophobic", "OBSERVATION_MODIFIER", 55, 72]]], ["Among the compounds listed in Table 1, Comp#1 has the strongest binding affinity with the two receptors PPAR\u03b1 and PPAR\u03b3, and hence it was singled out as the representative compound used for further investigation.Molecular dynamics trajectory analysis ::: Results and discussionTo acquire the relevant information from a dynamic point of view, the 10 ns molecular dynamic simulations were carried out, respectively, for the crystal structures of PPAR\u03b1 (1k7l), PPAR\u03b3 (1k74), as well as their complexes with ragaglitazar and Comp#1: PPAR\u03b1\u2013ragaglitazar, PPAR\u03b3\u2013ragaglitazar, PPAR\u03b1\u2013Comp#1, and PPAR\u03b3\u2013Comp#1.", [["ragaglitazar", "CHEMICAL", 505, 517], ["Comp#1", "GENE_OR_GENE_PRODUCT", 39, 45], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 114, 119], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 445, 450], ["1k7l)", "GENE_OR_GENE_PRODUCT", 452, 457], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 459, 464], ["1k74", "SIMPLE_CHEMICAL", 466, 470], ["ragaglitazar", "SIMPLE_CHEMICAL", 505, 517], ["Comp#1", "GENE_OR_GENE_PRODUCT", 522, 528], ["PPAR\u03b1\u2013ragaglitazar", "SIMPLE_CHEMICAL", 530, 548], ["PPAR\u03b3\u2013ragaglitazar", "SIMPLE_CHEMICAL", 550, 568], ["PPAR\u03b1\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 570, 582], ["PPAR\u03b1", "PROTEIN", 104, 109], ["PPAR\u03b3", "PROTEIN", 114, 119], ["PPAR\u03b1", "PROTEIN", 445, 450], ["1k7l", "PROTEIN", 452, 456], ["PPAR\u03b3", "PROTEIN", 459, 464], ["1k74", "PROTEIN", 466, 470], ["PPAR", "PROTEIN", 530, 534], ["PPAR", "PROTEIN", 550, 554], ["PPAR\u03b1", "PROTEIN", 570, 575], ["further investigation", "TEST", 190, 211], ["PPAR", "TEST", 445, 449], ["PPAR", "TEST", 459, 463], ["ragaglitazar", "TREATMENT", 505, 517], ["PPAR", "TREATMENT", 530, 534], ["\u2013ragaglitazar", "TREATMENT", 535, 548], ["PPAR", "TREATMENT", 550, 554], ["\u2013ragaglitazar", "TREATMENT", 555, 568]]], ["Shown in the panels A and B of Figure 3 are the backbone RMSD curves for PPAR\u03b1, PPAR\u03b3, PPAR\u03b1\u2013ragaglitazar, PPAR\u03b3\u2013ragaglitazar, PPAR\u03b1\u2013Comp#1, and PPAR\u03b3\u2013Comp#1.", [["Figure 3", "GENE_OR_GENE_PRODUCT", 31, 39], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 73, 78], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 80, 85], ["PPAR\u03b1\u2013ragaglitazar", "GENE_OR_GENE_PRODUCT", 87, 105], ["PPAR\u03b3\u2013ragaglitazar", "GENE_OR_GENE_PRODUCT", 107, 125], ["PPAR\u03b1\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 127, 139], ["PPAR\u03b3\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 145, 157], ["PPAR\u03b1", "PROTEIN", 73, 78], ["PPAR\u03b3", "PROTEIN", 80, 85], ["PPAR", "PROTEIN", 87, 91], ["\u03b1", "PROTEIN", 91, 92], ["PPAR\u03b3", "PROTEIN", 107, 112], ["PPAR\u03b1", "PROTEIN", 127, 132], ["Comp#1", "PROTEIN", 133, 139], ["PPAR\u03b3", "PROTEIN", 145, 150], ["Comp#1", "DNA", 151, 157], ["PPAR\u03b1", "TREATMENT", 73, 78], ["PPAR\u03b3", "TREATMENT", 80, 85], ["PPAR", "TREATMENT", 87, 91], ["\u2013ragaglitazar", "TREATMENT", 92, 105], ["PPAR", "TREATMENT", 107, 111], ["\u2013ragaglitazar", "TREATMENT", 112, 125]]], ["It is interesting to see that the RMSD values of PPAR\u03b1\u2013Comp#1 and PPAR\u03b3\u2013Comp#1 are remarkably smaller than those of PPAR\u03b1\u2013ragaglitazar and PPAR\u03b3\u2013ragaglitazar, indicating that the complexes of PPAR\u03b1\u2013Comp#1 and PPAR\u03b3\u2013Comp#1 are more stable than PPAR\u03b1\u2013ragaglitazar and PPAR\u03b3\u2013ragaglitazar.Molecular dynamics trajectory analysis ::: Results and discussionIn order to perform an in-depth study of the interactions of the AF2 helix with the agonist (Figure 1), the root mean square fluctuations for all the side-chain atoms of the receptors were also computed, as shown in panels C and D of Figure 3.", [["root", "ANATOMY", 458, 462], ["PPAR\u03b1\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 49, 61], ["PPAR\u03b3\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 66, 78], ["PPAR\u03b1\u2013ragaglitazar", "GENE_OR_GENE_PRODUCT", 116, 134], ["PPAR\u03b3\u2013ragaglitazar", "SIMPLE_CHEMICAL", 139, 157], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 192, 197], ["Comp#1", "GENE_OR_GENE_PRODUCT", 198, 204], ["PPAR\u03b3\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 209, 221], ["PPAR\u03b1\u2013ragaglitazar", "SIMPLE_CHEMICAL", 243, 261], ["PPAR\u03b3\u2013ragaglitazar", "SIMPLE_CHEMICAL", 266, 284], ["AF2", "GENE_OR_GENE_PRODUCT", 415, 418], ["PPAR\u03b1", "PROTEIN", 49, 54], ["PPAR\u03b1", "PROTEIN", 116, 121], ["PPAR\u03b1", "PROTEIN", 192, 197], ["PPAR\u03b1", "PROTEIN", 243, 248], ["PPAR\u03b3", "PROTEIN", 266, 271], ["AF2 helix", "PROTEIN", 415, 424], ["the RMSD values", "TEST", 30, 45], ["PPAR\u03b1", "TEST", 49, 54], ["PPAR", "TREATMENT", 116, 120], ["\u2013ragaglitazar", "TREATMENT", 121, 134], ["PPAR\u03b3\u2013ragaglitazar", "TREATMENT", 139, 157], ["PPAR", "TREATMENT", 243, 247], ["\u2013ragaglitazar", "TREATMENT", 248, 261], ["PPAR", "TREATMENT", 266, 270], ["\u2013ragaglitazar", "TREATMENT", 271, 284], ["an in-depth study", "TEST", 370, 387], ["smaller", "OBSERVATION_MODIFIER", 94, 101], ["root", "ANATOMY", 458, 462]]], ["It can be seen from the figure that the side-chain of the root mean square fluctuations of PPAR\u03b1\u2013Comp#1 or PPAR\u03b3\u2013Comp#1 were very similar to that of PPAR\u03b1\u2013ragaglitazar or PPAR\u03b3\u2013ragaglitazar, respectively.", [["root", "ANATOMY", 58, 62], ["PPAR\u03b1\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 91, 103], ["PPAR\u03b3\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 107, 119], ["PPAR\u03b1\u2013ragaglitazar", "SIMPLE_CHEMICAL", 149, 167], ["PPAR\u03b3\u2013ragaglitazar", "SIMPLE_CHEMICAL", 171, 189], ["PPAR\u03b1", "PROTEIN", 91, 96], ["PPAR\u03b3", "PROTEIN", 107, 112], ["PPAR\u03b1", "PROTEIN", 149, 154], ["PPAR\u03b1", "TEST", 91, 96], ["PPAR", "TEST", 149, 153], ["root", "ANATOMY", 58, 62]]], ["This is particularly true for the residues 459\u2013465 of PPAR\u03b1\u2013Comp#1 and the residues 469\u2013477 of PPAR\u03b3\u2013Comp#1 (see the gray framed box marked with AF2 in panels C and D of Figure 3), indicating that the new designed Comp#1 is very likely to perform exactly the same function in activating the AF2 helix as the compound ragaglitazar did.ADME prediction ::: Results and discussionAlso listed in Table 1 are the corresponding ADME properties that are directly relevant to pharmaceutical potentials.", [["ragaglitazar", "CHEMICAL", 317, 329], ["ragaglitazar", "CHEMICAL", 317, 329], ["PPAR\u03b1\u2013Comp#1", "GENE_OR_GENE_PRODUCT", 54, 66], ["Comp#1", "GENE_OR_GENE_PRODUCT", 101, 107], ["Comp#1", "GENE_OR_GENE_PRODUCT", 214, 220], ["AF2", "GENE_OR_GENE_PRODUCT", 291, 294], ["ragaglitazar", "SIMPLE_CHEMICAL", 317, 329], ["PPAR\u03b1", "PROTEIN", 54, 59], ["PPAR\u03b3\u2013Comp#1", "DNA", 95, 107], ["gray framed box", "DNA", 117, 132], ["AF2", "PROTEIN", 145, 148], ["Comp#1", "DNA", 214, 220], ["AF2 helix", "PROTEIN", 291, 300], ["the residues", "TEST", 71, 83], ["AF2 in panels", "TEST", 145, 158], ["the AF2 helix", "TREATMENT", 287, 300]]], ["It can be seen from the table that, compared with ragaglitazar, the predicted ADME properties, such as the polar surface area, logPo/w, logS, PPCaco, and percent of human oral absorption for the newly designed agonists are either much better than or quite close to that of ragaglitazar.", [["surface area", "ANATOMY", 113, 125], ["oral", "ANATOMY", 171, 175], ["ragaglitazar", "CHEMICAL", 50, 62], ["ragaglitazar", "CHEMICAL", 273, 285], ["ragaglitazar", "CHEMICAL", 50, 62], ["ragaglitazar", "CHEMICAL", 273, 285], ["ragaglitazar", "SIMPLE_CHEMICAL", 50, 62], ["human", "ORGANISM", 165, 170], ["oral", "ORGANISM_SUBDIVISION", 171, 175], ["ragaglitazar", "SIMPLE_CHEMICAL", 273, 285], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["PPCaco", "TREATMENT", 142, 148], ["human oral absorption", "TREATMENT", 165, 186], ["the newly designed agonists", "PROBLEM", 191, 218], ["ragaglitazar", "TREATMENT", 273, 285], ["polar", "OBSERVATION_MODIFIER", 107, 112], ["surface", "OBSERVATION_MODIFIER", 113, 120]]], ["Actually, these percentages are all within the acceptable ranges for humans, indicating that the ten compounds found in this study, particularly the Comp#1 compound, hold very high potential to become a new drug candidate.Binding pocket ::: Results and discussionIn drug design, particularly for conducting mutagenesis studies,17 the information of the binding pocket of a targeted receptor with its ligand is crucially important.", [["humans", "ORGANISM", 69, 75], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 69, 75], ["the ten compounds", "PROBLEM", 93, 110], ["this study", "TEST", 120, 130], ["conducting mutagenesis studies", "TEST", 296, 326], ["the binding pocket", "PROBLEM", 349, 367], ["pocket", "OBSERVATION_MODIFIER", 230, 236]]], ["According to a previous study,85 such binding pockets were defined by those residues of the receptor that have at least one heavy atom (ie, an atom other than hydrogen) with a distance \u2264 5 \u00c5 from a heavy atom of the ligand.", [["hydrogen", "CHEMICAL", 159, 167], ["hydrogen", "CHEMICAL", 159, 167], ["hydrogen", "SIMPLE_CHEMICAL", 159, 167], ["a previous study", "TEST", 13, 29], ["such binding pockets", "PROBLEM", 33, 53], ["ligand", "ANATOMY", 216, 222]]], ["Similar criteria were also used to define the binding pockets of many other receptor\u2013ligand interactions.37,51,86\u201391 The same criterion used in a previous study was also used in this study for defining the binding pockets of receptors PPAR\u03b1 and PPAR\u03b3 with the ligand, GW409544.85 From this point of view, the residues involved in forming the binding pocket of PPAR\u03b1 and PPAR\u03b3 for the docked ligand Comp#1 are listed in Table 2, which are identical to the other nine compounds, where those marked by an asterisk are the key residues for forming the H-bonding network, as shown in Figure 1.", [["H", "CHEMICAL", 548, 549], ["receptor\u2013ligand", "GENE_OR_GENE_PRODUCT", 76, 91], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 235, 240], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 245, 250], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 360, 365], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 370, 375], ["Comp#1", "GENE_OR_GENE_PRODUCT", 398, 404], ["PPAR\u03b1", "PROTEIN", 235, 240], ["PPAR\u03b3", "PROTEIN", 245, 250], ["PPAR\u03b1", "PROTEIN", 360, 365], ["PPAR\u03b3", "PROTEIN", 370, 375], ["H-bonding network", "PROTEIN", 548, 565], ["the binding pockets", "PROBLEM", 42, 61], ["a previous study", "TEST", 144, 160], ["this study", "TEST", 178, 188], ["the residues", "PROBLEM", 305, 317]]]], "08364df3cf47cf5dcd3b53413615fc568fbae254": [["Consequently, methods for the comparative evaluation of interval forecasts are in strong demand.", [["the comparative evaluation", "TEST", 26, 52]]], ["Likewise, researchers and practitioners need methods for choosing between different models for the generation of such intervals.IntroductionTechnically, three types of predictive intervals have been proposed and used in the literature, mostly under the assumption of a nominal coverage probability 1 \u2212 \u03b1, where \u03b1 \u2208 (0, 1).", [["methods", "TREATMENT", 45, 52]]], ["The equal-tailed interval lies between the \u03b1 2 -and (1 \u2212 \u03b1 2 )-quantiles, making it centered in terms of probability.", [["equal", "OBSERVATION_MODIFIER", 4, 9]]], ["The shortest interval has minimal length, subject to the interval covering the outcome with nominal probability of at least 1 \u2212 \u03b1.", [["shortest", "OBSERVATION_MODIFIER", 4, 12], ["minimal", "OBSERVATION_MODIFIER", 26, 33], ["length", "OBSERVATION_MODIFIER", 34, 40]]], ["Early work on the evaluation problem for interval forecasts can be found in Aitchison and Dunsmore (1968) , Winkler (1972) , Casella et al. (1993) , and Christoffersen (1998) .", [["the evaluation", "TEST", 14, 28]]], ["Recently, Askanazi et al. (2018) have emphasized that tools for the comparative evaluation of equal-tailed intervals are readily available, whereas fundamental questions remain open for the shortest interval.IntroductionConsistent scoring (or loss) functions are well-established tools for quantifying predictive performance and comparing forecasts, see e.g. Gneiting (2011a) and Dawid and Musio (2014) for reviews.", [["the comparative evaluation", "TEST", 64, 90]]], ["For recent progress see Lambert et al. (2008) , Heinrich (2014) , Steinwart et al. (2014) , Fissler and Ziegel (2016) , and Frongillo and Kash (2018) , among other works.IntroductionThe remainder of the paper is structured as follows.", [["Ziegel", "TREATMENT", 104, 110]]], ["Section 2 provides a short, technical introduction to the notions of elicitability and consistent scoring functions.", [["elicitability", "PROBLEM", 69, 82]]], ["We show that the Winkler interval score arises as a unique choice for the equal-tailed interval under desirable further conditions, and we resolve a challenge raised by Askanazi et al. (2018) , who state desiderata for loss functions tailored to the shortest interval, by showing that in practically relevant settings consistent scoring functions do not exist.", [["the Winkler interval score", "PROBLEM", 13, 39], ["loss functions", "PROBLEM", 219, 233]]], ["Although conceptually different, the modal interval has a close connection to the shortest interval and, perhaps surprisingly, it has a unique consistent scoring function, up to equivalence.", [["different", "OBSERVATION_MODIFIER", 22, 31]]], ["Proofs are generally deferred to the Appendix.Consistent scoring functions and elicitabilityHere we set up notation and provide general technical background and tools.Consistent scoring functions and elicitabilityLet Y be a random variable that takes values in a closed observation domain O \u2286 R, and let O be the Borel \u03c3-algebra on O. Let F be a class of probability measures on (O, O) that represents the possible distributions for Y .", [["Let Y", "GENE_OR_GENE_PRODUCT", 213, 218], ["Appendix", "ANATOMY", 37, 45]]], ["Typically, the observation domain O will either be the real line R, or the set N 0 of the nonnegative integers, corresponding to count data, which feature prominently in applications such as retail and epidemic forecasting.Consistent scoring functions and elicitabilityA statistical property is a functional T : F \u2192 2 A , where 2 A denotes the power set of the action domain A \u2286 R n that contains all possible reports for T .", [["action domain", "PROTEIN", 361, 374], ["count data", "TEST", 129, 139], ["epidemic", "OBSERVATION_MODIFIER", 202, 210]]], ["Moreover, we let E F denote the expectation operator when Y has distribution F \u2208 F. In the special case of an expectation of a derived binary variable we use the symbol P F in customary ways.", [["E F", "DNA", 17, 20], ["P F", "DNA", 169, 172]]], ["We identify probability distributions with their cumulative distribution functions (CDFs).Consistent scoring functions and elicitabilityAConsistent scoring functions and elicitabilityfor all F \u2208 F, t \u2208 T (F ), and x \u2208 A. It is strictly consistent for T if it is consistent for T and equality in (1) implies that x \u2208 T (F ).", [["strictly consistent for", "UNCERTAINTY", 227, 250]]], ["Since the ordering in (1) is not affected by scaling S with a positive constant or adding a report-independent function, we say that the scoring functionConsistent scoring functions and elicitabilityfor some c > 0 and an F-integrable function h : O \u2192 R.Consistent scoring functions and elicitabilityA basic example of an elicitable functional is the mean or expectation functional T (F ) := E F Y .", [["E F Y", "GENE_OR_GENE_PRODUCT", 391, 396], ["E F Y", "DNA", 391, 396], ["scaling S", "PROBLEM", 45, 54]]], ["The following examples illustrate why interval forecasts call for the full set-valued framework of Gneiting (2011a) , which assumes that functionals map into the power set 2 A .Consistent scoring functions and elicitabilityExample 2.2 (quantiles and equal-tailed interval).", [["elicitability", "TEST", 210, 223], ["Example", "TEST", 223, 230], ["quantiles", "TEST", 236, 245]]], ["The equal-tailed interval for F at level 1 \u2212 \u03b1 is defined via the quantiles at levels \u03b1 2 and 1 \u2212 \u03b1 2 , respectively.", [["equal", "OBSERVATION_MODIFIER", 4, 9]]], ["Hence, unless both quantiles reduce to single points, there are multiple equal-tailed intervals at level 1 \u2212 \u03b1, making the equal-tailed interval a set-valued functional, too.", [["multiple", "OBSERVATION_MODIFIER", 64, 72]]], ["A key characteristic of elicitable functionals is their behaviour under convex combinations of distributions.", [["elicitable", "OBSERVATION_MODIFIER", 24, 34], ["functionals", "OBSERVATION", 35, 46]]], ["The following theorem states the classical convex level sets (CxLS) result (Gneiting, 2011a, Theorem 6) Proposition 2.4 (convex level sets).", [["Theorem", "TEST", 93, 100], ["Proposition", "TEST", 104, 115]]], ["Let T : F \u2192 2 A be an elicitable functional.", [["Let T : F \u2192 2 A", "GENE_OR_GENE_PRODUCT", 0, 15]]], ["If F 0 , F 1 \u2208 F and \u03bb \u2208 (0, 1) are such thatConsistent scoring functions and elicitabilityIf T is a single-valued functional, the properties coincide and are simply referred to as CxLS.", [["CxLS", "PROTEIN", 181, 185]]], ["The most relevant examples of functionals that do not have convex level sets and thus fail to be elicitable, are the risk measure Expected Shortfall (ES) and the variance, see Gneiting (2011a) .", [["convex level sets", "PROBLEM", 59, 76]]], ["Under certain regularity conditions, convex level sets are also sufficient for elicitability, as demonstrated by Steinwart et al. (2014) .", [["convex level sets", "TEST", 37, 54]]], ["However, some statistical properties lack these conditions and fail to be elicitable, even though they have the CxLS property, such as the mode (Heinrich, 2014) and tail functionals (Brehmer and Strokorb, 2019) .", [["tail functionals", "TEST", 165, 181]]], ["In such settings, the following result can be useful, which is a refined version of Theorem 3.3 of Brehmer and Strokorb (2019) that allows for set-valued functionals.Consistent scoring functions and elicitabilityProposition 2.5.", [["Theorem", "TEST", 84, 91]]], ["Let T : F \u2192 2 A be a functional, and let F 0 , F 1 \u2208 F be such that F \u03bb = \u03bbF 1 + (1 \u2212 \u03bb)F 0 \u2208 F for all \u03bb \u2208 (0, 1).", [["Let T : F \u2192 2 A", "GENE_OR_GENE_PRODUCT", 0, 15], ["F 1 \u2208 F", "GENE_OR_GENE_PRODUCT", 47, 54]]], ["If there are t 0 \u2208 T (F 0 )(F 1 ) and t 1 \u2208 T (F 1 )(F 0 ) such that for every \u03bb \u2208 (0, 1) it holds that either t 0 \u2208 T (F \u03bb ) and t 1 / \u2208 T (F \u03bb ), or t 1 \u2208 T (F \u03bb ) and t 0 / \u2208 T (F \u03bb ), then T is not elicitable.Consistent scoring functions and elicitabilityRemarkably, the assertion of Proposition 2.5 overlaps with part (b) of Proposition 2.4 in the sense that if T (F 0 )\u2229T (F 1 ) = \u2205 and the conditions of Proposition 2.5 hold, then T cannot have the CxLS * property and thus fails to be elicitable.", [["\u2208 T", "PROTEIN", 176, 179], ["F \u03bb", "PROTEIN", 181, 184], ["then T", "TEST", 188, 194], ["elicitable", "PROBLEM", 202, 212], ["Proposition", "TEST", 330, 341]]], ["If T (F 0 )\u2229T (F 1 ) = \u2205, Proposition 2.5 provides a novel result, since Proposition 2.4(b) does not address this situation.Consistent scoring functions and elicitabilityThe criteria for elicitability presented here will be key tools in what follows.", [["elicitability", "PROBLEM", 187, 200]]], ["Like the proofs for the subsequent section, the proof of Proposition 2.5 is deferred to the Appendix.Types of intervalsWe proceed to study equal-tailed, shortest, and modal intervals as functionals on suitable distribution classes F.Types of intervalsTechnically, we encode intervals via their lower and upper endpoints and use the action domainTypes of intervalsThis choice implies that the predictive intervals we consider are closed with endpoints in the observation domain O. The endpoint requirement leads to a natural and desirable reduction of the set of possible intervals for discrete data, such as in the case of count data, where the end points are required to be nonnegative integers.", [["the subsequent section", "TREATMENT", 20, 42], ["Proposition", "TREATMENT", 57, 68], ["study", "TEST", 133, 138], ["count data", "TEST", 623, 633], ["Appendix", "ANATOMY", 92, 100], ["upper", "ANATOMY_MODIFIER", 304, 309]]], ["Closed intervals are compatible with the interpretation of the median as a '0% central prediction interval'.", [["compatible with", "UNCERTAINTY", 21, 36]]], ["Moreover, in discrete settings an interval forecast might genuinely collapse to a single point, so closed intervals allow for a unified treatment of discrete and continuous distributions.", [["a unified treatment", "TREATMENT", 126, 145], ["collapse", "OBSERVATION", 68, 76], ["discrete", "OBSERVATION_MODIFIER", 149, 157]]], ["Lastly, this setting is consistent with the extant literature, see e.g. Winkler (1972) , Lambert and Shoham (2009, Section 7.6) , and Askanazi et al. (2018) .", [["consistent with", "UNCERTAINTY", 24, 39]]], ["We denote the length of an interval I as len(I), and if A \u2282 A is a set of intervals that all have the same length, we refer to this common length as len(A ).Types of intervalsThe left-and right-hand limits of a function h : R \u2192 R at x are denoted by h(x\u2212) := lim y\u2191x h(y) and h(x+) := lim y\u2193x h(y), respectively.Intervals with coverage guaranteesA standard principle for interval forecasts is that a correct report I contains (or covers) the outcome with specified nominal probability of at least 1Intervals with coverage guaranteesA guaranteed coverage interval is thus locally, but not globally, as short as possible.", [["left", "ANATOMY", 179, 183], ["right-hand", "ANATOMY", 188, 198], ["R \u2192 R", "GENE_OR_GENE_PRODUCT", 224, 229], ["coverage guarantees", "TREATMENT", 513, 532], ["left", "ANATOMY_MODIFIER", 179, 183], ["right", "ANATOMY_MODIFIER", 188, 193], ["hand limits", "ANATOMY_MODIFIER", 194, 205]]], ["We write GCI \u03b1 (F ) for the set of the guaranteed coverage intervals at level \u03b1 of F .", [["the guaranteed coverage intervals", "TREATMENT", 35, 68]]], ["An early theoretical treatment is in Proposition 7.6 of Lambert and Shoham (2009) , according to which the GCI \u03b1 functional fails to be elicitable relative to the class of all distributions on the finite domain O = {1, . . . , n}.", [["GCI \u03b1", "DNA", 107, 112], ["An early theoretical treatment", "TREATMENT", 0, 30], ["the finite domain O", "TEST", 193, 212], ["early", "OBSERVATION_MODIFIER", 3, 8], ["theoretical treatment", "OBSERVATION", 9, 30]]], ["Frongillo and Kash (2019, Section 4.2) apply tools of convex analysis to extend this result to more general classes of distributions.Intervals with coverage guaranteesIt is straightforward to recover these findings by showing that the GCI \u03b1 functional lacks the CxLS * property.", [["GCI \u03b1", "DNA", 235, 240], ["convex analysis", "TEST", 54, 69], ["coverage guarantees", "TREATMENT", 148, 167], ["the GCI", "TEST", 231, 238]]], ["Specifically, let \u03b1 \u2208 (0, 1) and consider continuous distributions F 0 and F 1 that satisfyIntervals with coverage guaranteesPart (ii) of Proposition 2.4 thus implies that the GCI \u03b1 functional fails to be elicitable relative to classes F that contain distributions of the type used here.", [["GCI \u03b1", "DNA", 176, 181], ["coverage guarantees", "TREATMENT", 106, 125], ["distributions", "OBSERVATION_MODIFIER", 251, 264]]], ["A similar construction for discrete distributions is immediate.", [["discrete", "OBSERVATION_MODIFIER", 27, 35], ["distributions", "OBSERVATION_MODIFIER", 36, 49]]], ["In addition to lacking elicitability, the GCI \u03b1 functional has the unattractive feature that it fails to be unique for very many distributions, including but not limited to all continuous distributions.", [["GCI \u03b1", "DNA", 42, 47], ["lacking elicitability", "PROBLEM", 15, 36]]], ["This motivates the imposition of further constraints on the predictive intervals, as discussed now.Equal-tailed interval (ETI)A straightforward way to pick an interval with nominal coverage at least 1 \u2212 \u03b1 under F consists of choosing quantiles at level \u03b2 \u2208 (0, \u03b1) and \u03b2 + 1 \u2212 \u03b1 as the lower and upper endpoint of the interval, respectively.Equal-tailed interval (ETI)The ubiquitous choice is \u03b2 = \u03b1 2 , such that under a continuous F the outcomes fall above or below the interval with equal probability of \u03b1 2 .", [["\u03b2 + 1 \u2212 \u03b1", "GENE_OR_GENE_PRODUCT", 268, 277], ["\u03b1 2", "GENE_OR_GENE_PRODUCT", 505, 508], ["\u03b2", "PROTEIN", 268, 269], ["\u03b1 2", "PROTEIN", 505, 508], ["nominal coverage", "TREATMENT", 173, 189], ["lower", "ANATOMY_MODIFIER", 285, 290], ["upper", "ANATOMY_MODIFIER", 295, 300]]], ["In general, an equaltailed interval (ETI) at level \u03b1 of F is any member ofEqual-tailed interval (ETI)whereEqual-tailed interval (ETI)In the simplified situation where F is strictly increasing, all quantiles are unique and thus ETI \u03b1 (F ) reduces to a single interval.Equal-tailed interval (ETI)In view of the definition via quantiles, forecasting equal-tailed intervals amounts to forecasting quantiles.", [["increasing", "OBSERVATION_MODIFIER", 181, 191]]], ["Moreover, the ETI \u03b1 functional is elicitable, and we can construct consistent scoring functions for the ETI \u03b1 functional from the consistent scoring functions (2) for quantiles, as noted by and Askanazi et al. (2018) .", [["ETI \u03b1 functional", "DNA", 14, 30]]], ["Specifically, if w 1 , w 2 are nonnegative weights and g 1 , g 2 :Equal-tailed interval (ETI)is a consistent scoring function for the ETI \u03b1 functional.", [["weights", "TEST", 43, 50]]], ["Furthermore, S is strictly consistent if w 1 , w 2 \u2208 (0, \u221e) and g 1 , g 2 are strictly increasing.", [["increasing", "OBSERVATION_MODIFIER", 87, 97]]], ["The choice w 1 = w 2 = 2/\u03b1 and g 1 (x) = g 2 (x) = x in (4) obtains the classical interval score (IS) of Winkler (1972) , namely,Equal-tailed interval (ETI)which is strictly consistent relative to classes of distributions with finite first moment.", [["The choice w", "TEST", 0, 12], ["g", "TEST", 31, 32], ["g", "TEST", 41, 42], ["ETI", "TEST", 152, 155]]], ["The Winkler interval score (5) combines various additional, desirable properties of scoring functions on O = R, such as translation invariance, in the sense that for every z, y \u2208 R and a < bEqual-tailed interval (ETI)and positive homogeneity of order 1, in that for every c > 0, y \u2208 R, and a < b S([ca, cb], cy) = cS([a, b], y).Equal-tailed interval (ETI)Additionally, the score applies the same penalty terms to values falling above or below the reported interval, such that it is symmetric, in the sense thatEqual-tailed interval (ETI)for y \u2208 R and a < b.Equal-tailed interval (ETI)Our next two results concern scoring functions on O = R that are of the form (4) and share one or more of these often desirable additional properties.", [["O = R", "SIMPLE_CHEMICAL", 105, 110], ["O = R", "SIMPLE_CHEMICAL", 634, 639], ["The Winkler interval score", "PROBLEM", 0, 26], ["ETI", "TEST", 213, 216], ["ca", "TEST", 299, 301], ["cb", "TEST", 303, 305], ["cy", "TEST", 308, 310], ["cS", "TEST", 314, 316], ["the score", "TEST", 369, 378], ["tailed", "OBSERVATION_MODIFIER", 334, 340], ["symmetric", "OBSERVATION", 482, 491]]], ["In particular, the next theorem demonstrates that either translation invariance or positive homogeneity and differentiability, combined with symmetry, suffice to characterize the Winkler interval score (5), up to equivalence.", [["positive homogeneity and differentiability", "PROBLEM", 83, 125], ["positive", "OBSERVATION_MODIFIER", 83, 91], ["homogeneity", "OBSERVATION_MODIFIER", 92, 103]]], ["Let S be of the form (4) with non-constant, non-decreasing functions g 1 and g 2 .", [["Let S", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["If S is either (a) translation invariant, or (b) positively homogeneous and differentiable with respect to (a, b) \u2208 A \u2286 R 2 , except possibly along the diagonal, then g 1 and g 2 are linear.", [["diagonal", "ANATOMY_MODIFIER", 152, 160], ["linear", "OBSERVATION_MODIFIER", 183, 189]]], ["In particular, if S is symmetric and either (i) or (ii) applies, then S is equivalent to IS \u03b1 .Equal-tailed interval (ETI)If only symmetry is required in (4) the class of possible scoring functions for the equal-tailed interval is much larger than just the interval score.", [["larger", "OBSERVATION_MODIFIER", 236, 242]]], ["To characterize these functions take I to be the class of all non-decreasing functions g : R \u2192 R with the property that g(x) = 1 2 (g(x\u2212) + g(x+)) for x \u2208 R. In a trivial deviation from Ehm et al. (2016) we define the elementary quantile scoring function asEqual-tailed interval (ETI)which is the special case in (2) where g(x) = 1(\u03b8 < x) + 1 2 1(\u03b8 = x).", [["R \u2192 R", "GENE_OR_GENE_PRODUCT", 91, 96], ["g", "TEST", 132, 133], ["x\u2212", "TEST", 134, 136], ["g", "TEST", 140, 141], ["a trivial deviation", "PROBLEM", 161, 180], ["trivial deviation", "OBSERVATION", 163, 180]]], ["Given anyEqual-tailed interval (ETI)and refer to S \u03b1,\u03b8 as the elementary symmetric interval scoring function.", [["S \u03b1", "GENE_OR_GENE_PRODUCT", 49, 52], ["S \u03b1", "DNA", 49, 52], ["\u03b8", "DNA", 53, 54]]], ["Theorem 3.2.", [["Theorem", "TEST", 0, 7]]], ["Let S be of the form (4) with non-constant, non-decreasing functions g 1 , g 2 .", [["Let S", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["If S is symmetric then it is of the formEqual-tailed interval (ETI)The usual treatment considers distributions F \u2208 F with strictly increasing CDFs, such that all quantiles are unique.", [["strictly increasing CDFs", "PROBLEM", 122, 146], ["symmetric", "OBSERVATION", 8, 17], ["increasing", "OBSERVATION_MODIFIER", 131, 141], ["CDFs", "OBSERVATION", 142, 146]]], ["This ensures that the interval is trulyEqual-tailed interval (ETI)When F admits a Lebesgue density, but some quantiles are not unique, this property continues to hold.Equal-tailed interval (ETI)However, care is needed when interpreting equal-tailed intervals for discrete distributions.", [["a Lebesgue density", "PROBLEM", 80, 98], ["Equal", "OBSERVATION_MODIFIER", 39, 44], ["density", "OBSERVATION", 91, 98], ["discrete", "OBSERVATION_MODIFIER", 263, 271], ["distributions", "OBSERVATION_MODIFIER", 272, 285]]], ["As a simple example, let \u03b1 = 0.2 and consider the distribution G on N 0 that assigns probability 0.1, 0.4, 0.4, and 0.1, respectively, to 0, 1, 2, and 3.", [["a simple example", "TEST", 3, 19]]], ["Since neither the \u03b1 2 -nor the (1 \u2212 \u03b1 2 )-quantile are unique, there are four possible equal-tailed intervals, as listed in Table 1 .", [["\u03b1 2", "GENE_OR_GENE_PRODUCT", 18, 21], ["1 \u2212 \u03b1 2", "SIMPLE_CHEMICAL", 32, 39]]], ["A natural idea is to issue recommendations for such cases, e.g. 'report the shortest available interval' or 'report the interval with the highest coverage'.", [["the highest coverage'", "TREATMENT", 134, 155]]], ["However, consistent scoring functions for the ETI \u03b1 functional cannot be used to ensure that forecasters follow such further guidelines, since by the definition of consistency, any valid report attains the same expected score.Shortest interval (SI)Instead of defining an interval at the coverage level 1 \u2212 \u03b1 via fixed quantiles, the shortest of these intervals is often sought.", [["\u03b1", "DNA", 50, 51]]], ["Specifically, a shortest interval (SI) at level \u03b1 of F is any member of the setShortest interval (SI)The shortest interval is never longer than an equal-tailed interval, and in general the two types of intervals differ from each other.", [["a shortest interval (SI)", "PROBLEM", 14, 38]]], ["To see this we follow Askanazi et al. (2018, Appendix) and consider a distribution F on O = [0, \u221e) with strictly decreasing Lebesgue density, so that SI \u03b1 (F ) = [0, T 1\u2212\u03b1 (F )], whereas ETI \u03b1 (F ) = [T \u03b1/2 (F ), T 1\u2212\u03b1/2 (F )] with a lower endpoint that is strictly positive.", [["O = [0, \u221e", "SIMPLE_CHEMICAL", 88, 97], ["Lebesgue", "SIMPLE_CHEMICAL", 124, 132], ["strictly decreasing Lebesgue density", "PROBLEM", 104, 140], ["ETI", "TEST", 187, 190], ["T", "TEST", 213, 214], ["a lower endpoint", "TEST", 232, 248], ["positive", "OBSERVATION", 266, 274]]], ["However, for distributions with a symmetric, strictly unimodal Lebesgue density the two types of intervals are both unique and agree with each other.", [["symmetric", "OBSERVATION_MODIFIER", 34, 43]]], ["If a distribution has multiple shortest intervals, then neither of them needs to be an equal-tailed interval.Shortest interval (SI)As noted in Askanazi et al. (2018) , loss functions that have been proposed for interval forecasts fail to be strictly consistent for the SI \u03b1 functional, since they are usually tailored to the ETI \u03b1 functional.", [["loss functions", "PROBLEM", 168, 182], ["multiple", "OBSERVATION_MODIFIER", 22, 30]]], ["A first result in this direction is discussed in Section 4.2 of Frongillo and Kash (2019) , who show that the SI \u03b1 functional fails to be elicitable relative to classes F that contain piecewise uniform distributions.", [["SI \u03b1 functional", "DNA", 110, 125], ["piecewise", "OBSERVATION_MODIFIER", 184, 193], ["uniform", "OBSERVATION_MODIFIER", 194, 201], ["distributions", "OBSERVATION_MODIFIER", 202, 215]]], ["In the following we show non-elicitability for more general classes of distributions, and we also treat discrete distributions on N 0 .", [["discrete", "OBSERVATION_MODIFIER", 104, 112], ["distributions", "OBSERVATION_MODIFIER", 113, 126]]], ["We start by studying level sets.Proposition 3.3 (convex level sets).(a) The functional SI \u03b1 has the CxLS property.Proposition 3.3 (convex level sets).(b) If the class F consists of distributions with continuous CDFs only, then SI \u03b1 has the CxLS * property.Proposition 3.3 (convex level sets).The next example shows that the CxLS * property can be violated for discrete distributions.Proposition 3.3 (convex level sets).Example 3.4.", [["functional SI \u03b1", "PROTEIN", 76, 91], ["Proposition", "TEST", 32, 43], ["Proposition", "TEST", 114, 125], ["Proposition", "TEST", 256, 267], ["Proposition", "TEST", 383, 394], ["Example", "TEST", 419, 426]]], ["Let \u03b1 \u2208 (0, 1 3 ), and let k \u2265 1 be an integer.", [["Let \u03b1 \u2208 (0, 1 3", "GENE_OR_GENE_PRODUCT", 0, 15], ["let k \u2265 1", "GENE_OR_GENE_PRODUCT", 23, 32]]], ["Let \u03b5 \u2208 (0, \u03b1 3 ) and \u03b4 \u2208 (0, \u03b5).", [["\u03b1 3 )", "GENE_OR_GENE_PRODUCT", 12, 17], ["\u03b4 \u2208", "GENE_OR_GENE_PRODUCT", 22, 25], ["Let", "TEST", 0, 3], ["\u2208", "TEST", 24, 25]]], ["Let F 0 and F 1 be distributions on N 0 that assign mass \u03b5 + \u03b4 to k \u2212 1 and mass 1 \u2212 \u03b1 \u2212 \u03b5 to k.", [["Let F 0", "GENE_OR_GENE_PRODUCT", 0, 7], ["F 1", "GENE_OR_GENE_PRODUCT", 12, 15], ["F 1", "DNA", 12, 15], ["\u03b5", "PROTEIN", 57, 58], ["mass", "TEST", 52, 56], ["k", "TEST", 66, 67], ["mass", "TEST", 76, 80], ["mass", "OBSERVATION", 52, 56]]], ["Furthermore, F 0 and F 1 assign mass \u03b5 + \u03b4 and \u03b5 \u2212 \u03b4, respectively, to k + 1.Proposition 3.3 (convex level sets).and for \u03bb \u2208 [0, 1 2 ] we have SI \u03b1 (F \u03bb ) = SI \u03b1 (F 0 ) SI \u03b1 (F 1 ).", [["\u03b5 + \u03b4", "GENE_OR_GENE_PRODUCT", 37, 42], ["\u03b5 \u2212 \u03b4", "GENE_OR_GENE_PRODUCT", 47, 52], ["k + 1", "GENE_OR_GENE_PRODUCT", 71, 76], ["\u03b5", "PROTEIN", 37, 38], ["\u03b4", "PROTEIN", 41, 42], ["\u03b5", "PROTEIN", 47, 48], ["\u03b4", "PROTEIN", 51, 52], ["mass", "TEST", 32, 36], ["Proposition", "TEST", 77, 88], ["SI", "TEST", 143, 145], ["SI", "TEST", 157, 159], ["SI", "TEST", 169, 171], ["mass", "OBSERVATION", 32, 36]]], ["Therefore, SI \u03b1 does not have the CxLS * property relative to any convex class F that includes F 0 and F 1 .Proposition 3.3 (convex level sets).As the construction extends to all \u03b1 \u2208 (0, 1), we obtain the following result.Proposition 3.3 (convex level sets).Theorem 3.5.", [["F 1", "GENE_OR_GENE_PRODUCT", 103, 106], ["Proposition", "TEST", 108, 119], ["Proposition", "TEST", 222, 233], ["Theorem", "TEST", 258, 265]]], ["Let k \u2265 1 be an integer, and let F be a class of probability measures on N 0 that contains all unimodal distributions with mode k.", [["let F", "GENE_OR_GENE_PRODUCT", 29, 34]]], ["Then the SI \u03b1 functional is not elicitable relative to F.Proposition 3.3 (convex level sets).We turn to classes of distributions with Lebesgue densities, so that the SI \u03b1 functional has the CxLS * property, and a more refined analysis proves useful.", [["SI \u03b1 functional", "DNA", 9, 24], ["F.Proposition", "TEST", 55, 68], ["Lebesgue densities", "PROBLEM", 134, 152]]], ["First we take up an example in Section 4.2 of Frongillo and Kash (2019) .Proposition 3.3 (convex level sets).Example 3.6.", [["Proposition", "TEST", 73, 84], ["Example", "TEST", 109, 116]]], ["Given \u03b1 \u2208 (0, 3 5 ), we define distributions F 0 and F 1 via the piecewise uniform densitiesProposition 3.3 (convex level sets).so that SI \u03b1 (F 0 ) = [0, 1] and SI \u03b1 (F 1 ) = [0, 2], respectively.", [["SI", "TEST", 136, 138], ["uniform", "OBSERVATION_MODIFIER", 75, 82], ["densities", "OBSERVATION", 83, 92]]], ["As SI \u03b1 (F \u03bb ) = [0, 2] for all \u03bb \u2208 (0, 1), we conclude from Proposition 2.5 that the SI \u03b1 functional fails to be elicitable relative to convex classes of distributions that contain F 0 and F 1 .Proposition 3.3 (convex level sets).As noted, Example 3.6 applies in situations where the class F includes distributions with piecewise uniform densities.", [["F 1", "GENE_OR_GENE_PRODUCT", 190, 193], ["F 1", "PROTEIN", 190, 193], ["Proposition", "TEST", 195, 206], ["piecewise uniform densities", "PROBLEM", 321, 348], ["piecewise", "OBSERVATION_MODIFIER", 321, 330], ["uniform", "OBSERVATION_MODIFIER", 331, 338], ["densities", "OBSERVATION", 339, 348]]], ["As this assumption may be restrictive in practice, we proceed to demonstrate non-elicitability based on substantially more flexible criteria.Proposition 3.3 (convex level sets).Condition 3.7.", [["Proposition", "TEST", 141, 152], ["may be", "UNCERTAINTY", 19, 25], ["restrictive", "OBSERVATION", 26, 37]]], ["The distribution F admits a Lebesgue density, and there are numbers a < b and \u03b5 > 0 such that SI \u03b1 (F ) = [a, b], F (b) = F (b + \u03b5), and if \u03b2 < \u03b1 then len(SI \u03b2 (F )) > len(SI \u03b1 (F )) + 1 2 \u03b5.", [["\u03b2", "PROTEIN", 140, 141], ["\u03b1", "PROTEIN", 144, 145], ["a Lebesgue density", "TEST", 26, 44], ["\u03b5", "TEST", 78, 79], ["SI", "TEST", 94, 96], ["b", "TEST", 125, 126], ["\u03b5", "TEST", 129, 130], ["\u03b2", "TEST", 140, 141]]], ["Loosely speaking, this condition requires that there is an \u03b5 'gap' on the righthand side of the shortest interval at level \u03b1, while every shortest interval for a level \u03b2 < \u03b1 is notably longer than the one at level \u03b1.Proposition 3.3 (convex level sets).Theorem 3.8.", [["a level \u03b2", "TEST", 160, 169], ["Proposition", "TEST", 216, 227], ["Theorem", "TEST", 252, 259]]], ["If the class F contains the location-scale family of a distribution satisfying Condition 3.7, along with its finite mixtures, then the SI \u03b1 functional is not elicitable relative to F.Proposition 3.3 (convex level sets).Although Condition 3.7 might seem technical, suitable distributions F can be constructed under rather weak assumptions.", [["F.Proposition", "TEST", 181, 194]]], ["For instance, assume \u03b1 < 1 2 , and let the class F contain some compactly supported distribution, along with the respective location-scale family, and all finite mixtures thereof.", [["distribution", "OBSERVATION_MODIFIER", 84, 96]]], ["A more restrictive requirement is the identity F (b) = F (b + \u03b5), as it rules out distributions with strictly positive densities.", [["A more restrictive requirement", "PROBLEM", 0, 30], ["strictly positive densities", "PROBLEM", 101, 128], ["more restrictive", "OBSERVATION_MODIFIER", 2, 18], ["positive densities", "OBSERVATION", 110, 128]]], ["The existence of strictly consistent scoring functions relative to classes of distributions of this type, including but not limited to the important case of the finite mixture distributions with Gaussian components, remains an open problem.Modal interval (MI)In a stark contrast to shortest and equal-tailed intervals, we turn to a type of interval that seeks to maximize coverage, subject to constraints on length.Modal interval (MI)Specifically, given any c > 0, a modal interval (MI) of length 2c of F is any member of the setModal interval (MI)If F has a strictly unimodal Lebesgue density, then the modal interval shrinks towards the mode as c \u2192 0.", [["an open problem", "PROBLEM", 224, 239], ["Modal interval (MI)", "PROBLEM", 240, 259], ["Modal interval (MI", "PROBLEM", 415, 433], ["any c > 0", "PROBLEM", 454, 463], ["a modal interval (MI", "PROBLEM", 465, 485], ["a strictly unimodal Lebesgue density", "PROBLEM", 557, 593]]], ["These connections highlight the fact that the MI c functional is a location statistic, whereas the shortest and equal-tailed intervals contain information on location and spread simultaneously.Modal interval (MI)In what follows, separate discussions for classes F of continuous and discrete distributions will be warranted.", [["MI c", "GENE_OR_GENE_PRODUCT", 46, 50], ["MI c functional", "DNA", 46, 61], ["the MI", "PROBLEM", 42, 48], ["Modal interval (MI", "PROBLEM", 193, 211]]], ["For distributions on N 0 , the length of the modal interval will effectively be 2c , since expanding it further cannot add probability mass.", [["probability mass", "PROBLEM", 123, 139], ["mass", "OBSERVATION", 135, 139]]], ["In this situation it is convenient to consider c \u2265 0, substitute 2c = k where k \u2208 N 0 , and encode the interval via its lower endpoint functional l k , so thatModal interval (MI)is a strictly consistent scoring function for the functional l k on the class of all distributions on N 0 .", [["k", "TEST", 78, 79], ["MI", "PROBLEM", 175, 177]]], ["In particular, the l k and MI k/2 functionals are elicitable.Modal interval (MI)In the special case k = 0, l 0 is the mode functional and (8) becomes S(x, y) = \u22121(x = y), the familiar zero-one or misclassification loss.", [["the l k", "TEST", 15, 22], ["MI k/2 functionals", "TEST", 27, 45], ["Modal interval (MI", "PROBLEM", 61, 79], ["misclassification loss", "PROBLEM", 196, 218], ["l", "ANATOMY_MODIFIER", 19, 20], ["misclassification loss", "OBSERVATION", 196, 218]]], ["We extend this result to all integers k \u2265 0, showing that k-zeroone-loss (8) is essentially the only strictly consistent scoring function for the l k and MI k/2 functionals.Modal interval (MI)Theorem 3.9.", [["all integers k", "TEST", 25, 39], ["the l k", "TEST", 142, 149], ["MI k/2 functionals", "PROBLEM", 154, 172], ["Modal interval (MI)Theorem", "PROBLEM", 173, 199]]], ["Let k \u2265 0 be an integer, and let F be a class of probability measures on N 0 that contains all distributions with finite support.", [["let F", "GENE_OR_GENE_PRODUCT", 29, 34], ["finite support", "TREATMENT", 114, 128], ["finite support", "OBSERVATION", 114, 128]]], ["Then any scoring function that is strictly consistent for the l k functional relative to the class F is equivalent to k-zero-one-loss (8).Modal interval (MI)is a strictly consistent scoring function for m c on the class of distributions with Lebesgue densities, whence m c and MI c are elicitable.", [["MI c", "GENE_OR_GENE_PRODUCT", 277, 281], ["k-zero", "TEST", 118, 124], ["Modal interval (MI", "PROBLEM", 138, 156], ["Lebesgue densities", "PROBLEM", 242, 260], ["MI c", "PROBLEM", 277, 281], ["Lebesgue densities", "OBSERVATION", 242, 260]]], ["In the limit as c \u2192 0, the scoring function (9) becomes almost everywhere zero and thus cannot be strictly consistent for any functional.", [["the scoring function", "TEST", 23, 43]]], ["Heinrich (2014) shows that there are no alternative scoring functions, so the mode fails to be elicitable relative to sufficiently rich classes of distributions with densities.", [["no", "UNCERTAINTY", 37, 39], ["densities", "OBSERVATION", 166, 175]]], ["Further aspects are treated in a recent paper by Dearborn and Frongillo (2019) .Modal interval (MI)The following theorem demonstrates, perhaps surprisingly, that c-zero-one-loss (9) is essentially the only strictly consistent scoring function for the m c and MI c functionals.Modal interval (MI)Theorem 3.10.", [["Modal interval (MI", "PROBLEM", 80, 98], ["c-zero", "TEST", 162, 168], ["the m c and MI c functionals", "PROBLEM", 247, 275], ["Modal interval (MI)Theorem", "PROBLEM", 276, 302]]], ["Let c > 0, and let F be a class of probability measures on R that contains all distributions with Lebesgue densities on bounded support.", [["let F", "GENE_OR_GENE_PRODUCT", 15, 20], ["Lebesgue densities", "PROBLEM", 98, 116], ["all", "OBSERVATION_MODIFIER", 75, 78], ["distributions", "OBSERVATION_MODIFIER", 79, 92], ["Lebesgue densities", "OBSERVATION", 98, 116]]], ["Then any scoring function that is strictly consistent for the m c functional relative to F is almost everywhere equal to a scoring function which is equivalent to c-zero-oneloss (9).Modal interval (MI)We complete this section by connecting modal and shortest intervals.", [["Modal interval (MI", "PROBLEM", 182, 200], ["this section", "TREATMENT", 213, 225]]], ["While these are conceptually different types of intervals, a comparison of (6) and (7) shows that the SI \u03b1 and MI c functionals relate via their defining optimization problems.", [["the SI \u03b1 and MI c functionals", "PROBLEM", 98, 127], ["different", "OBSERVATION_MODIFIER", 29, 38], ["types", "OBSERVATION_MODIFIER", 39, 44]]], ["Specifically, the SI \u03b1 (F ) functional is a solution to the constrained optimization problemModal interval (MI)Consequently, if either len(SI \u03b1 (F )) = 2c or P F (Y \u2208 MI c (F )) = 1\u2212\u03b1, one condition implies the other, and MI c (F ) = SI \u03b1 (F ) holds.", [["a solution", "TREATMENT", 42, 52], ["MI", "PROBLEM", 108, 110], ["MI", "PROBLEM", 222, 224]]], ["It remains unclear whether this connection can be exploited to construct strictly consistent scoring functions for the SI \u03b1 functional on suitably restrictive, special classes of distributions.DiscussionA central task in interval forecasting is the evaluation of competing forecast methods or models, a problem that is often addressed by using scoring or loss functions.", [["the evaluation", "TEST", 245, 259], ["loss functions", "PROBLEM", 355, 369]]], ["For each method or model, and for each forecast case, the empirical loss is computed.", [["the empirical loss", "PROBLEM", 54, 72]]], ["Losses are then averaged over forecast cases, and methods with lower mean loss or score are preferred.", [["Losses", "DISEASE", 0, 6], ["lower mean loss or score", "PROBLEM", 63, 87]]], ["However, for this type of comparative evaluation to be decision theoretically justifiable, the loss function needs to strictly consistent for the predictive interval at hand.DiscussionOf the three types of predictive intervals discussed in this paper, the equaltailed and modal intervals are elicitable, and we have discussed the available strictly consistent scoring functions.", [["hand", "ORGANISM_SUBDIVISION", 169, 173], ["comparative evaluation", "TEST", 26, 48], ["the loss function", "PROBLEM", 91, 108]]], ["In this way, we resolve the questions raised by Askanazi et al. (2018) concerning the existence of suitable loss functions for the shortest interval in the negative.", [["suitable loss functions", "PROBLEM", 99, 122]]], ["Importantly, there is no obvious way of setting incentives for forecasters to report their true shortest intervals.", [["no obvious", "UNCERTAINTY", 22, 32]]], ["961) .DiscussionThe modal interval admits a unique strictly consistent scoring function relative to comprehensive classes of both discrete and continuous distributions, up to equivalence.", [["both", "OBSERVATION_MODIFIER", 125, 129], ["discrete", "OBSERVATION_MODIFIER", 130, 138]]], ["This appears to be a rather special situation, as functionals studied in the extant literature either fail to be elicitable, or admit rich classes of genuinely distinct consistent scoring functions (Gneiting, 2011a; Steinwart et al., 2014; Fissler and Ziegel, 2016; Frongillo and Kash, 2019) .", [["appears to be", "UNCERTAINTY", 5, 18]]], ["In particular, in the discrete case it may be unavoidable that the coverage probability of a perfect forecast exceeds the nominal level 1\u2212\u03b1.", [["1\u2212\u03b1", "GENE_OR_GENE_PRODUCT", 136, 139], ["1\u2212\u03b1", "PROTEIN", 136, 139]]], ["This raises problems when assessing interval calibration with the methods of Christoffersen (1998) , since asymptotically the null hypothesis of frequency calibration will then be rejected even under perfectly correct forecasts.", [["interval calibration", "TEST", 36, 56]]], ["Modifying the null hypothesis to nominal coverage greater than or equal to 1\u2212\u03b1 is not a remedy, since such a test does not have any power against forecast intervals with too high coverage.", [["the null hypothesis", "PROBLEM", 10, 29], ["a test", "TEST", 107, 113], ["too high coverage", "TREATMENT", 170, 187]]], ["Consequently, tests for correct forecast specification as in Christoffersen (1998) can be problematic when data fail to be well-approximated by continuous distributions, such as in the case of retail sales.", [["tests", "TEST", 14, 19]]], ["Fortunately, comparative evaluation via consistent scoring functions remains valid and unaffected (Czado et al., 2009; Kolassa, 2016) .DiscussionIn many ways, interval forecasts can be seen as an intermediate stage in the ongoing, transdiciplinary transition from point forecasts to fully probabilistic or distribution forecasts (Askanazi et al., 2018) .", [["comparative evaluation", "TEST", 13, 35]]], ["Indeed, probabilistic forecasts in the form of predictive distributions are the gold standard, as they allow for full-fledged decision making and well-understood, powerful evaluation methods are available (Dawid, 1986; Gneiting and Katzfuss, 2014) .", [["powerful evaluation", "TEST", 163, 182], ["predictive distributions", "OBSERVATION", 47, 71]]], ["Generally, probabilistic forecasts can be issued in a number of distinct formats, ranging from the use of parametric distributions, such as in the Bank of England Inflation Report (Clements, 2004) , to Monte Carlo samples from predictive models, as well as simultaneous quantile forecasts at pre-specified levels, such as in the Global Energy Forecasting Competition 2014 (Hong et al., 2016) , the M5 Competition (M Open Forecasting Center, 2020) and the COVID-19 Forecasting Hub (Bracher et al., 2020) .", [["predictive models", "TEST", 227, 244], ["the COVID", "TREATMENT", 451, 460]]], ["If the quantile levels requested are symmetric about the central level of 1 2 , the collection of quantile forecasts corresponds to a family of equal-tailed predictive intervals.", [["the quantile levels", "TEST", 3, 22]]], ["Predictive performance can then be assessed via weighted or unweighted averages of scaled or unscaled versions of the Winkler interval score (5).", [["Predictive performance", "TEST", 0, 22]]], ["Linearity of expectations yieldsAppendix: Proofswhere the first difference is positive, while the second is negative.", [["positive", "OBSERVATION", 78, 86], ["negative", "OBSERVATION", 108, 116]]], ["Consequently, E F \u03bb S(t 0 , Y ) = E F \u03bb S(t 1 , Y ) for some \u03bb \u2208 (0, 1).", [["Consequently", "TEST", 0, 12], ["some \u03bb \u2208", "TEST", 56, 64]]], ["Since either t 0 \u2208 T (F \u03bb ) and t 1 / \u2208 T (F \u03bb ), or t 1 \u2208 T (F \u03bb ) and t 0 / \u2208 T (F \u03bb ), we arrive at a contradiction.Proof of Theorem 3.1Let S be a scoring function of the form (4).", [["t 0 \u2208 T", "DNA", 13, 20], ["t 1", "DNA", 32, 35]]], ["Then translation invariance of S gives \u2212w 1 \u03b1 2 (g 1 (a) \u2212 g 1 (y)) = S([a, y], y)Proof of Theorem 3.1and rearranging yields g 1 (a) \u2212 g 1 (y) = g 1 (a \u2212 z) \u2212 g 1 (y \u2212 z) for a, y, z \u2208 R. Choose y = 0 and defineg(x) := g 1 (x) \u2212 g 1 (0) to obtaing(a \u2212 z) =g(a) +g(\u2212z) for a, z \u2208 R. Thusg obeys Cauchy's functional equation, and sinceg is non-constant and non-decreasing, we get g 1 (x) = \u03b3x + g 1 (0) for some \u03b3 > 0.", [["translation invariance", "TEST", 5, 27], ["S", "TEST", 31, 32], ["Theorem", "TEST", 91, 98], ["rearranging", "TEST", 106, 117], ["g", "TEST", 135, 136], ["g", "TEST", 145, 146], ["z", "TEST", 154, 155], ["g", "TEST", 159, 160], ["z", "TEST", 168, 169], ["a", "TEST", 175, 176], ["y", "TEST", 178, 179], ["z", "TEST", 181, 182], ["defineg", "TEST", 205, 212], ["g", "TEST", 219, 220], ["g", "TEST", 229, 230], ["obtaing", "TEST", 240, 247], ["z", "TEST", 252, 253], ["g", "TEST", 256, 257], ["\u2212z", "TEST", 264, 266], ["a", "TEST", 272, 273], ["z", "TEST", 275, 276], ["Thusg", "TEST", 282, 287], ["obeys", "TEST", 288, 293], ["Cauchy", "TEST", 294, 300], ["functional equation", "TEST", 303, 322], ["g", "TEST", 378, 379]]], ["If S is positively homogeneous then for all c > 0 \u2212w 1 c \u03b1 2 (g 1 (a) \u2212 g 1 (y)) = cS([a, y], y) = S([ca, cy], cy) = \u2212w 1 \u03b1 2 (g 1 (ca) \u2212 g 1 (cy)), and thus c(g 1 (a) \u2212 g 1 (y)) = g 1 (ca) \u2212 g 1 (cy) for a, y \u2208 R and c > 0.", [["cS([a, y], y) = S([ca, cy], cy)", "CHEMICAL", 83, 114], ["\u03b1", "TEST", 57, 58], ["g", "TEST", 62, 63], ["cS", "TEST", 83, 85], ["S", "TEST", 99, 100], ["ca", "TEST", 102, 104], ["cy", "TEST", 106, 108], ["cy", "TEST", 111, 113], ["\u2212w", "TEST", 117, 119], ["\u03b1", "TEST", 122, 123], ["g", "TEST", 127, 128], ["ca", "TEST", 132, 134], ["g", "TEST", 138, 139], ["cy", "TEST", 143, 145], ["c", "TEST", 158, 159], ["g", "TEST", 160, 161], ["a", "TEST", 165, 166], ["g", "TEST", 170, 171], ["g", "TEST", 181, 182], ["ca", "TEST", 186, 188], ["g", "TEST", 192, 193], ["cy", "TEST", 197, 199], ["a", "TEST", 205, 206], ["c", "TEST", 218, 219]]], ["Choose y = 0 and defineg(x) := g 1 (x) \u2212 g 1 (0) to obtain cg(a) =g(ca) for c > 0 and a \u2208 R, as in Section C of the Supplementary Material for Nolde and Ziegel (2017) .", [["g", "TEST", 41, 42], ["cg", "TEST", 59, 61], ["ca", "TEST", 68, 70], ["c", "TEST", 76, 77]]], ["Sinceg is non-constant, non-decreasing, and differentiable, g 1 (x) = \u03b3x + g 1 (0) for some \u03b3 > 0.", [["g", "TEST", 60, 61], ["\u03b3x", "TEST", 70, 72], ["non-decreasing", "OBSERVATION_MODIFIER", 24, 38]]], ["Now suppose S is also symmetric and g 2 (x) = \u03c1x + g 2 (0) for some \u03c1 > 0.", [["\u03c1", "PROTEIN", 68, 69], ["symmetric", "TEST", 22, 31]]], ["Then the same reasoning as in the proof of Theorem 3.2 shows that w 1 \u03b3 = w 2 \u03c1, which proves the equivalence to IS \u03b1 .Proof of Theorem 3.2Let S be a scoring function of the form (4) and let a, b, y \u2208 R with a < b and b = y.", [["Theorem", "TEST", 43, 50], ["Theorem", "TEST", 128, 135]]], ["Then the symmetry of S gives \u2212w 1 \u03b1 2 (g 1 (a) \u2212 g 1 (y)) = S([a, y], y) = S([\u2212y, \u2212a], \u2212y) = w 2 \u03b1 2 (g 2 (\u2212a) \u2212 g 2 (\u2212y)), and rearranging yields w 1 (g 1 (a) \u2212 g 1 (y)) = w 2 (g 2 (\u2212y) \u2212 g 2 (\u2212a)) for a, y \u2208 R. For x, y, \u03b8 \u2208 R, define the function f (x, y, \u03b8) := 1(\u03b8 < x) + 1 2Proof of Theorem 3.2which satisfies f (\u2212y, \u2212x, \u03b8) = f (x, y, \u2212\u03b8) for x, y, \u03b8 \u2208 R. Moreover, for any g \u2208 I and y < xProof of Theorem 3.2where \u00b5 g is the Borel measure on R induced by g.", [["S", "CHEMICAL", 75, 76], ["[\u2212y, \u2212a]", "SIMPLE_CHEMICAL", 77, 85], ["g 2 (\u2212a) \u2212 g 2 (\u2212y)", "SIMPLE_CHEMICAL", 102, 121], ["\u03b8", "PROTEIN", 223, 224], ["g", "TEST", 39, 40], ["g", "TEST", 49, 50], ["S", "TEST", 60, 61], ["y", "TEST", 70, 71], ["S", "TEST", 75, 76], ["\u2212y", "TEST", 78, 80], ["\u2212a", "TEST", 82, 84], ["\u2212y", "TEST", 87, 89], ["w", "TEST", 93, 94], ["\u03b1", "TEST", 97, 98], ["g", "TEST", 102, 103], ["\u2212a", "TEST", 107, 109], ["g", "TEST", 113, 114], ["\u2212y", "TEST", 118, 120], ["rearranging", "TEST", 128, 139], ["g", "TEST", 152, 153], ["a", "TEST", 157, 158], ["g", "TEST", 162, 163], ["y", "TEST", 167, 168], ["w", "TEST", 173, 174], ["g", "TEST", 178, 179], ["\u2212y", "TEST", 183, 185], ["\u2212", "TEST", 187, 188], ["g", "TEST", 189, 190], ["\u2212a", "TEST", 194, 196], ["a", "TEST", 203, 204], ["y", "TEST", 220, 221], ["the function f", "TEST", 237, 251], ["y", "TEST", 256, 257], ["\u03b8", "TEST", 259, 260], ["Theorem", "TEST", 288, 295], ["satisfies", "TEST", 305, 314], ["\u2212y", "TEST", 318, 320], ["\u2212x", "TEST", 322, 324], ["y", "TEST", 337, 338], ["y", "TEST", 351, 352], ["Moreover", "TEST", 361, 369], ["any g \u2208 I", "TEST", 375, 384], ["y", "TEST", 389, 390], ["Theorem", "TEST", 403, 410], ["the Borel measure", "TEST", 427, 444]]], ["If we define the measures \u00b5 1 = w 1 \u00b5 g 1 and \u00b5 2 = w 2 \u00b5 g 2 , then the first part of the proof implies f (x, y, \u03b8) d\u00b5 2 (\u03b8) = w 2 (g 2 (x) \u2212 g 2 (y))Proof of Theorem 3.2for y < x, and the proof is completed by defining \u00b5 via \u00b5((y, x]) = \u00b5 1 ((y, x]) + \u00b5 1 ([\u2212x, \u2212y)).Proof of Proposition 3.3Let F 0 , F 1 \u2208 F, and suppose that [a, b] \u2208 SI \u03b1 (F 0 ) \u2229 SI \u03b1 (F 1 ).", [["g", "TEST", 133, 134], ["g", "TEST", 143, 144], ["Proof", "TEST", 151, 156], ["Theorem", "TEST", 160, 167], ["y", "TEST", 175, 176], ["the proof", "TEST", 186, 195], ["\u00b5", "TEST", 221, 222], ["Proposition", "TEST", 278, 289], ["SI", "TEST", 352, 354]]], ["Set F \u03bb := \u03bbF 1 + (1 \u2212 \u03bb)F 0 and note that for all \u03bb \u2208 (0, 1) and all s, t \u2208 R we haveProof of Proposition 3.3In particular,Proof of Proposition 3.3, as otherwise (10) yields a contradiction to our initial assumption.", [["all s", "TEST", 66, 71], ["Proof", "TEST", 86, 91], ["Proposition", "TEST", 95, 106]]], ["This proves part (a).Proof of Proposition 3.3.", [["Proposition", "TREATMENT", 30, 41]]], ["Then by the first part of the proofProof of Proposition 3.3Furthermore, F \u03bb (b) \u2212 F \u03bb (a) = 1 \u2212 \u03b1 and we see from (10)Proof of Proposition 3.3Since this is a contradiction to [a, b] \u2208 SI \u03b1 (F 1 ) \u2229 SI \u03b1 (F 0 ) or (11) we have proved part (b).Proof of Theorem 3.8We proceed by constructing suitable convex combinations as in Example 3.6.", [["SI", "TEST", 198, 200]]], ["Specifically, let F 0 satisfy Condition 3.7, and without loss of generality assume that SI \u03b1 (F 0 ) = [0, b] for some b > 0.", [["loss of generality", "PROBLEM", 57, 75], ["some b", "PROBLEM", 113, 119]]], ["Define F 1 viaProof of Theorem 3.8x and set F \u03bb := \u03bbF 1 +(1\u2212\u03bb)F 0 .", [["Theorem", "TEST", 23, 30], ["\u03bbF", "TEST", 51, 53]]], ["We proceed to show that [0, b+ 1 2 \u03b5] \u2208 SI \u03b1 (F \u03bb ) for all \u03bb \u2208 (0, 1], which allows us to apply Proposition 2.5 and conclude non-elicitability.Proof of Theorem 3.8Clearly, SI \u03b1 (F 1 ) = [0, b + 1 2 \u03b5], and since F 0 (b) = F 0 (b + \u03b5) it holds that F \u03bb (b + 1 2 \u03b5) \u2212 F \u03bb (0) = 1 \u2212 \u03b1 for \u03bb \u2208 (0, 1).", [["[0, b+ 1 2 \u03b5", "SIMPLE_CHEMICAL", 24, 36], ["F 0 (b) = F 0 (b + \u03b5", "SIMPLE_CHEMICAL", 213, 233], ["SI", "TEST", 40, 42], ["Theorem", "TEST", 153, 160], ["SI", "TEST", 173, 175], ["b", "TEST", 191, 192], ["b", "TEST", 228, 229], ["\u03b5", "TEST", 232, 233], ["it", "TEST", 235, 237], ["b", "TEST", 254, 255]]], ["For a contradiction, suppose there are \u03bb \u2208 (0, 1) andProof of Theorem 3.8> 1\u2212\u03b1 must hold, for a contradiction to the final part of Condition 3.7.", [["Theorem", "TEST", 62, 69]]], ["Consequently, SI \u03b1 (F \u03bb ) = [0, b + 1 2 \u03b5] for all \u03bb \u2208 (0, 1], and the proof is complete.Proof of Theorem 3.9Let k \u2265 0 be an integer, and suppose that S is a strictly consistent scoring function for the functional l k relative to F. To facilitate the presentation, we use the notation S(I, y) for S(x, y), where x \u2208 R is the lower endpoint of an intervalProof of Theorem 3.9x \u2208 N 0 } being the relevant action domain.", [["Consequently", "TEST", 0, 12], ["SI", "TEST", 14, 16], ["the proof", "TEST", 67, 76], ["Theorem", "TEST", 98, 105]]], ["We proceed in three steps.Proof of Theorem 3.9Step 1 We show that S is of the form S(x, y) = g(x, y)1(x \u2264 y \u2264 x + k) + h(y)Proof of Theorem 3.9for functions g : N 0 \u00d7 N 0 \u2192 R and h : N 0 \u2192 R.Proof of Theorem 3.9To this end, let M 0 , M 1 \u2208 A and I \u2208 2 N 0 be pairwise disjoint intervals.", [["Theorem", "TEST", 35, 42], ["Theorem", "TEST", 132, 139], ["N", "TEST", 161, 162], ["R.Proof", "TEST", 189, 196], ["Theorem", "TEST", 200, 207], ["A", "TEST", 240, 241], ["pairwise disjoint intervals", "TEST", 259, 286]]], ["For a contradiction, suppose that the map y \u2192 S(M 0 , y) \u2212 S(M 1 , y) is non-zero on I.Proof of Theorem 3.9As the class F contains all distributions with bounded support, we can then find probability measures F 0 , F 0 , F 1 \u2208 F that satisfy the following three conditions:Proof of Theorem 3.9(i) There exists \u03bb * \u2208 (0, 1) such that for F \u03bb := \u03bbF 1 + (1 \u2212 \u03bb)F 0 and F \u03bb := \u03bbF 1 + (1 \u2212 \u03bb)F 0 MI k (F \u03bb ) = MI k (F \u03bb ) = M 0 , \u03bb < \u03bb * , M 1 , \u03bb > \u03bb * .Proof of Theorem 3.9(ii) F 0 and F 0 coincide outside I.Proof of Theorem 3.9(iii) I (S(M 0 , y) \u2212 S(M 1 , y)) dF 0 (y) = I (S(M 0 , y) \u2212 S(M 1 , y)) dF 0 (y).Proof of Theorem 3.9Consider the integrated score difference \u2206(F, G, \u03bb) := (S(M 0 , y) \u2212 S(M 1 , y)) d(\u03bbG + (1 \u2212 \u03bb)F )(y), which is linear in \u03bb \u2208 [0, 1].", [["a contradiction", "TEST", 4, 19], ["the map y \u2192 S", "TEST", 34, 47], ["F", "TEST", 366, 367], ["\u03bbF", "TEST", 373, 375], ["\u03bb", "TEST", 385, 386], ["MI k", "TEST", 391, 395], ["\u03bb", "TEST", 399, 400], ["MI k", "TEST", 405, 409], ["\u03bb", "TEST", 413, 414], ["M", "TEST", 419, 420], ["\u03bb", "TEST", 425, 426], ["M", "TEST", 435, 436], ["\u03bb", "TEST", 441, 442], ["Proof", "TEST", 450, 455], ["Theorem", "TEST", 459, 466], ["Theorem", "TEST", 515, 522], ["S", "TEST", 535, 536], ["S", "TEST", 548, 549], ["M", "TEST", 550, 551], ["S", "TEST", 574, 575], ["y", "TEST", 582, 583], ["\u2212 S", "TEST", 585, 588], ["Theorem", "TEST", 617, 624], ["the integrated score difference", "TEST", 637, 668], ["\u2206", "TEST", 669, 670], ["F", "TEST", 671, 672], ["G", "TEST", 674, 675], ["S", "TEST", 697, 698], ["d", "TEST", 709, 710], ["G", "TEST", 712, 713], ["linear", "TEST", 740, 746]]], ["The strict consistency of S in concert with (i) yields \u2206(F 0 , F 1 , 0) < 0, \u2206(F 0 , F 1 , 0) < 0, and \u2206(F 0 , F 1 , 1) = \u2206(F 0 , F 1 , 1) > 0.", [["\u2206", "TEST", 77, 78], ["\u2206", "TEST", 103, 104], ["F", "TEST", 111, 112], ["\u2206", "TEST", 122, 123]]], ["Since \u2206(F 0 , F 1 , 0) = \u2206(F 0 , F 1 , 0) by (ii) and (iii), the linear mappings \u03bb \u2192 \u2206(F 0 , F 1 , \u03bb) and \u03bb \u2192 \u2206(F 0 , F 1 , \u03bb) must have distinct roots.", [["roots", "ANATOMY", 146, 151], ["F 0 , F 1 , 0)", "SIMPLE_CHEMICAL", 27, 41], ["roots", "ORGAN", 146, 151], ["\u03bb", "PROTEIN", 99, 100], ["\u03bb", "PROTEIN", 106, 107], ["\u2206", "PROTEIN", 110, 111], ["\u03bb", "PROTEIN", 124, 125], ["the linear mappings", "TEST", 61, 80], ["\u2206", "TEST", 85, 86], ["\u2206", "TEST", 110, 111], ["distinct roots", "PROBLEM", 137, 151], ["roots", "ANATOMY_MODIFIER", 146, 151]]], ["This implies that one of the two mappings does not vanish at \u03bb * , in contradiction to the consistency of S. Consequently, S(M 0 , y)\u2212S(M 1 , y) = 0 on I, and since I was arbitrary we conclude that S(M 0 , y) = S(M 1 , y) for all y \u2208 (M 0 \u222aM 1 ) c .", [["arbitrary", "TEST", 171, 180], ["S", "TEST", 198, 199], ["M", "TEST", 240, 241], ["c", "TEST", 246, 247]]], ["By varying the intervals M 0 , M 1 \u2208 A we obtain that the values S(M, y) are the same for all y \u2208 I and all M \u2208 A with M \u2229 I = \u2205.", [["I", "PROTEIN", 98, 99]]], ["Then we can choose an interval M 1 such that M 1 \u2229 M 0 = \u2205 and distributions F 0 , F 0 , F 1 \u2208 F 1 that satisfy (i), (ii), and (iii) in Step 1, for I = M 0 .", [["Step", "TEST", 136, 140]]], ["As in Step 1 we obtain \u2206(F 0 , F 1 , 0) = \u2206(F 0 , F 1 , 0) such that the mappings \u03bb \u2192 \u2206(F 0 , F 1 , \u03bb) and \u03bb \u2192 \u2206(F 0 , F 1 , \u03bb) have distinct roots.", [["roots", "ANATOMY", 142, 147], ["F 1", "GENE_OR_GENE_PRODUCT", 119, 122], ["roots", "ORGAN", 142, 147], ["\u03bb", "PROTEIN", 82, 83], ["\u03bb", "PROTEIN", 100, 101], ["\u03bb", "PROTEIN", 107, 108], ["\u2206", "PROTEIN", 111, 112], ["F 0", "PROTEIN", 113, 116], ["F 1", "PROTEIN", 119, 122], ["\u03bb", "PROTEIN", 125, 126], ["\u2206", "TEST", 23, 24], ["\u2206", "TEST", 42, 43], ["the mappings", "TEST", 69, 81], ["\u2206", "TEST", 86, 87], ["distinct roots", "PROBLEM", 133, 147], ["roots", "ANATOMY_MODIFIER", 142, 147]]], ["We can thus replace g in (12) byg(x) for some functiong : N 0 \u2192 R.Proof of Theorem 3.9Step 3 It remains to be shown thatg reduces to a negative constant.", [["(12) byg", "CHEMICAL", 25, 33], ["negative", "OBSERVATION", 135, 143]]], ["To this end consider M 0 \u2208 A and M 1 \u2208 A and assume thatg(M 0 ) 0, and let S be a strictly consistent scoring function for the functional m c relative to F. In Step 1, we show that S is almost everywhere of the form S(x, y) = g(x, y)1(x \u2212 c \u2264 y \u2264 x + c) + h(y)Proof of Theorem 3.10for F-integrable functions g : R \u00d7 R \u2192 R and h : R \u2192 R. In Step 2 we prove that g reduces to a functiong(x), and in Step 3 we demonstrate thatg reduces to a negative constant.", [["R \u00d7 R \u2192 R", "GENE_OR_GENE_PRODUCT", 312, 321], ["Theorem", "TEST", 269, 276]]]], "PMC7117243": [["IntroductionCaliciviruses are nonenveloped, single-stranded RNA viruses with positive-sense genomes of 7.4\u20138.3 kb (Green et al., 2000).", [["Caliciviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["positive-sense genomes", "DNA", 77, 99], ["IntroductionCaliciviruses", "PROBLEM", 0, 25], ["stranded RNA viruses", "PROBLEM", 51, 71], ["Caliciviruses", "OBSERVATION", 12, 25]]], ["Based on the genomic organization and genetic analysis (Green et al., 2000), the family Caliciviridae is divided into at least four genera: Vesivirus, Lagovirus, Norovirus (NoV), and Sapovirus (SaV) with a new proposed genus, NB-like (Oliver et al., 2006, Smiley et al., 2002).", [["Norovirus (NoV), and Sapovirus", "DISEASE", 162, 192], ["Lagovirus, Norovirus", "ORGANISM", 151, 171], ["NoV", "ORGANISM", 173, 176], ["Sapovirus", "GENE_OR_GENE_PRODUCT", 183, 192], ["NoV", "SPECIES", 173, 176], ["genetic analysis", "TEST", 38, 54], ["the family Caliciviridae", "TREATMENT", 77, 101], ["Vesivirus", "TREATMENT", 140, 149], ["Norovirus", "PROBLEM", 162, 171], ["Sapovirus", "PROBLEM", 183, 192]]], ["The NoV genome is organized into three open reading frames (ORFs) that encode the nonstructural proteins (ORF1), the major capsid protein (ORF2) and the minor capsid protein (ORF3) (Jiang et al., 1993, Lambden et al., 1993).", [["ORF1", "GENE_OR_GENE_PRODUCT", 106, 110], ["ORF2", "GENE_OR_GENE_PRODUCT", 139, 143], ["ORF3", "GENE_OR_GENE_PRODUCT", 175, 179], ["NoV genome", "DNA", 4, 14], ["open reading frames", "DNA", 39, 58], ["ORFs", "DNA", 60, 64], ["nonstructural proteins", "PROTEIN", 82, 104], ["ORF1", "PROTEIN", 106, 110], ["major capsid protein", "PROTEIN", 117, 137], ["ORF2", "PROTEIN", 139, 143], ["minor capsid protein", "PROTEIN", 153, 173], ["ORF3", "PROTEIN", 175, 179], ["NoV", "SPECIES", 4, 7], ["NoV genome", "OBSERVATION", 4, 14]]], ["Based on the genetic divergence in the RNA-dependent RNA polymerase (RdRp) and capsid genes, the NoVs have been tentatively assigned to five genogroups (G) with multiple genotypes (Zheng et al., 2006).", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 39, 67], ["NoVs", "GENE_OR_GENE_PRODUCT", 97, 101], ["RNA-dependent RNA polymerase", "PROTEIN", 39, 67], ["RdRp", "PROTEIN", 69, 73], ["capsid genes", "DNA", 79, 91], ["NoVs", "DNA", 97, 101], ["the RNA", "TEST", 35, 42], ["dependent RNA polymerase (RdRp) and capsid genes", "PROBLEM", 43, 91], ["capsid genes", "OBSERVATION", 79, 91]]], ["The strains of three genogroups, GI, GII, and GIV, are found in humans (GII-11 and GII-19 are porcine), and GIII and GV strains are found in cows and mice (Zheng et al., 2006).IntroductionEnteric caliciviruses, morphologically indistinguishable from the human NoVs, were first reported in association with calf diarrhea in the United Kingdom in 1978 and in Germany in 1980 (Almeida et al., 1978, G\u00fcnther et al., 1984, Woode and Bridger, 1978).", [["Enteric caliciviruses", "DISEASE", 188, 209], ["diarrhea", "DISEASE", 311, 319], ["GIV", "GENE_OR_GENE_PRODUCT", 46, 49], ["humans", "ORGANISM", 64, 70], ["GII-11", "ORGANISM", 72, 78], ["GII-19", "ORGANISM", 83, 89], ["porcine", "ORGANISM", 94, 101], ["GIII", "GENE_OR_GENE_PRODUCT", 108, 112], ["GV strains", "ORGANISM", 117, 127], ["cows", "ORGANISM", 141, 145], ["mice", "ORGANISM", 150, 154], ["Enteric caliciviruses", "ORGANISM", 188, 209], ["human", "ORGANISM", 254, 259], ["NoVs", "GENE_OR_GENE_PRODUCT", 260, 264], ["calf", "ORGANISM_SUBDIVISION", 306, 310], ["humans", "SPECIES", 64, 70], ["cows", "SPECIES", 141, 145], ["mice", "SPECIES", 150, 154], ["human", "SPECIES", 254, 259], ["calf", "SPECIES", 306, 310], ["humans", "SPECIES", 64, 70], ["mice", "SPECIES", 150, 154], ["human", "SPECIES", 254, 259], ["GIV", "PROBLEM", 46, 49], ["GII", "TEST", 72, 75], ["GII", "TEST", 83, 86], ["GIII and GV strains", "PROBLEM", 108, 127], ["IntroductionEnteric caliciviruses", "PROBLEM", 176, 209], ["calf diarrhea", "PROBLEM", 306, 319], ["Enteric caliciviruses", "OBSERVATION", 188, 209], ["calf", "ANATOMY", 306, 310], ["diarrhea", "OBSERVATION", 311, 319]]], ["In recent years, genomic data has been obtained from the two viruses, Bo/Jena/80/DE and Bo/Newbury2/76/UK, and these strains were assigned into the prototype bovine NoVs (BNoVs) of genotype 1 (GIII-1) and genotype-2 (GIII-2) within GIII, respectively.", [["Bo/Newbury2/76", "ORGANISM", 88, 102], ["UK", "GENE_OR_GENE_PRODUCT", 103, 105], ["bovine", "ORGANISM", 158, 164], ["NoVs", "GENE_OR_GENE_PRODUCT", 165, 169], ["GIII-1", "GENE_OR_GENE_PRODUCT", 193, 199], ["bovine", "SPECIES", 158, 164], ["Bo/Jena/80/DE and Bo/Newbury2/76", "SPECIES", 70, 102], ["bovine", "SPECIES", 158, 164], ["genomic data", "TEST", 17, 29], ["Bo/Newbury2", "TEST", 88, 99], ["these strains", "PROBLEM", 111, 124], ["genotype", "TEST", 181, 189], ["GIII", "TEST", 193, 197], ["genotype-", "TEST", 205, 214], ["GIII", "TEST", 217, 221]]], ["Further isolates of the genotype 1 or genotype 2 BNoVs have been identified in the United Kingdom, The Netherlands, and United States (Liu et al., 1999, Oliver et al., 2003, Oliver et al., 2004, Smiley et al., 2003, van der Poel et al., 2003, Wise et al., 2004), which have confirmed the existence of the two distinct genotypes.IntroductionAlthough there are reports of the widespread occurrence of divergent human NoV strains, there are only a few reports of the prevalence and genetic diversity of BNoVs from England (Oliver et al., 2003, Woode and Bridger, 1978), Germany (Liu et al., 1999), The Netherlands (van der Poel et al., 2000, van der Poel et al., 2003) and the USA (Smiley et al., 2003, Wise et al., 2004).", [["human", "ORGANISM", 409, 414], ["BNoVs", "PATHOLOGICAL_FORMATION", 500, 505], ["human", "SPECIES", 409, 414], ["human NoV", "SPECIES", 409, 418], ["the genotype 1", "TREATMENT", 20, 34], ["the two distinct genotypes", "PROBLEM", 301, 327], ["divergent human NoV strains", "PROBLEM", 399, 426], ["divergent", "OBSERVATION_MODIFIER", 399, 408], ["human", "OBSERVATION", 409, 414], ["NoV strains", "OBSERVATION", 415, 426], ["few", "OBSERVATION_MODIFIER", 445, 448]]], ["The aim of this study was to examine the prevalence and genetic diversity of BNoVs in diarrheic calves in South Korea.Specimens ::: Materials and methodsFrom 2004 to 2005, a total of 645 fecal specimens obtained from diarrheic calves in 629 bovine beef herds were collected in South Korea during the spring (407 samples/406 herds), summer (107 samples/98 herds), autumn (73 samples/69 herds) and winter (58 samples/56 herds).", [["fecal specimens", "ANATOMY", 187, 202], ["BNoVs", "CHEMICAL", 77, 82], ["BNoVs", "SIMPLE_CHEMICAL", 77, 82], ["calves", "ORGANISM_SUBDIVISION", 96, 102], ["fecal specimens", "CANCER", 187, 202], ["calves", "ORGANISM", 227, 233], ["bovine", "ORGANISM", 241, 247], ["calves", "SPECIES", 96, 102], ["calves", "SPECIES", 227, 233], ["bovine", "SPECIES", 241, 247], ["beef", "SPECIES", 248, 252], ["beef", "SPECIES", 248, 252], ["this study", "TEST", 11, 21], ["BNoVs in diarrheic calves", "PROBLEM", 77, 102], ["fecal specimens", "TEST", 187, 202], ["diarrheic calves", "PROBLEM", 217, 233], ["bovine beef herds", "TREATMENT", 241, 258], ["diarrheic calves", "OBSERVATION", 86, 102]]], ["The ages of the calves tested ranged from 2 to 90 days.", [["calves", "ORGANISM", 16, 22], ["calves", "SPECIES", 16, 22], ["calves", "ANATOMY", 16, 22]]], ["The fecal samples were examined for common bacterial enteric pathogens including Salmonella spp., Clostridium spp., Campylobacter spp. using specific agar media, and any suspect colonies were identified using biochemical tests.", [["fecal samples", "ANATOMY", 4, 17], ["colonies", "ANATOMY", 178, 186], ["Campylobacter spp", "DISEASE", 116, 133], ["fecal samples", "ORGANISM_SUBSTANCE", 4, 17], ["Salmonella spp.", "ORGANISM", 81, 96], ["Clostridium spp.", "ORGANISM", 98, 114], ["Campylobacter spp", "ORGANISM", 116, 133], ["Salmonella spp.", "SPECIES", 81, 96], ["Clostridium spp.", "SPECIES", 98, 114], ["Campylobacter spp", "SPECIES", 116, 133], ["Salmonella spp.", "SPECIES", 81, 96], ["Clostridium spp.", "SPECIES", 98, 114], ["The fecal samples", "TEST", 0, 17], ["common bacterial enteric pathogens", "PROBLEM", 36, 70], ["Salmonella spp.", "TREATMENT", 81, 96], ["Clostridium spp.", "PROBLEM", 98, 114], ["Campylobacter spp", "PROBLEM", 116, 133], ["specific agar media", "TEST", 141, 160], ["any suspect colonies", "PROBLEM", 166, 186], ["biochemical tests", "TEST", 209, 226], ["fecal", "ANATOMY", 4, 9], ["Campylobacter spp", "OBSERVATION", 116, 133]]], ["The shiga-toxin-producing Escherichia coli was detected using a PCR assay, as described elsewhere (Asakura et al., 1998).", [["shiga-toxin", "CHEMICAL", 4, 15], ["shiga-toxin", "SIMPLE_CHEMICAL", 4, 15], ["Escherichia coli", "ORGANISM", 26, 42], ["Escherichia coli", "SPECIES", 26, 42], ["Escherichia coli", "SPECIES", 26, 42], ["The shiga-toxin", "TEST", 0, 15], ["Escherichia coli", "PROBLEM", 26, 42], ["a PCR assay", "TEST", 62, 73], ["Escherichia coli", "OBSERVATION", 26, 42]]], ["For the viral assays, fecal suspensions of each sample were prepared immediately by diluting the feces 1:10 in 0.01 M phosphate-buffered saline (PBS), pH 7.2.", [["fecal suspensions", "ANATOMY", 22, 39], ["sample", "ANATOMY", 48, 54], ["phosphate", "CHEMICAL", 118, 127], ["phosphate", "CHEMICAL", 118, 127], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 118, 143], ["the viral assays", "TEST", 4, 20], ["buffered saline (PBS", "TREATMENT", 128, 148], ["pH", "TEST", 151, 153]]], ["The suspensions were then vortexed for 30 s, centrifuged (1200 \u00d7g for 20 min), and the supernatants were collected and stored at \u221280 \u00b0C for further testing.RNA extraction ::: Materials and methodsThe RNA was extracted from a 200 \u03bcl starting volume of the centrifuged 10% fecal suspensions using the Trizol-LS (Gibco-BRL, Life Tech, Grand Island, USA) procedure.", [["supernatants", "ANATOMY", 87, 99], ["The suspensions", "TREATMENT", 0, 15], ["further testing", "TEST", 140, 155], ["the centrifuged", "TREATMENT", 251, 266], ["fecal suspensions", "TREATMENT", 271, 288], ["the Trizol", "TREATMENT", 295, 305], ["Life Tech", "TREATMENT", 321, 330], ["procedure", "TREATMENT", 351, 360]]], ["The total RNA recovered was suspended in 50 \u03bcl of RNase free water and stored at \u221280 \u00b0C until needed.RT-PCR and nested PCR ::: Materials and methodsThe BNoV, bovine coronavirus (BCoV), groups A, B and C bovine rotaviruses (BRV A\u2013C), bovine enteric Nebraska-like calicivirus (BEC-NBV), bovine torovirus (BToV) and bovine viral diarrhea virus (BVDV) were detected using standard one-step RT-PCR with different specific primer sets (Table 1) using the RNA extracted from the fecal samples, as described previously (Cho et al., 2001, Park et al., 2006).", [["fecal samples", "ANATOMY", 472, 485], ["bovine viral diarrhea virus", "DISEASE", 313, 340], ["RNase", "GENE_OR_GENE_PRODUCT", 50, 55], ["BNoV", "ORGANISM", 152, 156], ["bovine coronavirus", "ORGANISM", 158, 176], ["BCoV", "ORGANISM", 178, 182], ["B", "GENE_OR_GENE_PRODUCT", 195, 196], ["C bovine rotaviruses", "ORGANISM", 201, 221], ["BRV A\u2013C", "ORGANISM", 223, 230], ["bovine", "ORGANISM", 233, 239], ["enteric Nebraska-like calicivirus", "ORGANISM", 240, 273], ["BEC-NBV", "ORGANISM", 275, 282], ["bovine torovirus (BToV", "ORGANISM", 285, 307], ["bovine viral diarrhea virus", "ORGANISM", 313, 340], ["BVDV", "ORGANISM", 342, 346], ["fecal samples", "ORGANISM_SUBSTANCE", 472, 485], ["RNase", "PROTEIN", 50, 55], ["bovine", "SPECIES", 158, 164], ["bovine", "SPECIES", 203, 209], ["bovine", "SPECIES", 233, 239], ["Nebraska-like calicivirus", "SPECIES", 248, 273], ["bovine", "SPECIES", 285, 291], ["bovine", "SPECIES", 313, 319], ["viral diarrhea virus", "SPECIES", 320, 340], ["BVDV", "SPECIES", 342, 346], ["BNoV", "SPECIES", 152, 156], ["bovine coronavirus", "SPECIES", 158, 176], ["BCoV", "SPECIES", 178, 182], ["BRV", "SPECIES", 223, 226], ["bovine", "SPECIES", 233, 239], ["Nebraska-like calicivirus", "SPECIES", 248, 273], ["NBV", "SPECIES", 279, 282], ["bovine", "SPECIES", 285, 291], ["BToV", "SPECIES", 303, 307], ["bovine viral diarrhea virus", "SPECIES", 313, 340], ["BVDV", "SPECIES", 342, 346], ["The total RNA", "TEST", 0, 13], ["RNase free water", "TREATMENT", 50, 66], ["RT-PCR", "TEST", 101, 107], ["nested PCR", "TEST", 112, 122], ["methods", "TEST", 141, 148], ["The BNoV", "TEST", 148, 156], ["bovine coronavirus", "TEST", 158, 176], ["BCoV", "TEST", 178, 182], ["groups", "TEST", 185, 191], ["C bovine rotaviruses", "PROBLEM", 201, 221], ["BRV A\u2013C", "TEST", 223, 230], ["bovine enteric Nebraska", "TEST", 233, 256], ["calicivirus", "PROBLEM", 262, 273], ["BEC", "TEST", 275, 278], ["bovine torovirus (BToV", "TREATMENT", 285, 307], ["bovine viral diarrhea virus", "PROBLEM", 313, 340], ["BVDV", "PROBLEM", 342, 346], ["step RT-PCR", "TREATMENT", 381, 392], ["the RNA", "TREATMENT", 445, 452], ["the fecal samples", "TEST", 468, 485], ["fecal", "ANATOMY", 472, 477]]], ["The mixture for RT-PCR was incubated at 42 \u00b0C for 60 min, preheated at 94 \u00b0C for 5 min, subjected to 35 cycles of 1 min at 94 \u00b0C, 1 min at the required temperature for each primer pair (Table 1), 2 min at 72 \u00b0C and a final 7 min incubation at 72 \u00b0C. Nested PCR assays with the primer pairs specific to BNoV, BCoV, BRV A, BToV and BEC-NBV were performed in order to increase the sensitivity and specificity of the RT-PCR as described previously (Cho et al., 2001, Park et al., 2006).", [["BNoV", "GENE_OR_GENE_PRODUCT", 302, 306], ["BCoV", "GENE_OR_GENE_PRODUCT", 308, 312], ["BRV A", "CELL", 314, 319], ["BToV", "GENE_OR_GENE_PRODUCT", 321, 325], ["BEC-NBV", "CELL", 330, 337], ["primer pairs", "DNA", 277, 289], ["BNoV, BCoV, BRV A, BToV and BEC-NBV", "DNA", 302, 337], ["BNoV", "SPECIES", 302, 306], ["BCoV", "SPECIES", 308, 312], ["BRV", "SPECIES", 314, 317], ["BToV", "SPECIES", 321, 325], ["RT-PCR", "TEST", 16, 22], ["Nested PCR assays", "TEST", 250, 267], ["BNoV", "TEST", 302, 306], ["BCoV", "TEST", 308, 312], ["BEC-NBV", "TEST", 330, 337], ["the sensitivity", "TEST", 374, 389], ["the RT-PCR", "TEST", 409, 419]]], ["The mixture for nested PCR was preheated at 94 \u00b0C for 5 min, subjected to 30 cycles of 1 min at 94 \u00b0C, 1 min at the required temperature for each primer pair (Table 1), 2 min at 72 \u00b0C and a final 7 min incubation at 72 \u00b0C. As a negative control, the RNA was extracted from the normal feces of a colostrums-deprived calf that had been inoculated with 50 ml sterile PBS.", [["feces", "ANATOMY", 284, 289], ["colostrums", "ANATOMY", 295, 305], ["feces", "ORGANISM_SUBSTANCE", 284, 289], ["calf", "ORGANISM", 315, 319], ["calf", "SPECIES", 315, 319], ["The mixture", "TREATMENT", 0, 11], ["nested PCR", "TEST", 16, 26], ["negative", "OBSERVATION", 228, 236], ["normal", "OBSERVATION", 277, 283], ["feces", "OBSERVATION_MODIFIER", 284, 289], ["calf", "ANATOMY", 315, 319]]], ["The amplification products were analyzed using 1.5% or 2% agarose gel electrophoresis and visualized by irradiating the ethidium bromide stained samples with UV.DNA sequencing ::: Materials and methodsThe nested PCR products for a portion of the RdRp gene (326 bp) were selected from different test reactions and sequenced to verify the reaction specificity as well as to obtain the genomic data for phylogenetic analysis.", [["samples", "ANATOMY", 145, 152], ["ethidium bromide", "CHEMICAL", 120, 136], ["ethidium bromide", "CHEMICAL", 120, 136], ["agarose", "SIMPLE_CHEMICAL", 58, 65], ["ethidium bromide", "SIMPLE_CHEMICAL", 120, 136], ["nested PCR products", "DNA", 205, 224], ["RdRp gene", "DNA", 246, 255], ["The amplification products", "TREATMENT", 0, 26], ["2% agarose gel electrophoresis", "TREATMENT", 55, 85], ["the ethidium bromide", "TREATMENT", 116, 136], ["The nested PCR products", "TREATMENT", 201, 224], ["different test reactions", "TEST", 284, 308], ["the genomic data", "TEST", 379, 395], ["phylogenetic analysis", "TEST", 400, 421]]], ["The nested PCR products were purified using a GenClean II kit (BIO 101, Inc., LaJolla, USA) according to the manufacturer's instructions.", [["The nested PCR products", "TREATMENT", 0, 23], ["a GenClean II kit", "TREATMENT", 44, 61]]], ["DNA sequencing was carried out using an automated DNA sequencer (ABI system 3700, Applied Biosystem Inc., Foster City, USA).Molecular analysis ::: Materials and methodsThe nucleotide (nt) and deduced amino acid (aa) sequences of the partial BNoV RdRp region were compared with those of other known caliciviruses using the DNA Basic module (DNAsis MAX, Alameda, USA) (Table 2).", [["nucleotide", "CHEMICAL", 172, 182], ["amino acid", "CHEMICAL", 200, 210], ["nucleotide", "CHEMICAL", 172, 182], ["amino acid", "CHEMICAL", 200, 210], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["amino acid", "AMINO_ACID", 200, 210], ["caliciviruses", "CANCER", 298, 311], ["DNA", "CELLULAR_COMPONENT", 322, 325], ["BNoV RdRp region", "DNA", 241, 257], ["DNA sequencing", "TEST", 0, 14], ["an automated DNA sequencer", "TEST", 37, 63], ["ABI system", "TEST", 65, 75], ["The nucleotide (nt)", "TEST", 168, 187], ["deduced amino acid (aa) sequences", "TEST", 192, 225], ["the partial BNoV RdRp region", "PROBLEM", 229, 257], ["partial", "OBSERVATION_MODIFIER", 233, 240], ["caliciviruses", "OBSERVATION", 298, 311]]], ["Phylogenetic analysis based on the nt and aa alignments were constructed using the neighbor-joining method and the unweighted-pair group method with the average linkages of Molecular Evolutionary Genetics Analysis (MEGA, Version 3.1) with a pairwise distance (Kumar et al., 2004).", [["nt and aa alignments", "DNA", 35, 55], ["Phylogenetic analysis", "TEST", 0, 21], ["the nt and aa alignments", "TEST", 31, 55]]], ["A sequence similarity search was carried out for the bovine calicivirus the RdRp protein using the LALIGN Query program of the GENESTREAM network server at Institut de G\u00e9n\u00e9tque Humaine, Montpellier, FRANCE (http://www.eng.uiowa.edu/\u223ctscheetz/sequence-analysis/examples/LALIGN/lalign-guess.html).Prevalence of BNoVs in calves with diarrhea in South Korea ::: ResultsEighteen (2.8%) out of 645 fecal samples (18/629 herds; 2.9%) tested positive using a 1-step RT-PCR assay, targeting a 532 bp fragment of the RdRp region of the BNoV.", [["fecal samples", "ANATOMY", 392, 405], ["BNoVs", "CHEMICAL", 309, 314], ["diarrhea", "DISEASE", 330, 338], ["bovine", "ORGANISM", 53, 59], ["calicivirus", "ORGANISM", 60, 71], ["calves", "ORGANISM", 318, 324], ["fecal samples", "CANCER", 392, 405], ["RdRp protein", "PROTEIN", 76, 88], ["532 bp fragment", "DNA", 484, 499], ["RdRp region", "DNA", 507, 518], ["BNoV", "DNA", 526, 530], ["bovine", "SPECIES", 53, 59], ["calicivirus", "SPECIES", 60, 71], ["calves", "SPECIES", 318, 324], ["bovine calicivirus", "SPECIES", 53, 71], ["A sequence similarity search", "TEST", 0, 28], ["the bovine calicivirus", "TREATMENT", 49, 71], ["diarrhea", "PROBLEM", 330, 338], ["fecal samples", "TEST", 392, 405], ["herds", "TEST", 414, 419], ["a 532 bp fragment", "TREATMENT", 482, 499], ["RdRp", "ANATOMY_MODIFIER", 507, 511], ["region", "ANATOMY_MODIFIER", 512, 518]]], ["Nested PCR, targeting a 326 bp fragment of the RdRp region of the BNoV, detected 60 (9.3%) positive fecal samples from 60 herds (9.4%).Other enteric pathogens ::: ResultsOf the 60 BNoV-positive fecal specimens from 60 calf herds with diarrhea, 22 fecal samples (3.4%) from 22 herds (3.5%) tested positive for the BNoV alone, while the 38 fecal samples (5.9%) from the other 38 herds (5.9%) also tested positive for other enteric pathogens (Table 3).", [["fecal samples", "ANATOMY", 100, 113], ["fecal specimens", "ANATOMY", 194, 209], ["fecal samples", "ANATOMY", 247, 260], ["fecal samples", "ANATOMY", 338, 351], ["diarrhea", "DISEASE", 234, 242], ["BNoV", "CHEMICAL", 313, 317], ["enteric pathogens", "DISEASE", 421, 438], ["BNoV", "GENE_OR_GENE_PRODUCT", 66, 70], ["fecal samples", "CANCER", 100, 113], ["BNoV", "GENE_OR_GENE_PRODUCT", 180, 184], ["fecal specimens", "CANCER", 194, 209], ["calf", "ORGANISM", 218, 222], ["fecal samples", "CANCER", 247, 260], ["fecal samples", "CANCER", 338, 351], ["326 bp fragment", "DNA", 24, 39], ["RdRp region", "DNA", 47, 58], ["BNoV", "DNA", 66, 70], ["calf", "SPECIES", 218, 222], ["BNoV", "SPECIES", 313, 317], ["a 326 bp fragment", "TREATMENT", 22, 39], ["fecal samples", "TEST", 100, 113], ["BNoV", "TEST", 180, 184], ["fecal specimens", "TEST", 194, 209], ["diarrhea", "PROBLEM", 234, 242], ["fecal samples", "TEST", 247, 260], ["fecal samples", "TEST", 338, 351], ["herds", "TEST", 377, 382], ["other enteric pathogens", "PROBLEM", 415, 438], ["RdRp", "ANATOMY_MODIFIER", 47, 51], ["region", "ANATOMY_MODIFIER", 52, 58], ["enteric", "ANATOMY", 141, 148], ["pathogens", "OBSERVATION", 149, 158], ["fecal", "ANATOMY", 194, 199], ["calf", "ANATOMY", 218, 222]]], ["Of the concurrent infections of the BNoV with the other enteric pathogens, BRV A was the most common [15 fecal samples (2.2%) from 15 herds (2.3%)].", [["samples", "ANATOMY", 111, 118], ["infections", "DISEASE", 18, 28], ["BNoV", "CANCER", 36, 40], ["BRV A", "CANCER", 75, 80], ["BRV", "SPECIES", 75, 78], ["the concurrent infections of the BNoV", "PROBLEM", 3, 40], ["the other enteric pathogens", "PROBLEM", 46, 73], ["fecal samples", "TEST", 105, 118], ["infections", "OBSERVATION", 18, 28], ["enteric", "OBSERVATION_MODIFIER", 56, 63], ["pathogens", "OBSERVATION", 64, 73]]], ["Interestingly, one diarrheic fecal sample tested positive for four enteric pathogens including BNoV, BEC-NBV, BRV A and BVDV.", [["fecal sample", "ANATOMY", 29, 41], ["BEC-NBV", "CELL", 101, 108], ["BRV A", "CELL", 110, 115], ["BVDV", "ORGANISM", 120, 124], ["BVDV", "SPECIES", 120, 124], ["BNoV", "SPECIES", 95, 99], ["BRV", "SPECIES", 110, 113], ["BVDV", "SPECIES", 120, 124], ["one diarrheic fecal sample", "TEST", 15, 41], ["four enteric pathogens", "PROBLEM", 62, 84], ["BNoV", "TEST", 95, 99], ["BEC", "TEST", 101, 104], ["BVDV", "PROBLEM", 120, 124], ["enteric", "ANATOMY", 67, 74], ["pathogens", "OBSERVATION", 75, 84], ["BVDV", "OBSERVATION", 120, 124]]], ["In addition, 397 fecal specimens from 395 herds that tested negative for BNoV also tested positive for other enteric pathogens (Table 3).", [["fecal specimens", "ANATOMY", 17, 32], ["enteric pathogens", "DISEASE", 109, 126], ["fecal specimens", "CANCER", 17, 32], ["BNoV", "SPECIES", 73, 77], ["fecal specimens", "TEST", 17, 32], ["BNoV", "PROBLEM", 73, 77], ["other enteric pathogens", "PROBLEM", 103, 126]]], ["No enteric pathogens were detected in 189 fecal samples from 175 herds.Genetic diversity of BNoVs ::: ResultsThe genetic diversity of the BNoVs and their genetic similarity to the other genogroup strains were investigated by sequencing 326 bp of the nt 4690 to nt 5015 RdRp region from the 12 BNoVs detected from the diarrheic fecal samples.", [["fecal samples", "ANATOMY", 42, 55], ["fecal samples", "ANATOMY", 327, 340], ["fecal samples", "ORGANISM_SUBSTANCE", 42, 55], ["BNoVs", "CANCER", 138, 143], ["BNoVs", "CANCER", 293, 298], ["fecal samples", "ORGANISM_SUBSTANCE", 327, 340], ["BNoVs", "PROTEIN", 92, 97], ["BNoVs", "DNA", 138, 143], ["nt 4690 to nt 5015 RdRp region", "DNA", 250, 280], ["BNoVs", "DNA", 293, 298], ["enteric pathogens", "PROBLEM", 3, 20], ["fecal samples", "TEST", 42, 55], ["the BNoVs", "PROBLEM", 134, 143], ["the other genogroup strains", "PROBLEM", 176, 203], ["bp", "TEST", 240, 242], ["the nt", "TEST", 246, 252], ["the diarrheic fecal samples", "TEST", 313, 340], ["enteric", "ANATOMY", 3, 10], ["pathogens", "OBSERVATION", 11, 20], ["diversity", "OBSERVATION_MODIFIER", 121, 130]]], ["The alignment indicated that the Korean Bo/MA88/KOR strain clustered with the GIII-1 prototype, the Bo/Jena/DE strain, whereas the remaining 11 Korean BNoVs clustered with the GIII-2 prototype, the Bo/Newbury2/UK strain (Fig. 1).", [["MA88", "GENE_OR_GENE_PRODUCT", 43, 47], ["KOR", "GENE_OR_GENE_PRODUCT", 48, 51], ["GIII-1", "ORGANISM", 78, 84], ["BNoVs", "CANCER", 151, 156], ["UK", "GENE_OR_GENE_PRODUCT", 210, 212], ["Korean Bo/MA88/KOR strain", "SPECIES", 33, 58], ["Bo/Jena/DE strain", "SPECIES", 100, 117], ["Bo/Newbury2/UK strain", "SPECIES", 198, 219], ["the Korean Bo/MA88/KOR strain", "TREATMENT", 29, 58], ["the Bo/Jena/DE strain", "PROBLEM", 96, 117]]], ["Among the 11 Korean BNoVs, 10 Korean BNoVs clustered together on a separate branch within GIII-2, whereas the Bo/MA156/KOR, which belongs to GIII-2, clustered with the Bo/Dumfries/UK strain (Fig. 1).", [["BNoVs", "CANCER", 20, 25], ["BNoVs", "CANCER", 37, 42], ["GIII-2", "GENE_OR_GENE_PRODUCT", 90, 96], ["MA156", "GENE_OR_GENE_PRODUCT", 113, 118], ["KOR", "GENE_OR_GENE_PRODUCT", 119, 122], ["GIII-2", "GENE_OR_GENE_PRODUCT", 141, 147], ["UK", "GENE_OR_GENE_PRODUCT", 180, 182], ["GIII-2", "DNA", 90, 96], ["MA156", "DNA", 113, 118], ["KOR", "DNA", 119, 122], ["GIII-2", "DNA", 141, 147], ["Bo/Dumfries/UK strain", "SPECIES", 168, 189], ["GIII", "TEST", 141, 145], ["branch", "ANATOMY_MODIFIER", 76, 82]]], ["Among the BNoVs examined, the Korean Bo/MA88/KOR strain had the highest nt (86.8%) and aa (99.1%) identity with the GIII-1 prototype, the Bo/Jena/DE strain, but shared 75.2\u201378.2% nt and 85.2\u201390.7% aa identity with the GIII-2 BNoVs.", [["BNoVs", "CANCER", 10, 15], ["MA88", "GENE_OR_GENE_PRODUCT", 40, 44], ["KOR", "GENE_OR_GENE_PRODUCT", 45, 48], ["GIII-1", "ORGANISM", 116, 122], ["Bo/Jena/DE strain", "ORGANISM", 138, 155], ["GIII-2 BNoVs", "DNA", 218, 230], ["Korean Bo/MA88/KOR strain", "SPECIES", 30, 55], ["Bo/Jena/DE strain", "SPECIES", 138, 155], ["the Korean Bo/MA88", "TEST", 26, 44], ["KOR strain", "TEST", 45, 55], ["aa", "TEST", 87, 89], ["the GIII", "TEST", 112, 120], ["the Bo/Jena/DE strain", "TEST", 134, 155], ["nt", "TEST", 179, 181], ["aa identity", "TEST", 197, 208], ["the GIII", "TEST", 214, 222]]], ["The remaining 11 Korean BNoVs shared a higher nt (88.0\u201390.5%) and aa (93.5\u201399.1%) identity with the GIII-2 prototype, Bo/Newbery2/UK strain, than those from the GIII-1 prototype, Bo/Jena/DE strain, sharing a 73.6\u201379.1% nt and 84.3\u201389.8% aa identity.", [["BNoVs", "CANCER", 24, 29], ["Newbery2", "GENE_OR_GENE_PRODUCT", 121, 129], ["UK", "GENE_OR_GENE_PRODUCT", 130, 132], ["GIII-1", "ORGANISM", 161, 167], ["Bo/Jena/DE strain", "SPECIES", 179, 196], ["a higher nt", "PROBLEM", 37, 48], ["aa", "TEST", 66, 68], ["the GIII", "TEST", 96, 104], ["UK strain", "PROBLEM", 130, 139], ["the GIII", "TEST", 157, 165], ["nt", "TEST", 219, 221], ["aa identity", "TEST", 237, 248]]], ["In addition, the GIII-1 BNoV strains, one Korean strain Bo/MA88/KOR and one German strain (Bo/Jena/DE; Liu et al., 1999), showed a low aa identity with the human sapovirus (SaV) (24.1%), BEC-NBV (18.5%), rabbit hemorrhagic disease virus (RHDV) (21.3%), and feline calicivirus (FCV) (27.8%) strains, whereas there was slightly higher aa identity with the human GI, GII and GIV NoV (56.5\u201372.2%), porcine GII-2 NoV (59.3\u201360.2%), and murine GV NoV (50.0\u201350.9%) strains.", [["rabbit hemorrhagic disease", "DISEASE", 204, 230], ["feline calicivirus", "DISEASE", 257, 275], ["GIII-1 BNoV", "ORGANISM", 17, 28], ["KOR", "GENE_OR_GENE_PRODUCT", 64, 67], ["human", "ORGANISM", 156, 161], ["sapovirus", "GENE_OR_GENE_PRODUCT", 162, 171], ["SaV", "GENE_OR_GENE_PRODUCT", 173, 176], ["BEC-NBV", "ORGANISM", 187, 194], ["rabbit hemorrhagic disease virus", "ORGANISM", 204, 236], ["RHDV", "ORGANISM", 238, 242], ["feline calicivirus", "ORGANISM", 257, 275], ["FCV", "ORGANISM", 277, 280], ["human", "ORGANISM", 354, 359], ["GI", "CANCER", 360, 362], ["GII", "ORGANISM", 364, 367], ["GIV NoV", "ORGANISM", 372, 379], ["porcine", "ORGANISM", 394, 401], ["GII-2 NoV", "ORGANISM", 402, 411], ["murine", "ORGANISM", 430, 436], ["GV NoV", "ORGANISM", 437, 443], ["human", "SPECIES", 156, 161], ["rabbit hemorrhagic disease virus", "SPECIES", 204, 236], ["RHDV", "SPECIES", 238, 242], ["feline calicivirus", "SPECIES", 257, 275], ["human", "SPECIES", 354, 359], ["porcine", "SPECIES", 394, 401], ["murine", "SPECIES", 430, 436], ["Bo/MA88", "SPECIES", 56, 63], ["Bo/Jena/DE", "SPECIES", 91, 101], ["human sapovirus", "SPECIES", 156, 171], ["rabbit hemorrhagic disease virus", "SPECIES", 204, 236], ["RHDV", "SPECIES", 238, 242], ["feline calicivirus", "SPECIES", 257, 275], ["FCV", "SPECIES", 277, 280], ["human", "SPECIES", 354, 359], ["GIV NoV", "SPECIES", 372, 379], ["porcine GII-2 NoV", "SPECIES", 394, 411], ["murine GV NoV", "SPECIES", 430, 443], ["the GIII", "TEST", 13, 21], ["a low aa identity", "PROBLEM", 129, 146], ["the human sapovirus", "PROBLEM", 152, 171], ["BEC", "TEST", 187, 190], ["NBV", "TEST", 191, 194], ["rabbit hemorrhagic disease virus", "PROBLEM", 204, 236], ["RHDV", "TEST", 238, 242], ["feline calicivirus (FCV", "PROBLEM", 257, 280], ["strains", "PROBLEM", 290, 297], ["slightly higher aa identity", "PROBLEM", 317, 344], ["GII", "TEST", 364, 367], ["GIV NoV", "TEST", 372, 379], ["porcine GII", "TEST", 394, 405], ["murine GV NoV", "TEST", 430, 443], ["strains", "PROBLEM", 457, 464], ["feline calicivirus", "ANATOMY", 257, 275]]], ["The GIII-2 strains (Bo/MA88/KOR and Bo/Jena/DE) also had a low aa identity with the human SaV (22.2\u201323.1%), BEC-NBV (17.6\u201318.5%), RHDV (22.2\u201323.1%), and FCV (25.9%) strains, whereas there was slightly higher aa identity with the human GI, GII and GIV NoV (53.7\u201375.0%), porcine GII-2 NoV (56.5\u201360.2%), and murine GV NoV (52.8\u201354.6%) strains.DiscussionBased on a comparison of the aa and nt sequences of the partial RdRp region, the 12 BNoV strains that was detected in diarrheic fecal samples from calves in South Korea were classified as Norovirus GIII/1 (Bo/Jena/DE strain-like, 1 strain) and GIII/2 (Bo/Newbury2/UK strain-like, 11 strains).", [["GI", "ANATOMY", 235, 237], ["fecal samples", "ANATOMY", 478, 491], ["GIII-2 strains", "ORGANISM", 4, 18], ["Bo/MA88/KOR", "ORGANISM", 20, 31], ["human", "ORGANISM", 84, 89], ["SaV", "GENE_OR_GENE_PRODUCT", 90, 93], ["BEC-NBV", "CELL", 108, 115], ["RHDV", "ORGANISM", 130, 134], ["FCV", "ORGANISM", 153, 156], ["human", "ORGANISM", 229, 234], ["GI", "CANCER", 235, 237], ["GII", "ORGANISM", 239, 242], ["GIV NoV", "ORGANISM", 247, 254], ["porcine", "ORGANISM", 269, 276], ["GII-2 NoV", "ORGANISM", 277, 286], ["murine", "ORGANISM", 305, 311], ["GV NoV", "ORGANISM", 312, 318], ["BNoV", "GENE_OR_GENE_PRODUCT", 434, 438], ["fecal samples", "ORGANISM_SUBSTANCE", 478, 491], ["calves", "ORGANISM", 497, 503], ["Bo/Jena/DE strain-like", "ORGANISM", 556, 578], ["GIII/2", "ORGANISM", 594, 600], ["Newbury2/UK strain", "ORGANISM", 605, 623], ["KOR", "PROTEIN", 28, 31], ["aa and nt sequences", "DNA", 379, 398], ["partial RdRp region", "DNA", 406, 425], ["human", "SPECIES", 84, 89], ["RHDV", "SPECIES", 130, 134], ["human", "SPECIES", 229, 234], ["porcine", "SPECIES", 269, 276], ["murine", "SPECIES", 305, 311], ["calves", "SPECIES", 497, 503], ["Bo/MA88/KOR and Bo/Jena/DE", "SPECIES", 20, 46], ["human", "SPECIES", 84, 89], ["RHDV", "SPECIES", 130, 134], ["FCV", "SPECIES", 153, 156], ["human", "SPECIES", 229, 234], ["GIV NoV", "SPECIES", 247, 254], ["porcine GII-2 NoV", "SPECIES", 269, 286], ["murine GV NoV", "SPECIES", 305, 318], ["Norovirus GIII/1 (Bo/Jena/DE strain", "SPECIES", 538, 573], ["The GIII", "TEST", 0, 8], ["MA88", "TEST", 23, 27], ["a low aa identity", "PROBLEM", 57, 74], ["the human SaV", "TEST", 80, 93], ["BEC", "TEST", 108, 111], ["NBV", "TEST", 112, 115], ["RHDV", "TEST", 130, 134], ["FCV", "TEST", 153, 156], ["strains", "PROBLEM", 165, 172], ["slightly higher aa identity", "PROBLEM", 192, 219], ["GII", "TEST", 239, 242], ["GIV NoV", "TEST", 247, 254], ["porcine GII", "TEST", 269, 280], ["murine GV NoV", "TEST", 305, 318], ["strains", "PROBLEM", 332, 339], ["the aa and nt sequences", "TEST", 375, 398], ["the partial RdRp region", "PROBLEM", 402, 425], ["the 12 BNoV strains", "PROBLEM", 427, 446], ["diarrheic fecal samples", "PROBLEM", 468, 491], ["Norovirus GIII", "TEST", 538, 552], ["Bo/Jena/DE strain", "TEST", 556, 573], ["GIII", "TEST", 594, 598], ["Bo/Newbury2/UK strain", "TEST", 602, 623]]], ["These results highlight the existence of the two distinct genotypes within the group and confirming the genotype 2 as the main genotype (Oliver et al., 2003, Smiley et al., 2003, van der Poel et al., 2000, van der Poel et al., 2003, Wise et al., 2004).", [["distinct", "OBSERVATION_MODIFIER", 49, 57], ["genotypes", "OBSERVATION", 58, 67], ["main", "OBSERVATION_MODIFIER", 122, 126]]], ["The phylogenetic data for the nt and aa sequences of the partial RdRp region also support the findings (Oliver et al., 2003, Smiley et al., 2003, van der Poel et al., 2000, van der Poel et al., 2003, Wise et al., 2004) that the Korean BNoVs were classified as Norovirus GIII with the main genotype being GIII/2.", [["Norovirus", "DISEASE", 260, 269], ["BNoVs", "CANCER", 235, 240], ["nt and aa sequences", "DNA", 30, 49], ["RdRp region", "DNA", 65, 76], ["The phylogenetic data", "TEST", 0, 21], ["the nt and aa sequences", "TEST", 26, 49], ["Norovirus GIII", "PROBLEM", 260, 274], ["Norovirus", "OBSERVATION", 260, 269]]], ["These results, along with other reports (Oliver et al., 2003, Smiley et al., 2003, van der Poel et al., 2000, van der Poel et al., 2003, Wise et al., 2004), suggest GIII/2 to be the dominant genotype of BNoVs.DiscussionThe aa identity within the GIII/2 BNoVs ranged from 93.5% to 99.1% (88.0\u201390.5% nt identity), in which genetic divergence was observed not only in the Korean BNoVs but also between the Korean BNoVs and BNoVs reported in the other countries, which indicates the genetic variability in the BNoVs belonging to GIII/2.", [["GIII/2", "GENE_OR_GENE_PRODUCT", 165, 171], ["BNoVs", "CANCER", 203, 208], ["BNoVs", "CANCER", 376, 381], ["BNoVs", "CANCER", 420, 425], ["BNoVs", "GENE_OR_GENE_PRODUCT", 506, 511], ["GIII/2 BNoVs", "DNA", 246, 258], ["BNoVs", "TEST", 253, 258]]], ["This aa identity is similar to findings reported by Oliver et al. (2003) and Wise et al. (2004) who showed that the aa identity within the GIII BNoVs in England and USA shared a 92\u2013100% and 91.2\u2013100% homology with the other known strain in the partial RdRp region.", [["partial RdRp region", "DNA", 244, 263], ["the other known strain in the partial RdRp region", "PROBLEM", 214, 263], ["GIII BNoVs", "ANATOMY", 139, 149], ["strain", "OBSERVATION", 230, 236], ["partial RdRp", "OBSERVATION", 244, 256]]], ["Like the other RNA viruses, the NoVs show broad genomic sequence diversity between the circulating strains, which is partly due to the poor template fidelity of their RNA polymerases (Zheng et al., 2006).", [["NoVs", "GENE_OR_GENE_PRODUCT", 32, 36], ["NoVs", "DNA", 32, 36], ["RNA polymerases", "PROTEIN", 167, 182], ["the other RNA viruses", "PROBLEM", 5, 26], ["the NoVs", "TEST", 28, 36], ["broad genomic sequence diversity", "PROBLEM", 42, 74], ["the circulating strains", "PROBLEM", 83, 106], ["RNA viruses", "OBSERVATION", 15, 26], ["circulating strains", "OBSERVATION", 87, 106]]], ["Therefore, it is expected that more genetic clusters will be identigied within GIII in the future when more sequence data of the BNoVs circulating in cattle becomes available.DiscussionThe fecal prevalence of BNoV infections in diarrheic calves have been reported to be 8.0% in England (Oliver et al., 2003), 31.1% in The Netherlands, and 72.0% in the Ohio, USA (Smiley et al., 2003).", [["fecal", "ANATOMY", 189, 194], ["BNoV infections", "DISEASE", 209, 224], ["diarrheic", "DISEASE", 228, 237], ["BNoVs", "GENE_OR_GENE_PRODUCT", 129, 134], ["cattle", "ORGANISM", 150, 156], ["fecal", "ORGANISM_SUBDIVISION", 189, 194], ["BNoV", "ORGANISM", 209, 213], ["calves", "ORGANISM", 238, 244], ["cattle", "SPECIES", 150, 156], ["calves", "SPECIES", 238, 244], ["cattle", "SPECIES", 150, 156], ["BNoV", "SPECIES", 209, 213], ["BNoV infections", "PROBLEM", 209, 224], ["diarrheic calves", "PROBLEM", 228, 244], ["fecal", "ANATOMY", 189, 194], ["infections", "OBSERVATION", 214, 224]]], ["Based on the nested PCR assay, the BNoVs were detected in 9.3% of the fecal samples examined in this study.", [["fecal samples", "ANATOMY", 70, 83], ["BNoVs", "GENE_OR_GENE_PRODUCT", 35, 40], ["BNoVs", "DNA", 35, 40], ["the nested PCR assay", "TEST", 9, 29], ["the BNoVs", "TEST", 31, 40], ["the fecal samples", "TEST", 66, 83], ["this study", "TEST", 96, 106]]], ["This suggests that BNoV infection are endemic in diarrheic calves in South Korea in a similar manner to the prevalence of BNoV infections in England (Oliver et al., 2003).DiscussionAlthough it was reported that BNoVs induce diarrhea in experimental calves (Bridger et al., 1984), the pathogenicity and mechanisms of BNoVs infections are largely obscure.", [["infection", "DISEASE", 24, 33], ["diarrheic", "DISEASE", 49, 58], ["BNoV infections", "DISEASE", 122, 137], ["BNoVs", "CHEMICAL", 211, 216], ["diarrhea", "DISEASE", 224, 232], ["infections", "DISEASE", 322, 332], ["BNoV", "GENE_OR_GENE_PRODUCT", 19, 23], ["calves", "ORGANISM_SUBDIVISION", 59, 65], ["BNoVs", "SIMPLE_CHEMICAL", 211, 216], ["calves", "ORGANISM", 249, 255], ["BNoVs", "GENE_OR_GENE_PRODUCT", 316, 321], ["calves", "SPECIES", 59, 65], ["calves", "SPECIES", 249, 255], ["BNoV", "SPECIES", 19, 23], ["BNoV", "SPECIES", 122, 126], ["calves", "SPECIES", 249, 255], ["BNoV infection", "PROBLEM", 19, 33], ["diarrheic calves", "PROBLEM", 49, 65], ["BNoV infections", "PROBLEM", 122, 137], ["diarrhea", "PROBLEM", 224, 232], ["the pathogenicity", "PROBLEM", 280, 297], ["BNoVs infections", "PROBLEM", 316, 332], ["BNoV", "OBSERVATION_MODIFIER", 19, 23], ["infection", "OBSERVATION", 24, 33], ["endemic", "OBSERVATION_MODIFIER", 38, 45], ["diarrheic calves", "OBSERVATION", 49, 65], ["infections", "OBSERVATION", 127, 137], ["diarrhea", "OBSERVATION", 224, 232], ["BNoVs infections", "OBSERVATION", 316, 332]]], ["Therefore, other bovine enteric pathogens might play a role in the clinical and pathological presentation of this disease because many other enteric viruses have been found to be associated with diarrhea in cattle and cause lesions of villous atrophy (BRVs, BCoVs, BToVs, BEC-NBV, etc.).", [["lesions", "ANATOMY", 224, 231], ["villous", "ANATOMY", 235, 242], ["BRVs", "ANATOMY", 252, 256], ["diarrhea", "DISEASE", 195, 203], ["villous atrophy", "DISEASE", 235, 250], ["bovine", "ORGANISM", 17, 23], ["lesions", "PATHOLOGICAL_FORMATION", 224, 231], ["villous", "TISSUE", 235, 242], ["bovine", "SPECIES", 17, 23], ["cattle", "SPECIES", 207, 213], ["bovine", "SPECIES", 17, 23], ["cattle", "SPECIES", 207, 213], ["other bovine enteric pathogens", "PROBLEM", 11, 41], ["this disease", "PROBLEM", 109, 121], ["many other enteric viruses", "PROBLEM", 130, 156], ["diarrhea", "PROBLEM", 195, 203], ["lesions", "PROBLEM", 224, 231], ["villous atrophy", "PROBLEM", 235, 250], ["BRVs", "TEST", 252, 256], ["BCoVs", "TEST", 258, 263], ["BToVs", "TEST", 265, 270], ["lesions", "OBSERVATION", 224, 231], ["villous atrophy", "OBSERVATION", 235, 250]]], ["In this study, 5.9% of the diarrheic fecal samples testing positive to the BNoVs also tested positive to other pathogens including the BEC-NBV, BRVs A, B and C, BCoV, BToV, BVDV and shiga-toxin-producing E. coli.", [["fecal samples", "ANATOMY", 37, 50], ["fecal samples", "ORGANISM_SUBSTANCE", 37, 50], ["BNoVs", "GENE_OR_GENE_PRODUCT", 75, 80], ["BEC-NBV", "CELL", 135, 142], ["BRVs A", "CELL", 144, 150], ["B", "GENE_OR_GENE_PRODUCT", 152, 153], ["C", "GENE_OR_GENE_PRODUCT", 158, 159], ["BCoV", "GENE_OR_GENE_PRODUCT", 161, 165], ["BToV", "GENE_OR_GENE_PRODUCT", 167, 171], ["BVDV", "ORGANISM", 173, 177], ["shiga-toxin", "ORGANISM", 182, 193], ["E. coli", "ORGANISM", 204, 211], ["BVDV", "SPECIES", 173, 177], ["E. coli", "SPECIES", 204, 211], ["BRVs", "SPECIES", 144, 148], ["BCoV", "SPECIES", 161, 165], ["BToV", "SPECIES", 167, 171], ["BVDV", "SPECIES", 173, 177], ["E. coli", "SPECIES", 204, 211], ["this study", "TEST", 3, 13], ["the diarrheic fecal samples testing", "TEST", 23, 58], ["the BNoVs", "TEST", 71, 80], ["other pathogens", "PROBLEM", 105, 120], ["the BEC", "TEST", 131, 138], ["NBV", "TEST", 139, 142], ["BRVs", "TEST", 144, 148], ["C", "TEST", 158, 159], ["BCoV", "TEST", 161, 165], ["BToV", "TEST", 167, 171], ["BVDV", "PROBLEM", 173, 177], ["shiga-toxin", "TEST", 182, 193], ["E. coli", "PROBLEM", 204, 211], ["E. coli", "OBSERVATION", 204, 211]]], ["This suggests that a number of enteric pathogens, either singly or in combination, can influence the clinical course of BNoV infections (Almeida et al., 1978, Reynolds et al., 1986, Woode and Bridger, 1978).DiscussionIn summary, this study identified the existence of two distinct genotypes of BNoVs within the GIII, and confirmed the GIII/2 BNoVs to be the principal genotype, which is analogous to the previously reported BNoV genogroup and genotypes.", [["infections", "DISEASE", 125, 135], ["BNoV", "ORGANISM", 120, 124], ["BNoVs", "GENE_OR_GENE_PRODUCT", 294, 299], ["BNoVs", "GENE_OR_GENE_PRODUCT", 342, 347], ["BNoV", "GENE_OR_GENE_PRODUCT", 424, 428], ["BNoV", "SPECIES", 120, 124], ["enteric pathogens", "PROBLEM", 31, 48], ["BNoV infections", "PROBLEM", 120, 135], ["this study", "TEST", 229, 239], ["BNoVs within the GIII", "PROBLEM", 294, 315], ["number", "OBSERVATION_MODIFIER", 21, 27], ["enteric", "OBSERVATION_MODIFIER", 31, 38], ["pathogens", "OBSERVATION", 39, 48], ["distinct", "OBSERVATION_MODIFIER", 272, 280], ["genotypes", "OBSERVATION", 281, 290], ["GIII", "ANATOMY", 311, 315]]], ["In addition, these BNoVs cause endemic infections in diarrheic calves in South Korea.", [["BNoVs", "CHEMICAL", 19, 24], ["infections", "DISEASE", 39, 49], ["diarrheic", "DISEASE", 53, 62], ["BNoVs", "GENE_OR_GENE_PRODUCT", 19, 24], ["calves", "ORGANISM_SUBDIVISION", 63, 69], ["calves", "SPECIES", 63, 69], ["endemic infections in diarrheic calves", "PROBLEM", 31, 69], ["endemic", "OBSERVATION_MODIFIER", 31, 38], ["infections", "OBSERVATION", 39, 49], ["diarrheic calves", "OBSERVATION", 53, 69]]]], "PMC3163371": [["IntroductionAfrican sleeping sickness remains one of the most neglected life threatening diseases that have been left untreated till date.", [["sleeping sickness", "DISEASE", 20, 37], ["IntroductionAfrican sleeping sickness", "PROBLEM", 0, 37], ["left", "ANATOMY_MODIFIER", 113, 117]]], ["Two forms of human African trypanosomiasis (HAT) have been identified that are parasite dependent.", [["human African trypanosomiasis", "DISEASE", 13, 42], ["HAT", "DISEASE", 44, 47], ["human", "ORGANISM", 13, 18], ["African trypanosomiasis", "ORGANISM", 19, 42], ["HAT", "CANCER", 44, 47], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["human African trypanosomiasis", "PROBLEM", 13, 42], ["parasite dependent", "PROBLEM", 79, 97], ["parasite", "OBSERVATION_MODIFIER", 79, 87], ["dependent", "OBSERVATION_MODIFIER", 88, 97]]], ["The first one Trypanosoma brucei gambiense (T. b. gambiense) causes a human chronic infection, endemic in Western and Central Africa while the other Trypanosoma brucei rhodesiense (T. b. rhodesiense) has a vast animal reservoir and causes acute illness in people in eastern and Southern African countries.", [["Trypanosoma brucei gambiense", "DISEASE", 14, 42], ["T. b. gambiense", "DISEASE", 44, 59], ["chronic infection", "DISEASE", 76, 93], ["Trypanosoma brucei rhodesiense", "DISEASE", 149, 179], ["T. b. rhodesiense", "DISEASE", 181, 198], ["acute illness", "DISEASE", 239, 252], ["Trypanosoma brucei gambiense", "ORGANISM", 14, 42], ["T. b. gambiense", "ORGANISM", 44, 59], ["human", "ORGANISM", 70, 75], ["Trypanosoma brucei rhodesiense", "ORGANISM", 149, 179], ["T. b. rhodesiense", "ORGANISM", 181, 198], ["people", "ORGANISM", 256, 262], ["Trypanosoma brucei", "SPECIES", 14, 32], ["gambiense", "SPECIES", 33, 42], ["T.", "SPECIES", 44, 46], ["b. gambiense", "SPECIES", 47, 59], ["human", "SPECIES", 70, 75], ["Trypanosoma brucei", "SPECIES", 149, 167], ["rhodesiense", "SPECIES", 168, 179], ["T. b. rhodesiense", "SPECIES", 181, 198], ["people", "SPECIES", 256, 262], ["Trypanosoma brucei gambiense", "SPECIES", 14, 42], ["T. b. gambiense", "SPECIES", 44, 59], ["human", "SPECIES", 70, 75], ["Trypanosoma brucei rhodesiense", "SPECIES", 149, 179], ["T. b. rhodesiense", "SPECIES", 181, 198], ["The first one Trypanosoma brucei gambiense", "PROBLEM", 0, 42], ["a human chronic infection", "PROBLEM", 68, 93], ["Central Africa", "PROBLEM", 118, 132], ["the other Trypanosoma brucei rhodesiense", "PROBLEM", 139, 179], ["a vast animal reservoir", "TREATMENT", 204, 227], ["acute illness", "PROBLEM", 239, 252], ["Trypanosoma", "OBSERVATION_MODIFIER", 14, 25], ["brucei gambiense", "OBSERVATION", 26, 42], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["infection", "OBSERVATION", 84, 93], ["Central", "OBSERVATION_MODIFIER", 118, 125], ["Africa", "OBSERVATION_MODIFIER", 126, 132], ["Trypanosoma", "OBSERVATION", 149, 160], ["brucei rhodesiense", "OBSERVATION", 161, 179], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["illness", "OBSERVATION", 245, 252]]], ["HAT has high occurance in the remote rural areas, where the surveillance is weak or nonexistent, with 50 to 70 thousand estimated cases.", [["high occurance", "PROBLEM", 8, 22], ["high", "OBSERVATION_MODIFIER", 8, 12], ["occurance", "OBSERVATION_MODIFIER", 13, 22], ["weak", "OBSERVATION", 76, 80]]], ["According to World Health Organization (WHO) estimation there are half-million cases of HAT or \u201csleeping sickness\u201d resulting from infections with T. brucei rhodesiense and T. brucei gambiense.", [["HAT", "DISEASE", 88, 91], ["sleeping sickness", "DISEASE", 96, 113], ["infections", "DISEASE", 130, 140], ["T. brucei rhodesiense", "DISEASE", 146, 167], ["T. brucei gambiense", "DISEASE", 172, 191], ["T. brucei rhodesiense", "ORGANISM", 146, 167], ["T. brucei gambiense", "ORGANISM", 172, 191], ["T. brucei", "SPECIES", 146, 155], ["rhodesiense", "SPECIES", 156, 167], ["T. brucei", "SPECIES", 172, 181], ["gambiense", "SPECIES", 182, 191], ["T. brucei rhodesiense", "SPECIES", 146, 167], ["T. brucei gambiense", "SPECIES", 172, 191], ["HAT", "PROBLEM", 88, 91], ["sleeping sickness", "PROBLEM", 96, 113], ["infections", "PROBLEM", 130, 140], ["T. brucei rhodesiense", "PROBLEM", 146, 167], ["T. brucei gambiense", "PROBLEM", 172, 191], ["brucei rhodesiense", "OBSERVATION", 149, 167], ["brucei gambiense", "OBSERVATION", 175, 191]]], ["WHO has attributed 50.000 deaths annually to the disease [1].", [["deaths", "DISEASE", 26, 32]]], ["By more recent estimates, up to 25.000 new cases occur per year, and 50 million people are at risk [2, 3].IntroductionOut of six clinically approved drugs for the treatment of HAT, five (suramin, pentamidine, melarsoprol, eflornithine and nifurtimox) have had been discovered more than 30 years ago.", [["HAT", "DISEASE", 176, 179], ["suramin", "CHEMICAL", 187, 194], ["pentamidine", "CHEMICAL", 196, 207], ["melarsoprol", "CHEMICAL", 209, 220], ["eflornithine", "CHEMICAL", 222, 234], ["nifurtimox", "CHEMICAL", 239, 249], ["suramin", "CHEMICAL", 187, 194], ["pentamidine", "CHEMICAL", 196, 207], ["melarsoprol", "CHEMICAL", 209, 220], ["eflornithine", "CHEMICAL", 222, 234], ["nifurtimox", "CHEMICAL", 239, 249], ["people", "ORGANISM", 80, 86], ["suramin", "SIMPLE_CHEMICAL", 187, 194], ["pentamidine", "SIMPLE_CHEMICAL", 196, 207], ["melarsoprol", "SIMPLE_CHEMICAL", 209, 220], ["eflornithine", "SIMPLE_CHEMICAL", 222, 234], ["nifurtimox", "SIMPLE_CHEMICAL", 239, 249], ["people", "SPECIES", 80, 86], ["drugs", "TREATMENT", 149, 154], ["the treatment of HAT", "TREATMENT", 159, 179], ["suramin", "TREATMENT", 187, 194], ["pentamidine", "TREATMENT", 196, 207], ["melarsoprol", "TREATMENT", 209, 220], ["eflornithine", "TREATMENT", 222, 234], ["nifurtimox", "TREATMENT", 239, 249]]], ["Because suramin and pentamidine are ionized at physiological pH, they are unable to cross the blood brain barrier in therapeutic concentrations and are thus used for the treatment of hemolymphatic early stage HAT, caused by T. b. rhodesiense and T. b. gambiense infections, respectively.", [["blood brain barrier", "ANATOMY", 94, 113], ["suramin", "CHEMICAL", 8, 15], ["pentamidine", "CHEMICAL", 20, 31], ["HAT", "DISEASE", 209, 212], ["T. b. rhodesiense", "DISEASE", 224, 241], ["T. b. gambiense infections", "DISEASE", 246, 272], ["suramin", "CHEMICAL", 8, 15], ["pentamidine", "CHEMICAL", 20, 31], ["suramin", "SIMPLE_CHEMICAL", 8, 15], ["pentamidine", "SIMPLE_CHEMICAL", 20, 31], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 94, 113], ["T. b. rhodesiense", "ORGANISM", 224, 241], ["T. b. gambiense", "ORGANISM", 246, 261], ["infections", "ORGANISM", 262, 272], ["T.", "SPECIES", 224, 226], ["b. rhodesiense", "SPECIES", 227, 241], ["T. b. gambiense", "SPECIES", 246, 261], ["T. b. rhodesiense", "SPECIES", 224, 241], ["T. b. gambiense", "SPECIES", 246, 261], ["suramin", "TREATMENT", 8, 15], ["pentamidine", "TREATMENT", 20, 31], ["the treatment", "TREATMENT", 166, 179], ["hemolymphatic early stage HAT", "PROBLEM", 183, 212], ["T. b. rhodesiense", "PROBLEM", 224, 241], ["T. b. gambiense infections", "PROBLEM", 246, 272]]], ["The treatment of the second or neurological stage, when the parasites invade the central nervous system (CNS), relies on the organo-arsenical drug melarsoprol and the more recently registered eflornithine.", [["neurological", "ANATOMY", 31, 43], ["central nervous system", "ANATOMY", 81, 103], ["CNS", "ANATOMY", 105, 108], ["melarsoprol", "CHEMICAL", 147, 158], ["eflornithine", "CHEMICAL", 192, 204], ["melarsoprol", "CHEMICAL", 147, 158], ["eflornithine", "CHEMICAL", 192, 204], ["central nervous system", "ANATOMICAL_SYSTEM", 81, 103], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["melarsoprol", "SIMPLE_CHEMICAL", 147, 158], ["eflornithine", "SIMPLE_CHEMICAL", 192, 204], ["The treatment", "TREATMENT", 0, 13], ["neurological stage", "PROBLEM", 31, 49], ["the parasites", "PROBLEM", 56, 69], ["the organo-arsenical drug melarsoprol", "TREATMENT", 121, 158], ["central", "ANATOMY_MODIFIER", 81, 88], ["nervous system", "ANATOMY", 89, 103]]], ["The latter is ineffective against T. b. rhodesiense sleeping sickness and is used primarily to control CNS-involved HAT caused by T. b. gambiense.", [["CNS", "ANATOMY", 103, 106], ["sleeping sickness", "DISEASE", 52, 69], ["HAT", "DISEASE", 116, 119], ["T. b. gambiense", "DISEASE", 130, 145], ["T. b. rhodesiense", "ORGANISM", 34, 51], ["CNS", "ANATOMICAL_SYSTEM", 103, 106], ["T. b. gambiense", "ORGANISM", 130, 145], ["T.", "SPECIES", 34, 36], ["b. rhodesiense", "SPECIES", 37, 51], ["T.", "SPECIES", 130, 132], ["b. gambiense", "SPECIES", 133, 145], ["T. b. rhodesiense", "SPECIES", 34, 51], ["T. b. gambiense", "SPECIES", 130, 145], ["T. b. rhodesiense sleeping sickness", "PROBLEM", 34, 69], ["ineffective", "OBSERVATION_MODIFIER", 14, 25]]], ["All the existing anti-trypanosomal therapies suffer from unacceptable toxicity, poor efficacy, difficulties of administration, and increasing treatment failures due to the development of parasite resistance [4\u20139].", [["toxicity", "DISEASE", 70, 78], ["anti-trypanosomal therapies", "TREATMENT", 17, 44], ["unacceptable toxicity", "PROBLEM", 57, 78], ["increasing treatment failures", "TREATMENT", 131, 160], ["parasite resistance", "PROBLEM", 187, 206], ["parasite resistance", "OBSERVATION", 187, 206]]], ["In the last couple of decades, no new drug has been developed for treatment of early-stage HAT, and only one drug has been developed for late-stage HAT [1, 3, 5].", [["HAT", "DISEASE", 91, 94], ["early-stage HAT", "PROBLEM", 79, 94], ["no", "UNCERTAINTY", 31, 33], ["new", "OBSERVATION_MODIFIER", 34, 37], ["drug", "OBSERVATION", 38, 42], ["stage HAT", "OBSERVATION_MODIFIER", 85, 94]]], ["The need is great for new orally active drugs for the control and eradication of this disease.IntroductionNovel medicines are typically developed using a trial-and-error approach, which is time-consuming and costly but yet has the potential to yield new drugs.", [["orally", "ANATOMY", 26, 32], ["new orally active drugs", "TREATMENT", 22, 45], ["the control", "TREATMENT", 50, 61], ["this disease", "PROBLEM", 81, 93], ["new drugs", "TREATMENT", 250, 259], ["great", "OBSERVATION_MODIFIER", 12, 17]]], ["The application of computer-assisted drug design (CADD) methodologies to this problem has the potential to greatly decrease the time and effort required to discover new medicines or improve current ones in term of their efficacy.IntroductionThis review focuses on the synthetic and computer-assisted drug design (CADD) approaches made by various research groups for the development of newer anti-trypanosomal agents having improved efficacy and oral bioavailability.", [["oral", "ANATOMY", 445, 449], ["oral", "ORGANISM_SUBDIVISION", 445, 449], ["computer-assisted drug design (CADD) methodologies", "TREATMENT", 19, 69], ["new medicines", "TREATMENT", 165, 178], ["computer-assisted drug design (CADD) approaches", "TREATMENT", 282, 329], ["newer anti-trypanosomal agents", "TREATMENT", 385, 415], ["oral bioavailability", "TREATMENT", 445, 465]]], ["The current research also endeavors [10] to investigate the relationship between the various physio-chemical parameters and anti-trypanosomal activity that may be helpful in development of potent anti-trypanosomal agents against sleeping sickness.Pentamidine analogues ::: DNA minor groove binders ::: Synthetic advancesLarge numbers of structurally related congeners of pentamidine were synthesized by Tidwell RR et al [24] by introducing substitutions on the cationic groups, changing the position of dications from 4,4\u2032 to 3,3\u2032 position, changing the length of the aliphatic chain between the two aromatic rings, adding substituent on the aromatic rings at 2,2\u2032 and 3,3\u2032 position and replacing oxygen atoms in the alkyl linker with isosteric sulfur or nitrogen atoms (Figure 2a\u2013g).", [["anti-trypanosomal", "ANATOMY", 196, 213], ["sleeping sickness", "DISEASE", 229, 246], ["Pentamidine", "CHEMICAL", 247, 258], ["pentamidine", "CHEMICAL", 371, 382], ["oxygen", "CHEMICAL", 697, 703], ["alkyl", "CHEMICAL", 717, 722], ["isosteric sulfur", "CHEMICAL", 735, 751], ["Pentamidine", "CHEMICAL", 247, 258], ["pentamidine", "CHEMICAL", 371, 382], ["oxygen", "CHEMICAL", 697, 703], ["sulfur", "CHEMICAL", 745, 751], ["nitrogen", "CHEMICAL", 755, 763], ["Pentamidine", "SIMPLE_CHEMICAL", 247, 258], ["DNA", "CELLULAR_COMPONENT", 273, 276], ["pentamidine", "SIMPLE_CHEMICAL", 371, 382], ["2,2\u2032", "SIMPLE_CHEMICAL", 660, 664], ["3,3\u2032 position", "SIMPLE_CHEMICAL", 669, 682], ["oxygen atoms", "SIMPLE_CHEMICAL", 697, 709], ["isosteric sulfur", "SIMPLE_CHEMICAL", 735, 751], ["nitrogen atoms", "SIMPLE_CHEMICAL", 755, 769], ["4,4\u2032 to 3,3\u2032 position", "PROTEIN", 518, 539], ["anti-trypanosomal activity", "TREATMENT", 124, 150], ["potent anti-trypanosomal agents", "TREATMENT", 189, 220], ["sleeping sickness", "PROBLEM", 229, 246], ["Pentamidine analogues", "TREATMENT", 247, 268], ["pentamidine", "TREATMENT", 371, 382], ["substitutions on the cationic groups", "TREATMENT", 440, 476], ["the aliphatic chain", "TREATMENT", 564, 583], ["the two aromatic rings", "TREATMENT", 592, 614], ["the aromatic rings", "TREATMENT", 638, 656], ["oxygen atoms in the alkyl linker", "TREATMENT", 697, 729], ["isosteric sulfur or nitrogen atoms", "TREATMENT", 735, 769], ["groove", "OBSERVATION_MODIFIER", 283, 289], ["binders", "OBSERVATION", 290, 297], ["aliphatic chain", "OBSERVATION", 568, 583], ["aromatic rings", "OBSERVATION", 600, 614], ["aromatic rings", "OBSERVATION", 642, 656], ["oxygen atoms", "OBSERVATION", 697, 709]]], ["On comparing the activities of the synthesized compounds with pentamidine and melarsoprol, it was found that few compounds showed activity in the range or better than that of pentamidine and/or melarsoprol.", [["pentamidine", "CHEMICAL", 62, 73], ["melarsoprol", "CHEMICAL", 78, 89], ["pentamidine", "CHEMICAL", 175, 186], ["melarsoprol", "CHEMICAL", 194, 205], ["pentamidine", "CHEMICAL", 62, 73], ["melarsoprol", "CHEMICAL", 78, 89], ["pentamidine", "CHEMICAL", 175, 186], ["melarsoprol", "CHEMICAL", 194, 205], ["pentamidine", "SIMPLE_CHEMICAL", 62, 73], ["melarsoprol", "SIMPLE_CHEMICAL", 78, 89], ["pentamidine", "SIMPLE_CHEMICAL", 175, 186], ["melarsoprol", "SIMPLE_CHEMICAL", 194, 205], ["pentamidine", "TREATMENT", 62, 73], ["melarsoprol", "TREATMENT", 78, 89], ["pentamidine", "TREATMENT", 175, 186], ["melarsoprol", "TREATMENT", 194, 205], ["activity", "OBSERVATION_MODIFIER", 130, 138]]], ["The unsubstituted diamidine compound 64 (Figure 3a) with secondary amino group in place of oxygen atom exhibited subnanomolar activity (<0.001 \u03bcM) against T. b. rhodesiense and was nearly twice as selective against the pathogen as pentamidine.", [["diamidine", "CHEMICAL", 18, 27], ["amino", "CHEMICAL", 67, 72], ["oxygen", "CHEMICAL", 91, 97], ["T. b. rhodesiense", "DISEASE", 155, 172], ["pentamidine", "CHEMICAL", 231, 242], ["diamidine", "CHEMICAL", 18, 27], ["amino", "CHEMICAL", 67, 72], ["oxygen", "CHEMICAL", 91, 97], ["pentamidine", "CHEMICAL", 231, 242], ["diamidine compound 64", "SIMPLE_CHEMICAL", 18, 39], ["amino", "AMINO_ACID", 67, 72], ["oxygen atom", "SIMPLE_CHEMICAL", 91, 102], ["T. b. rhodesiense", "ORGANISM", 155, 172], ["pentamidine", "SIMPLE_CHEMICAL", 231, 242], ["T. b. rhodesiense", "SPECIES", 155, 172], ["T. b. rhodesiense", "SPECIES", 155, 172], ["The unsubstituted diamidine compound", "TREATMENT", 0, 36], ["secondary amino group", "TREATMENT", 57, 78], ["oxygen atom", "PROBLEM", 91, 102], ["subnanomolar activity", "PROBLEM", 113, 134], ["T. b. rhodesiense", "PROBLEM", 155, 172], ["pentamidine", "TREATMENT", 231, 242], ["amino group", "OBSERVATION", 67, 78], ["subnanomolar activity", "OBSERVATION", 113, 134]]], ["At the same time the diimidazoline compound 66 (Figure 3b) exhibited the second highest anti-trypanosomal activity in the series with the IC50 value of 0.001 \u03bcM and also had the highest parasite selectivity (SIT= 34500), being 63 times more selective against T. b. rhodesiense than pentamidine.", [["diimidazoline", "CHEMICAL", 21, 34], ["pentamidine", "CHEMICAL", 282, 293], ["diimidazoline", "CHEMICAL", 21, 34], ["pentamidine", "CHEMICAL", 282, 293], ["diimidazoline", "SIMPLE_CHEMICAL", 21, 34], ["T. b. rhodesiense", "ORGANISM", 259, 276], ["pentamidine", "SIMPLE_CHEMICAL", 282, 293], ["T. b. rhodesiense", "SPECIES", 259, 276], ["T. b. rhodesiense", "SPECIES", 259, 276], ["the diimidazoline compound", "TREATMENT", 17, 43], ["the IC50 value", "TEST", 134, 148], ["pentamidine", "TREATMENT", 282, 293]]], ["The replacement of oxygen atom with sulphur atom as in compound 62 (Figure 3c) also generated active congeners having IC50 (0.005 \u03bcM) value better than that of pentamidine (0.007 \u03bcM).", [["oxygen", "CHEMICAL", 19, 25], ["sulphur atom", "CHEMICAL", 36, 48], ["pentamidine", "CHEMICAL", 160, 171], ["oxygen", "CHEMICAL", 19, 25], ["sulphur", "CHEMICAL", 36, 43], ["pentamidine", "CHEMICAL", 160, 171], ["oxygen atom", "SIMPLE_CHEMICAL", 19, 30], ["sulphur atom", "SIMPLE_CHEMICAL", 36, 48], ["pentamidine", "SIMPLE_CHEMICAL", 160, 171], ["The replacement of oxygen atom", "TREATMENT", 0, 30], ["sulphur atom", "PROBLEM", 36, 48], ["IC50", "TEST", 118, 122], ["pentamidine", "TREATMENT", 160, 171], ["replacement", "OBSERVATION", 4, 15], ["oxygen atom", "OBSERVATION", 19, 30], ["sulphur atom", "OBSERVATION", 36, 48]]], ["The compounds 20\u201331 (Figure 2c) in which the cationic groups were present in the 3,3\u2032-position of the aromatic rings and the length of the carbon linker was varied from 3\u20136 exhibited lower anti-trypanosomal activity compared to pentamidine whereas among the compounds 12\u201319 (Figure 2b) of the series, in which the amidine groups were present at 4,4\u2032 position and the length of aliphatic chain was varied from three carbon atoms to six carbon atoms, compound 12 (Figure 3d, IC50=0.007 \u03bcM) with three methylene linker between the aromatic rings had same in vitro activity as that of pentamidine (0.007 \u03bcM).", [["carbon", "CHEMICAL", 139, 145], ["3\u20136", "CHEMICAL", 169, 172], ["pentamidine", "CHEMICAL", 228, 239], ["amidine", "CHEMICAL", 314, 321], ["aliphatic", "CHEMICAL", 377, 386], ["carbon atoms", "CHEMICAL", 435, 447], ["methylene", "CHEMICAL", 499, 508], ["pentamidine", "CHEMICAL", 581, 592], ["carbon", "CHEMICAL", 139, 145], ["pentamidine", "CHEMICAL", 228, 239], ["amidine", "CHEMICAL", 314, 321], ["carbon", "CHEMICAL", 415, 421], ["carbon", "CHEMICAL", 435, 441], ["methylene", "CHEMICAL", 499, 508], ["pentamidine", "CHEMICAL", 581, 592], ["3\u20136", "SIMPLE_CHEMICAL", 169, 172], ["pentamidine", "SIMPLE_CHEMICAL", 228, 239], ["amidine", "SIMPLE_CHEMICAL", 314, 321], ["carbon atoms", "SIMPLE_CHEMICAL", 415, 427], ["carbon atoms", "SIMPLE_CHEMICAL", 435, 447], ["methylene linker", "SIMPLE_CHEMICAL", 499, 515], ["pentamidine", "SIMPLE_CHEMICAL", 581, 592], ["the cationic groups", "TREATMENT", 41, 60], ["the aromatic rings", "TREATMENT", 98, 116], ["the carbon linker", "TREATMENT", 135, 152], ["lower anti-trypanosomal activity", "PROBLEM", 183, 215], ["pentamidine", "TREATMENT", 228, 239], ["the series", "TEST", 289, 299], ["the amidine groups", "TREATMENT", 310, 328], ["the length of aliphatic chain", "TREATMENT", 363, 392], ["IC50", "TEST", 473, 477], ["three methylene linker", "TREATMENT", 493, 515], ["the aromatic rings", "TREATMENT", 524, 542], ["pentamidine", "TREATMENT", 581, 592], ["aromatic rings", "OBSERVATION", 102, 116], ["length", "OBSERVATION_MODIFIER", 125, 131], ["carbon linker", "OBSERVATION", 139, 152], ["lower", "OBSERVATION_MODIFIER", 183, 188], ["anti-trypanosomal activity", "OBSERVATION", 189, 215], ["length", "OBSERVATION_MODIFIER", 367, 373], ["aliphatic chain", "OBSERVATION", 377, 392], ["aromatic rings", "OBSERVATION", 528, 542]]], ["Further introduction of 2,2\u2032-dichloro substituent in compound 12 improved the anti-trypanosomal properties as evident from the in vitro activity of compound 32 (Figure 3e, IC50=0.004 \u03bcM).Pentamidine analogues ::: DNA minor groove binders ::: Synthetic advancesThese compounds having excellent in vitro activity were evaluated in vivo in the STIB900 mouse model of African trypanosomiasis.", [["anti-trypanosomal", "ANATOMY", 78, 95], ["2,2\u2032-dichloro substituent", "CHEMICAL", 24, 49], ["compound 32", "CHEMICAL", 148, 159], ["Pentamidine", "CHEMICAL", 187, 198], ["trypanosomiasis", "DISEASE", 372, 387], ["2,2\u2032-dichloro", "CHEMICAL", 24, 37], ["Pentamidine", "CHEMICAL", 187, 198], ["2,2\u2032-dichloro substituent", "SIMPLE_CHEMICAL", 24, 49], ["compound 12", "SIMPLE_CHEMICAL", 53, 64], ["Pentamidine", "SIMPLE_CHEMICAL", 187, 198], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["mouse", "ORGANISM", 349, 354], ["mouse", "SPECIES", 349, 354], ["mouse", "SPECIES", 349, 354], ["Further introduction of 2,2\u2032-dichloro substituent", "TREATMENT", 0, 49], ["IC50", "TEST", 172, 176], ["Pentamidine analogues", "TREATMENT", 187, 208], ["African trypanosomiasis", "PROBLEM", 364, 387], ["groove", "OBSERVATION_MODIFIER", 223, 229], ["binders", "OBSERVATION", 230, 237], ["excellent", "OBSERVATION_MODIFIER", 283, 292]]], ["The screening was conducted using intraperitoneal dosing at 20 mg/kg daily for four days.", [["intraperitoneal", "ANATOMY", 34, 49], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 49], ["The screening", "TEST", 0, 13], ["intraperitoneal dosing", "TREATMENT", 34, 56]]], ["The compounds 12, 62 and 64 showed very poor in vivo activity, whereas compound 32 and 66 exhibited excellent in vivo efficacies in the acute mouse model of trypanosomiasis, providing cures of all infected animals.Pentamidine analogues ::: DNA minor groove binders ::: Synthetic advancesThus, because of high selectivity, excellent in vitro and in vivo activity compounds 66 and 32 can serve as a novel lead for further pre-clinical and clinical trials, but its cytotoxcity profile needs to be monitored during its evaluation.", [["compounds 12, 62 and 64", "CHEMICAL", 4, 27], ["trypanosomiasis", "DISEASE", 157, 172], ["Pentamidine", "CHEMICAL", 214, 225], ["Pentamidine", "CHEMICAL", 214, 225], ["mouse", "ORGANISM", 142, 147], ["Pentamidine", "SIMPLE_CHEMICAL", 214, 225], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["mouse", "SPECIES", 142, 147], ["mouse", "SPECIES", 142, 147], ["trypanosomiasis", "SPECIES", 157, 172], ["The compounds", "TEST", 0, 13], ["trypanosomiasis", "PROBLEM", 157, 172], ["Pentamidine analogues", "TREATMENT", 214, 235], ["high selectivity", "PROBLEM", 304, 320], ["its cytotoxcity profile", "TEST", 458, 481], ["its evaluation", "TEST", 511, 525], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["trypanosomiasis", "OBSERVATION", 157, 172], ["groove", "OBSERVATION_MODIFIER", 250, 256], ["binders", "OBSERVATION", 257, 264], ["high selectivity", "OBSERVATION", 304, 320]]], ["Also compound 64 which showed excellent in vitro, in vivo activity and high selectivity index against the T. b. rhodesiense merits further SAR optimization in order to synthesized newer lead compounds with reduced cytotoxicity compared to pentamidine.Pyridyl analogues of Pentamidine ::: DNA minor groove binders ::: Synthetic advancesIncreased efficacies of pyridyl analogues of 2,5-bis(4-amidinophenoxy)furan (furamidine) [25\u201327] encouraged Tidwell RR et al [28] to synthesize pentamidine analogues in which the phenyl rings of pentamidine were replaced with pyridyl fragments.", [["pentamidine", "CHEMICAL", 239, 250], ["Pyridyl", "CHEMICAL", 251, 258], ["Pentamidine", "CHEMICAL", 272, 283], ["pyridyl", "CHEMICAL", 359, 366], ["2,5-bis(4-amidinophenoxy)furan", "CHEMICAL", 380, 410], ["furamidine", "CHEMICAL", 412, 422], ["pentamidine", "CHEMICAL", 479, 490], ["pentamidine", "CHEMICAL", 530, 541], ["pentamidine", "CHEMICAL", 239, 250], ["Pyridyl", "CHEMICAL", 251, 258], ["Pentamidine", "CHEMICAL", 272, 283], ["pyridyl", "CHEMICAL", 359, 366], ["2,5-bis(4-amidinophenoxy)furan", "CHEMICAL", 380, 410], ["furamidine", "CHEMICAL", 412, 422], ["pentamidine", "CHEMICAL", 479, 490], ["phenyl", "CHEMICAL", 514, 520], ["pentamidine", "CHEMICAL", 530, 541], ["pyridyl", "CHEMICAL", 561, 568], ["T. b. rhodesiense", "ORGANISM", 106, 123], ["pentamidine", "SIMPLE_CHEMICAL", 239, 250], ["Pyridyl", "SIMPLE_CHEMICAL", 251, 258], ["Pentamidine", "SIMPLE_CHEMICAL", 272, 283], ["DNA", "CELLULAR_COMPONENT", 288, 291], ["pyridyl analogues", "SIMPLE_CHEMICAL", 359, 376], ["2,5-bis(4-amidinophenoxy)furan", "SIMPLE_CHEMICAL", 380, 410], ["furamidine) [25\u201327]", "SIMPLE_CHEMICAL", 412, 431], ["pentamidine analogues", "SIMPLE_CHEMICAL", 479, 500], ["phenyl rings", "SIMPLE_CHEMICAL", 514, 526], ["pentamidine", "SIMPLE_CHEMICAL", 530, 541], ["pyridyl fragments", "SIMPLE_CHEMICAL", 561, 578], ["T. b. rhodesiense", "SPECIES", 106, 123], ["T. b. rhodesiense", "SPECIES", 106, 123], ["high selectivity index", "PROBLEM", 71, 93], ["the T. b. rhodesiense", "PROBLEM", 102, 123], ["further SAR optimization", "TREATMENT", 131, 155], ["reduced cytotoxicity", "PROBLEM", 206, 226], ["pentamidine", "TREATMENT", 239, 250], ["Pentamidine", "TREATMENT", 272, 283], ["pyridyl analogues", "TEST", 359, 376], ["furan (furamidine)", "TREATMENT", 405, 423], ["Tidwell RR et al", "TREATMENT", 443, 459], ["synthesize pentamidine analogues", "TREATMENT", 468, 500], ["the phenyl rings of pentamidine", "TREATMENT", 510, 541], ["pyridyl fragments", "TREATMENT", 561, 578], ["excellent", "OBSERVATION_MODIFIER", 30, 39], ["groove", "OBSERVATION_MODIFIER", 298, 304], ["binders", "OBSERVATION", 305, 312]]], ["This replacement resulted in series of 18 compounds (Figure 4a), most of which had lower cytotoxicity than pentamidine.", [["pentamidine", "CHEMICAL", 107, 118], ["pentamidine", "CHEMICAL", 107, 118], ["pentamidine", "SIMPLE_CHEMICAL", 107, 118], ["This replacement", "TREATMENT", 0, 16], ["lower cytotoxicity", "PROBLEM", 83, 101], ["pentamidine", "TREATMENT", 107, 118]]], ["SAR study pointed out that the antiprotozoal properties of these compounds depended on the placement of cationic moieties on the pyridine rings as well as the nature of substituents on the amidine groups.", [["pyridine", "CHEMICAL", 129, 137], ["amidine", "CHEMICAL", 189, 196], ["pyridine", "CHEMICAL", 129, 137], ["amidine", "CHEMICAL", 189, 196], ["pyridine rings", "SIMPLE_CHEMICAL", 129, 143], ["amidine", "SIMPLE_CHEMICAL", 189, 196], ["SAR study", "TEST", 0, 9], ["these compounds", "PROBLEM", 59, 74], ["the placement of cationic moieties", "TREATMENT", 87, 121], ["the pyridine rings", "TREATMENT", 125, 143], ["the amidine groups", "TREATMENT", 185, 203], ["antiprotozoal", "OBSERVATION_MODIFIER", 31, 44]]], ["The N-substituted congeners were lesser cytotoxic than the unsubstituted diamidines whereas the N-alkylation of cationic fragments reduces the activity of compounds against T. brucei rhodesiense compared to pentamidine.", [["N-substituted", "CHEMICAL", 4, 17], ["diamidines", "CHEMICAL", 73, 83], ["T. brucei rhodesiense", "DISEASE", 173, 194], ["pentamidine", "CHEMICAL", 207, 218], ["N", "CHEMICAL", 4, 5], ["diamidines", "CHEMICAL", 73, 83], ["N", "CHEMICAL", 96, 97], ["pentamidine", "CHEMICAL", 207, 218], ["N-substituted congeners", "SIMPLE_CHEMICAL", 4, 27], ["diamidines", "SIMPLE_CHEMICAL", 73, 83], ["T. brucei rhodesiense", "ORGANISM", 173, 194], ["pentamidine", "SIMPLE_CHEMICAL", 207, 218], ["T. brucei", "SPECIES", 173, 182], ["rhodesiense", "SPECIES", 183, 194], ["T. brucei rhodesiense", "SPECIES", 173, 194], ["lesser cytotoxic", "PROBLEM", 33, 49], ["the unsubstituted diamidines", "TREATMENT", 55, 83], ["the N-alkylation of cationic fragments", "TREATMENT", 92, 130], ["T. brucei rhodesiense", "PROBLEM", 173, 194], ["pentamidine", "TREATMENT", 207, 218], ["lesser", "OBSERVATION_MODIFIER", 33, 39], ["cytotoxic", "OBSERVATION_MODIFIER", 40, 49], ["cationic fragments", "OBSERVATION", 112, 130], ["brucei rhodesiense", "OBSERVATION", 176, 194]]], ["A same trend was observed in pentamidine analogues series.", [["pentamidine", "CHEMICAL", 29, 40], ["pentamidine", "CHEMICAL", 29, 40], ["pentamidine analogues", "SIMPLE_CHEMICAL", 29, 50], ["pentamidine analogues series", "TREATMENT", 29, 57]]], ["The 2, 6-substituted dications (compounds 11\u201313, figure 4a) and 2,4-substituted dications (compounds 14\u201318, figure 4a) displayed lower potencies against T. brucei rhodesiense than the corresponding 2,5-substituted isomers (compounds 1\u201310, figure 4a), while among the 2, 5-substituted dications, the compounds possessing cationic substituents adjacent to nitrogen atoms in pyridine rings displayed superior activities against parasites compared to pentamidine as evident from compound 6 (figure 4b) which showed promising anti-trypanosomal activity (0.001\u03bcM) and lower cytotoxicity (4.90\u03bcM) than pentamidine and melarsoprol, but had poor in vivo activity giving only 1/4 cures in the STIB900 mouse model.", [["2, 6-substituted dications", "CHEMICAL", 4, 30], ["compounds 11\u201313, figure 4a", "CHEMICAL", 32, 58], ["2,4-substituted dications", "CHEMICAL", 64, 89], ["compounds 14\u201318, figure 4a", "CHEMICAL", 91, 117], ["T. brucei rhodesiense", "DISEASE", 153, 174], ["2,5-substituted", "CHEMICAL", 198, 213], ["compounds 1\u201310, figure 4a", "CHEMICAL", 223, 248], ["nitrogen atoms", "CHEMICAL", 354, 368], ["pyridine", "CHEMICAL", 372, 380], ["pentamidine", "CHEMICAL", 447, 458], ["pentamidine", "CHEMICAL", 595, 606], ["melarsoprol", "CHEMICAL", 611, 622], ["nitrogen", "CHEMICAL", 354, 362], ["pyridine", "CHEMICAL", 372, 380], ["pentamidine", "CHEMICAL", 447, 458], ["pentamidine", "CHEMICAL", 595, 606], ["melarsoprol", "CHEMICAL", 611, 622], ["6-substituted dications", "SIMPLE_CHEMICAL", 7, 30], ["compounds 11\u201313, figure 4a", "SIMPLE_CHEMICAL", 32, 58], ["2,4-substituted dications", "SIMPLE_CHEMICAL", 64, 89], ["T. brucei rhodesiense", "ORGANISM", 153, 174], ["2,5-substituted isomers", "SIMPLE_CHEMICAL", 198, 221], ["5-substituted dications", "SIMPLE_CHEMICAL", 270, 293], ["cationic substituents", "SIMPLE_CHEMICAL", 320, 341], ["nitrogen atoms", "SIMPLE_CHEMICAL", 354, 368], ["pyridine rings", "SIMPLE_CHEMICAL", 372, 386], ["pentamidine", "SIMPLE_CHEMICAL", 447, 458], ["pentamidine", "SIMPLE_CHEMICAL", 595, 606], ["melarsoprol", "SIMPLE_CHEMICAL", 611, 622], ["mouse", "ORGANISM", 691, 696], ["T. brucei", "SPECIES", 153, 162], ["mouse", "SPECIES", 691, 696], ["T. brucei rhodesiense", "SPECIES", 153, 174], ["mouse", "SPECIES", 691, 696], ["substituted dications (compounds", "TREATMENT", 9, 41], ["lower potencies against T. brucei rhodesiense", "PROBLEM", 129, 174], ["5-substituted dications", "TREATMENT", 270, 293], ["the compounds possessing cationic substituents", "TREATMENT", 295, 341], ["nitrogen atoms in pyridine rings", "TREATMENT", 354, 386], ["parasites", "PROBLEM", 425, 434], ["pentamidine", "TREATMENT", 447, 458], ["promising anti-trypanosomal activity", "PROBLEM", 511, 547], ["lower cytotoxicity", "PROBLEM", 562, 580], ["pentamidine", "TREATMENT", 595, 606], ["melarsoprol", "TREATMENT", 611, 622], ["brucei rhodesiense", "OBSERVATION", 156, 174], ["nitrogen atoms", "OBSERVATION", 354, 368]]], ["However diamidoxime compound 9 (Figure 4c), an oral prodrug of diamidine compound 6 (Figure 4b), exhibited excellent in vivo activity curing four out of four animals upon oral administration in STIB900 mouse model.", [["oral", "ANATOMY", 47, 51], ["oral", "ANATOMY", 171, 175], ["diamidoxime compound 9", "CHEMICAL", 8, 30], ["Figure 4c", "CHEMICAL", 32, 41], ["diamidine compound 6", "CHEMICAL", 63, 83], ["diamidoxime", "CHEMICAL", 8, 19], ["diamidine", "CHEMICAL", 63, 72], ["diamidoxime compound 9", "SIMPLE_CHEMICAL", 8, 30], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["diamidine compound 6", "SIMPLE_CHEMICAL", 63, 83], ["oral", "ORGANISM_SUBDIVISION", 171, 175], ["mouse", "ORGANISM", 202, 207], ["mouse", "SPECIES", 202, 207], ["mouse", "SPECIES", 202, 207], ["diamidoxime compound", "PROBLEM", 8, 28], ["an oral prodrug of diamidine compound", "TREATMENT", 44, 81], ["oral administration in STIB900 mouse model", "TREATMENT", 171, 213]]], ["Although compound 9 did not provide cure in the CNS mouse model of infection but its BBB permeability could potentially be improved by developing prodrug using lipophillic substitutions in place of hydrophilic substitution as used in compound 9.", [["CNS", "ANATOMY", 48, 51], ["BBB", "ANATOMY", 85, 88], ["compound 9", "CHEMICAL", 9, 19], ["infection", "DISEASE", 67, 76], ["compound 9", "CHEMICAL", 234, 244], ["mouse", "ORGANISM", 52, 57], ["BBB", "MULTI-TISSUE_STRUCTURE", 85, 88], ["prodrug", "SIMPLE_CHEMICAL", 146, 153], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 52, 57], ["infection", "PROBLEM", 67, 76], ["lipophillic substitutions", "TREATMENT", 160, 185], ["hydrophilic substitution", "TREATMENT", 198, 222], ["infection", "OBSERVATION", 67, 76], ["lipophillic substitutions", "OBSERVATION", 160, 185], ["hydrophilic substitution", "OBSERVATION", 198, 222]]], ["This could provide higher concentration of compound 6 in CNS.Pyridyl analogues of Pentamidine ::: DNA minor groove binders ::: Synthetic advancesThus excellent in vitro activity of diamidine 6 and high in vivo efficacy of its prodrug diamidoxime 9 warrant further investigation of these dications as potential anti-trypanosomal drug candidates with improved oral efficacies.Comparison of two most potent pentamidine analogues: compound 6 (Figure 4bf4-scipharm.2011.79.389fig) and compound 66 (Figure 3bf3-scipharm.2011.79.389fig) ::: DNA minor groove binders ::: Synthetic advancesThe structure activity relationship of the two series indicates that in both the cases the unsubstituted diamidines were more active than the N-substituted diamidines.", [["CNS", "ANATOMY", 57, 60], ["oral", "ANATOMY", 358, 362], ["Pyridyl", "CHEMICAL", 61, 68], ["Pentamidine", "CHEMICAL", 82, 93], ["diamidine 6", "CHEMICAL", 181, 192], ["diamidoxime 9", "CHEMICAL", 234, 247], ["pentamidine", "CHEMICAL", 404, 415], ["diamidines", "CHEMICAL", 686, 696], ["Pyridyl", "CHEMICAL", 61, 68], ["Pentamidine", "CHEMICAL", 82, 93], ["diamidine", "CHEMICAL", 181, 190], ["diamidoxime", "CHEMICAL", 234, 245], ["pentamidine", "CHEMICAL", 404, 415], ["diamidines", "CHEMICAL", 686, 696], ["N-substituted diamidines", "CHEMICAL", 723, 747], ["CNS", "ANATOMICAL_SYSTEM", 57, 60], ["Pyridyl", "SIMPLE_CHEMICAL", 61, 68], ["Pentamidine", "SIMPLE_CHEMICAL", 82, 93], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["diamidine 6", "SIMPLE_CHEMICAL", 181, 192], ["dications", "SIMPLE_CHEMICAL", 287, 296], ["oral", "ORGANISM_SUBDIVISION", 358, 362], ["pentamidine analogues", "SIMPLE_CHEMICAL", 404, 425], ["4bf4-scipharm", "SIMPLE_CHEMICAL", 446, 459], ["DNA", "CELLULAR_COMPONENT", 534, 537], ["diamidines", "SIMPLE_CHEMICAL", 686, 696], ["N-substituted diamidines", "SIMPLE_CHEMICAL", 723, 747], ["Pentamidine", "TREATMENT", 82, 93], ["diamidine", "TREATMENT", 181, 190], ["its prodrug diamidoxime", "TREATMENT", 222, 245], ["these dications", "TREATMENT", 281, 296], ["potential anti-trypanosomal drug candidates", "TREATMENT", 300, 343], ["improved oral efficacies", "PROBLEM", 349, 373], ["two most potent pentamidine analogues", "TREATMENT", 388, 425], ["compound", "TEST", 480, 488], ["the N-substituted diamidines", "TREATMENT", 719, 747], ["groove", "OBSERVATION_MODIFIER", 108, 114], ["binders", "OBSERVATION", 115, 122], ["excellent", "OBSERVATION_MODIFIER", 150, 159], ["groove", "OBSERVATION_MODIFIER", 544, 550], ["binders", "OBSERVATION", 551, 558], ["activity", "OBSERVATION_MODIFIER", 595, 603]]], ["The replacement of oxygen atoms in alkyl chain with secondary amino group improves the activity against T. b. rhodesiense of pentamidine analogues while in case of pyridyl analogue the compounds with oxygen atoms in the alkyl chain have been the active one.", [["oxygen", "CHEMICAL", 19, 25], ["alkyl", "CHEMICAL", 35, 40], ["amino", "CHEMICAL", 62, 67], ["pentamidine", "CHEMICAL", 125, 136], ["oxygen", "CHEMICAL", 200, 206], ["alkyl", "CHEMICAL", 220, 225], ["oxygen", "CHEMICAL", 19, 25], ["amino", "CHEMICAL", 62, 67], ["pentamidine", "CHEMICAL", 125, 136], ["pyridyl", "CHEMICAL", 164, 171], ["oxygen", "CHEMICAL", 200, 206], ["oxygen atoms", "SIMPLE_CHEMICAL", 19, 31], ["alkyl chain", "SIMPLE_CHEMICAL", 35, 46], ["T. b. rhodesiense", "ORGANISM", 104, 121], ["pentamidine analogues", "SIMPLE_CHEMICAL", 125, 146], ["pyridyl analogue", "SIMPLE_CHEMICAL", 164, 180], ["oxygen atoms", "SIMPLE_CHEMICAL", 200, 212], ["T. b. rhodesiense", "SPECIES", 104, 121], ["The replacement of oxygen atoms in alkyl chain", "TREATMENT", 0, 46], ["secondary amino group", "TREATMENT", 52, 73], ["pentamidine analogues", "TREATMENT", 125, 146], ["pyridyl analogue", "TREATMENT", 164, 180], ["oxygen atoms in the alkyl chain", "TREATMENT", 200, 231], ["replacement", "OBSERVATION", 4, 15], ["oxygen atoms", "OBSERVATION", 19, 31], ["active", "OBSERVATION_MODIFIER", 246, 252]]], ["The most potent compound of these two series are compound 6 (Figure 4b) and compound 66 (Figure 3b), which have excellent in vitro activity (0.001\u03bcM) better than pentamidine and melarsoprol and also have high selective against the T. b. rhodesiense parasite as evident from their selectivity index (SI of compound 6 = 4900 and compound 66 = 34500 \u03bcM).", [["pentamidine", "CHEMICAL", 162, 173], ["melarsoprol", "CHEMICAL", 178, 189], ["pentamidine", "CHEMICAL", 162, 173], ["melarsoprol", "CHEMICAL", 178, 189], ["Figure 4b", "SIMPLE_CHEMICAL", 61, 70], ["compound 66", "SIMPLE_CHEMICAL", 76, 87], ["Figure 3b", "SIMPLE_CHEMICAL", 89, 98], ["pentamidine", "SIMPLE_CHEMICAL", 162, 173], ["melarsoprol", "SIMPLE_CHEMICAL", 178, 189], ["T. b. rhodesiense", "ORGANISM", 231, 248], ["parasite", "ORGANISM", 249, 257], ["T. b. rhodesiense", "SPECIES", 231, 248], ["T. b. rhodesiense", "SPECIES", 231, 248], ["pentamidine", "TREATMENT", 162, 173], ["melarsoprol", "TREATMENT", 178, 189], ["the T. b. rhodesiense parasite", "PROBLEM", 227, 257], ["most potent", "OBSERVATION_MODIFIER", 4, 15], ["excellent", "OBSERVATION_MODIFIER", 112, 121]]], ["Initially it has been believed that the oxygen atom in the aliphatic linker and the amidine groups are important for anti-trypanosomal activity of pentamidine as these groups were part of recognition motif for P2 amino purine transporter in trypanosoma species.", [["oxygen", "CHEMICAL", 40, 46], ["amidine", "CHEMICAL", 84, 91], ["pentamidine", "CHEMICAL", 147, 158], ["amino purine", "CHEMICAL", 213, 225], ["oxygen", "CHEMICAL", 40, 46], ["amidine", "CHEMICAL", 84, 91], ["pentamidine", "CHEMICAL", 147, 158], ["amino purine", "CHEMICAL", 213, 225], ["oxygen", "SIMPLE_CHEMICAL", 40, 46], ["amidine", "SIMPLE_CHEMICAL", 84, 91], ["pentamidine", "SIMPLE_CHEMICAL", 147, 158], ["P2 amino purine", "SIMPLE_CHEMICAL", 210, 225], ["trypanosoma species", "ORGANISM", 241, 260], ["P2 amino purine transporter", "PROTEIN", 210, 237], ["the oxygen atom", "PROBLEM", 36, 51], ["the aliphatic linker", "TREATMENT", 55, 75], ["the amidine groups", "TREATMENT", 80, 98], ["anti-trypanosomal activity of pentamidine", "TREATMENT", 117, 158], ["P2 amino purine transporter in trypanosoma species", "PROBLEM", 210, 260], ["oxygen atom", "OBSERVATION", 40, 51], ["aliphatic linker", "OBSERVATION", 59, 75], ["trypanosoma species", "OBSERVATION", 241, 260]]], ["Thus the activity of compound 6 can be explained on this basis, but in case of compound 66 the amidine groups have been replaced by imidazoline and the oxygen atom has been replaced by secondary amino groups.", [["amidine", "CHEMICAL", 95, 102], ["imidazoline", "CHEMICAL", 132, 143], ["oxygen", "CHEMICAL", 152, 158], ["amidine", "CHEMICAL", 95, 102], ["imidazoline", "CHEMICAL", 132, 143], ["oxygen", "CHEMICAL", 152, 158], ["amino", "CHEMICAL", 195, 200], ["amidine", "SIMPLE_CHEMICAL", 95, 102], ["imidazoline", "SIMPLE_CHEMICAL", 132, 143], ["oxygen atom", "SIMPLE_CHEMICAL", 152, 163], ["the amidine groups", "TREATMENT", 91, 109], ["imidazoline", "TREATMENT", 132, 143], ["the oxygen atom", "TREATMENT", 148, 163], ["oxygen atom", "OBSERVATION", 152, 163]]], ["Despite these replacements, the compound has shown excellent in vitro and in vivo activity.", [["these replacements", "TREATMENT", 8, 26], ["replacements", "OBSERVATION", 14, 26], ["excellent", "OBSERVATION_MODIFIER", 51, 60]]], ["Thus this is in accordance to recently reported work [29] according to which there is no direct connection between the affinity for P2 carrier and anti-trypanosomal activity.Comparison of two most potent pentamidine analogues: compound 6 (Figure 4bf4-scipharm.2011.79.389fig) and compound 66 (Figure 3bf3-scipharm.2011.79.389fig) ::: DNA minor groove binders ::: Synthetic advancesIn view of this, these two compounds can serve as a lead structure for the development of newer analogues of pentamidine with reduced side effect and improved pharmacokinetic profile.Benzofuran derivatives ::: DNA minor groove binders ::: Synthetic advancesIn the early 1970s Dann O et al [30\u201332] reported the anti-trypanosomal properties of two bisbenzofuran diactions (Figure 5a & 5b) and two phenylbenzofuran (Figure 6a & 6b), but since then these compounds received very little attention.", [["pentamidine", "CHEMICAL", 204, 215], ["pentamidine", "CHEMICAL", 490, 501], ["Benzofuran", "CHEMICAL", 564, 574], ["bisbenzofuran", "CHEMICAL", 727, 740], ["phenylbenzofuran", "CHEMICAL", 776, 792], ["pentamidine", "CHEMICAL", 204, 215], ["pentamidine", "CHEMICAL", 490, 501], ["Benzofuran", "CHEMICAL", 564, 574], ["bisbenzofuran", "CHEMICAL", 727, 740], ["phenylbenzofuran", "CHEMICAL", 776, 792], ["pentamidine analogues", "SIMPLE_CHEMICAL", 204, 225], ["4bf4-scipharm", "SIMPLE_CHEMICAL", 246, 259], ["DNA", "CELLULAR_COMPONENT", 334, 337], ["pentamidine", "SIMPLE_CHEMICAL", 490, 501], ["Benzofuran derivatives", "SIMPLE_CHEMICAL", 564, 586], ["DNA", "CELLULAR_COMPONENT", 591, 594], ["bisbenzofuran", "SIMPLE_CHEMICAL", 727, 740], ["phenylbenzofuran", "SIMPLE_CHEMICAL", 776, 792], ["P2 carrier", "TREATMENT", 132, 142], ["two most potent pentamidine analogues", "TREATMENT", 188, 225], ["compound", "TEST", 280, 288], ["pentamidine", "TREATMENT", 490, 501], ["reduced side effect", "PROBLEM", 507, 526], ["two bisbenzofuran diactions", "TREATMENT", 723, 750], ["Figure 5a", "TREATMENT", 752, 761], ["two phenylbenzofuran (Figure 6a", "TREATMENT", 772, 803], ["groove", "OBSERVATION_MODIFIER", 344, 350], ["binders", "OBSERVATION", 351, 358], ["groove", "OBSERVATION_MODIFIER", 601, 607], ["binders", "OBSERVATION", 608, 615]]], ["However recently lead optimization study of these dications had been carried out by Tidwell RR et al, who have synthesized and reported the in vitro, in vivo activities and cytototixicity of about 43 dicationic bisbenzofuran derivatives (Figure 7a) [33] as heterocyclic pentamidine analogues in which phenoxy fragments were included into a benzofuran structural motif, Tidwell RR et al also synthesized a series of 49 diactionic 2-phenylbenzofuran derivatives (Figure 8) [34].Dicationic bisbenzofuran derivatives ::: DNA minor groove binders ::: Synthetic advancesTidwell RR et al found that the in vitro anti-trypanosomal activities of bisbenzofuran derivatives against Trypanosoma brucei rhodesiense, and cytotoxicity against mammalian cells depended on the position and the type of cationic substituents as well as the length of the carbon linker between aromatic moieties.", [["mammalian cells", "ANATOMY", 728, 743], ["bisbenzofuran", "CHEMICAL", 211, 224], ["pentamidine", "CHEMICAL", 270, 281], ["phenoxy", "CHEMICAL", 301, 308], ["2-phenylbenzofuran", "CHEMICAL", 429, 447], ["bisbenzofuran", "CHEMICAL", 487, 500], ["bisbenzofuran", "CHEMICAL", 637, 650], ["Trypanosoma brucei rhodesiense", "DISEASE", 671, 701], ["bisbenzofuran", "CHEMICAL", 211, 224], ["pentamidine", "CHEMICAL", 270, 281], ["phenoxy", "CHEMICAL", 301, 308], ["benzofuran", "CHEMICAL", 340, 350], ["2-phenylbenzofuran", "CHEMICAL", 429, 447], ["bisbenzofuran", "CHEMICAL", 487, 500], ["bisbenzofuran", "CHEMICAL", 637, 650], ["carbon", "CHEMICAL", 836, 842], ["bisbenzofuran derivatives", "SIMPLE_CHEMICAL", 211, 236], ["Figure 7a) [33] as heterocyclic pentamidine analogues", "SIMPLE_CHEMICAL", 238, 291], ["diactionic 2-phenylbenzofuran derivatives", "SIMPLE_CHEMICAL", 418, 459], ["Dicationic bisbenzofuran derivatives", "SIMPLE_CHEMICAL", 476, 512], ["DNA", "CELLULAR_COMPONENT", 517, 520], ["bisbenzofuran derivatives", "SIMPLE_CHEMICAL", 637, 662], ["Trypanosoma brucei rhodesiense", "ORGANISM", 671, 701], ["mammalian cells", "CELL", 728, 743], ["aromatic moieties", "SIMPLE_CHEMICAL", 858, 875], ["mammalian cells", "CELL_TYPE", 728, 743], ["Trypanosoma brucei", "SPECIES", 671, 689], ["rhodesiense", "SPECIES", 690, 701], ["Trypanosoma brucei rhodesiense", "SPECIES", 671, 701], ["recently lead optimization study", "TEST", 8, 40], ["dicationic bisbenzofuran derivatives", "TREATMENT", 200, 236], ["heterocyclic pentamidine analogues", "TREATMENT", 257, 291], ["phenoxy fragments", "PROBLEM", 301, 318], ["a benzofuran structural motif", "TREATMENT", 338, 367], ["diactionic 2-phenylbenzofuran derivatives", "TREATMENT", 418, 459], ["bisbenzofuran derivatives", "TREATMENT", 637, 662], ["Trypanosoma brucei rhodesiense", "PROBLEM", 671, 701], ["cytotoxicity", "PROBLEM", 707, 719], ["mammalian cells", "PROBLEM", 728, 743], ["cationic substituents", "TREATMENT", 785, 806], ["the carbon linker between aromatic moieties", "TREATMENT", 832, 875], ["groove", "OBSERVATION_MODIFIER", 527, 533], ["binders", "OBSERVATION", 534, 541], ["mammalian cells", "OBSERVATION", 728, 743], ["cationic substituents", "OBSERVATION", 785, 806], ["carbon linker", "OBSERVATION", 836, 849], ["aromatic moieties", "OBSERVATION", 858, 875]]], ["As observed in most of the dicationic molecules, the N-substituted congeners were lesser cytotoxic than the unsubstituted diamidines whereas the N-alkylation of cationic fragments reduced the activity of compounds against T. brucei rhodesiense compared to pentamidine.", [["N-substituted", "CHEMICAL", 53, 66], ["T. brucei rhodesiense", "DISEASE", 222, 243], ["pentamidine", "CHEMICAL", 256, 267], ["N", "CHEMICAL", 53, 54], ["diamidines", "CHEMICAL", 122, 132], ["N", "CHEMICAL", 145, 146], ["pentamidine", "CHEMICAL", 256, 267], ["N-substituted congeners", "SIMPLE_CHEMICAL", 53, 76], ["diamidines", "SIMPLE_CHEMICAL", 122, 132], ["T. brucei rhodesiense", "ORGANISM", 222, 243], ["pentamidine", "SIMPLE_CHEMICAL", 256, 267], ["T. brucei", "SPECIES", 222, 231], ["rhodesiense", "SPECIES", 232, 243], ["T. brucei rhodesiense", "SPECIES", 222, 243], ["the N-substituted congeners", "TREATMENT", 49, 76], ["lesser cytotoxic", "PROBLEM", 82, 98], ["the unsubstituted diamidines", "TREATMENT", 104, 132], ["the N-alkylation of cationic fragments", "TREATMENT", 141, 179], ["T. brucei rhodesiense", "PROBLEM", 222, 243], ["pentamidine", "TREATMENT", 256, 267], ["lesser", "OBSERVATION_MODIFIER", 82, 88], ["cytotoxic", "OBSERVATION_MODIFIER", 89, 98], ["cationic fragments", "OBSERVATION", 161, 179], ["brucei rhodesiense", "OBSERVATION", 225, 243]]], ["At same time the 5-substituted bisbenzofurans were generally less cytotoxic than compounds bearing substituents in the 4- or 6-positions where as the 4-substituted bisbenzofurans were significantly less active against T. b. rhodesiense than corresponding 5- and 6-substituted isomers.", [["5-substituted bisbenzofurans", "CHEMICAL", 17, 45], ["4-substituted bisbenzofurans", "CHEMICAL", 150, 178], ["5- and 6-substituted", "CHEMICAL", 255, 275], ["5-substituted bisbenzofurans", "CHEMICAL", 17, 45], ["bisbenzofurans", "CHEMICAL", 164, 178], ["5-substituted bisbenzofurans", "SIMPLE_CHEMICAL", 17, 45], ["4-substituted bisbenzofurans", "SIMPLE_CHEMICAL", 150, 178], ["T. b. rhodesiense", "ORGANISM", 218, 235], ["5- and 6-substituted isomers", "SIMPLE_CHEMICAL", 255, 283], ["T. b. rhodesiense", "SPECIES", 218, 235], ["T. b. rhodesiense", "SPECIES", 218, 235], ["less cytotoxic", "OBSERVATION_MODIFIER", 61, 75]]], ["The in vitro activity of the bisbenzofuran series was not so promising and only lead compound 8, (Figure 5b) exhibited in vitro anti-trypanosomal activity (0.008 \u03bcM) comparable to that of pentamidine and melarsoprol.", [["bisbenzofuran", "CHEMICAL", 29, 42], ["pentamidine", "CHEMICAL", 188, 199], ["melarsoprol", "CHEMICAL", 204, 215], ["bisbenzofuran", "CHEMICAL", 29, 42], ["pentamidine", "CHEMICAL", 188, 199], ["melarsoprol", "CHEMICAL", 204, 215], ["bisbenzofuran", "SIMPLE_CHEMICAL", 29, 42], ["pentamidine", "SIMPLE_CHEMICAL", 188, 199], ["melarsoprol", "SIMPLE_CHEMICAL", 204, 215], ["the bisbenzofuran series", "TEST", 25, 49], ["vitro anti-trypanosomal activity", "TREATMENT", 122, 154], ["pentamidine", "TREATMENT", 188, 199], ["melarsoprol", "TREATMENT", 204, 215]]], ["However some compounds from Tidwell series (Figure 7b) showed reduced cytotoxicity profile compared to pentamidine (for example compound 43 has cytotoxicity of 1.85 \u03bcM), but had very poor selectivity profile.", [["pentamidine", "CHEMICAL", 103, 114], ["pentamidine", "CHEMICAL", 103, 114], ["Tidwell series", "SIMPLE_CHEMICAL", 28, 42], ["pentamidine", "SIMPLE_CHEMICAL", 103, 114], ["Tidwell series", "TEST", 28, 42], ["Figure 7b", "TEST", 44, 53], ["reduced cytotoxicity profile", "PROBLEM", 62, 90], ["pentamidine", "TREATMENT", 103, 114], ["cytotoxicity", "TEST", 144, 156], ["poor selectivity", "OBSERVATION", 183, 199]]], ["Thus was proved that the selectivity of bisbenzofurans against T. b. rhodesiense decreases as number of methylene groups in the alkyl bridge increases.Dicationic bisbenzofuran derivatives ::: DNA minor groove binders ::: Synthetic advancesHowever, how the substitution on the amidine groups affects the anti-trypanosomal properties of bisbenzofurans has not been explained.", [["anti-trypanosomal", "ANATOMY", 303, 320], ["bisbenzofurans", "CHEMICAL", 40, 54], ["b. rhodesiense", "DISEASE", 66, 80], ["methylene", "CHEMICAL", 104, 113], ["alkyl", "CHEMICAL", 128, 133], ["bisbenzofuran", "CHEMICAL", 162, 175], ["amidine", "CHEMICAL", 276, 283], ["bisbenzofurans", "CHEMICAL", 335, 349], ["bisbenzofurans", "CHEMICAL", 40, 54], ["methylene", "CHEMICAL", 104, 113], ["bisbenzofuran", "CHEMICAL", 162, 175], ["amidine", "CHEMICAL", 276, 283], ["bisbenzofurans", "CHEMICAL", 335, 349], ["bisbenzofurans", "SIMPLE_CHEMICAL", 40, 54], ["T. b. rhodesiense", "ORGANISM", 63, 80], ["methylene groups", "SIMPLE_CHEMICAL", 104, 120], ["alkyl bridge", "SIMPLE_CHEMICAL", 128, 140], ["Dicationic bisbenzofuran derivatives", "SIMPLE_CHEMICAL", 151, 187], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["amidine", "SIMPLE_CHEMICAL", 276, 283], ["bisbenzofurans", "SIMPLE_CHEMICAL", 335, 349], ["T. b. rhodesiense", "SPECIES", 63, 80], ["T. b. rhodesiense", "SPECIES", 63, 80], ["bisbenzofurans", "TREATMENT", 40, 54], ["T. b. rhodesiense", "PROBLEM", 63, 80], ["methylene groups", "TREATMENT", 104, 120], ["the alkyl bridge", "TREATMENT", 124, 140], ["the amidine groups", "TREATMENT", 272, 290], ["bisbenzofurans", "TREATMENT", 335, 349], ["alkyl bridge", "OBSERVATION", 128, 140], ["groove", "OBSERVATION_MODIFIER", 202, 208], ["binders", "OBSERVATION", 209, 216]]], ["Thus in light of their reduced cytotoxicity compared to pentamidine these molecules require further investigation to study the influence of the type of cationic substituents and the distance between aromatic moieties on uptake and intracellular distribution of dicationic bisbenzofurans in order to understand better the mode of action and thus improve the efficacy of aromatic diamidines.Cationic 2-phenylbenzofuran derivatives ::: DNA minor groove binders ::: Synthetic advancesTidwell RR et al synthesized and evaluated the activity of 49 dicationic 2-phenyl-benzofurans derivatives (Figure 8) against Trypanosoma brucei rhodesiense.", [["intracellular", "ANATOMY", 231, 244], ["pentamidine", "CHEMICAL", 56, 67], ["bisbenzofurans", "CHEMICAL", 272, 286], ["aromatic diamidines", "CHEMICAL", 369, 388], ["2-phenylbenzofuran", "CHEMICAL", 398, 416], ["2-phenyl-benzofurans", "CHEMICAL", 553, 573], ["Trypanosoma brucei rhodesiense", "DISEASE", 605, 635], ["pentamidine", "CHEMICAL", 56, 67], ["bisbenzofurans", "CHEMICAL", 272, 286], ["aromatic diamidines", "CHEMICAL", 369, 388], ["2-phenylbenzofuran", "CHEMICAL", 398, 416], ["2-phenyl-benzofurans", "CHEMICAL", 553, 573], ["pentamidine", "SIMPLE_CHEMICAL", 56, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 231, 244], ["bisbenzofurans", "SIMPLE_CHEMICAL", 272, 286], ["aromatic diamidines", "SIMPLE_CHEMICAL", 369, 388], ["Cationic 2-phenylbenzofuran derivatives", "SIMPLE_CHEMICAL", 389, 428], ["DNA", "CELLULAR_COMPONENT", 433, 436], ["dicationic 2-phenyl-benzofurans derivatives", "SIMPLE_CHEMICAL", 542, 585], ["Trypanosoma brucei rhodesiense", "ORGANISM", 605, 635], ["Trypanosoma brucei", "SPECIES", 605, 623], ["rhodesiense", "SPECIES", 624, 635], ["Trypanosoma brucei rhodesiense", "SPECIES", 605, 635], ["their reduced cytotoxicity", "PROBLEM", 17, 43], ["pentamidine", "TREATMENT", 56, 67], ["further investigation", "TEST", 92, 113], ["cationic substituents", "TREATMENT", 152, 173], ["dicationic bisbenzofurans", "TREATMENT", 261, 286], ["aromatic diamidines", "TREATMENT", 369, 388], ["phenyl-benzofurans derivatives", "TREATMENT", 555, 585], ["Trypanosoma brucei rhodesiense", "PROBLEM", 605, 635], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["cytotoxicity", "OBSERVATION", 31, 43], ["groove", "OBSERVATION_MODIFIER", 443, 449], ["binders", "OBSERVATION", 450, 457], ["Trypanosoma", "OBSERVATION", 605, 616], ["brucei rhodesiense", "OBSERVATION", 617, 635]]], ["Six compounds (Figure 9) among the series including lead compound 1 (Figure 6a) exhibited excellent in vitro and in vivo anti-trypanosomal activity and were highly selective for the T. b. rhodesiense parasite.", [["T. b. rhodesiense", "ORGANISM", 182, 199], ["parasite", "ORGANISM", 200, 208], ["T. b. rhodesiense", "SPECIES", 182, 199], ["T. b. rhodesiense", "SPECIES", 182, 199], ["lead compound", "PROBLEM", 52, 65], ["the T. b. rhodesiense parasite", "PROBLEM", 178, 208]]], ["All the six active compounds contained diamidine groups, which clearly suggested that diamidines exhibited higher anti-trypanosomal activities compared to di(N-isopropyl)amidines and diimidazolines.", [["diamidine", "CHEMICAL", 39, 48], ["diamidines", "CHEMICAL", 86, 96], ["di(N-isopropyl)amidines", "CHEMICAL", 155, 178], ["diimidazolines", "CHEMICAL", 183, 197], ["diamidine", "CHEMICAL", 39, 48], ["diamidines", "CHEMICAL", 86, 96], ["di(N-isopropyl)amidines", "CHEMICAL", 155, 178], ["diimidazolines", "CHEMICAL", 183, 197], ["diamidine", "SIMPLE_CHEMICAL", 39, 48], ["diamidines", "SIMPLE_CHEMICAL", 86, 96], ["di(N-isopropyl)amidines", "SIMPLE_CHEMICAL", 155, 178], ["diimidazolines", "SIMPLE_CHEMICAL", 183, 197], ["diamidine groups", "TREATMENT", 39, 55], ["diamidines", "TREATMENT", 86, 96], ["di(N-isopropyl)amidines", "TREATMENT", 155, 178], ["diimidazolines", "TREATMENT", 183, 197], ["active", "OBSERVATION_MODIFIER", 12, 18], ["compounds", "OBSERVATION", 19, 28]]], ["The 5,-substituted dicationic compounds 29 (IC50=0.002 \u03bcM, Figure 9e) and 32 (IC50=0.002 \u03bcM, Figure 9c) showed better anti-trypanosomal activity than the 6-substituted dicationic compound 38 (IC50=0.003 \u03bcM, Figure 9d).", [["5,-substituted", "CHEMICAL", 4, 18], ["5,-substituted dicationic compounds 29", "SIMPLE_CHEMICAL", 4, 42], ["6-substituted dicationic compound 38", "SIMPLE_CHEMICAL", 154, 190], ["substituted dicationic compounds", "TEST", 7, 39], ["IC50", "TEST", 44, 48], ["Figure", "TEST", 59, 65], ["IC50", "TEST", 78, 82], ["Figure 9c", "TEST", 93, 102], ["IC50", "TEST", 192, 196]]], ["Whereas among the 5,5\u2032 substituted diamidines and 5,4\u2032 substituted diamidine, selectivity against the parasite of 5,5\u2032-substituted dications was higher than 5,4\u2032-substituted congeners.", [["diamidines", "CHEMICAL", 35, 45], ["5,4\u2032 substituted diamidine", "CHEMICAL", 50, 76], ["5,5\u2032-substituted", "CHEMICAL", 114, 130], ["5,4\u2032-substituted", "CHEMICAL", 157, 173], ["5,5\u2032 substituted diamidines", "CHEMICAL", 18, 45], ["5,4\u2032 substituted diamidine", "CHEMICAL", 50, 76], ["5,5\u2032-substituted dications", "CHEMICAL", 114, 140], ["5,5\u2032 substituted diamidines", "SIMPLE_CHEMICAL", 18, 45], ["5,4\u2032 substituted diamidine", "SIMPLE_CHEMICAL", 50, 76], ["5,5\u2032-substituted dications", "SIMPLE_CHEMICAL", 114, 140], ["5,4\u2032-substituted congeners", "SIMPLE_CHEMICAL", 157, 183], ["substituted diamidines", "TREATMENT", 23, 45], ["substituted diamidine", "TREATMENT", 55, 76], ["the parasite", "TEST", 98, 110]]], ["Introduction of the hydroxy substituents in the 7-or 2\u2032-position of compound 1 (Figure 6a) resulted into compound 20 (Figure 9a) and compound 32 (Figure 9c) with enhanced anti-trypanosomal activity and higher selectivity against T. b. rhodesiense.", [["hydroxy substituents", "CHEMICAL", 20, 40], ["T. b. rhodesiense", "DISEASE", 229, 246], ["hydroxy", "CHEMICAL", 20, 27], ["hydroxy substituents", "SIMPLE_CHEMICAL", 20, 40], ["T. b. rhodesiense", "ORGANISM", 229, 246], ["T. b. rhodesiense", "SPECIES", 229, 246], ["T. b. rhodesiense", "SPECIES", 229, 246], ["the hydroxy substituents", "TREATMENT", 16, 40], ["enhanced anti-trypanosomal activity", "TREATMENT", 162, 197], ["hydroxy substituents", "OBSERVATION", 20, 40]]], ["These dicationic compounds were further evaluated in the STIB900 animal model of African trypanosomiasisn.", [["trypanosomiasisn", "DISEASE", 89, 105], ["These dicationic compounds", "TREATMENT", 0, 26]]], ["Only compounds 1, 32 and 20 showed exclellent in vivo activity providing 3/4 and 4/4 cures respectively when administered intraperitoneally.Cationic 2-phenylbenzofuran derivatives ::: DNA minor groove binders ::: Synthetic advancesThus promising in vitro, anti-trypanosomal activity, excellent potency in the acute mouse model of trypanosomiasis and the reduced cytotoxicity (1.9 \u03bcM) of compound 1 compared to pentamidine warrants further pre-clinical and clinical trials of this molecule.", [["2-phenylbenzofuran", "CHEMICAL", 149, 167], ["trypanosomiasis", "DISEASE", 330, 345], ["pentamidine", "CHEMICAL", 410, 421], ["2-phenylbenzofuran", "CHEMICAL", 149, 167], ["pentamidine", "CHEMICAL", 410, 421], ["20", "SIMPLE_CHEMICAL", 25, 27], ["Cationic 2-phenylbenzofuran derivatives", "SIMPLE_CHEMICAL", 140, 179], ["DNA", "CELLULAR_COMPONENT", 184, 187], ["mouse", "ORGANISM", 315, 320], ["pentamidine", "SIMPLE_CHEMICAL", 410, 421], ["mouse", "SPECIES", 315, 320], ["mouse", "SPECIES", 315, 320], ["trypanosomiasis", "PROBLEM", 330, 345], ["the reduced cytotoxicity", "PROBLEM", 350, 374], ["compound 1", "PROBLEM", 387, 397], ["pentamidine", "TREATMENT", 410, 421], ["groove", "OBSERVATION_MODIFIER", 194, 200], ["binders", "OBSERVATION", 201, 208], ["excellent", "OBSERVATION_MODIFIER", 284, 293], ["potency", "OBSERVATION_MODIFIER", 294, 301], ["acute", "OBSERVATION_MODIFIER", 309, 314], ["trypanosomiasis", "OBSERVATION", 330, 345], ["reduced", "OBSERVATION_MODIFIER", 354, 361], ["cytotoxicity", "OBSERVATION_MODIFIER", 362, 374]]], ["While compound 32 and 20 can serve as lead compounds for further SAR optimization to derive congener with enhanced activity and lesser cytotoxicity.Pentamidine congeners bearing the benzofuran motif ::: DNA minor groove binders ::: Synthetic advancesTo combine the rigidity of 2-phenylbenzofurans with the flexibility of pentamidine congeners, Tidwell RR et al [35] incorporated the benzofuran ring into molecules of pentamidine-related analogues.", [["Pentamidine", "CHEMICAL", 148, 159], ["rigidity", "DISEASE", 265, 273], ["2-phenylbenzofurans", "CHEMICAL", 277, 296], ["pentamidine", "CHEMICAL", 321, 332], ["pentamidine", "CHEMICAL", 417, 428], ["Pentamidine", "CHEMICAL", 148, 159], ["benzofuran", "CHEMICAL", 182, 192], ["2-phenylbenzofurans", "CHEMICAL", 277, 296], ["pentamidine", "CHEMICAL", 321, 332], ["benzofuran", "CHEMICAL", 383, 393], ["pentamidine", "CHEMICAL", 417, 428], ["20", "SIMPLE_CHEMICAL", 22, 24], ["Pentamidine", "SIMPLE_CHEMICAL", 148, 159], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["2-phenylbenzofurans", "SIMPLE_CHEMICAL", 277, 296], ["pentamidine congeners", "SIMPLE_CHEMICAL", 321, 342], ["benzofuran ring", "SIMPLE_CHEMICAL", 383, 398], ["pentamidine-related analogues", "SIMPLE_CHEMICAL", 417, 446], ["lead compounds", "TREATMENT", 38, 52], ["further SAR optimization", "TREATMENT", 57, 81], ["lesser cytotoxicity", "PROBLEM", 128, 147], ["Pentamidine congeners", "TREATMENT", 148, 169], ["phenylbenzofurans", "TREATMENT", 279, 296], ["pentamidine congeners", "TREATMENT", 321, 342], ["the benzofuran ring", "TREATMENT", 379, 398], ["pentamidine", "TREATMENT", 417, 428], ["groove", "OBSERVATION_MODIFIER", 213, 219], ["binders", "OBSERVATION", 220, 227]]], ["A series of 48 pentamidine congeners containing benzofuran fragments (Figure 10a, b) were synthesized and tested in vitro against T. b. rhodesiense.", [["pentamidine", "CHEMICAL", 15, 26], ["benzofuran", "CHEMICAL", 48, 58], ["T. b. rhodesiense", "DISEASE", 130, 147], ["pentamidine", "CHEMICAL", 15, 26], ["benzofuran", "CHEMICAL", 48, 58], ["pentamidine congeners", "SIMPLE_CHEMICAL", 15, 36], ["benzofuran fragments", "SIMPLE_CHEMICAL", 48, 68], ["T. b. rhodesiense", "ORGANISM", 130, 147], ["T.", "SPECIES", 130, 132], ["b. rhodesiense", "SPECIES", 133, 147], ["T. b. rhodesiense", "SPECIES", 130, 147], ["A series of 48 pentamidine congeners", "TREATMENT", 0, 36], ["benzofuran fragments", "TREATMENT", 48, 68]]], ["Most of the compounds in the series showed cytotoxicity less than that of pentamidine, but had lesser potency and selectivity index as compared to pentamidine.", [["pentamidine", "CHEMICAL", 74, 85], ["pentamidine", "CHEMICAL", 147, 158], ["pentamidine", "CHEMICAL", 74, 85], ["pentamidine", "CHEMICAL", 147, 158], ["pentamidine", "SIMPLE_CHEMICAL", 74, 85], ["pentamidine", "SIMPLE_CHEMICAL", 147, 158], ["the series", "TEST", 25, 35], ["cytotoxicity", "PROBLEM", 43, 55], ["pentamidine", "TREATMENT", 74, 85], ["lesser potency and selectivity index", "PROBLEM", 95, 131], ["pentamidine", "TREATMENT", 147, 158]]], ["The properties and cytotoxicities of these dications depended on the nature of the cationic substituents, the placement of the benzofuran motif, and the length of the carbon linker.", [["benzofuran", "CHEMICAL", 127, 137], ["carbon", "CHEMICAL", 167, 173], ["these dications", "TREATMENT", 37, 52], ["the cationic substituents", "TREATMENT", 79, 104], ["the benzofuran motif", "TREATMENT", 123, 143], ["the carbon linker", "TREATMENT", 163, 180], ["cytotoxicities", "OBSERVATION_MODIFIER", 19, 33], ["carbon linker", "OBSERVATION", 167, 180]]], ["Within the series cytotoxicity of the compounds decreased with the substitution on cationic groups and increased with the elongation of the carbon linker.Pentamidine congeners bearing the benzofuran motif ::: DNA minor groove binders ::: Synthetic advancesDications with the benzofuran motif in the 4\u2032-position (compounds 25\u201348, Figure 10b) and connected by the propylene linker are the most potent and more selective against T. b. rhodesiense among the series.", [["Pentamidine", "CHEMICAL", 154, 165], ["propylene", "CHEMICAL", 362, 371], ["T. b. rhodesiense", "DISEASE", 426, 443], ["carbon", "CHEMICAL", 140, 146], ["Pentamidine", "CHEMICAL", 154, 165], ["benzofuran", "CHEMICAL", 188, 198], ["benzofuran", "CHEMICAL", 275, 285], ["propylene", "CHEMICAL", 362, 371], ["Pentamidine", "SIMPLE_CHEMICAL", 154, 165], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["propylene linker", "SIMPLE_CHEMICAL", 362, 378], ["T. b. rhodesiense", "ORGANISM", 426, 443], ["T. b. rhodesiense", "SPECIES", 426, 443], ["T. b. rhodesiense", "SPECIES", 426, 443], ["the compounds", "PROBLEM", 34, 47], ["the substitution on cationic groups", "TREATMENT", 63, 98], ["the carbon linker", "TREATMENT", 136, 153], ["Pentamidine congeners", "TREATMENT", 154, 175], ["Synthetic advancesDications", "TREATMENT", 238, 265], ["the benzofuran motif", "TREATMENT", 271, 291], ["the propylene linker", "TREATMENT", 358, 378], ["compounds", "OBSERVATION_MODIFIER", 38, 47], ["decreased", "OBSERVATION_MODIFIER", 48, 57], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["elongation", "OBSERVATION_MODIFIER", 122, 132], ["carbon linker", "OBSERVATION", 140, 153], ["groove", "OBSERVATION_MODIFIER", 219, 225], ["binders", "OBSERVATION", 226, 233], ["most potent", "OBSERVATION_MODIFIER", 387, 398]]], ["Thus on the basis of SAR study further improvements can be made in order to produce newer anti-trypanosomal agents with improved pharmacological activity.Comparision of Benzofuran derivatives ::: DNA minor groove binders ::: Synthetic advancesThe SAR of the three series clearly indicates that the nature of cationic substituents and their position is important in deciding the anti-trypanosomal activity of benzofuran derivatives.", [["Benzofuran", "CHEMICAL", 169, 179], ["benzofuran", "CHEMICAL", 408, 418], ["Benzofuran", "CHEMICAL", 169, 179], ["benzofuran", "CHEMICAL", 408, 418], ["Benzofuran derivatives", "SIMPLE_CHEMICAL", 169, 191], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["cationic substituents", "SIMPLE_CHEMICAL", 308, 329], ["benzofuran derivatives", "SIMPLE_CHEMICAL", 408, 430], ["SAR study", "TEST", 21, 30], ["newer anti-trypanosomal agents", "TREATMENT", 84, 114], ["cationic substituents", "TREATMENT", 308, 329], ["benzofuran derivatives", "TREATMENT", 408, 430], ["pharmacological activity", "OBSERVATION", 129, 153], ["groove", "OBSERVATION_MODIFIER", 206, 212], ["binders", "OBSERVATION", 213, 220], ["cationic substituents", "OBSERVATION", 308, 329]]], ["The introduction of phenoxy fragment into a benzofuran structural motif may result into retention of affinity for the aminopurine P2 transporter, which could be the reason for anti-trypanospomal activity of benzofuran derivatives.", [["phenoxy", "CHEMICAL", 20, 27], ["benzofuran", "CHEMICAL", 44, 54], ["aminopurine", "CHEMICAL", 118, 129], ["benzofuran", "CHEMICAL", 207, 217], ["phenoxy", "CHEMICAL", 20, 27], ["benzofuran", "CHEMICAL", 44, 54], ["aminopurine P2", "CHEMICAL", 118, 132], ["benzofuran", "CHEMICAL", 207, 217], ["benzofuran", "SIMPLE_CHEMICAL", 44, 54], ["aminopurine P2", "GENE_OR_GENE_PRODUCT", 118, 132], ["anti-trypanospomal", "SIMPLE_CHEMICAL", 176, 194], ["benzofuran derivatives", "SIMPLE_CHEMICAL", 207, 229], ["benzofuran structural motif", "PROTEIN", 44, 71], ["aminopurine P2 transporter", "PROTEIN", 118, 144], ["The introduction of phenoxy fragment", "TREATMENT", 0, 36], ["a benzofuran structural motif", "TREATMENT", 42, 71], ["the aminopurine P2 transporter", "TREATMENT", 114, 144], ["benzofuran derivatives", "TREATMENT", 207, 229]]], ["Among the three series the 2-phenylbenzofuran derivatives are attractive molecules because of their high activity, low cytotoxicity and high selectivity against the HAT parasite.", [["2-phenylbenzofuran", "CHEMICAL", 27, 45], ["2-phenylbenzofuran", "CHEMICAL", 27, 45], ["2-phenylbenzofuran derivatives", "SIMPLE_CHEMICAL", 27, 57], ["HAT parasite", "ORGANISM", 165, 177], ["phenylbenzofuran derivatives", "TREATMENT", 29, 57], ["attractive molecules", "PROBLEM", 62, 82], ["their high activity", "PROBLEM", 94, 113], ["low cytotoxicity", "PROBLEM", 115, 131], ["the HAT parasite", "PROBLEM", 161, 177], ["high activity", "OBSERVATION_MODIFIER", 100, 113], ["high selectivity", "OBSERVATION_MODIFIER", 136, 152]]], ["The introduction of phenoxy fragment into the aromatic ring protects the phenylbenzofuran dervatives from metabolic deactivation.", [["phenoxy", "CHEMICAL", 20, 27], ["phenylbenzofuran", "CHEMICAL", 73, 89], ["phenoxy", "CHEMICAL", 20, 27], ["phenylbenzofuran", "CHEMICAL", 73, 89], ["phenylbenzofuran", "SIMPLE_CHEMICAL", 73, 89], ["The introduction of phenoxy fragment", "TREATMENT", 0, 36], ["the aromatic ring", "TREATMENT", 42, 59], ["the phenylbenzofuran dervatives", "TREATMENT", 69, 100], ["metabolic deactivation", "PROBLEM", 106, 128], ["phenoxy fragment", "OBSERVATION", 20, 36], ["aromatic ring", "OBSERVATION", 46, 59], ["metabolic deactivation", "OBSERVATION", 106, 128]]], ["This structural modification retains affinity for the aminopurine P2 transporter.", [["aminopurine", "CHEMICAL", 54, 65], ["aminopurine P2", "CHEMICAL", 54, 68], ["aminopurine P2", "GENE_OR_GENE_PRODUCT", 54, 68], ["aminopurine P2 transporter", "PROTEIN", 54, 80], ["the aminopurine P2 transporter", "TREATMENT", 50, 80]]], ["The diamidine and the hydroxy or methoxy group may be involved in binding to the DNA minor groove.", [["diamidine", "CHEMICAL", 4, 13], ["hydroxy", "CHEMICAL", 22, 29], ["methoxy", "CHEMICAL", 33, 40], ["diamidine", "CHEMICAL", 4, 13], ["hydroxy", "CHEMICAL", 22, 29], ["methoxy", "CHEMICAL", 33, 40], ["diamidine", "SIMPLE_CHEMICAL", 4, 13], ["hydroxy", "SIMPLE_CHEMICAL", 22, 29], ["methoxy", "SIMPLE_CHEMICAL", 33, 40], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["The diamidine", "TREATMENT", 0, 13], ["the hydroxy or methoxy group", "TREATMENT", 18, 46]]], ["Thus multiple modes of action may be the reason for promising anti-trypanosomal propertries of 2-phenylbenzofuran derivatives.", [["2-phenylbenzofuran", "CHEMICAL", 95, 113], ["2-phenylbenzofuran", "CHEMICAL", 95, 113], ["2-phenylbenzofuran derivatives", "SIMPLE_CHEMICAL", 95, 125], ["promising anti-trypanosomal propertries", "TREATMENT", 52, 91], ["phenylbenzofuran derivatives", "TREATMENT", 97, 125]]], ["Thus these compounds require further assessment in order to develop as newer anti-trypanosomal agents with promising pharmacokinetic profile.Furamidine compounds ::: DNA minor groove binders ::: Synthetic advancesSince a prodrug of furamidine, 2,5-bis[4-(N-methoxy)amidinophenyl]furan (pafuramidine), has shown promising results in clinical trials against HAT [36], therefore Furamidine (Figure 11a) has gained attention for further evaluation to produce newer anti-trypanosomal analogous.", [["anti-trypanosomal", "ANATOMY", 77, 94], ["Furamidine", "CHEMICAL", 141, 151], ["furamidine", "CHEMICAL", 232, 242], ["2,5-bis[4-(N-methoxy)amidinophenyl]furan", "CHEMICAL", 244, 284], ["pafuramidine", "CHEMICAL", 286, 298], ["Furamidine", "CHEMICAL", 376, 386], ["Figure 11a", "CHEMICAL", 388, 398], ["Furamidine", "CHEMICAL", 141, 151], ["furamidine", "CHEMICAL", 232, 242], ["2,5-bis[4-(N-methoxy)amidinophenyl]furan", "CHEMICAL", 244, 284], ["pafuramidine", "CHEMICAL", 286, 298], ["Furamidine", "CHEMICAL", 376, 386], ["Furamidine", "SIMPLE_CHEMICAL", 141, 151], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["furamidine", "SIMPLE_CHEMICAL", 232, 242], ["2,5-bis[4-(N-methoxy)amidinophenyl]furan", "SIMPLE_CHEMICAL", 244, 284], ["pafuramidine", "SIMPLE_CHEMICAL", 286, 298], ["Furamidine", "SIMPLE_CHEMICAL", 376, 386], ["further assessment", "TEST", 29, 47], ["newer anti-trypanosomal agents", "TREATMENT", 71, 101], ["a prodrug of furamidine", "TREATMENT", 219, 242], ["(N-methoxy)amidinophenyl]furan (pafuramidine)", "TREATMENT", 254, 299], ["Furamidine", "TREATMENT", 376, 386], ["further evaluation", "TEST", 425, 443], ["groove", "OBSERVATION_MODIFIER", 176, 182], ["binders", "OBSERVATION", 183, 190]]], ["Two other analogues of furamidine (Figure 11b &c) have been evaluated against T. b. rhodesiense mouse model and have shown promising results.", [["furamidine", "CHEMICAL", 23, 33], ["Figure 11b &c", "CHEMICAL", 35, 48], ["furamidine", "CHEMICAL", 23, 33], ["furamidine", "SIMPLE_CHEMICAL", 23, 33], ["Figure 11b &c", "SIMPLE_CHEMICAL", 35, 48], ["T. b. rhodesiense", "ORGANISM", 78, 95], ["mouse", "ORGANISM", 96, 101], ["T. b. rhodesiense", "SPECIES", 78, 95], ["mouse", "SPECIES", 96, 101], ["T. b. rhodesiense", "SPECIES", 78, 95], ["furamidine", "TREATMENT", 23, 33]]], ["One approach to enhance the activity of furamidine has been the replacement of the central furan ring with other heterocyclic systems, including thiophene, pyrrole, oxazole, oxadiazole, thiadiazole, pyridazine, methylpyrimidine, and triazine [37\u201341].", [["furamidine", "CHEMICAL", 40, 50], ["furan", "CHEMICAL", 91, 96], ["thiophene", "CHEMICAL", 145, 154], ["pyrrole", "CHEMICAL", 156, 163], ["oxazole", "CHEMICAL", 165, 172], ["oxadiazole", "CHEMICAL", 174, 184], ["thiadiazole", "CHEMICAL", 186, 197], ["pyridazine", "CHEMICAL", 199, 209], ["methylpyrimidine", "CHEMICAL", 211, 227], ["triazine", "CHEMICAL", 233, 241], ["furamidine", "CHEMICAL", 40, 50], ["furan", "CHEMICAL", 91, 96], ["thiophene", "CHEMICAL", 145, 154], ["pyrrole", "CHEMICAL", 156, 163], ["oxazole", "CHEMICAL", 165, 172], ["oxadiazole", "CHEMICAL", 174, 184], ["thiadiazole", "CHEMICAL", 186, 197], ["pyridazine", "CHEMICAL", 199, 209], ["methylpyrimidine", "CHEMICAL", 211, 227], ["triazine", "CHEMICAL", 233, 241], ["furamidine", "SIMPLE_CHEMICAL", 40, 50], ["thiophene, pyrrole, oxazole,", "SIMPLE_CHEMICAL", 145, 173], ["oxadiazole", "SIMPLE_CHEMICAL", 174, 184], ["thiadiazole", "SIMPLE_CHEMICAL", 186, 197], ["pyridazine", "SIMPLE_CHEMICAL", 199, 209], ["methylpyrimidine", "SIMPLE_CHEMICAL", 211, 227], ["triazine [37\u201341]", "SIMPLE_CHEMICAL", 233, 249], ["furamidine", "TREATMENT", 40, 50], ["the replacement", "TREATMENT", 60, 75], ["the central furan ring", "TREATMENT", 79, 101], ["other heterocyclic systems", "TREATMENT", 107, 133], ["thiophene", "TREATMENT", 145, 154], ["pyrrole", "TREATMENT", 156, 163], ["oxazole", "TREATMENT", 165, 172], ["oxadiazole", "TREATMENT", 174, 184], ["thiadiazole", "TREATMENT", 186, 197], ["pyridazine", "TREATMENT", 199, 209], ["methylpyrimidine", "TREATMENT", 211, 227], ["triazine", "TREATMENT", 233, 241], ["central", "ANATOMY_MODIFIER", 83, 90], ["furan ring", "OBSERVATION", 91, 101], ["heterocyclic systems", "OBSERVATION", 113, 133]]], ["Such structural modification in past has resulted into compound with good anti-parasitic activity.", [["modification", "OBSERVATION", 16, 28], ["anti-parasitic activity", "OBSERVATION", 74, 97]]], ["For example in 1977 Boykin DW and Das PB have reported the synthesis and antiprotozoal activity of eighteen substituted 2,5-bis(4-guanylphenyl)furans and related analogues, including \u201cmasked\u201d amidines in which the guanyl function was incorporated into a heterocyclic ring.", [["2,5-bis(4-guanylphenyl)furans", "CHEMICAL", 120, 149], ["amidines", "CHEMICAL", 192, 200], ["guanyl", "CHEMICAL", 214, 220], ["2,5-bis(4-guanylphenyl)furans", "CHEMICAL", 120, 149], ["amidines", "CHEMICAL", 192, 200], ["guanyl", "CHEMICAL", 214, 220], ["2,5-bis(4-guanylphenyl)furans", "SIMPLE_CHEMICAL", 120, 149], ["\u201cmasked\u201d amidines", "SIMPLE_CHEMICAL", 183, 200], ["guanyl", "SIMPLE_CHEMICAL", 214, 220], ["the synthesis", "TREATMENT", 55, 68], ["antiprotozoal activity", "TEST", 73, 95], ["guanylphenyl)furans", "TREATMENT", 130, 149], ["related analogues", "PROBLEM", 154, 171], ["masked\u201d amidines", "TREATMENT", 184, 200], ["the guanyl function", "TREATMENT", 210, 229], ["a heterocyclic ring", "TREATMENT", 252, 271], ["heterocyclic ring", "OBSERVATION", 254, 271]]], ["Among these, six compounds have produced cures in mice at submilligram dosage levels and have been somewhat more active in this screen than stilbamidine, hydroxystilbamidine, and pentamidine.", [["stilbamidine", "CHEMICAL", 140, 152], ["hydroxystilbamidine", "CHEMICAL", 154, 173], ["pentamidine", "CHEMICAL", 179, 190], ["stilbamidine", "CHEMICAL", 140, 152], ["hydroxystilbamidine", "CHEMICAL", 154, 173], ["pentamidine", "CHEMICAL", 179, 190], ["mice", "ORGANISM", 50, 54], ["stilbamidine", "SIMPLE_CHEMICAL", 140, 152], ["hydroxystilbamidine", "SIMPLE_CHEMICAL", 154, 173], ["pentamidine", "SIMPLE_CHEMICAL", 179, 190], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["stilbamidine", "TREATMENT", 140, 152], ["hydroxystilbamidine", "TREATMENT", 154, 173], ["pentamidine", "TREATMENT", 179, 190]]], ["In 1994 Boykin DW et al have reported the synthesis of dicationic diaryltriazines nucleic acid binding agents, while in year 1998 Boykin DW et al have also reported the anti-Pneumocystis carinii pneumonia activity of dicationic diaryl methylprimidines.", [["nucleic acid", "CHEMICAL", 82, 94], ["anti-Pneumocystis carinii pneumonia", "DISEASE", 169, 204], ["diaryl methylprimidines", "CHEMICAL", 228, 251], ["diaryltriazines", "CHEMICAL", 66, 81], ["diaryl methylprimidines", "CHEMICAL", 228, 251], ["dicationic diaryltriazines nucleic acid", "SIMPLE_CHEMICAL", 55, 94], ["anti-Pneumocystis carinii", "ORGANISM", 169, 194], ["dicationic diaryl methylprimidines", "SIMPLE_CHEMICAL", 217, 251], ["anti-Pneumocystis carinii", "SPECIES", 169, 194], ["anti-Pneumocystis carinii", "SPECIES", 169, 194], ["the synthesis of dicationic diaryltriazines nucleic acid binding agents", "TREATMENT", 38, 109], ["the anti-Pneumocystis carinii pneumonia", "PROBLEM", 165, 204], ["dicationic diaryl methylprimidines", "TREATMENT", 217, 251], ["carinii pneumonia", "OBSERVATION", 187, 204]]], ["Dann O et al in the year 1975 have reported that 3,5-bis(4-amidinophenyl)isoxazole (Figure 13b) which is the most structurally similar to furamidine, is reported to have high activity against a murine T. brucei rhodesiense modelc [42].", [["3,5-bis(4-amidinophenyl)isoxazole", "CHEMICAL", 49, 82], ["furamidine", "CHEMICAL", 138, 148], ["3,5-bis(4-amidinophenyl)isoxazole", "CHEMICAL", 49, 82], ["furamidine", "CHEMICAL", 138, 148], ["3,5-bis(4-amidinophenyl)isoxazole", "SIMPLE_CHEMICAL", 49, 82], ["Figure 13b", "SIMPLE_CHEMICAL", 84, 94], ["furamidine", "SIMPLE_CHEMICAL", 138, 148], ["murine", "ORGANISM", 194, 200], ["T. brucei", "ORGANISM", 201, 210], ["rhodesiense", "ORGANISM", 211, 222], ["murine", "SPECIES", 194, 200], ["T. brucei", "SPECIES", 201, 210], ["rhodesiense", "SPECIES", 211, 222], ["T. brucei rhodesiense", "SPECIES", 201, 222], ["bis(4-amidinophenyl)isoxazole (Figure", "TREATMENT", 53, 90], ["furamidine", "TREATMENT", 138, 148], ["high activity", "OBSERVATION_MODIFIER", 170, 183]]], ["Recently the optimization of the few of the compounds has been reported and as a result several lead compounds have been synthesized.", [["few", "OBSERVATION_MODIFIER", 33, 36]]], ["Here in are listed some of the compounds.Dicationic 3,5-diphenylisoxazoles ::: DNA minor groove binders ::: Synthetic advancesTidwell RR et al [43] has recently synthesized a series of 3,5-diphenylisoxazole analogues (Figure 12), in which the central ring of furamidine was replaced by isoxazole, and their activities with furamidine and melarsoprol were compared.", [["3,5-diphenylisoxazoles", "CHEMICAL", 52, 74], ["3,5-diphenylisoxazole", "CHEMICAL", 185, 206], ["furamidine", "CHEMICAL", 259, 269], ["isoxazole", "CHEMICAL", 286, 295], ["furamidine", "CHEMICAL", 323, 333], ["melarsoprol", "CHEMICAL", 338, 349], ["Dicationic 3,5-diphenylisoxazoles", "CHEMICAL", 41, 74], ["3,5-diphenylisoxazole", "CHEMICAL", 185, 206], ["furamidine", "CHEMICAL", 259, 269], ["isoxazole", "CHEMICAL", 286, 295], ["furamidine", "CHEMICAL", 323, 333], ["melarsoprol", "CHEMICAL", 338, 349], ["Dicationic 3,5-diphenylisoxazoles", "SIMPLE_CHEMICAL", 41, 74], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["3,5-diphenylisoxazole analogues", "SIMPLE_CHEMICAL", 185, 216], ["furamidine", "SIMPLE_CHEMICAL", 259, 269], ["isoxazole", "SIMPLE_CHEMICAL", 286, 295], ["furamidine", "SIMPLE_CHEMICAL", 323, 333], ["melarsoprol", "SIMPLE_CHEMICAL", 338, 349], ["Dicationic", "TREATMENT", 41, 51], ["diphenylisoxazoles", "TREATMENT", 56, 74], ["3,5-diphenylisoxazole analogues", "TREATMENT", 185, 216], ["furamidine", "TREATMENT", 259, 269], ["isoxazole", "TREATMENT", 286, 295], ["furamidine", "TREATMENT", 323, 333], ["melarsoprol", "TREATMENT", 338, 349], ["groove", "OBSERVATION_MODIFIER", 89, 95], ["binders", "OBSERVATION", 96, 103], ["central", "ANATOMY_MODIFIER", 243, 250]]], ["Among 43 synthesized dications, the compounds with at least one p-amidine moiety (compound 22, Figure 13a and compound 3, Figure 13b), displayed good IC50 values (3.5 nM and 5.1 nM respectively) comparable to that of furamidine (4.3 nM) while loss in potency was observed in compounds with substituted diamidine at m-position (compound 32, IC50=29 nM, Figure 13c).", [["compound 22, Figure 13a", "CHEMICAL", 82, 105], ["furamidine", "CHEMICAL", 217, 227], ["diamidine", "CHEMICAL", 302, 311], ["p-amidine", "CHEMICAL", 64, 73], ["furamidine", "CHEMICAL", 217, 227], ["diamidine", "CHEMICAL", 302, 311], ["p-amidine moiety", "SIMPLE_CHEMICAL", 64, 80], ["13a", "SIMPLE_CHEMICAL", 102, 105], ["furamidine", "SIMPLE_CHEMICAL", 217, 227], ["diamidine", "SIMPLE_CHEMICAL", 302, 311], ["m-position", "SIMPLE_CHEMICAL", 315, 325], ["43 synthesized dications", "TREATMENT", 6, 30], ["furamidine", "TREATMENT", 217, 227], ["loss in potency", "PROBLEM", 243, 258], ["substituted diamidine at m-position", "TREATMENT", 290, 325], ["IC50", "TEST", 340, 344]]], ["In general, the introduction of nitro, chloro, or methoxy substituents on either aromatic ring resulted in decreased anti-trypanosomal activity.", [["anti-trypanosomal", "ANATOMY", 117, 134], ["nitro, chloro, or methoxy substituents", "CHEMICAL", 32, 70], ["nitro", "CHEMICAL", 32, 37], ["chloro", "CHEMICAL", 39, 45], ["methoxy", "CHEMICAL", 50, 57], ["nitro, chloro, or methoxy substituents", "SIMPLE_CHEMICAL", 32, 70], ["aromatic ring", "SIMPLE_CHEMICAL", 81, 94], ["anti-trypanosomal", "SIMPLE_CHEMICAL", 117, 134], ["nitro", "TREATMENT", 32, 37], ["chloro", "TREATMENT", 39, 45], ["methoxy substituents", "TREATMENT", 50, 70], ["either aromatic ring", "TREATMENT", 74, 94], ["decreased anti-trypanosomal activity", "PROBLEM", 107, 143], ["decreased", "OBSERVATION_MODIFIER", 107, 116], ["anti-trypanosomal activity", "OBSERVATION", 117, 143]]], ["However, the introduction of methoxy group on the aromatic rings of compound 32 resulted into compound 41 (Figure 13b) with comparable anti-trypanosomal activity (4.2 nM) as that of furamidine.", [["methoxy", "CHEMICAL", 29, 36], ["compound 32", "CHEMICAL", 68, 79], ["furamidine", "CHEMICAL", 182, 192], ["methoxy", "CHEMICAL", 29, 36], ["furamidine", "CHEMICAL", 182, 192], ["furamidine", "SIMPLE_CHEMICAL", 182, 192], ["methoxy group", "TREATMENT", 29, 42], ["furamidine", "TREATMENT", 182, 192]]], ["Hence these compounds of the isoxazole series that showed good in vitro anti-trypanosomal activity and less cytotoxcity profile relative to furamidine, could be a candidate for further evaluation against animal models of the diseases.Dicationic 3,5-diphenylisoxazoles ::: DNA minor groove binders ::: Synthetic advancesHowever in vivo evaluation of the present 3,5-diphenylisoxazole series has not been reported yet.Cationic 1,4-diphenyl-1H-1,2,3-triazoles ::: DNA minor groove binders ::: Synthetic advancesThe excellent anti-trypanosomal activities of selected cationic diphenylisoxazoles provided the basis of synthesis of a series of 60 cationic 1,4-diphenyl-1H-1,2,3-triazoles [44] (Figure 14 a\u2013d) by Tidwell RR et al. The 1,2,3-triazole fragment was used because it was a suitable isosteric replacement for the central five-membered ring of furamidine [45\u201355] and also because 1,4-diphenyl-1,2,3-triazoles showed geometrical resemblance to furamidine.", [["isoxazole", "CHEMICAL", 29, 38], ["furamidine", "CHEMICAL", 140, 150], ["3,5-diphenylisoxazoles", "CHEMICAL", 245, 267], ["3,5-diphenylisoxazole", "CHEMICAL", 361, 382], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 425, 456], ["diphenylisoxazoles", "CHEMICAL", 572, 590], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 650, 681], ["1,2,3-triazole", "CHEMICAL", 728, 742], ["furamidine [45\u201355]", "CHEMICAL", 847, 865], ["1,4-diphenyl-1,2,3-triazoles", "CHEMICAL", 883, 911], ["furamidine", "CHEMICAL", 946, 956], ["isoxazole", "CHEMICAL", 29, 38], ["furamidine", "CHEMICAL", 140, 150], ["Dicationic 3,5-diphenylisoxazoles", "CHEMICAL", 234, 267], ["3,5-diphenylisoxazole", "CHEMICAL", 361, 382], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 425, 456], ["diphenylisoxazoles", "CHEMICAL", 572, 590], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 650, 681], ["1,2,3-triazole", "CHEMICAL", 728, 742], ["furamidine", "CHEMICAL", 847, 857], ["1,4-diphenyl-1,2,3-triazoles", "CHEMICAL", 883, 911], ["furamidine", "CHEMICAL", 946, 956], ["isoxazole", "SIMPLE_CHEMICAL", 29, 38], ["furamidine", "SIMPLE_CHEMICAL", 140, 150], ["Dicationic 3,5-diphenylisoxazoles", "SIMPLE_CHEMICAL", 234, 267], ["DNA", "CELLULAR_COMPONENT", 272, 275], ["3,5-diphenylisoxazole", "SIMPLE_CHEMICAL", 361, 382], ["Cationic 1,4-diphenyl-1H-1,2,3-triazoles", "SIMPLE_CHEMICAL", 416, 456], ["DNA", "CELLULAR_COMPONENT", 461, 464], ["cationic diphenylisoxazoles", "SIMPLE_CHEMICAL", 563, 590], ["60 cationic 1,4-diphenyl-1H-1,2,3-triazoles [44]", "SIMPLE_CHEMICAL", 638, 686], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 728, 742], ["furamidine [45\u201355]", "SIMPLE_CHEMICAL", 847, 865], ["1,4-diphenyl-1,2,3-triazoles", "SIMPLE_CHEMICAL", 883, 911], ["furamidine", "SIMPLE_CHEMICAL", 946, 956], ["the isoxazole series", "TEST", 25, 45], ["furamidine", "TREATMENT", 140, 150], ["further evaluation", "TEST", 177, 195], ["the diseases", "PROBLEM", 221, 233], ["Dicationic", "TREATMENT", 234, 244], ["diphenylisoxazoles", "TREATMENT", 249, 267], ["vivo evaluation", "TEST", 330, 345], ["Cationic", "TEST", 416, 424], ["diphenyl-1H", "TREATMENT", 429, 440], ["triazoles", "TREATMENT", 447, 456], ["selected cationic diphenylisoxazoles", "TREATMENT", 554, 590], ["diphenyl", "TREATMENT", 654, 662], ["triazoles", "TREATMENT", 672, 681], ["The 1,2,3-triazole fragment", "TREATMENT", 724, 751], ["a suitable isosteric replacement", "TREATMENT", 776, 808], ["the central five-membered ring of furamidine", "TREATMENT", 813, 857], ["diphenyl", "TREATMENT", 887, 895], ["triazoles", "TREATMENT", 902, 911], ["furamidine", "TREATMENT", 946, 956], ["good", "OBSERVATION_MODIFIER", 58, 62], ["diseases", "OBSERVATION", 225, 233], ["groove", "OBSERVATION_MODIFIER", 282, 288], ["binders", "OBSERVATION", 289, 296], ["groove", "OBSERVATION_MODIFIER", 471, 477], ["binders", "OBSERVATION", 478, 485], ["isosteric replacement", "OBSERVATION", 787, 808]]], ["It was observed that the cytotoxicities of triazoles were as lower compared to that of pentamidine and were not affected by the alkylation on the amidine groups or the substitution on the aromatic rings.", [["triazoles", "CHEMICAL", 43, 52], ["pentamidine", "CHEMICAL", 87, 98], ["amidine", "CHEMICAL", 146, 153], ["triazoles", "CHEMICAL", 43, 52], ["pentamidine", "CHEMICAL", 87, 98], ["amidine", "CHEMICAL", 146, 153], ["triazoles", "SIMPLE_CHEMICAL", 43, 52], ["pentamidine", "SIMPLE_CHEMICAL", 87, 98], ["amidine", "SIMPLE_CHEMICAL", 146, 153], ["the cytotoxicities of triazoles", "TREATMENT", 21, 52], ["pentamidine", "TREATMENT", 87, 98], ["the alkylation", "TREATMENT", 124, 138], ["the amidine groups", "TREATMENT", 142, 160], ["the aromatic rings", "TREATMENT", 184, 202], ["alkylation", "OBSERVATION", 128, 138], ["aromatic rings", "OBSERVATION", 188, 202]]], ["However, the placement of the cationic moiety in the 4-position increased the cytotoxicities of diamidines 46 (Figure 15) with respect to the pentamidine.", [["diamidines", "CHEMICAL", 96, 106], ["pentamidine", "CHEMICAL", 142, 153], ["diamidines", "CHEMICAL", 96, 106], ["pentamidine", "CHEMICAL", 142, 153], ["diamidines", "SIMPLE_CHEMICAL", 96, 106], ["pentamidine", "SIMPLE_CHEMICAL", 142, 153], ["the cationic moiety", "TREATMENT", 26, 45], ["the cytotoxicities of diamidines", "TREATMENT", 74, 106], ["the pentamidine", "TREATMENT", 138, 153]]], ["Except few, majority of unsubstituted diamidines exhibited higher in vitro activities against T. brucei rhodesiense than bis(N-isopropyl)amidines and diimidazolines.", [["diamidines", "CHEMICAL", 38, 48], ["T. brucei rhodesiense", "DISEASE", 94, 115], ["bis(N-isopropyl)amidines", "CHEMICAL", 121, 145], ["diimidazolines", "CHEMICAL", 150, 164], ["diamidines", "CHEMICAL", 38, 48], ["bis(N-isopropyl)amidines", "CHEMICAL", 121, 145], ["diimidazolines", "CHEMICAL", 150, 164], ["unsubstituted diamidines", "SIMPLE_CHEMICAL", 24, 48], ["T. brucei", "ORGANISM", 94, 103], ["rhodesiense", "ORGANISM", 104, 115], ["bis(N-isopropyl)amidines", "SIMPLE_CHEMICAL", 121, 145], ["diimidazolines", "SIMPLE_CHEMICAL", 150, 164], ["T. brucei", "SPECIES", 94, 103], ["rhodesiense", "SPECIES", 104, 115], ["T. brucei rhodesiense", "SPECIES", 94, 115], ["unsubstituted diamidines", "PROBLEM", 24, 48], ["T. brucei rhodesiense", "PROBLEM", 94, 115], ["bis(N-isopropyl)amidines", "TREATMENT", 121, 145], ["diimidazolines", "TREATMENT", 150, 164], ["few", "OBSERVATION_MODIFIER", 7, 10]]], ["The compounds with cationic fragments in the 5,5\u2032-position (compounds 1\u201315, Figure 14a) of the aromatic rings were in most cases less potent against T. brucei rhodesiense than isomers bearing at least one cationic moiety in the 4- or 4\u2032-position (compounds 16\u201360, Figure 14b\u2013d).", [["T. brucei rhodesiense", "DISEASE", 149, 170], ["aromatic rings", "SIMPLE_CHEMICAL", 95, 109], ["T. brucei rhodesiense", "ORGANISM", 149, 170], ["4\u2032-position", "SIMPLE_CHEMICAL", 234, 245], ["T. brucei", "SPECIES", 149, 158], ["T. brucei rhodesiense", "SPECIES", 149, 170], ["cationic fragments", "TREATMENT", 19, 37], ["the aromatic rings", "TREATMENT", 91, 109], ["T. brucei rhodesiense", "PROBLEM", 149, 170], ["cationic fragments", "OBSERVATION", 19, 37], ["aromatic rings", "OBSERVATION", 95, 109]]], ["However compound 46 (Figure 15) with dicationic moiety at 4,4\u2032 position showed excellent in vitro activity (0.004 \u03bcM).", [["compound 46", "CHEMICAL", 8, 19], ["dicationic moiety", "SIMPLE_CHEMICAL", 37, 54], ["4,4\u2032 position", "SIMPLE_CHEMICAL", 58, 71], ["dicationic moiety", "TREATMENT", 37, 54], ["excellent", "OBSERVATION_MODIFIER", 79, 88]]], ["The introduction of the hydroxy group in the 2-position of the phenyl ring significantly reduced activities and increased the cytotoxcity against T. brucei rhodesiense because of the formation of the intramolecular hydrogen bond between the hydrogen atom of the 2-hydroxy group and the 2-nitrogen of the triazole ring.", [["phenyl", "CHEMICAL", 63, 69], ["T. brucei rhodesiense", "DISEASE", 146, 167], ["2-hydroxy", "CHEMICAL", 262, 271], ["2-nitrogen", "CHEMICAL", 286, 296], ["triazole", "CHEMICAL", 304, 312], ["hydroxy", "CHEMICAL", 24, 31], ["phenyl", "CHEMICAL", 63, 69], ["hydrogen", "CHEMICAL", 215, 223], ["hydrogen", "CHEMICAL", 241, 249], ["2-hydroxy", "CHEMICAL", 262, 271], ["2-nitrogen", "CHEMICAL", 286, 296], ["triazole", "CHEMICAL", 304, 312], ["hydroxy", "SIMPLE_CHEMICAL", 24, 31], ["phenyl ring", "SIMPLE_CHEMICAL", 63, 74], ["T. brucei rhodesiense", "ORGANISM", 146, 167], ["2-hydroxy", "SIMPLE_CHEMICAL", 262, 271], ["2-nitrogen", "SIMPLE_CHEMICAL", 286, 296], ["triazole ring", "SIMPLE_CHEMICAL", 304, 317], ["T. brucei", "SPECIES", 146, 155], ["rhodesiense", "SPECIES", 156, 167], ["T. brucei rhodesiense", "SPECIES", 146, 167], ["the hydroxy group", "TREATMENT", 20, 37], ["the phenyl ring", "TREATMENT", 59, 74], ["T. brucei rhodesiense", "PROBLEM", 146, 167], ["the intramolecular hydrogen bond", "PROBLEM", 196, 228], ["the triazole ring", "TREATMENT", 300, 317], ["brucei rhodesiense", "OBSERVATION", 149, 167], ["intramolecular hydrogen", "OBSERVATION", 200, 223], ["triazole ring", "OBSERVATION", 304, 317]]], ["The in vivo analysis of compound 46 showed that when administered at 4 \u00d7 5 mg/kg, 4 \u00d7 1 mg/kg and 1 \u00d7 10 mg/kg by the intraperitoneal route it cured all the infected animals in the acute mouse model of African trypanosomiasis.Cationic 1,4-diphenyl-1H-1,2,3-triazoles ::: DNA minor groove binders ::: Synthetic advancesThus promising in vitro and in vivo anti-trypanosomal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles derivatives and in particular compound 46 necessitate further investigation of this class of compounds as potential anti-trypanosomal drug candidates.Comparision of isoxazole and triazole derivative of furamidine ::: DNA minor groove binders ::: Synthetic advancesThe replacement of central furan ring of furamidine either by isoxazole or 1,2,3-triazole resulted into compounds with better activity than that of furamidine.", [["intraperitoneal", "ANATOMY", 118, 133], ["trypanosomiasis", "DISEASE", 210, 225], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 235, 266], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 393, 424], ["isoxazole", "CHEMICAL", 590, 599], ["triazole", "CHEMICAL", 604, 612], ["furamidine", "CHEMICAL", 627, 637], ["furamidine", "CHEMICAL", 730, 740], ["isoxazole", "CHEMICAL", 751, 760], ["1,2,3-triazole", "CHEMICAL", 764, 778], ["furamidine", "CHEMICAL", 837, 847], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 235, 266], ["1,4-diphenyl-1H-1,2,3-triazoles", "CHEMICAL", 393, 424], ["isoxazole", "CHEMICAL", 590, 599], ["triazole", "CHEMICAL", 604, 612], ["furamidine", "CHEMICAL", 627, 637], ["furan", "CHEMICAL", 716, 721], ["furamidine", "CHEMICAL", 730, 740], ["isoxazole", "CHEMICAL", 751, 760], ["1,2,3-triazole", "CHEMICAL", 764, 778], ["furamidine", "CHEMICAL", 837, 847], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 133], ["mouse", "ORGANISM", 187, 192], ["Cationic 1,4-diphenyl-1H-1,2,3-triazoles", "SIMPLE_CHEMICAL", 226, 266], ["DNA", "CELLULAR_COMPONENT", 271, 274], ["cationic 1,4-diphenyl-1H-1,2,3-triazoles derivatives", "SIMPLE_CHEMICAL", 384, 436], ["isoxazole", "SIMPLE_CHEMICAL", 590, 599], ["triazole derivative", "SIMPLE_CHEMICAL", 604, 623], ["furamidine", "SIMPLE_CHEMICAL", 627, 637], ["DNA", "CELLULAR_COMPONENT", 642, 645], ["furamidine", "SIMPLE_CHEMICAL", 730, 740], ["isoxazole", "SIMPLE_CHEMICAL", 751, 760], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 764, 778], ["furamidine", "SIMPLE_CHEMICAL", 837, 847], ["mouse", "SPECIES", 187, 192], ["mouse", "SPECIES", 187, 192], ["The in vivo analysis", "TEST", 0, 20], ["the intraperitoneal route", "TREATMENT", 114, 139], ["African trypanosomiasis", "PROBLEM", 202, 225], ["Cationic", "TEST", 226, 234], ["diphenyl-1H", "TREATMENT", 239, 250], ["triazoles", "TREATMENT", 257, 266], ["vitro", "TREATMENT", 336, 341], ["diphenyl", "TREATMENT", 397, 405], ["triazoles derivatives", "TREATMENT", 415, 436], ["potential anti-trypanosomal drug candidates", "TREATMENT", 531, 574], ["isoxazole", "TREATMENT", 590, 599], ["triazole derivative of furamidine", "TREATMENT", 604, 637], ["The replacement of central furan ring of furamidine", "TREATMENT", 689, 740], ["isoxazole", "TREATMENT", 751, 760], ["triazole", "TREATMENT", 770, 778], ["furamidine", "TREATMENT", 837, 847], ["infected", "OBSERVATION", 157, 165], ["acute mouse", "OBSERVATION", 181, 192], ["groove", "OBSERVATION_MODIFIER", 281, 287], ["binders", "OBSERVATION", 288, 295], ["groove", "OBSERVATION_MODIFIER", 652, 658], ["binders", "OBSERVATION", 659, 666], ["replacement", "OBSERVATION", 693, 704], ["central furan ring", "OBSERVATION", 708, 726]]], ["Position and the nature of the cationic substituent governed the anti-trypanosomal activity of the two series.", [["the cationic substituent", "TREATMENT", 27, 51]]], ["In general the para substituted diamidines in both the series were the most promising compounds with good activity.", [["diamidines", "CHEMICAL", 32, 42], ["diamidines", "CHEMICAL", 32, 42], ["para substituted diamidines", "SIMPLE_CHEMICAL", 15, 42], ["the para substituted diamidines", "TREATMENT", 11, 42], ["good activity", "OBSERVATION", 101, 114]]], ["Thus these compounds should be further evaluated to produce better analogue of furamidineBis(2-aminoimidazoline) and Bisguanidine ::: DNA minor groove binders ::: Synthetic advancesThe recent report on N,N'-bis(4-amidinophenyl)piperazine (Figure 16), which was shown to be very effective in vivo anti-trypanosomal agent has attracted the interest in this compound [56].", [["furamidineBis", "CHEMICAL", 79, 92], ["2-aminoimidazoline", "CHEMICAL", 93, 111], ["Bisguanidine", "CHEMICAL", 117, 129], ["N,N'-bis(4-amidinophenyl)piperazine", "CHEMICAL", 202, 237], ["furamidineBis(2-aminoimidazoline)", "CHEMICAL", 79, 112], ["Bisguanidine", "CHEMICAL", 117, 129], ["N,N'-bis(4-amidinophenyl)piperazine", "CHEMICAL", 202, 237], ["furamidineBis(2-aminoimidazoline", "SIMPLE_CHEMICAL", 79, 111], ["Bisguanidine", "SIMPLE_CHEMICAL", 117, 129], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["N,N'-bis(4-amidinophenyl)piperazine", "SIMPLE_CHEMICAL", 202, 237], ["Figure 16", "SIMPLE_CHEMICAL", 239, 248], ["furamidineBis", "TREATMENT", 79, 92], ["N,N'-bis(4-amidinophenyl)piperazine (Figure", "TREATMENT", 202, 245], ["vivo anti-trypanosomal agent", "TREATMENT", 291, 319], ["groove", "OBSERVATION_MODIFIER", 144, 150], ["binders", "OBSERVATION", 151, 158]]], ["Hence in search for new HAT chemotherapy Dardonville C et al [57] decided to carry out an in vitro screening of a total of 62 compounds against the parasite T. brucei rhodesiense taken from their in-house library.", [["parasite", "ORGANISM", 148, 156], ["T. brucei rhodesiense", "ORGANISM", 157, 178], ["T. brucei", "SPECIES", 157, 166], ["rhodesiense", "SPECIES", 167, 178], ["T. brucei rhodesiense", "SPECIES", 157, 178], ["new HAT chemotherapy Dardonville", "TREATMENT", 20, 52]]], ["Based on this they showed that bisguanidine and especially bis(2-aminoimidazoline)diphenyl compounds displayed potent anti-trypanosomal activity in vitro and vivo against T. b. rhodesiense, the causative agent of acute HAT [58, 59].", [["bisguanidine", "CHEMICAL", 31, 43], ["bis(2-aminoimidazoline)diphenyl compounds", "CHEMICAL", 59, 100], ["T. b. rhodesiense", "DISEASE", 171, 188], ["bisguanidine", "CHEMICAL", 31, 43], ["bis(2-aminoimidazoline)diphenyl", "CHEMICAL", 59, 90], ["bisguanidine", "SIMPLE_CHEMICAL", 31, 43], ["bis(2-aminoimidazoline)diphenyl compounds", "SIMPLE_CHEMICAL", 59, 100], ["anti-trypanosomal", "CANCER", 118, 135], ["T. b. rhodesiense", "ORGANISM", 171, 188], ["T. b. rhodesiense", "SPECIES", 171, 188], ["T. b. rhodesiense", "SPECIES", 171, 188], ["bisguanidine", "TREATMENT", 31, 43], ["bis(2-aminoimidazoline)diphenyl compounds", "TREATMENT", 59, 100], ["potent anti-trypanosomal activity", "TREATMENT", 111, 144]]], ["Among the 62 compounds screened, compounds1c, 28b, 32b and 41b (Figure 17) showed excellent in vitro activity (49nM, 69 nM, 22 nM and 118 nM respectively) as well as high selectivity (>5294, 3072, 29.5 and 881 respectively) for the parasite.", [["compounds1c, 28b, 32b and 41b", "CHEMICAL", 33, 62], ["compounds1c", "SIMPLE_CHEMICAL", 33, 44], ["28b", "SIMPLE_CHEMICAL", 46, 49], ["32b", "SIMPLE_CHEMICAL", 51, 54], ["41b", "SIMPLE_CHEMICAL", 59, 62], ["the parasite", "PROBLEM", 228, 240]]], ["These studies revealed that compounds bearing 2-aminoimidazoline cations had higher selectivity for the parasite and similar activities with respect to their guanidine counterparts.", [["2-aminoimidazoline", "CHEMICAL", 46, 64], ["2-aminoimidazoline", "CHEMICAL", 46, 64], ["guanidine", "CHEMICAL", 158, 167], ["2-aminoimidazoline cations", "SIMPLE_CHEMICAL", 46, 72], ["These studies", "TEST", 0, 13], ["compounds bearing 2-aminoimidazoline cations", "TREATMENT", 28, 72], ["the parasite", "PROBLEM", 100, 112], ["their guanidine counterparts", "TREATMENT", 152, 180]]], ["In addition, a correlation between anti-trypanosomal activity and DNA binding affinity was observed, suggesting a possible mechanism of action for these compounds.", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["DNA binding affinity", "PROBLEM", 66, 86], ["these compounds", "PROBLEM", 147, 162]]], ["Those molecules that showed an excellent in vitro activity as well as high selectivity for the parasite represent new anti-trypanosomal lead compounds.Bis(2-aminoimidazoline) and Bisguanidine ::: DNA minor groove binders ::: Synthetic advancesIn light of these promising results, bis(2-aminoimidazoline) derivatives deserve more investigation as anti-trypanosomal agents and DNA minor groove binders.", [["Bis(2-aminoimidazoline", "CHEMICAL", 151, 173], ["Bisguanidine", "CHEMICAL", 179, 191], ["bis(2-aminoimidazoline", "CHEMICAL", 280, 302], ["Bis(2-aminoimidazoline)", "CHEMICAL", 151, 174], ["Bisguanidine", "CHEMICAL", 179, 191], ["bis(2-aminoimidazoline)", "CHEMICAL", 280, 303], ["Bis(2-aminoimidazoline", "SIMPLE_CHEMICAL", 151, 173], ["Bisguanidine", "SIMPLE_CHEMICAL", 179, 191], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["bis(2-aminoimidazoline) derivatives", "SIMPLE_CHEMICAL", 280, 315], ["anti-trypanosomal agents", "SIMPLE_CHEMICAL", 346, 370], ["DNA", "CELLULAR_COMPONENT", 375, 378], ["the parasite", "PROBLEM", 91, 103], ["new anti-trypanosomal lead compounds", "PROBLEM", 114, 150], ["Bis", "TEST", 151, 154], ["bis(2-aminoimidazoline) derivatives", "TREATMENT", 280, 315], ["anti-trypanosomal agents", "TREATMENT", 346, 370], ["DNA minor groove binders", "TREATMENT", 375, 399], ["excellent", "OBSERVATION_MODIFIER", 31, 40], ["vitro activity", "OBSERVATION", 44, 58], ["high selectivity", "OBSERVATION_MODIFIER", 70, 86], ["new", "OBSERVATION_MODIFIER", 114, 117], ["anti-trypanosomal lead compounds", "OBSERVATION", 118, 150], ["groove", "OBSERVATION_MODIFIER", 206, 212], ["binders", "OBSERVATION", 213, 220]]], ["The synthesis and study of new derivatives and prodrugs of these lead compounds is ongoing.Trypanothione Reductase Inhibitors ::: Other target and lead compounds ::: Synthetic advancesThe enzyme trypanothione reductase (TR) which restores the oxidized trypanothione to reduced state has evolved as an effective drug target.", [["Trypanothione", "CHEMICAL", 91, 104], ["trypanothione", "CHEMICAL", 252, 265], ["Trypanothione", "CHEMICAL", 91, 104], ["trypanothione", "CHEMICAL", 195, 208], ["trypanothione", "CHEMICAL", 252, 265], ["Trypanothione", "SIMPLE_CHEMICAL", 91, 104], ["trypanothione reductase", "GENE_OR_GENE_PRODUCT", 195, 218], ["TR", "GENE_OR_GENE_PRODUCT", 220, 222], ["trypanothione", "SIMPLE_CHEMICAL", 252, 265], ["enzyme trypanothione reductase", "PROTEIN", 188, 218], ["TR", "PROTEIN", 220, 222], ["new derivatives", "TREATMENT", 27, 42], ["prodrugs", "TREATMENT", 47, 55], ["these lead compounds", "TREATMENT", 59, 79], ["The enzyme trypanothione reductase (TR)", "PROBLEM", 184, 223], ["the oxidized trypanothione", "PROBLEM", 239, 265], ["reduced state", "PROBLEM", 269, 282], ["trypanothione reductase", "OBSERVATION", 195, 218]]], ["Many inhibitors of this enzyme have been developed but most of them combat with problems related to bioavailability, pharmacokinetics and metabolism.", [["this enzyme", "TEST", 19, 30]]], ["Despite this quinolines have evolved as most important class of compounds against TR due to their broad spectrum of activity, excellent pharmacological and pharmacokinetic properties such as high plasma levels, high clearance, oral and parenteral applicability, chemical stability and rare side effect.Trypanothione Reductase Inhibitors ::: Other target and lead compounds ::: Synthetic advancesIn view of this Gilbert IH [60] reported the screening of 62000 compound libraries against T. brucei.", [["plasma", "ANATOMY", 196, 202], ["oral", "ANATOMY", 227, 231], ["quinolines", "CHEMICAL", 13, 23], ["Trypanothione", "CHEMICAL", 302, 315], ["quinolines", "CHEMICAL", 13, 23], ["Trypanothione", "CHEMICAL", 302, 315], ["quinolines", "SIMPLE_CHEMICAL", 13, 23], ["plasma", "ORGANISM_SUBSTANCE", 196, 202], ["oral", "ORGANISM_SUBDIVISION", 227, 231], ["Trypanothione", "SIMPLE_CHEMICAL", 302, 315], ["T. brucei", "ORGANISM", 486, 495], ["TR", "PROTEIN", 82, 84], ["T. brucei", "SPECIES", 486, 495], ["T. brucei", "SPECIES", 486, 495], ["this quinolines", "TREATMENT", 8, 23], ["TR", "PROBLEM", 82, 84], ["high plasma levels", "TEST", 191, 209], ["oral and parenteral applicability", "TREATMENT", 227, 260], ["rare side effect", "PROBLEM", 285, 301], ["the screening", "TEST", 436, 449], ["T. brucei", "PROBLEM", 486, 495]]], ["High through put screening (HTS) which resulted into identification of two novel compound series active against the enzyme trypanothione reductase.", [["trypanothione", "CHEMICAL", 123, 136], ["trypanothione reductase", "GENE_OR_GENE_PRODUCT", 123, 146], ["enzyme trypanothione reductase", "PROTEIN", 116, 146], ["the enzyme trypanothione reductase", "TREATMENT", 112, 146]]], ["Series 1 was based on the quinoline scaffold (Figure 18a) in which compound 2 (Figure 19a) with methylfuran group at R3 position, Br at 6th position of quinoline ring and N-methylethanamine group at R1 position was the most potent and significant TR inhibitor with TR inhibitory activity of 1.1 \u03bcM.", [["quinoline", "CHEMICAL", 26, 35], ["methylfuran", "CHEMICAL", 96, 107], ["Br", "CHEMICAL", 130, 132], ["quinoline", "CHEMICAL", 152, 161], ["N-methylethanamine", "CHEMICAL", 171, 189], ["quinoline", "CHEMICAL", 26, 35], ["methylfuran", "CHEMICAL", 96, 107], ["Br", "CHEMICAL", 130, 132], ["quinoline", "CHEMICAL", 152, 161], ["N-methylethanamine", "CHEMICAL", 171, 189], ["Figure 19a", "SIMPLE_CHEMICAL", 79, 89], ["methylfuran", "SIMPLE_CHEMICAL", 96, 107], ["quinoline ring", "SIMPLE_CHEMICAL", 152, 166], ["N-methylethanamine", "SIMPLE_CHEMICAL", 171, 189], ["TR", "PROTEIN", 265, 267], ["the quinoline scaffold (Figure 18a)", "TREATMENT", 22, 57], ["methylfuran group at R3 position", "TREATMENT", 96, 128], ["Br", "TREATMENT", 130, 132], ["quinoline ring", "TREATMENT", 152, 166], ["N-methylethanamine group at R1 position", "TREATMENT", 171, 210], ["significant TR inhibitor", "TREATMENT", 235, 259], ["TR inhibitory activity", "TREATMENT", 265, 287], ["quinoline ring", "OBSERVATION", 152, 166], ["most potent", "OBSERVATION_MODIFIER", 219, 230]]], ["According to SAR study the replacement of methylfuran with other groups like furan, phenyl, pyridinyl, thiophene led to decrease in activity.", [["methylfuran", "CHEMICAL", 42, 53], ["furan, phenyl, pyridinyl, thiophene", "CHEMICAL", 77, 112], ["methylfuran", "CHEMICAL", 42, 53], ["furan", "CHEMICAL", 77, 82], ["phenyl", "CHEMICAL", 84, 90], ["pyridinyl", "CHEMICAL", 92, 101], ["thiophene", "CHEMICAL", 103, 112], ["methylfuran", "SIMPLE_CHEMICAL", 42, 53], ["furan", "SIMPLE_CHEMICAL", 77, 82], ["phenyl, pyridinyl, thiophene", "SIMPLE_CHEMICAL", 84, 112], ["SAR study", "TEST", 13, 22], ["the replacement of methylfuran", "TREATMENT", 23, 53], ["furan", "TREATMENT", 77, 82], ["phenyl", "TREATMENT", 84, 90], ["pyridinyl", "TREATMENT", 92, 101], ["thiophene", "TREATMENT", 103, 112], ["decrease", "OBSERVATION_MODIFIER", 120, 128]]], ["Also the replacement of Br with H or F reduced the activity while Cl group retained the activity.", [["Br", "CHEMICAL", 24, 26], ["H", "CHEMICAL", 32, 33], ["Cl", "CHEMICAL", 66, 68], ["Br", "CHEMICAL", 24, 26], ["H", "CHEMICAL", 32, 33], ["Cl", "CHEMICAL", 66, 68], ["H or F", "SIMPLE_CHEMICAL", 32, 38], ["Cl", "SIMPLE_CHEMICAL", 66, 68], ["the replacement of Br", "TREATMENT", 5, 26], ["replacement", "OBSERVATION", 9, 20], ["activity", "OBSERVATION_MODIFIER", 51, 59], ["activity", "OBSERVATION_MODIFIER", 88, 96]]], ["At 4th position the NH and NMe groups were equally active.", [["NH", "CHEMICAL", 20, 22], ["NMe", "CHEMICAL", 27, 30], ["active", "OBSERVATION", 51, 57]]], ["The alkylamines at R1 were active whereas the simple alkyl or aryl groups led to inactive compounds.", [["alkylamines", "CHEMICAL", 4, 15], ["alkyl", "CHEMICAL", 53, 58], ["aryl", "CHEMICAL", 62, 66], ["alkylamines", "CHEMICAL", 4, 15], ["aryl", "CHEMICAL", 62, 66], ["alkylamines", "SIMPLE_CHEMICAL", 4, 15], ["alkyl", "SIMPLE_CHEMICAL", 53, 58], ["aryl", "SIMPLE_CHEMICAL", 62, 66], ["The alkylamines at R1", "TREATMENT", 0, 21], ["inactive compounds", "PROBLEM", 81, 99], ["alkylamines", "OBSERVATION_MODIFIER", 4, 15], ["active", "OBSERVATION_MODIFIER", 27, 33], ["inactive compounds", "OBSERVATION", 81, 99]]], ["The second series was based on the pyrimidopyridazine scaffold (Figure 18b), in which the compound 49 (Figure 19b) showed promising inhibitory activity of 2.6 \u03bcM.", [["pyrimidopyridazine", "CHEMICAL", 35, 53], ["pyrimidopyridazine", "CHEMICAL", 35, 53], ["pyrimidopyridazine", "SIMPLE_CHEMICAL", 35, 53]]], ["In case of series 2 replacement of methyl group at R1 position by H led to the decrease in activity.", [["methyl", "CHEMICAL", 35, 41], ["H", "CHEMICAL", 66, 67], ["methyl", "CHEMICAL", 35, 41], ["H", "CHEMICAL", 66, 67], ["methyl group", "SIMPLE_CHEMICAL", 35, 47], ["series 2 replacement of methyl group at R1 position", "TREATMENT", 11, 62], ["decrease", "OBSERVATION_MODIFIER", 79, 87], ["activity", "OBSERVATION_MODIFIER", 91, 99]]], ["At R2 position methyl and ethyl group showed activity while the H and chain extensions to propyl, butyl and cyclopentane led to decrease in activity.", [["R2 position methyl and ethyl", "CHEMICAL", 3, 31], ["H", "CHEMICAL", 64, 65], ["propyl, butyl", "CHEMICAL", 90, 103], ["cyclopentane", "CHEMICAL", 108, 120], ["methyl", "CHEMICAL", 15, 21], ["ethyl", "CHEMICAL", 26, 31], ["H", "CHEMICAL", 64, 65], ["propyl", "CHEMICAL", 90, 96], ["butyl", "CHEMICAL", 98, 103], ["cyclopentane", "CHEMICAL", 108, 120], ["methyl", "SIMPLE_CHEMICAL", 15, 21], ["ethyl", "SIMPLE_CHEMICAL", 26, 31], ["propyl", "SIMPLE_CHEMICAL", 90, 96], ["butyl", "SIMPLE_CHEMICAL", 98, 103], ["cyclopentane", "SIMPLE_CHEMICAL", 108, 120], ["R2 position methyl and ethyl group", "TREATMENT", 3, 37], ["the H and chain extensions to propyl", "TREATMENT", 60, 96], ["butyl", "TREATMENT", 98, 103], ["cyclopentane", "TREATMENT", 108, 120], ["decrease", "OBSERVATION_MODIFIER", 128, 136]]], ["Substituted phenyl and alkenylphenyl group at R3 position gave the most active compound of the series.", [["phenyl", "CHEMICAL", 12, 18], ["alkenylphenyl", "CHEMICAL", 23, 36], ["phenyl", "CHEMICAL", 12, 18], ["alkenylphenyl", "CHEMICAL", 23, 36], ["Substituted phenyl", "SIMPLE_CHEMICAL", 0, 18], ["alkenylphenyl", "SIMPLE_CHEMICAL", 23, 36], ["Substituted phenyl and alkenylphenyl group at R3 position", "TREATMENT", 0, 57]]], ["Thus these quinoline compounds with promising activity could serve as lead compounds for further development of targeted drugs against African trypanosomiasis.Trypanothione Reductase Inhibitors ::: Other target and lead compounds ::: Synthetic advancesIn addition to this synthetic optimization study based on the lead anti-trypanosomal compound 1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate (Figure 20) was undertaken by Werbovetz KA et al [61] in an attempt to discover new trypanocides with potent in vivo activity targeting TR enzyme.", [["quinoline", "CHEMICAL", 11, 20], ["trypanosomiasis", "DISEASE", 143, 158], ["Trypanothione", "CHEMICAL", 159, 172], ["1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate", "CHEMICAL", 346, 408], ["KA", "CHEMICAL", 449, 451], ["trypanocides", "CHEMICAL", 493, 505], ["quinoline", "CHEMICAL", 11, 20], ["Trypanothione", "CHEMICAL", 159, 172], ["1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate", "CHEMICAL", 346, 408], ["trypanocides", "CHEMICAL", 493, 505], ["quinoline compounds", "SIMPLE_CHEMICAL", 11, 30], ["Trypanothione", "SIMPLE_CHEMICAL", 159, 172], ["1,2-dihydro-2,2,4-trimethylquinolin-6-yl 3,5-dimethoxybenzoate", "SIMPLE_CHEMICAL", 346, 408], ["trypanocides", "SIMPLE_CHEMICAL", 493, 505], ["TR enzyme", "GENE_OR_GENE_PRODUCT", 545, 554], ["TR enzyme", "PROTEIN", 545, 554], ["African trypanosomiasis", "SPECIES", 135, 158], ["these quinoline compounds", "TREATMENT", 5, 30], ["targeted drugs", "TREATMENT", 112, 126], ["African trypanosomiasis", "PROBLEM", 135, 158], ["this synthetic optimization study", "TEST", 267, 300], ["the lead anti-trypanosomal compound", "TREATMENT", 310, 345], ["dihydro", "TREATMENT", 350, 357], ["trimethylquinolin", "TREATMENT", 364, 381], ["dimethoxybenzoate (Figure", "TREATMENT", 391, 416], ["new trypanocides", "PROBLEM", 489, 505], ["TR enzyme", "TEST", 545, 554], ["quinoline compounds", "OBSERVATION", 11, 30]]], ["In course of this a total of 53 compounds were evaluated in vitro for their anti-trypanosomal activity and cytotoxicity.", [["cytotoxicity", "PROBLEM", 107, 119]]], ["The compounds with oxygen atom at 6th position were the most active compounds in the series, for example compound 9 (Figure 21) showed better anti-trypanosomal activity (0.007 \u03bcM) and low cytotoxicity (6.8 \u03bcM) than melarsoprol (IC50 = 0.008\u03bcM and cytotoxicity = 7.9\u03bcM).", [["oxygen", "CHEMICAL", 19, 25], ["compound 9", "CHEMICAL", 105, 115], ["melarsoprol", "CHEMICAL", 215, 226], ["oxygen", "CHEMICAL", 19, 25], ["melarsoprol", "CHEMICAL", 215, 226], ["oxygen atom", "SIMPLE_CHEMICAL", 19, 30], ["melarsoprol", "SIMPLE_CHEMICAL", 215, 226], ["oxygen atom", "TREATMENT", 19, 30], ["example compound", "TEST", 97, 113], ["low cytotoxicity", "PROBLEM", 184, 200], ["melarsoprol", "TREATMENT", 215, 226], ["IC50", "TEST", 228, 232], ["cytotoxicity", "TEST", 247, 259], ["oxygen atom", "OBSERVATION", 19, 30]]], ["Whereas compounds lacking the 6-oxygen atom or bearing an oxygen atom at the 7-position rather than the 6- position were far less potent than those containing an alcohol or acyloxy group at the 6-position.", [["oxygen", "CHEMICAL", 32, 38], ["oxygen", "CHEMICAL", 58, 64], ["alcohol", "CHEMICAL", 162, 169], ["acyloxy", "CHEMICAL", 173, 180], ["6-oxygen", "CHEMICAL", 30, 38], ["oxygen", "CHEMICAL", 58, 64], ["alcohol", "CHEMICAL", 162, 169], ["acyloxy", "CHEMICAL", 173, 180], ["6-oxygen atom", "SIMPLE_CHEMICAL", 30, 43], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["alcohol", "SIMPLE_CHEMICAL", 162, 169], ["acyloxy", "SIMPLE_CHEMICAL", 173, 180], ["oxygen atom", "TREATMENT", 32, 43], ["an oxygen atom", "TREATMENT", 55, 69], ["acyloxy group", "TREATMENT", 173, 186]]], ["Compounds carrying aliphatic or a 2-phenylacetyl ester side chains were as potent and selective as their benzoylated or acetylated counterparts.", [["aliphatic", "CHEMICAL", 19, 28], ["2-phenylacetyl ester", "CHEMICAL", 34, 54], ["2-phenylacetyl ester", "CHEMICAL", 34, 54], ["2-phenylacetyl ester side chains", "SIMPLE_CHEMICAL", 34, 66], ["benzoylated", "SIMPLE_CHEMICAL", 105, 116], ["a 2-phenylacetyl ester side chains", "TREATMENT", 32, 66], ["aliphatic", "OBSERVATION_MODIFIER", 19, 28]]], ["However compound 9a was unstable due to auto-oxidation, so the unstable alcohols were esterified to generate prodrug 10a (Figure 21) having promising activity of 0.014\u03bcM against these parasites and a selectivity index of 1700.", [["compound 9a", "CHEMICAL", 8, 19], ["prodrug 10a", "CHEMICAL", 109, 120], ["alcohols", "CHEMICAL", 72, 80], ["alcohols", "SIMPLE_CHEMICAL", 72, 80], ["prodrug 10a", "SIMPLE_CHEMICAL", 109, 120], ["auto-oxidation", "PROBLEM", 40, 54], ["the unstable alcohols", "PROBLEM", 59, 80], ["a selectivity index", "TEST", 198, 217]]], ["The in vivo evaluation of compound 10a in a murine model of African trypanosomiasis showed good results as the prodrug extended the lifespan of mice infected with T. b. brucei.Trypanothione Reductase Inhibitors ::: Other target and lead compounds ::: Synthetic advancesThus compound 10a can serve as lead compound for further investigation of this class of molecules as potential candidates against HAT.", [["compound 10a", "CHEMICAL", 26, 38], ["trypanosomiasis", "DISEASE", 68, 83], ["Trypanothione", "CHEMICAL", 176, 189], ["compound 10a", "CHEMICAL", 274, 286], ["HAT", "DISEASE", 399, 402], ["Trypanothione", "CHEMICAL", 176, 189], ["murine", "ORGANISM", 44, 50], ["mice", "ORGANISM", 144, 148], ["T. b. brucei", "ORGANISM", 163, 175], ["Trypanothione Reductase", "GENE_OR_GENE_PRODUCT", 176, 199], ["compound 10a", "SIMPLE_CHEMICAL", 274, 286], ["HAT", "CANCER", 399, 402], ["murine", "SPECIES", 44, 50], ["mice", "SPECIES", 144, 148], ["T. b. brucei", "SPECIES", 163, 175], ["mice", "SPECIES", 144, 148], ["T. b. brucei", "SPECIES", 163, 175], ["The in vivo evaluation", "TEST", 0, 22], ["African trypanosomiasis", "PROBLEM", 60, 83], ["T. b. brucei", "PROBLEM", 163, 175], ["Trypanothione Reductase Inhibitors", "TREATMENT", 176, 210], ["further investigation", "TEST", 318, 339], ["HAT", "PROBLEM", 399, 402]]], ["Efforts are also be undertaken to further elucidate the metabolism, pharmacokinetics, and the anti-trypanosomal mechanism of action of this novel and promising class of compounds.Topoisomerase inhibitors ::: Other target and lead compounds ::: Synthetic advancesDNA topoisomerases have evolved as an effective drug target in prokaryotic and eukaryotic systems as these enzyme mediate mechanistic interactions such as supercoiling, relaxation, knotting or catenating of DNA double helices.", [["Topoisomerase", "GENE_OR_GENE_PRODUCT", 179, 192], ["advancesDNA topoisomerases", "GENE_OR_GENE_PRODUCT", 254, 280], ["DNA", "CELLULAR_COMPONENT", 469, 472], ["advancesDNA topoisomerases", "PROTEIN", 254, 280], ["DNA double helices", "PROTEIN", 469, 487], ["Topoisomerase inhibitors", "TREATMENT", 179, 203], ["Synthetic advancesDNA topoisomerases", "TREATMENT", 244, 280], ["DNA double helices", "TREATMENT", 469, 487]]], ["Based on their mechanism of action, topoisomerases can be classified as type I enzymes, which break a single strand of the DNA helix during the catalytic cycle, and type II enzymes, which make double-stranded breaks.", [["topoisomerases", "GENE_OR_GENE_PRODUCT", 36, 50], ["type I enzymes", "GENE_OR_GENE_PRODUCT", 72, 86], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["type II enzymes", "GENE_OR_GENE_PRODUCT", 165, 180], ["topoisomerases", "PROTEIN", 36, 50], ["type I enzymes", "PROTEIN", 72, 86], ["type II enzymes", "PROTEIN", 165, 180], ["topoisomerases", "TREATMENT", 36, 50], ["type I enzymes", "PROBLEM", 72, 86], ["the DNA helix", "TREATMENT", 119, 132], ["the catalytic cycle", "TEST", 140, 159], ["type II enzymes", "TEST", 165, 180], ["double-stranded breaks", "PROBLEM", 193, 215], ["stranded breaks", "OBSERVATION", 200, 215]]], ["On the basis of primary sequence and reaction mechanism, type I topoisomerases are further subdivided into type IA and type IB.Topoisomerase inhibitors ::: Other target and lead compounds ::: Synthetic advancesRecently Shapiro TA et al [62] evaluated the activity of indenoisoquinolines (Figure 22), originally known to have anti-cancer activity, against T. brucei and found that most of the compounds showed in vitro activity at submicromolar concentrations.", [["indenoisoquinolines", "CHEMICAL", 267, 286], ["indenoisoquinolines", "CHEMICAL", 267, 286], ["type I topoisomerases", "GENE_OR_GENE_PRODUCT", 57, 78], ["Topoisomerase", "GENE_OR_GENE_PRODUCT", 127, 140], ["indenoisoquinolines", "SIMPLE_CHEMICAL", 267, 286], ["T. brucei", "ORGANISM", 355, 364], ["type I topoisomerases", "PROTEIN", 57, 78], ["T. brucei", "SPECIES", 355, 364], ["T. brucei", "SPECIES", 355, 364], ["primary sequence and reaction mechanism", "TREATMENT", 16, 55], ["type I topoisomerases", "PROBLEM", 57, 78], ["Topoisomerase inhibitors", "TREATMENT", 127, 151], ["anti-cancer activity", "PROBLEM", 325, 345], ["T. brucei", "PROBLEM", 355, 364]]], ["The compound 12 (Figure 23) with propylamino group at R6 position and methoxy group at R2, R3 and R9 was the most active one with in vitro anti-trypanosomal activity of 0.05 \u03bcM.", [["propylamino", "CHEMICAL", 33, 44], ["methoxy", "CHEMICAL", 70, 77], ["propylamino", "CHEMICAL", 33, 44], ["methoxy", "CHEMICAL", 70, 77], ["propylamino", "SIMPLE_CHEMICAL", 33, 44], ["methoxy", "SIMPLE_CHEMICAL", 70, 77], ["R9", "SIMPLE_CHEMICAL", 98, 100], ["propylamino group at R6 position", "TREATMENT", 33, 65], ["methoxy group at R2", "TREATMENT", 70, 89]]], ["The compound also showed good in vivo activity as it delayed parasitemia and extended survival in infected mice.", [["parasitemia", "DISEASE", 61, 72], ["mice", "ORGANISM", 107, 111], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["delayed parasitemia", "PROBLEM", 53, 72], ["good", "OBSERVATION_MODIFIER", 25, 29], ["parasitemia", "OBSERVATION", 61, 72], ["infected mice", "OBSERVATION", 98, 111]]], ["According to structure-activity analysis the compounds with enhanced potency included alkylamino substitutions on N-6, methoxy groups on C-2 and C-3, and a methylenedioxy bridge between C-8 and C-9.", [["alkylamino", "CHEMICAL", 86, 96], ["N-6, methoxy", "CHEMICAL", 114, 126], ["methylenedioxy", "CHEMICAL", 156, 170], ["C-8 and C-9", "CHEMICAL", 186, 197], ["alkylamino", "CHEMICAL", 86, 96], ["methoxy", "CHEMICAL", 119, 126], ["methylenedioxy", "CHEMICAL", 156, 170], ["alkylamino", "SIMPLE_CHEMICAL", 86, 96], ["N-6, methoxy groups", "SIMPLE_CHEMICAL", 114, 133], ["C-2", "SIMPLE_CHEMICAL", 137, 140], ["C-3", "SIMPLE_CHEMICAL", 145, 148], ["methylenedioxy", "SIMPLE_CHEMICAL", 156, 170], ["C-8", "SIMPLE_CHEMICAL", 186, 189], ["C-9", "SIMPLE_CHEMICAL", 194, 197], ["C-8 and C-9", "PROTEIN", 186, 197], ["alkylamino substitutions", "PROBLEM", 86, 110], ["N", "TEST", 114, 115], ["C", "TEST", 137, 138], ["a methylenedioxy bridge", "TREATMENT", 154, 177], ["C", "TEST", 186, 187]]], ["Testing of indenoisoquinolines with promising activity on L1210 mouse leukemia cells revealed all the compounds were more effective against trypanosomes than against mammalian cells.", [["L1210 mouse leukemia cells", "ANATOMY", 58, 84], ["cells", "ANATOMY", 176, 181], ["indenoisoquinolines", "CHEMICAL", 11, 30], ["leukemia", "DISEASE", 70, 78], ["indenoisoquinolines", "CHEMICAL", 11, 30], ["indenoisoquinolines", "SIMPLE_CHEMICAL", 11, 30], ["L1210 mouse leukemia cells", "CELL", 58, 84], ["mammalian cells", "CELL", 166, 181], ["L1210 mouse leukemia cells", "CELL_LINE", 58, 84], ["mammalian cells", "CELL_TYPE", 166, 181], ["mouse", "SPECIES", 64, 69], ["mouse", "SPECIES", 64, 69], ["Testing of indenoisoquinolines", "PROBLEM", 0, 30], ["promising activity on L1210 mouse leukemia cells", "PROBLEM", 36, 84], ["all the compounds", "PROBLEM", 94, 111], ["trypanosomes", "PROBLEM", 140, 152], ["mammalian cells", "PROBLEM", 166, 181]]], ["The indenoisoquinolines also showed appreciable water solubility indicating that these compounds have good quality for drug development.", [["indenoisoquinolines", "CHEMICAL", 4, 23], ["indenoisoquinolines", "CHEMICAL", 4, 23], ["indenoisoquinolines", "SIMPLE_CHEMICAL", 4, 23], ["water", "SIMPLE_CHEMICAL", 48, 53], ["appreciable water solubility", "PROBLEM", 36, 64], ["appreciable", "OBSERVATION_MODIFIER", 36, 47], ["water solubility", "OBSERVATION", 48, 64]]], ["The study indicated that they stabilize topoisomerase-DNA complexes in situ and may also impede topoisomerase binding to DNA.", [["topoisomerase", "GENE_OR_GENE_PRODUCT", 40, 53], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["topoisomerase", "GENE_OR_GENE_PRODUCT", 96, 109], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["topoisomerase-DNA complexes", "PROTEIN", 40, 67], ["topoisomerase", "PROTEIN", 96, 109], ["The study", "TEST", 0, 9], ["topoisomerase-DNA complexes", "TREATMENT", 40, 67]]], ["These agents markedly inhibited DNA synthesis by interfering with topoisomerase and possibly other DNA-metabolizing enzymes.Topoisomerase inhibitors ::: Other target and lead compounds ::: Synthetic advancesThus multiple mechanisms of action of these compounds against trypanosomes are an attractive feature, since such compounds are less prone to drug resistance.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["topoisomerase", "GENE_OR_GENE_PRODUCT", 66, 79], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["Topoisomerase", "GENE_OR_GENE_PRODUCT", 124, 137], ["trypanosomes", "CELL", 269, 281], ["topoisomerase", "PROTEIN", 66, 79], ["DNA-metabolizing enzymes", "PROTEIN", 99, 123], ["DNA synthesis", "TREATMENT", 32, 45], ["topoisomerase", "TREATMENT", 66, 79], ["metabolizing enzymes", "TEST", 103, 123], ["Topoisomerase inhibitors", "TREATMENT", 124, 148], ["trypanosomes", "PROBLEM", 269, 281]]], ["Therefore indenoisoquinoline compound 12 is a promising lead for the development of drugs against sleeping sickness.Topoisomerase inhibitors ::: Other target and lead compounds ::: Synthetic advancesIn addition Burri C et al [63] tested about 160 fluroquinolones and their derivatives which are specific inhibitors of topoisomerases, against cultured bloodstream forms of T. b. rhodesiense.", [["bloodstream", "ANATOMY", 351, 362], ["indenoisoquinoline", "CHEMICAL", 10, 28], ["sleeping sickness", "DISEASE", 98, 115], ["fluroquinolones", "CHEMICAL", 247, 262], ["T. b. rhodesiense", "DISEASE", 372, 389], ["indenoisoquinoline", "CHEMICAL", 10, 28], ["fluroquinolones", "CHEMICAL", 247, 262], ["indenoisoquinoline", "SIMPLE_CHEMICAL", 10, 28], ["Topoisomerase", "GENE_OR_GENE_PRODUCT", 116, 129], ["fluroquinolones", "SIMPLE_CHEMICAL", 247, 262], ["topoisomerases", "GENE_OR_GENE_PRODUCT", 318, 332], ["T. b. rhodesiense", "ORGANISM", 372, 389], ["topoisomerases", "PROTEIN", 318, 332], ["T. b. rhodesiense", "SPECIES", 372, 389], ["T. b. rhodesiense", "SPECIES", 372, 389], ["indenoisoquinoline compound", "PROBLEM", 10, 37], ["drugs", "TREATMENT", 84, 89], ["sleeping sickness", "PROBLEM", 98, 115], ["Topoisomerase inhibitors", "TREATMENT", 116, 140], ["Synthetic advancesIn addition Burri C et al", "TREATMENT", 181, 224], ["fluroquinolones", "TREATMENT", 247, 262], ["their derivatives", "TREATMENT", 267, 284], ["specific inhibitors of topoisomerases", "TREATMENT", 295, 332], ["rhodesiense", "PROBLEM", 378, 389]]], ["The modifications in the quinolone core nucleus (Figure 24) led to characteristic in vitro activity and toxicity.", [["quinolone", "CHEMICAL", 25, 34], ["toxicity", "DISEASE", 104, 112], ["quinolone", "CHEMICAL", 25, 34], ["quinolone", "SIMPLE_CHEMICAL", 25, 34], ["nucleus", "CELLULAR_COMPONENT", 40, 47], ["toxicity", "PROBLEM", 104, 112], ["vitro activity", "OBSERVATION", 85, 99]]], ["The metal quinolone UL 5 (Figure 25a) with F group at the position 6 and piperazin at R7 position was the most potent compound with IC50 values of 100 ng/ml.", [["quinolone", "CHEMICAL", 10, 19], ["piperazin", "CHEMICAL", 73, 82], ["quinolone", "CHEMICAL", 10, 19], ["piperazin", "CHEMICAL", 73, 82], ["metal quinolone", "SIMPLE_CHEMICAL", 4, 19], ["piperazin", "SIMPLE_CHEMICAL", 73, 82], ["The metal quinolone UL", "TREATMENT", 0, 22], ["piperazin", "TREATMENT", 73, 82], ["IC50 values", "TEST", 132, 143], ["most potent", "OBSERVATION_MODIFIER", 106, 117]]], ["DW 271 (Figure 25b), thiazolopyrazine incorporated tetracyclic quinolines Kanebo 8g and Kanebo 8h (Figure 25c), and the two sulphanyl fluoroquinolones N (CH3)2SNx and OCH3SNx (Figure 25d) were also active, with IC50 concentrations in the range of 300 ng/ml up to 900 ng/ml.", [["DW 271", "CHEMICAL", 0, 6], ["thiazolopyrazine", "CHEMICAL", 21, 37], ["tetracyclic quinolines Kanebo 8g", "CHEMICAL", 51, 83], ["fluoroquinolones", "CHEMICAL", 134, 150], ["2SNx", "CHEMICAL", 158, 162], ["OCH3SNx", "CHEMICAL", 167, 174], ["thiazolopyrazine", "CHEMICAL", 21, 37], ["tetracyclic quinolines", "CHEMICAL", 51, 73], ["sulphanyl fluoroquinolones", "CHEMICAL", 124, 150], ["N (CH3)2SNx", "CHEMICAL", 151, 162], ["OCH3SNx", "CHEMICAL", 167, 174], ["thiazolopyrazine", "SIMPLE_CHEMICAL", 21, 37], ["tetracyclic quinolines Kanebo 8g", "SIMPLE_CHEMICAL", 51, 83], ["sulphanyl fluoroquinolones N (CH3)2SNx", "SIMPLE_CHEMICAL", 124, 162], ["OCH3SNx", "SIMPLE_CHEMICAL", 167, 174], ["Figure 25d", "SIMPLE_CHEMICAL", 176, 186], ["DW", "TEST", 0, 2], ["Figure", "TEST", 8, 14], ["thiazolopyrazine", "TREATMENT", 21, 37], ["tetracyclic quinolines Kanebo", "TREATMENT", 51, 80], ["Kanebo", "TREATMENT", 88, 94], ["the two sulphanyl fluoroquinolones N (CH3)2SNx and OCH3SNx (Figure 25d)", "TREATMENT", 116, 187], ["IC50 concentrations", "TREATMENT", 211, 230]]], ["Some of the DuPont compounds, developed as anti-tumour drugs, were highly active but also showed high cytotoxicity on HT-29 cells.", [["anti-tumour", "ANATOMY", 43, 54], ["HT-29 cells", "ANATOMY", 118, 129], ["DuPont compounds", "SIMPLE_CHEMICAL", 12, 28], ["anti-tumour", "CANCER", 43, 54], ["HT-29 cells", "CELL", 118, 129], ["HT-29 cells", "CELL_LINE", 118, 129], ["the DuPont compounds", "PROBLEM", 8, 28], ["anti-tumour drugs", "TREATMENT", 43, 60], ["high cytotoxicity", "PROBLEM", 97, 114], ["HT", "TEST", 118, 120]]], ["It was observed that the position R1 and position R2 in the quinolone core nucleus was not prerequisite for anti-trypanosomal activity and also substitution at R8 position was not necessary for trypanocidal activity.", [["nucleus", "ANATOMY", 75, 82], ["quinolone", "CHEMICAL", 60, 69], ["quinolone", "CHEMICAL", 60, 69], ["nucleus", "CELLULAR_COMPONENT", 75, 82], ["position R1 and position R2", "DNA", 25, 52], ["anti-trypanosomal activity", "TREATMENT", 108, 134], ["substitution at R8 position", "TREATMENT", 144, 171], ["trypanocidal activity", "PROBLEM", 194, 215]]], ["Thus, based on the result obtained from SAR analysis special attention should be given to R7 position and the tetracyclic derivatives.", [["tetracyclic derivatives", "SIMPLE_CHEMICAL", 110, 133], ["SAR analysis", "TEST", 40, 52], ["the tetracyclic derivatives", "TREATMENT", 106, 133], ["tetracyclic derivatives", "OBSERVATION", 110, 133]]], ["The in vivo results of these compounds were very poor, as none of the compounds evaluated produced cure of mice in dose escalation experiment up to 100mg/kg i.p.", [["mice", "ORGANISM", 107, 111], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["mice in dose escalation experiment", "TREATMENT", 107, 141]]], ["However no signs of toxicity were observed during the experiments.", [["toxicity", "DISEASE", 20, 28], ["signs of toxicity", "PROBLEM", 11, 28], ["no signs of", "UNCERTAINTY", 8, 19], ["toxicity", "OBSERVATION", 20, 28]]], ["The in vivo ineffectiveness had not been explained and no drug level determination in the plasma of the treated mice was performed.Topoisomerase inhibitors ::: Other target and lead compounds ::: Synthetic advancesDespite these failures, this class of compounds is very attractive for further search for trypanocidal compounds because of complete lack of any toxic signs at all dosage levels tested in vivo.Polyamine metabolism inhibitors ::: Other target and lead compounds ::: Synthetic advancesPolyamines are generally involved in growth and differentiation [64\u201367] within the cell and their analogs are also used as anticancer agents, antiparasitic agents, antidiarrhoeals, anti-HIV agents, metal chelators, and gene delivery agents.", [["plasma", "ANATOMY", 90, 96], ["cell", "ANATOMY", 580, 584], ["anticancer", "ANATOMY", 620, 630], ["Polyamine", "CHEMICAL", 407, 416], ["Polyamine", "CHEMICAL", 407, 416], ["Polyamines", "CHEMICAL", 497, 507], ["plasma", "ORGANISM_SUBSTANCE", 90, 96], ["mice", "ORGANISM", 112, 116], ["Topoisomerase", "GENE_OR_GENE_PRODUCT", 131, 144], ["Polyamine", "SIMPLE_CHEMICAL", 407, 416], ["Polyamines", "SIMPLE_CHEMICAL", 497, 507], ["cell", "CELL", 580, 584], ["anticancer", "CANCER", 620, 630], ["antidiarrhoeals", "SIMPLE_CHEMICAL", 661, 676], ["metal chelators", "SIMPLE_CHEMICAL", 695, 710], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["HIV", "SPECIES", 683, 686], ["drug level determination", "TEST", 58, 82], ["Topoisomerase inhibitors", "TREATMENT", 131, 155], ["these failures", "PROBLEM", 222, 236], ["trypanocidal compounds", "PROBLEM", 304, 326], ["any toxic signs", "PROBLEM", 355, 370], ["Polyamine metabolism inhibitors", "TREATMENT", 407, 438], ["Polyamines", "TREATMENT", 497, 507], ["anticancer agents", "TREATMENT", 620, 637], ["antiparasitic agents", "TREATMENT", 639, 659], ["antidiarrhoeals", "TREATMENT", 661, 676], ["anti-HIV agents", "TREATMENT", 678, 693], ["metal chelators", "TREATMENT", 695, 710], ["gene delivery agents", "TREATMENT", 716, 736], ["failures", "OBSERVATION", 228, 236], ["metabolism inhibitors", "OBSERVATION", 417, 438], ["growth", "OBSERVATION_MODIFIER", 534, 540]]], ["Since the inhibition of the initial polyamine biosynthesis enzyme, ornithine decarboxylase, by DL-\u03b1-difluoromethyl-ornithine (DFMO) is toxic to African trypanosomes cells, [68, 69] polyamines can become a promising anti-trypanosomal compound.Polyamine metabolism inhibitors ::: Other target and lead compounds ::: Synthetic advancesDFMO [70\u201372] is the most recently developed agent for late stage T. b. gambiense and T. b. brucei sleeping sickness, but has not been active against all strains of T. b. rhodesiense.", [["cells", "ANATOMY", 165, 170], ["polyamine", "CHEMICAL", 36, 45], ["ornithine", "CHEMICAL", 67, 76], ["DL-\u03b1-difluoromethyl-ornithine", "CHEMICAL", 95, 124], ["DFMO", "CHEMICAL", 126, 130], ["[68, 69] polyamines", "CHEMICAL", 172, 191], ["Polyamine", "CHEMICAL", 242, 251], ["advancesDFMO [70\u201372]", "CHEMICAL", 324, 344], ["T. b. gambiense", "DISEASE", 397, 412], ["sleeping sickness", "DISEASE", 430, 447], ["T. b. rhodesiense", "DISEASE", 496, 513], ["polyamine", "CHEMICAL", 36, 45], ["ornithine", "CHEMICAL", 67, 76], ["DL-\u03b1-difluoromethyl-ornithine", "CHEMICAL", 95, 124], ["DFMO", "CHEMICAL", 126, 130], ["[68, 69] polyamines", "CHEMICAL", 172, 191], ["Polyamine", "CHEMICAL", 242, 251], ["polyamine", "SIMPLE_CHEMICAL", 36, 45], ["ornithine decarboxylase", "GENE_OR_GENE_PRODUCT", 67, 90], ["DL-\u03b1-difluoromethyl-ornithine", "SIMPLE_CHEMICAL", 95, 124], ["DFMO", "SIMPLE_CHEMICAL", 126, 130], ["cells", "CELL", 165, 170], ["[68, 69] polyamines", "SIMPLE_CHEMICAL", 172, 191], ["Polyamine", "SIMPLE_CHEMICAL", 242, 251], ["T.", "ORGANISM", 397, 399], ["b. gambiense", "ORGANISM", 400, 412], ["T. b. brucei", "ORGANISM", 417, 429], ["T. b. rhodesiense", "ORGANISM", 496, 513], ["polyamine biosynthesis enzyme", "PROTEIN", 36, 65], ["ornithine decarboxylase", "PROTEIN", 67, 90], ["African trypanosomes cells", "CELL_TYPE", 144, 170], ["T.", "SPECIES", 397, 399], ["b. gambiense", "SPECIES", 400, 412], ["T. b. brucei", "SPECIES", 417, 429], ["T.", "SPECIES", 496, 498], ["b. rhodesiense", "SPECIES", 499, 513], ["T. b. gambiense", "SPECIES", 397, 412], ["T. b. brucei", "SPECIES", 417, 429], ["T. b. rhodesiense", "SPECIES", 496, 513], ["the initial polyamine biosynthesis enzyme", "TEST", 24, 65], ["ornithine decarboxylase", "TEST", 67, 90], ["DL", "TEST", 95, 97], ["ornithine (DFMO)", "TREATMENT", 115, 131], ["toxic to African trypanosomes cells", "PROBLEM", 135, 170], ["polyamines", "TREATMENT", 181, 191], ["a promising anti-trypanosomal compound", "PROBLEM", 203, 241], ["Polyamine metabolism inhibitors", "TREATMENT", 242, 273], ["late stage T. b. gambiense", "PROBLEM", 386, 412], ["T. b. brucei sleeping sickness", "PROBLEM", 417, 447], ["metabolism inhibitors", "OBSERVATION", 252, 273]]], ["The major drawbacks of DFMO are its cost, the duration of treatment and its availability.", [["DFMO", "CHEMICAL", 23, 27], ["DFMO", "CHEMICAL", 23, 27], ["DFMO", "SIMPLE_CHEMICAL", 23, 27], ["DFMO", "TREATMENT", 23, 27], ["treatment", "TREATMENT", 58, 67]]], ["Recent clinical studies have investigated that DMFO can be used in combination with clinically used trypanocides including suramin, nifurtimox and melarsoprol [73, 74].", [["DMFO", "CHEMICAL", 47, 51], ["suramin", "CHEMICAL", 123, 130], ["nifurtimox", "CHEMICAL", 132, 142], ["melarsoprol", "CHEMICAL", 147, 158], ["DMFO", "CHEMICAL", 47, 51], ["trypanocides", "CHEMICAL", 100, 112], ["suramin", "CHEMICAL", 123, 130], ["nifurtimox", "CHEMICAL", 132, 142], ["melarsoprol", "CHEMICAL", 147, 158], ["DMFO", "SIMPLE_CHEMICAL", 47, 51], ["trypanocides", "SIMPLE_CHEMICAL", 100, 112], ["suramin", "SIMPLE_CHEMICAL", 123, 130], ["nifurtimox", "SIMPLE_CHEMICAL", 132, 142], ["melarsoprol", "SIMPLE_CHEMICAL", 147, 158], ["Recent clinical studies", "TEST", 0, 23], ["DMFO", "TREATMENT", 47, 51], ["trypanocides", "TREATMENT", 100, 112], ["suramin", "TREATMENT", 123, 130], ["nifurtimox", "TREATMENT", 132, 142], ["melarsoprol", "TREATMENT", 147, 158]]], ["These combinations result in significant reduction in DFMO dosage and time of administration.", [["DFMO", "CHEMICAL", 54, 58], ["DFMO", "CHEMICAL", 54, 58], ["DFMO", "SIMPLE_CHEMICAL", 54, 58], ["significant reduction", "PROBLEM", 29, 50], ["DFMO dosage", "TREATMENT", 54, 65], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["reduction", "OBSERVATION_MODIFIER", 41, 50], ["DFMO dosage", "OBSERVATION", 54, 65]]], ["Initial clinical study has shown that DFMO + nifurtimox are superior to DFMO + melarsoprol and melarsoprol + nifurtimox.", [["DFMO", "CHEMICAL", 38, 42], ["nifurtimox", "CHEMICAL", 45, 55], ["DFMO", "CHEMICAL", 72, 76], ["melarsoprol", "CHEMICAL", 79, 90], ["melarsoprol", "CHEMICAL", 95, 106], ["nifurtimox", "CHEMICAL", 109, 119], ["DFMO", "CHEMICAL", 38, 42], ["nifurtimox", "CHEMICAL", 45, 55], ["DFMO", "CHEMICAL", 72, 76], ["melarsoprol", "CHEMICAL", 79, 90], ["melarsoprol", "CHEMICAL", 95, 106], ["nifurtimox", "CHEMICAL", 109, 119], ["DFMO", "SIMPLE_CHEMICAL", 38, 42], ["nifurtimox", "SIMPLE_CHEMICAL", 45, 55], ["DFMO", "SIMPLE_CHEMICAL", 72, 76], ["melarsoprol", "SIMPLE_CHEMICAL", 79, 90], ["melarsoprol + nifurtimox", "SIMPLE_CHEMICAL", 95, 119], ["Initial clinical study", "TEST", 0, 22], ["DFMO", "TREATMENT", 38, 42], ["nifurtimox", "TREATMENT", 45, 55], ["DFMO", "TREATMENT", 72, 76], ["melarsoprol", "TREATMENT", 79, 90], ["melarsoprol", "TREATMENT", 95, 106], ["nifurtimox", "TREATMENT", 109, 119]]], ["The DFMO + nifurtimox regimen (NECT regimen) allowed reduction in DFMO regimen from 14 to 7 days (56 versus 28 infusions) with a 94% cure rate and are associated with significantly reduced adverse side effects as compared to melarsoprol-based therapy.", [["DFMO", "CHEMICAL", 4, 8], ["nifurtimox", "CHEMICAL", 11, 21], ["NECT regimen", "CHEMICAL", 31, 43], ["DFMO", "CHEMICAL", 66, 70], ["melarsoprol", "CHEMICAL", 225, 236], ["DFMO", "CHEMICAL", 4, 8], ["nifurtimox", "CHEMICAL", 11, 21], ["DFMO", "CHEMICAL", 66, 70], ["melarsoprol", "CHEMICAL", 225, 236], ["DFMO", "SIMPLE_CHEMICAL", 4, 8], ["nifurtimox", "SIMPLE_CHEMICAL", 11, 21], ["NECT", "SIMPLE_CHEMICAL", 31, 35], ["DFMO", "SIMPLE_CHEMICAL", 66, 70], ["melarsoprol", "SIMPLE_CHEMICAL", 225, 236], ["The DFMO + nifurtimox regimen", "TREATMENT", 0, 29], ["NECT regimen", "TREATMENT", 31, 43], ["reduction in DFMO regimen", "TREATMENT", 53, 78], ["significantly reduced adverse side effects", "PROBLEM", 167, 209], ["melarsoprol-based therapy", "TREATMENT", 225, 250]]], ["The success of the combined regimen has been most likely due to ability of DMFO to reduce trypanothione levels and resistance to oxidative stress and the ability of nifurtimox to generate oxidative stress.Polyamine metabolism inhibitors ::: Other target and lead compounds ::: Synthetic advancesIn addition to DFMO, a number of other agents targeting polyamine metabolism have shown promise.", [["DMFO", "CHEMICAL", 75, 79], ["trypanothione", "CHEMICAL", 90, 103], ["nifurtimox", "CHEMICAL", 165, 175], ["Polyamine", "CHEMICAL", 205, 214], ["DFMO", "CHEMICAL", 310, 314], ["polyamine", "CHEMICAL", 351, 360], ["DMFO", "CHEMICAL", 75, 79], ["trypanothione", "CHEMICAL", 90, 103], ["nifurtimox", "CHEMICAL", 165, 175], ["Polyamine", "CHEMICAL", 205, 214], ["DFMO", "CHEMICAL", 310, 314], ["polyamine", "CHEMICAL", 351, 360], ["DMFO", "SIMPLE_CHEMICAL", 75, 79], ["trypanothione", "SIMPLE_CHEMICAL", 90, 103], ["nifurtimox", "SIMPLE_CHEMICAL", 165, 175], ["Polyamine", "SIMPLE_CHEMICAL", 205, 214], ["DFMO", "SIMPLE_CHEMICAL", 310, 314], ["polyamine", "SIMPLE_CHEMICAL", 351, 360], ["the combined regimen", "TREATMENT", 15, 35], ["DMFO", "TREATMENT", 75, 79], ["trypanothione levels", "TEST", 90, 110], ["oxidative stress", "PROBLEM", 129, 145], ["nifurtimox", "TREATMENT", 165, 175], ["oxidative stress", "PROBLEM", 188, 204], ["Polyamine metabolism inhibitors", "TREATMENT", 205, 236], ["DFMO", "TREATMENT", 310, 314], ["other agents", "TREATMENT", 328, 340], ["polyamine metabolism", "TREATMENT", 351, 371], ["most likely due to", "UNCERTAINTY", 45, 63], ["metabolism inhibitors", "OBSERVATION", 215, 236]]], ["These include MDL 73811 (5\u2032-{amino}-5\u2032-deoxyadenosine), an enzyme-activated inhibitor of S-adenosylmethionine (AdoMet) decarboxylase which supplies decarboxylated AdoMet, the source of aminopropyl groups for spermidine and spermine synthesis [75].Polyamine metabolism inhibitors ::: Other target and lead compounds ::: Synthetic advancesRecently Gilbert et al [76] designed, synthesized, and evaluated substituted polyamines, carrying 1,3,5-triazine units, as potential anti-trypanosomal drugs.", [["MDL 73811", "CHEMICAL", 14, 23], ["5\u2032-{amino}-5\u2032-deoxyadenosine", "CHEMICAL", 25, 53], ["S-adenosylmethionine", "CHEMICAL", 89, 109], ["AdoMet", "CHEMICAL", 111, 117], ["AdoMet", "CHEMICAL", 163, 169], ["aminopropyl", "CHEMICAL", 185, 196], ["spermidine", "CHEMICAL", 208, 218], ["spermine", "CHEMICAL", 223, 231], ["Polyamine", "CHEMICAL", 247, 256], ["polyamines", "CHEMICAL", 414, 424], ["1,3,5-triazine", "CHEMICAL", 435, 449], ["MDL 73811", "CHEMICAL", 14, 23], ["5\u2032-{amino}-5\u2032-deoxyadenosine", "CHEMICAL", 25, 53], ["S-adenosylmethionine", "CHEMICAL", 89, 109], ["AdoMet", "CHEMICAL", 111, 117], ["AdoMet", "CHEMICAL", 163, 169], ["aminopropyl", "CHEMICAL", 185, 196], ["spermidine", "CHEMICAL", 208, 218], ["spermine", "CHEMICAL", 223, 231], ["Polyamine", "CHEMICAL", 247, 256], ["polyamines", "CHEMICAL", 414, 424], ["1,3,5-triazine", "CHEMICAL", 435, 449], ["MDL 73811 (5\u2032-{amino}-5\u2032-deoxyadenosine", "SIMPLE_CHEMICAL", 14, 53], ["S-adenosylmethionine", "SIMPLE_CHEMICAL", 89, 109], ["AdoMet", "SIMPLE_CHEMICAL", 111, 117], ["AdoMet", "SIMPLE_CHEMICAL", 163, 169], ["aminopropyl", "SIMPLE_CHEMICAL", 185, 196], ["spermidine", "SIMPLE_CHEMICAL", 208, 218], ["spermine", "SIMPLE_CHEMICAL", 223, 231], ["Polyamine", "SIMPLE_CHEMICAL", 247, 256], ["polyamines", "SIMPLE_CHEMICAL", 414, 424], ["1,3,5-triazine units", "SIMPLE_CHEMICAL", 435, 455], ["anti-trypanosomal drugs", "SIMPLE_CHEMICAL", 470, 493], ["S-adenosylmethionine (AdoMet) decarboxylase", "PROTEIN", 89, 132], ["MDL", "TEST", 14, 17], ["deoxyadenosine", "TREATMENT", 39, 53], ["an enzyme-activated inhibitor", "TREATMENT", 56, 85], ["S-adenosylmethionine (AdoMet) decarboxylase", "TREATMENT", 89, 132], ["decarboxylated AdoMet", "TREATMENT", 148, 169], ["aminopropyl groups", "TREATMENT", 185, 203], ["spermidine and spermine synthesis", "TREATMENT", 208, 241], ["Polyamine metabolism inhibitors", "TREATMENT", 247, 278], ["substituted polyamines", "TREATMENT", 402, 424], ["carrying 1,3,5-triazine units", "TREATMENT", 426, 455], ["potential anti-trypanosomal drugs", "TREATMENT", 460, 493], ["metabolism inhibitors", "OBSERVATION", 257, 278]]], ["Preliminary results indicated that this route might be successful, and lead structure A (Figure 26) was used as a starting point for the synthesis of two series of analogues.", [["the synthesis of two series of analogues", "TREATMENT", 133, 173]]], ["In the first series, the influence of structural changes of the central core unit was investigated while in the second series, the effect of additional methyl substituents on the 1,3,5-triazine was studied.", [["methyl substituents", "CHEMICAL", 152, 171], ["1,3,5-triazine", "CHEMICAL", 179, 193], ["methyl", "CHEMICAL", 152, 158], ["1,3,5-triazine", "CHEMICAL", 179, 193], ["methyl substituents", "SIMPLE_CHEMICAL", 152, 171], ["1,3,5-triazine", "SIMPLE_CHEMICAL", 179, 193], ["additional methyl substituents", "TREATMENT", 141, 171], ["triazine", "TREATMENT", 185, 193], ["central core", "ANATOMY_MODIFIER", 64, 76]]], ["The compounds were designed with the intention to selectively target the interior of T. brucei via the P2 amino-purine transporter.", [["amino-purine", "CHEMICAL", 106, 118], ["amino-purine", "CHEMICAL", 106, 118], ["T. brucei", "ORGANISM", 85, 94], ["P2 amino-purine transporter", "PROTEIN", 103, 130], ["T. brucei", "SPECIES", 85, 94], ["T. brucei", "SPECIES", 85, 94]]], ["In the first series the compound containing the n-dodecyl chain as core unit, showed weak activity against T. b. rhodesiense.", [["n-dodecyl", "CHEMICAL", 48, 57], ["T. b. rhodesiense", "DISEASE", 107, 124], ["n-dodecyl", "CHEMICAL", 48, 57], ["T. b. rhodesiense", "ORGANISM", 107, 124], ["n-dodecyl chain", "PROTEIN", 48, 63], ["T. b. rhodesiense", "SPECIES", 107, 124], ["T. b. rhodesiense", "SPECIES", 107, 124], ["weak activity against T. b. rhodesiense", "PROBLEM", 85, 124], ["weak activity", "OBSERVATION_MODIFIER", 85, 98]]], ["The compound with n-nonyl chain was the most promising compound and its various analogues were designed by replacing NH2 groups on the triazine ring with NHMe and NMe2 groups.", [["n-nonyl", "CHEMICAL", 18, 25], ["triazine", "CHEMICAL", 135, 143], ["NHMe", "CHEMICAL", 154, 158], ["NMe2", "CHEMICAL", 163, 167], ["n-nonyl", "CHEMICAL", 18, 25], ["NH2", "CHEMICAL", 117, 120], ["triazine", "CHEMICAL", 135, 143], ["NHMe", "CHEMICAL", 154, 158], ["NMe2", "CHEMICAL", 163, 167], ["n-nonyl chain", "SIMPLE_CHEMICAL", 18, 31], ["triazine ring", "SIMPLE_CHEMICAL", 135, 148], ["NHMe", "SIMPLE_CHEMICAL", 154, 158], ["NMe2", "SIMPLE_CHEMICAL", 163, 167], ["NH2", "PROTEIN", 117, 120], ["n-nonyl chain", "PROBLEM", 18, 31], ["NH2 groups", "TREATMENT", 117, 127], ["the triazine ring", "TREATMENT", 131, 148], ["NHMe and NMe2 groups", "TREATMENT", 154, 174]]], ["Introduction of one or two methyl groups per triazine unit resulted in a 10-fold increase in anti-trypanosomal activity.", [["anti-trypanosomal", "ANATOMY", 93, 110], ["methyl", "CHEMICAL", 27, 33], ["triazine", "CHEMICAL", 45, 53], ["methyl", "CHEMICAL", 27, 33], ["triazine", "CHEMICAL", 45, 53], ["methyl groups", "SIMPLE_CHEMICAL", 27, 40], ["triazine", "SIMPLE_CHEMICAL", 45, 53], ["anti-trypanosomal", "CANCER", 93, 110], ["anti-trypanosomal activity", "TREATMENT", 93, 119], ["anti-trypanosomal activity", "OBSERVATION", 93, 119]]], ["When four methyl groups per triazine unit were introduced, an 80-fold increase in activity was observed.", [["methyl", "CHEMICAL", 10, 16], ["triazine", "CHEMICAL", 28, 36], ["methyl", "CHEMICAL", 10, 16], ["triazine", "CHEMICAL", 28, 36], ["triazine unit", "SIMPLE_CHEMICAL", 28, 41], ["four methyl groups per triazine unit", "TREATMENT", 5, 41], ["increase", "OBSERVATION_MODIFIER", 70, 78]]], ["Similarly, replacement of NH2 group in n-dodecyl chain led to 2\u201320-fold higher anti-trypanosomal activity for the methylated derivatives.", [["n-dodecyl", "CHEMICAL", 39, 48], ["NH2", "CHEMICAL", 26, 29], ["n-dodecyl", "CHEMICAL", 39, 48], ["n-dodecyl chain", "SIMPLE_CHEMICAL", 39, 54], ["NH2", "PROTEIN", 26, 29], ["n-dodecyl chain", "PROTEIN", 39, 54], ["replacement of NH2 group in n-dodecyl chain", "TREATMENT", 11, 54], ["the methylated derivatives", "TREATMENT", 110, 136], ["replacement", "OBSERVATION", 11, 22]]], ["Monosubstituted compounds showed a slight increase in activity against T. b. rhodesiense as compared to the disubstituted compounds.", [["T. b. rhodesiense", "ORGANISM", 71, 88], ["T. b. rhodesiense", "SPECIES", 71, 88], ["T. b. rhodesiense", "SPECIES", 71, 88], ["Monosubstituted compounds", "PROBLEM", 0, 25], ["a slight increase in activity against T. b. rhodesiense", "PROBLEM", 33, 88], ["slight", "OBSERVATION_MODIFIER", 35, 41], ["increase", "OBSERVATION_MODIFIER", 42, 50]]], ["The methylamino substituted triazines attached to the C9- (compound 8c, Figure 27) or C12-(compound 8f, Figure 27) polyamine precursor via an additional CH2 linker resulted in most active trypanocidal compounds(IC50 of 8c = 0.27\u03bcM and 8f = 0.18 \u03bcM).", [["methylamino", "CHEMICAL", 4, 15], ["triazines", "CHEMICAL", 28, 37], ["C12-(compound 8f", "CHEMICAL", 86, 102], ["polyamine", "CHEMICAL", 115, 124], ["methylamino", "CHEMICAL", 4, 15], ["triazines", "CHEMICAL", 28, 37], ["C12", "CHEMICAL", 86, 89], ["polyamine", "CHEMICAL", 115, 124], ["CH2", "CHEMICAL", 153, 156], ["methylamino substituted triazines", "SIMPLE_CHEMICAL", 4, 37], ["C9- (compound 8c", "SIMPLE_CHEMICAL", 54, 70], ["Figure 27)", "SIMPLE_CHEMICAL", 72, 82], ["C12-(compound 8f", "SIMPLE_CHEMICAL", 86, 102], ["Figure 27) polyamine precursor", "SIMPLE_CHEMICAL", 104, 134], ["CH2 linker", "PROTEIN", 153, 163], ["The methylamino substituted triazines", "TREATMENT", 0, 37], ["Figure", "TEST", 72, 78], ["C12", "TEST", 86, 89], ["Figure", "TEST", 104, 110], ["polyamine precursor", "PROBLEM", 115, 134], ["an additional CH2 linker", "TREATMENT", 139, 163], ["most active trypanocidal compounds", "PROBLEM", 176, 210], ["IC50", "TEST", 211, 215], ["8c", "TEST", 219, 221], ["most", "OBSERVATION_MODIFIER", 176, 180], ["active", "OBSERVATION_MODIFIER", 181, 187], ["trypanocidal compounds", "OBSERVATION", 188, 210]]], ["Beside good activity, the compounds showed poor in vivo activity producing no cure to the infected mice and concentrations greater than 10 mg kg\u22121 induced severe acute toxicity.Polyamine metabolism inhibitors ::: Other target and lead compounds ::: Synthetic advancesThe actual mode of action for the reported triazine substituted polyamines remains unclear.", [["toxicity", "DISEASE", 168, 176], ["Polyamine", "CHEMICAL", 177, 186], ["triazine", "CHEMICAL", 310, 318], ["polyamines", "CHEMICAL", 331, 341], ["Polyamine", "CHEMICAL", 177, 186], ["triazine", "CHEMICAL", 310, 318], ["polyamines", "CHEMICAL", 331, 341], ["mice", "ORGANISM", 99, 103], ["Polyamine", "SIMPLE_CHEMICAL", 177, 186], ["triazine substituted polyamines", "SIMPLE_CHEMICAL", 310, 341], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["severe acute toxicity", "PROBLEM", 155, 176], ["Polyamine metabolism inhibitors", "TREATMENT", 177, 208], ["the reported triazine substituted polyamines", "TREATMENT", 297, 341], ["good activity", "OBSERVATION", 7, 20], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["toxicity", "OBSERVATION", 168, 176], ["metabolism inhibitors", "OBSERVATION", 187, 208]]], ["So to understand and improve the activities of these compounds, further research has to verify intracellular drug targets and possible metabolic pathways.AdoHcy hydrolase inhibitors ::: Other target and lead compounds ::: Synthetic advancesStanislaw FW et al [77] have reported the anti-trypanosomal activity of 5\u2032-deoxy-5\u2032-(E)-(iodomethylene)adenosine, which is a known inhibitor of AdoHcy hydrolase, [78, 79] and the synthesis and inhibition of T. brucei by a series of 6-N-cyclopropyladenosine analogues modified at carbon-5\u2032 including halomethylene, acetylenic, and oxime derivatives.AdoHcy hydrolase inhibitors ::: Other target and lead compounds ::: Synthetic advancesThe 5\u2032-deoxy-5\u2032-(E)-(iodomethylene)adenosine (EIDDHA) and its 6-N cyclopropyl analogue (Figure 28a, b) have shown promising in vitro inhibitory activity (IC50 at 9 and 12 \u03bcg/mL) against T. brucei.", [["intracellular", "ANATOMY", 95, 108], ["AdoHcy", "CHEMICAL", 154, 160], ["5\u2032-deoxy-5\u2032-(E)-(iodomethylene", "CHEMICAL", 312, 342], ["adenosine", "CHEMICAL", 343, 352], ["AdoHcy", "CHEMICAL", 384, 390], ["[78, 79]", "CHEMICAL", 402, 410], ["6-N-cyclopropyladenosine", "CHEMICAL", 472, 496], ["carbon-5\u2032", "CHEMICAL", 519, 528], ["halomethylene, acetylenic, and oxime", "CHEMICAL", 539, 575], ["AdoHcy", "CHEMICAL", 588, 594], ["5\u2032-deoxy-5\u2032-(E)-(iodomethylene", "CHEMICAL", 678, 708], ["adenosine", "CHEMICAL", 709, 718], ["EIDDHA", "CHEMICAL", 720, 726], ["6-N cyclopropyl", "CHEMICAL", 736, 751], ["AdoHcy", "CHEMICAL", 154, 160], ["5\u2032-deoxy-5\u2032-(E)-(iodomethylene)adenosine", "CHEMICAL", 312, 352], ["AdoHcy", "CHEMICAL", 384, 390], ["6-N-cyclopropyladenosine", "CHEMICAL", 472, 496], ["carbon", "CHEMICAL", 519, 525], ["halomethylene", "CHEMICAL", 539, 552], ["acetylenic", "CHEMICAL", 554, 564], ["oxime", "CHEMICAL", 570, 575], ["AdoHcy", "CHEMICAL", 588, 594], ["5\u2032-deoxy-5\u2032-(E)-(iodomethylene)adenosine", "CHEMICAL", 678, 718], ["EIDDHA", "CHEMICAL", 720, 726], ["6-N cyclopropyl", "CHEMICAL", 736, 751], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["AdoHcy", "SIMPLE_CHEMICAL", 154, 160], ["5\u2032-deoxy-5\u2032-(E)-(iodomethylene)adenosine", "SIMPLE_CHEMICAL", 312, 352], ["AdoHcy", "SIMPLE_CHEMICAL", 384, 390], ["[78, 79]", "SIMPLE_CHEMICAL", 402, 410], ["T. brucei", "ORGANISM", 447, 456], ["6-N-cyclopropyladenosine analogues", "SIMPLE_CHEMICAL", 472, 506], ["carbon-5\u2032", "SIMPLE_CHEMICAL", 519, 528], ["halomethylene", "SIMPLE_CHEMICAL", 539, 552], ["acetylenic", "SIMPLE_CHEMICAL", 554, 564], ["oxime derivatives", "SIMPLE_CHEMICAL", 570, 587], ["AdoHcy", "SIMPLE_CHEMICAL", 588, 594], ["5\u2032-deoxy-5\u2032-(E)-(iodomethylene)adenosine", "SIMPLE_CHEMICAL", 678, 718], ["EIDDHA", "SIMPLE_CHEMICAL", 720, 726], ["6-N cyclopropyl analogue", "SIMPLE_CHEMICAL", 736, 760], ["Figure 28a, b", "SIMPLE_CHEMICAL", 762, 775], ["T. brucei", "ORGANISM", 860, 869], ["AdoHcy hydrolase", "PROTEIN", 384, 400], ["T. brucei", "SPECIES", 447, 456], ["T. brucei", "SPECIES", 860, 869], ["T. brucei", "SPECIES", 447, 456], ["T. brucei", "SPECIES", 860, 869], ["intracellular drug targets", "TREATMENT", 95, 121], ["AdoHcy hydrolase inhibitors", "TREATMENT", 154, 181], ["the anti-trypanosomal activity", "TREATMENT", 278, 308], ["deoxy", "TEST", 315, 320], ["(iodomethylene)adenosine", "TREATMENT", 328, 352], ["AdoHcy hydrolase", "TEST", 384, 400], ["the synthesis", "TREATMENT", 415, 428], ["T. brucei", "PROBLEM", 447, 456], ["a series", "TEST", 460, 468], ["cyclopropyladenosine analogues", "TREATMENT", 476, 506], ["carbon", "TREATMENT", 519, 525], ["halomethylene", "TREATMENT", 539, 552], ["acetylenic", "TREATMENT", 554, 564], ["oxime derivatives", "TREATMENT", 570, 587], ["AdoHcy hydrolase inhibitors", "TREATMENT", 588, 615], ["The 5\u2032-deoxy", "TREATMENT", 674, 686], ["(E)-(iodomethylene)adenosine (EIDDHA)", "TREATMENT", 690, 727], ["its 6-N cyclopropyl analogue", "TREATMENT", 732, 760], ["vitro inhibitory activity (IC50", "TREATMENT", 801, 832], ["T. brucei", "PROBLEM", 860, 869]]], ["The utilization of adenosine analogues as anti-parasitics should be explored as a therapeutic paradigm, as it has been shown previously that inhibitors of AdoHcy hydrolase are also very potent inhibitors against the growth of Plasmodium falciparum [79].", [["adenosine", "CHEMICAL", 19, 28], ["AdoHcy", "CHEMICAL", 155, 161], ["Plasmodium falciparum", "DISEASE", 226, 247], ["adenosine", "CHEMICAL", 19, 28], ["AdoHcy", "CHEMICAL", 155, 161], ["adenosine analogues", "SIMPLE_CHEMICAL", 19, 38], ["AdoHcy hydrolase", "GENE_OR_GENE_PRODUCT", 155, 171], ["Plasmodium falciparum", "ORGANISM", 226, 247], ["AdoHcy hydrolase", "PROTEIN", 155, 171], ["Plasmodium falciparum", "SPECIES", 226, 247], ["Plasmodium falciparum", "SPECIES", 226, 247], ["adenosine analogues", "TREATMENT", 19, 38], ["anti-parasitics", "TREATMENT", 42, 57], ["AdoHcy hydrolase", "TREATMENT", 155, 171], ["very potent inhibitors", "TREATMENT", 181, 203], ["Plasmodium falciparum", "PROBLEM", 226, 247]]], ["This class of 6-N-cyclopropyl adenosine analogues modified at carbon 5\u2032, does not exhibit an inhibitory effect on human or parasite forms of the enzyme and displays only marginal antiviral activity in comparison to analogues which have been unmodified at 6-amino position (that are potent inhibitor of AdoHcy hydrolase).", [["6-N-cyclopropyl", "CHEMICAL", 14, 29], ["adenosine", "CHEMICAL", 30, 39], ["carbon 5\u2032", "CHEMICAL", 62, 71], ["AdoHcy", "CHEMICAL", 302, 308], ["6-N-cyclopropyl adenosine", "CHEMICAL", 14, 39], ["carbon", "CHEMICAL", 62, 68], ["6-amino", "CHEMICAL", 255, 262], ["AdoHcy", "CHEMICAL", 302, 308], ["6-N-cyclopropyl adenosine analogues", "SIMPLE_CHEMICAL", 14, 49], ["carbon 5\u2032", "SIMPLE_CHEMICAL", 62, 71], ["human", "ORGANISM", 114, 119], ["AdoHcy hydrolase", "GENE_OR_GENE_PRODUCT", 302, 318], ["AdoHcy hydrolase", "PROTEIN", 302, 318], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["N-cyclopropyl adenosine analogues", "TREATMENT", 16, 49], ["the enzyme", "TEST", 141, 151], ["analogues", "TREATMENT", 215, 224], ["AdoHcy hydrolase", "TREATMENT", 302, 318], ["marginal", "OBSERVATION_MODIFIER", 170, 178], ["antiviral activity", "OBSERVATION", 179, 197]]], ["Therefore these compounds require further structural modification in order to develop newer analogues with improved activity against T. brucei.New 4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine derivatives ::: Other target and lead compounds ::: Synthetic advancesThe synthesis of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl] morpholine derivatives by Perozzo R et al [80] resulted in to the discovery of newer class of anti-trypanosomal compounds having stage specific action, as these compounds have shown moderate to very good activity against the blood stage of T. b. rhodesiense.", [["blood", "ANATOMY", 549, 554], ["4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine", "CHEMICAL", 147, 196], ["4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl] morpholine", "CHEMICAL", 284, 334], ["Perozzo", "CHEMICAL", 350, 357], ["T. b. rhodesiense", "DISEASE", 564, 581], ["4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine", "CHEMICAL", 147, 196], ["4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl] morpholine", "CHEMICAL", 284, 334], ["T. brucei", "ORGANISM", 133, 142], ["4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine derivatives", "SIMPLE_CHEMICAL", 147, 208], ["4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl] morpholine derivatives", "SIMPLE_CHEMICAL", 284, 346], ["Perozzo R", "SIMPLE_CHEMICAL", 350, 359], ["blood", "ORGANISM_SUBSTANCE", 549, 554], ["T. b. rhodesiense", "ORGANISM", 564, 581], ["T. brucei", "SPECIES", 133, 142], ["T. b. rhodesiense", "SPECIES", 564, 581], ["T. brucei", "SPECIES", 133, 142], ["T. b. rhodesiense", "SPECIES", 564, 581], ["further structural modification", "TREATMENT", 34, 65], ["newer analogues", "TREATMENT", 86, 101], ["T. brucei", "PROBLEM", 133, 142], ["phenoxyphenyl)", "TREATMENT", 155, 169], ["pyrazol", "TREATMENT", 173, 180], ["The synthesis", "TREATMENT", 267, 280], ["phenoxyphenyl)", "TREATMENT", 292, 306], ["pyrazol", "TREATMENT", 310, 317], ["morpholine derivatives", "TREATMENT", 324, 346], ["Perozzo R et al", "TREATMENT", 350, 365], ["anti-trypanosomal compounds", "PROBLEM", 418, 445], ["stage specific action", "PROBLEM", 453, 474], ["T. b. rhodesiense", "PROBLEM", 564, 581], ["moderate", "OBSERVATION_MODIFIER", 506, 514]]], ["The two compounds, 4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine (1.0\u03bcM) (Figure 29a) and 1-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]piperazine (1.1 \u03bcM) (Figure 29b) with a pyrazol ring, are the most potent anti-trypanosomals of the series and have same cytotoxicity (61.6 \u03bcM), indicating that the pyrazol ring is very important for anti-trypanosomal activity.", [["anti-trypanosomal", "ANATOMY", 333, 350], ["4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine", "CHEMICAL", 19, 68], ["1-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]piperazine", "CHEMICAL", 94, 143], ["pyrazol", "CHEMICAL", 173, 180], ["pyrazol", "CHEMICAL", 298, 305], ["4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine", "CHEMICAL", 19, 68], ["1-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]piperazine", "CHEMICAL", 94, 143], ["pyrazol", "CHEMICAL", 173, 180], ["pyrazol", "CHEMICAL", 298, 305], ["4-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]morpholine", "SIMPLE_CHEMICAL", 19, 68], ["1-[3-(4-phenoxyphenyl)-1H-pyrazol-5-yl]piperazine", "SIMPLE_CHEMICAL", 94, 143], ["pyrazol ring", "SIMPLE_CHEMICAL", 173, 185], ["pyrazol ring", "SIMPLE_CHEMICAL", 298, 310], ["anti-trypanosomal", "SIMPLE_CHEMICAL", 333, 350], ["The two compounds", "TREATMENT", 0, 17], ["phenoxyphenyl)", "TREATMENT", 27, 41], ["pyrazol", "TREATMENT", 45, 52], ["morpholine", "TREATMENT", 58, 68], ["phenoxyphenyl)", "TREATMENT", 102, 116], ["pyrazol", "TREATMENT", 120, 127], ["piperazine", "TREATMENT", 133, 143], ["a pyrazol ring", "TREATMENT", 171, 185], ["the pyrazol ring", "TREATMENT", 294, 310]]], ["The substitution of pyrazol ring with isoxazole derivative leads to a six fold reduction in activity as compared to the most potent compound.", [["pyrazol", "CHEMICAL", 20, 27], ["isoxazole", "CHEMICAL", 38, 47], ["pyrazol", "CHEMICAL", 20, 27], ["isoxazole", "CHEMICAL", 38, 47], ["pyrazol ring", "SIMPLE_CHEMICAL", 20, 32], ["isoxazole derivative", "SIMPLE_CHEMICAL", 38, 58], ["The substitution of pyrazol ring", "TREATMENT", 0, 32], ["isoxazole derivative", "TREATMENT", 38, 58], ["a six fold reduction", "TREATMENT", 68, 88], ["six fold", "OBSERVATION_MODIFIER", 70, 78], ["reduction", "OBSERVATION_MODIFIER", 79, 88], ["activity", "OBSERVATION_MODIFIER", 92, 100], ["most potent", "OBSERVATION_MODIFIER", 120, 131]]], ["In addition, substitution with nitrophenyl or aminophenyl also results in strong reduction in activity.", [["nitrophenyl", "CHEMICAL", 31, 42], ["aminophenyl", "CHEMICAL", 46, 57], ["nitrophenyl", "CHEMICAL", 31, 42], ["aminophenyl", "CHEMICAL", 46, 57], ["nitrophenyl", "SIMPLE_CHEMICAL", 31, 42], ["aminophenyl", "SIMPLE_CHEMICAL", 46, 57], ["nitrophenyl", "TREATMENT", 31, 42], ["aminophenyl", "TREATMENT", 46, 57], ["strong", "OBSERVATION_MODIFIER", 74, 80], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["activity", "OBSERVATION_MODIFIER", 94, 102]]], ["The phenoxy ring in the compounds is also important for activity as replacing it by an ethylene group results in nine fold reduction in efficacy.", [["phenoxy", "CHEMICAL", 4, 11], ["ethylene", "CHEMICAL", 87, 95], ["phenoxy", "CHEMICAL", 4, 11], ["ethylene", "CHEMICAL", 87, 95], ["phenoxy ring", "SIMPLE_CHEMICAL", 4, 16], ["ethylene", "SIMPLE_CHEMICAL", 87, 95], ["The phenoxy ring", "TREATMENT", 0, 16], ["an ethylene group", "TREATMENT", 84, 101], ["nine fold reduction in efficacy", "TREATMENT", 113, 144], ["phenoxy ring", "OBSERVATION", 4, 16], ["nine fold", "OBSERVATION_MODIFIER", 113, 122], ["reduction", "OBSERVATION_MODIFIER", 123, 132]]], ["Further substitution with a nitro group or an amino group reduces potency up to 4-fold or 18-fold respectively.", [["nitro", "CHEMICAL", 28, 33], ["amino", "CHEMICAL", 46, 51], ["nitro", "CHEMICAL", 28, 33], ["amino", "CHEMICAL", 46, 51], ["Further substitution", "TREATMENT", 0, 20], ["a nitro group", "TREATMENT", 26, 39], ["an amino group reduces potency", "TREATMENT", 43, 73]]], ["The stage specific action of these compounds is unknown.", [["stage specific", "OBSERVATION_MODIFIER", 4, 18]]], ["Further optimization of this class of compounds is required in order to lower the cytotoxicity profile of the compound.Glutathione derivatives ::: Other target and lead compounds ::: Synthetic advancesIn vitro evaluation of a series of N-, S-, and COOH-blocked glutathione derivatives have been carried out by D'Silva and Daunes [81] against bloodstream form Trypanosoma brucei trypomastigotes, to identify the determinants necessary for activity and for further development into an active lead structure.", [["trypomastigotes", "ANATOMY", 378, 393], ["Glutathione", "CHEMICAL", 119, 130], ["N-, S-", "CHEMICAL", 236, 242], ["glutathione", "CHEMICAL", 261, 272], ["Glutathione", "CHEMICAL", 119, 130], ["N-, S-, and COOH-blocked glutathione", "CHEMICAL", 236, 272], ["Glutathione", "SIMPLE_CHEMICAL", 119, 130], ["N-, S-, and COOH-blocked glutathione derivatives", "SIMPLE_CHEMICAL", 236, 284], ["D'Silva", "SIMPLE_CHEMICAL", 310, 317], ["Daunes [81]", "SIMPLE_CHEMICAL", 322, 333], ["Trypanosoma brucei", "ORGANISM", 359, 377], ["trypomastigotes", "ORGANISM", 378, 393], ["Trypanosoma brucei", "SPECIES", 359, 377], ["Trypanosoma brucei", "SPECIES", 359, 377], ["Glutathione derivatives", "TREATMENT", 119, 142], ["vitro evaluation", "TEST", 204, 220], ["N", "TREATMENT", 236, 237], ["S-", "TREATMENT", 240, 242], ["COOH-blocked glutathione derivatives", "TREATMENT", 248, 284], ["Trypanosoma brucei trypomastigotes", "PROBLEM", 359, 393], ["Trypanosoma brucei", "OBSERVATION", 359, 377], ["active", "OBSERVATION", 483, 489]]], ["The results shows that N, S-blocked glutathione diesters are the most active inhibitors of T. brucei parasites and that N-acetyl-S-benzyloxy-carbonylglutathione dimethyl ester (compound 5) and the N,S-benzyloxycarbonyl-S-2,4-dinitrophenylglutathione diester derivatives (compounds 17\u201319 & 21) (Figure 30) represent lead structures possessing minimal toxicity which potentially could be developed further to yield a therapeutically active agent for the treatment of trypanosomiasis.O-Alkoxyamidine Prodrugs of Furamidine ::: Prodrug approaches ::: Synthetic advancesBoykin DW et al [85] syhthesized and evaluated five O-alkoxyamidine analogues of the prodrug 2,5-bis[4-methoxyamidinophenyl]furan against Trypanosoma brucei rhodesiense in the STIB900 mouse model by oral administration.", [["oral", "ANATOMY", 764, 768], ["glutathione", "CHEMICAL", 36, 47], ["N-acetyl-S-benzyloxy-carbonylglutathione dimethyl ester", "CHEMICAL", 120, 175], ["compound 5", "CHEMICAL", 177, 187], ["N,S-benzyloxycarbonyl-S-2,4-dinitrophenylglutathione diester", "CHEMICAL", 197, 257], ["toxicity", "DISEASE", 350, 358], ["trypanosomiasis", "DISEASE", 465, 480], ["O-Alkoxyamidine", "CHEMICAL", 481, 496], ["Furamidine", "CHEMICAL", 509, 519], ["O-alkoxyamidine", "CHEMICAL", 617, 632], ["2,5-bis[4-methoxyamidinophenyl]furan", "CHEMICAL", 658, 694], ["Trypanosoma brucei rhodesiense", "DISEASE", 703, 733], ["N", "CHEMICAL", 23, 24], ["glutathione diesters", "CHEMICAL", 36, 56], ["N-acetyl-S-benzyloxy-carbonylglutathione dimethyl ester", "CHEMICAL", 120, 175], ["N,S-benzyloxycarbonyl-S-2,4-dinitrophenylglutathione diester", "CHEMICAL", 197, 257], ["O-Alkoxyamidine", "CHEMICAL", 481, 496], ["Furamidine", "CHEMICAL", 509, 519], ["O-alkoxyamidine", "CHEMICAL", 617, 632], ["2,5-bis[4-methoxyamidinophenyl]furan", "CHEMICAL", 658, 694], ["glutathione diesters", "SIMPLE_CHEMICAL", 36, 56], ["T. brucei", "ORGANISM", 91, 100], ["parasites", "ORGANISM", 101, 110], ["N-acetyl-S-benzyloxy-carbonylglutathione dimethyl ester", "SIMPLE_CHEMICAL", 120, 175], ["compound 5", "SIMPLE_CHEMICAL", 177, 187], ["N,S-benzyloxycarbonyl-S-2,4-dinitrophenylglutathione diester derivatives", "SIMPLE_CHEMICAL", 197, 269], ["O-Alkoxyamidine Prodrugs", "SIMPLE_CHEMICAL", 481, 505], ["Furamidine", "SIMPLE_CHEMICAL", 509, 519], ["O-alkoxyamidine", "SIMPLE_CHEMICAL", 617, 632], ["prodrug 2,5-bis[4-methoxyamidinophenyl]furan", "SIMPLE_CHEMICAL", 650, 694], ["Trypanosoma brucei rhodesiense", "ORGANISM", 703, 733], ["mouse", "ORGANISM", 749, 754], ["oral", "ORGANISM_SUBDIVISION", 764, 768], ["T. brucei", "SPECIES", 91, 100], ["Trypanosoma brucei", "SPECIES", 703, 721], ["rhodesiense", "SPECIES", 722, 733], ["mouse", "SPECIES", 749, 754], ["T. brucei", "SPECIES", 91, 100], ["Trypanosoma brucei rhodesiense", "SPECIES", 703, 733], ["mouse", "SPECIES", 749, 754], ["blocked glutathione diesters", "TREATMENT", 28, 56], ["T. brucei parasites", "PROBLEM", 91, 110], ["N-acetyl", "TEST", 120, 128], ["benzyloxy", "TREATMENT", 131, 140], ["carbonylglutathione dimethyl ester", "TREATMENT", 141, 175], ["the N", "TREATMENT", 193, 198], ["benzyloxycarbonyl", "TREATMENT", 201, 218], ["dinitrophenylglutathione diester derivatives", "TREATMENT", 225, 269], ["lead structures", "PROBLEM", 315, 330], ["minimal toxicity", "PROBLEM", 342, 358], ["a therapeutically active agent", "TREATMENT", 413, 443], ["trypanosomiasis", "PROBLEM", 465, 480], ["Alkoxyamidine Prodrugs", "TREATMENT", 483, 505], ["the prodrug", "TREATMENT", 646, 657], ["bis", "TREATMENT", 662, 665], ["methoxyamidinophenyl", "TREATMENT", 668, 688], ["furan", "TREATMENT", 689, 694], ["Trypanosoma brucei rhodesiense", "TREATMENT", 703, 733], ["the STIB900 mouse model", "TREATMENT", 737, 760], ["brucei parasites", "OBSERVATION", 94, 110], ["minimal toxicity", "OBSERVATION", 342, 358], ["trypanosomiasis", "OBSERVATION", 465, 480]]], ["It was observed that the size of the O-alkyl side-chain determined the metabolic stability of the prodrugs.", [["O-alkyl", "CHEMICAL", 37, 44], ["O", "CHEMICAL", 37, 38], ["O-alkyl", "SIMPLE_CHEMICAL", 37, 44], ["the prodrugs", "TREATMENT", 94, 106], ["size", "OBSERVATION_MODIFIER", 25, 29], ["metabolic stability", "OBSERVATION", 71, 90]]], ["The prodrugs with the O-methyl analogue were most susceptible to metabolism while the larger O-n-butyl and O-n-hexyl groups were least susceptible to metabolism.", [["O-methyl", "CHEMICAL", 22, 30], ["O-n-butyl", "CHEMICAL", 93, 102], ["O-n-hexyl", "CHEMICAL", 107, 116], ["O-methyl", "CHEMICAL", 22, 30], ["O-n-butyl", "CHEMICAL", 93, 102], ["O-n-hexyl", "CHEMICAL", 107, 116], ["O-methyl analogue", "SIMPLE_CHEMICAL", 22, 39], ["O-n-butyl", "SIMPLE_CHEMICAL", 93, 102], ["O-n-hexyl", "SIMPLE_CHEMICAL", 107, 116], ["The prodrugs", "TREATMENT", 0, 12], ["methyl analogue", "TREATMENT", 24, 39], ["n-hexyl groups", "TREATMENT", 109, 123]]], ["The in vivo studies in the STIB900 mouse model for T. b. rhodesiense showed that compounds with an O-methoxyamidine or O-ethoxyamidine group effectively cured all trypanosome-infected mice, whereas prodrugs with larger side-chains did not completely cure the mice.", [["b. rhodesiense", "DISEASE", 54, 68], ["O-methoxyamidine", "CHEMICAL", 99, 115], ["O-ethoxyamidine", "CHEMICAL", 119, 134], ["trypanosome-infected", "DISEASE", 163, 183], ["O-methoxyamidine", "CHEMICAL", 99, 115], ["O-ethoxyamidine", "CHEMICAL", 119, 134], ["mouse", "ORGANISM", 35, 40], ["T. b. rhodesiense", "ORGANISM", 51, 68], ["O-methoxyamidine", "SIMPLE_CHEMICAL", 99, 115], ["O-ethoxyamidine", "SIMPLE_CHEMICAL", 119, 134], ["mice", "ORGANISM", 184, 188], ["prodrugs", "SIMPLE_CHEMICAL", 198, 206], ["mice", "ORGANISM", 259, 263], ["mouse", "SPECIES", 35, 40], ["T. b. rhodesiense", "SPECIES", 51, 68], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 259, 263], ["mouse", "SPECIES", 35, 40], ["T. b. rhodesiense", "SPECIES", 51, 68], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 259, 263], ["vivo studies", "TEST", 7, 19], ["T. b. rhodesiense", "TEST", 51, 68], ["methoxyamidine", "TREATMENT", 101, 115], ["O-ethoxyamidine group", "TREATMENT", 119, 140], ["larger side-chains", "TREATMENT", 212, 230]]], ["Therefore the O-alkoxyamidine prodrugs, where the alkyl chain is less than three carbons, could effectively be used as prodrugs for amidines.Aza-Analogues of Furamidine ::: Prodrug approaches ::: Synthetic advancesBoykin DW et al [26] have also prepared aza-analogues of furamidine that exhibit high in vitro activity against T. b. rhodesiense.", [["O-alkoxyamidine", "CHEMICAL", 14, 29], ["alkyl", "CHEMICAL", 50, 55], ["amidines", "CHEMICAL", 132, 140], ["Furamidine", "CHEMICAL", 158, 168], ["furamidine", "CHEMICAL", 271, 281], ["T. b. rhodesiense", "DISEASE", 326, 343], ["O-alkoxyamidine", "CHEMICAL", 14, 29], ["carbons", "CHEMICAL", 81, 88], ["amidines", "CHEMICAL", 132, 140], ["Aza-", "CHEMICAL", 141, 145], ["Furamidine", "CHEMICAL", 158, 168], ["furamidine", "CHEMICAL", 271, 281], ["O-alkoxyamidine prodrugs", "SIMPLE_CHEMICAL", 14, 38], ["amidines", "SIMPLE_CHEMICAL", 132, 140], ["Furamidine", "SIMPLE_CHEMICAL", 158, 168], ["aza-analogues", "SIMPLE_CHEMICAL", 254, 267], ["furamidine", "SIMPLE_CHEMICAL", 271, 281], ["T. b. rhodesiense", "ORGANISM", 326, 343], ["T. b. rhodesiense", "SPECIES", 326, 343], ["T. b. rhodesiense", "SPECIES", 326, 343], ["the O-alkoxyamidine prodrugs", "TREATMENT", 10, 38], ["the alkyl chain", "TREATMENT", 46, 61], ["amidines", "TREATMENT", 132, 140], ["Synthetic advancesBoykin DW et al", "TREATMENT", 196, 229], ["furamidine", "TREATMENT", 271, 281]]], ["Several prodrugs of these aza-analogues (8c) (Figure 31) show excellent oral activity in vivo which is superior to that of furamidine, 2,5-Bis[4-(methoxyamidino)phenyl]furan and 2,5-bis[4-(N-hydroxyamidinophenyl]furan against T. b. rhodesiense in this mouse model.", [["oral", "ANATOMY", 72, 76], ["furamidine", "CHEMICAL", 123, 133], ["2,5-Bis[4-(methoxyamidino)phenyl]furan", "CHEMICAL", 135, 173], ["2,5-bis[4-(N-hydroxyamidinophenyl]furan", "CHEMICAL", 178, 217], ["aza-analogues", "CHEMICAL", 26, 39], ["furamidine", "CHEMICAL", 123, 133], ["2,5-Bis[4-(methoxyamidino)phenyl]furan", "CHEMICAL", 135, 173], ["2,5-bis[4-(N-hydroxyamidinophenyl]furan", "CHEMICAL", 178, 217], ["aza-analogues (8c)", "SIMPLE_CHEMICAL", 26, 44], ["oral", "ORGANISM_SUBDIVISION", 72, 76], ["furamidine", "SIMPLE_CHEMICAL", 123, 133], ["2,5-Bis[4-(methoxyamidino)phenyl]furan", "SIMPLE_CHEMICAL", 135, 173], ["2,5-bis[4-(N-hydroxyamidinophenyl]furan", "SIMPLE_CHEMICAL", 178, 217], ["T. b. rhodesiense", "ORGANISM", 226, 243], ["mouse", "ORGANISM", 252, 257], ["T. b. rhodesiense", "SPECIES", 226, 243], ["mouse", "SPECIES", 252, 257], ["T. b. rhodesiense", "SPECIES", 226, 243], ["mouse", "SPECIES", 252, 257], ["these aza-analogues", "TEST", 20, 39], ["furamidine", "TREATMENT", 123, 133], ["(methoxyamidino)phenyl]furan", "TREATMENT", 145, 173], ["bis", "TREATMENT", 182, 185], ["N-hydroxyamidinophenyl", "TREATMENT", 189, 211], ["furan", "TREATMENT", 212, 217]]], ["They have found several excellent candidates for further evaluation against T. b. rhodesiense.Terphenyl Diamidines and Analogues ::: Prodrug approaches ::: Synthetic advancesIn addition to above mentioned prodrug synthesis Boykin DW et al [86] also reported that bis-amidoximes and bis-O-alkylamidoximes of a number of diamidine systems are effective prodrugs.", [["T. b. rhodesiense", "DISEASE", 76, 93], ["Terphenyl Diamidines", "CHEMICAL", 94, 114], ["Boykin", "CHEMICAL", 223, 229], ["bis-amidoximes", "CHEMICAL", 263, 277], ["bis-O-alkylamidoximes", "CHEMICAL", 282, 303], ["diamidine", "CHEMICAL", 319, 328], ["Terphenyl Diamidines", "CHEMICAL", 94, 114], ["bis-amidoximes", "CHEMICAL", 263, 277], ["bis-O-alkylamidoximes", "CHEMICAL", 282, 303], ["diamidine", "CHEMICAL", 319, 328], ["T. b. rhodesiense", "ORGANISM", 76, 93], ["Terphenyl Diamidines", "SIMPLE_CHEMICAL", 94, 114], ["prodrug", "SIMPLE_CHEMICAL", 205, 212], ["Boykin", "SIMPLE_CHEMICAL", 223, 229], ["bis-amidoximes", "SIMPLE_CHEMICAL", 263, 277], ["bis-O-alkylamidoximes", "SIMPLE_CHEMICAL", 282, 303], ["diamidine", "SIMPLE_CHEMICAL", 319, 328], ["T.", "SPECIES", 76, 78], ["b. rhodesiense", "SPECIES", 79, 93], ["T. b. rhodesiense", "SPECIES", 76, 93], ["further evaluation", "TEST", 49, 67], ["T. b. rhodesiense", "PROBLEM", 76, 93], ["above mentioned prodrug synthesis", "TREATMENT", 189, 222], ["bis-amidoximes", "TREATMENT", 263, 277], ["bis-O", "TREATMENT", 282, 287], ["alkylamidoximes", "TREATMENT", 288, 303], ["a number of diamidine systems", "TREATMENT", 307, 336], ["effective prodrugs", "TREATMENT", 341, 359]]], ["In order to develop orally effective anti-trypanosomal agents, they synthesized these two types of potential prodrugs in the terphenyl series.", [["terphenyl", "CHEMICAL", 125, 134], ["terphenyl", "CHEMICAL", 125, 134], ["terphenyl", "SIMPLE_CHEMICAL", 125, 134], ["orally effective anti-trypanosomal agents", "TREATMENT", 20, 61], ["potential prodrugs", "TREATMENT", 99, 117]]], ["It was found that compound 10b and 10d (Figure 32) showed good activity in the range of 2 nM.", [["compound 10b", "CHEMICAL", 18, 30], ["10d", "CHEMICAL", 35, 38], ["10b", "SIMPLE_CHEMICAL", 27, 30], ["10d", "SIMPLE_CHEMICAL", 35, 38], ["good activity", "OBSERVATION", 58, 71]]], ["Among these compounds 10b had lower cytotoxicity (6.4\u03bcM) profile but had very poor in vivo activity (cured none of the infected animal in STIB900 mouse model).", [["10b", "SIMPLE_CHEMICAL", 22, 25], ["mouse", "ORGANISM", 146, 151], ["mouse", "SPECIES", 146, 151], ["mouse", "SPECIES", 146, 151], ["lower cytotoxicity", "PROBLEM", 30, 48]]], ["Whereas compound 10d showed excellent in vivo activity, by curing all the infected animals upon oral administration in STIB900 mouse model.", [["oral", "ANATOMY", 96, 100], ["compound 10d", "CHEMICAL", 8, 20], ["10d", "SIMPLE_CHEMICAL", 17, 20], ["oral", "ORGANISM_SUBDIVISION", 96, 100], ["mouse", "ORGANISM", 127, 132], ["mouse", "SPECIES", 127, 132], ["mouse", "SPECIES", 127, 132], ["oral administration", "TREATMENT", 96, 115], ["STIB900 mouse model", "TREATMENT", 119, 138], ["excellent", "OBSERVATION_MODIFIER", 28, 37], ["vivo activity", "OBSERVATION", 41, 54], ["infected", "OBSERVATION", 74, 82]]], ["To capitalize on the efficacy of these potent dications, other prodrugs that rely on different bioconversion pathways need to be developed.Fused ring dicationic compounds and their prodrugs ::: Prodrug approaches ::: Synthetic advancesBoykin DW et al [87] showed that some of the dicationic guanidine, N-alkylguanidine, and reversed amidine derivatives of fused ring systems have good in vitro activity against Trypanosoma brucei rhodesiense [87, 88].", [["guanidine", "CHEMICAL", 291, 300], ["N-alkylguanidine", "CHEMICAL", 302, 318], ["amidine", "CHEMICAL", 333, 340], ["Trypanosoma brucei rhodesiense", "DISEASE", 411, 441], ["guanidine", "CHEMICAL", 291, 300], ["N-alkylguanidine", "CHEMICAL", 302, 318], ["amidine", "CHEMICAL", 333, 340], ["guanidine", "SIMPLE_CHEMICAL", 291, 300], ["N-alkylguanidine", "SIMPLE_CHEMICAL", 302, 318], ["amidine derivatives", "SIMPLE_CHEMICAL", 333, 352], ["Trypanosoma brucei", "ORGANISM", 411, 429], ["rhodesiense", "ORGANISM", 430, 441], ["Trypanosoma brucei", "SPECIES", 411, 429], ["rhodesiense", "SPECIES", 430, 441], ["Trypanosoma brucei rhodesiense", "SPECIES", 411, 441], ["these potent dications", "TREATMENT", 33, 55], ["other prodrugs", "TREATMENT", 57, 71], ["different bioconversion pathways", "TREATMENT", 85, 117], ["the dicationic guanidine", "TREATMENT", 276, 300], ["alkylguanidine", "TREATMENT", 304, 318], ["reversed amidine derivatives of fused ring systems", "TREATMENT", 324, 374], ["Trypanosoma brucei rhodesiense", "PROBLEM", 411, 441], ["ring", "OBSERVATION_MODIFIER", 145, 149], ["dicationic compounds", "OBSERVATION", 150, 170]]], ["The dicationic N-isopropylguanidino-9H-fluorene (12c, Figure 33) showed promising in vivo biological results by giving 4/4 cures of the treated animals in the STIB900 animal model for African trypanosomiasis.", [["N-isopropylguanidino-9H-fluorene", "CHEMICAL", 15, 47], ["trypanosomiasis", "DISEASE", 192, 207], ["N-isopropylguanidino-9H-fluorene", "CHEMICAL", 15, 47], ["dicationic N-isopropylguanidino-9H-fluorene", "SIMPLE_CHEMICAL", 4, 47], ["12c", "SIMPLE_CHEMICAL", 49, 52], ["The dicationic N-isopropylguanidino", "TREATMENT", 0, 35], ["fluorene", "TREATMENT", 39, 47], ["African trypanosomiasis", "PROBLEM", 184, 207]]], ["In addition the N-methyl analogue (12a, Figure 33) also showed high activity giving 3/4 cures of the treated animals in the STIB900 animal model for African trypanosomiasis.", [["N-methyl", "CHEMICAL", 16, 24], ["trypanosomiasis", "DISEASE", 157, 172], ["N-methyl", "CHEMICAL", 16, 24], ["N-methyl analogue", "SIMPLE_CHEMICAL", 16, 33], ["African trypanosomiasis", "SPECIES", 149, 172], ["the N-methyl analogue", "TREATMENT", 12, 33], ["high activity", "PROBLEM", 63, 76], ["African trypanosomiasis", "PROBLEM", 149, 172], ["high activity", "OBSERVATION_MODIFIER", 63, 76]]], ["In order to enhance the oral bioavailability, two novel classes of potential guanidine prodrugs were prepared.", [["oral", "ANATOMY", 24, 28], ["guanidine", "CHEMICAL", 77, 86], ["guanidine", "CHEMICAL", 77, 86], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["guanidine prodrugs", "SIMPLE_CHEMICAL", 77, 95], ["potential guanidine prodrugs", "TREATMENT", 67, 95]]], ["The N-alkoxyguanidine derivatives 12d and 12e (Figure 33) were not effective as prodrugs.", [["N-alkoxyguanidine derivatives 12d and 12e", "CHEMICAL", 4, 45], ["N-alkoxyguanidine", "CHEMICAL", 4, 21], ["N-alkoxyguanidine derivatives 12d", "SIMPLE_CHEMICAL", 4, 37], ["12e", "SIMPLE_CHEMICAL", 42, 45], ["The N-alkoxyguanidine derivatives", "TREATMENT", 0, 33]]], ["Whereas the carbamate prodrugs (11c, Figure 33), gave promising results with 4/4 cures on oral administration in the STIB900 mouse model.", [["oral", "ANATOMY", 90, 94], ["carbamate", "CHEMICAL", 12, 21], ["carbamate", "CHEMICAL", 12, 21], ["carbamate prodrugs", "SIMPLE_CHEMICAL", 12, 30], ["11c", "SIMPLE_CHEMICAL", 32, 35], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["mouse", "ORGANISM", 125, 130], ["mouse", "SPECIES", 125, 130], ["mouse", "SPECIES", 125, 130], ["the carbamate prodrugs", "TREATMENT", 8, 30], ["oral administration", "TREATMENT", 90, 109], ["the STIB900 mouse model", "TREATMENT", 113, 136]]], ["The result showed that these compounds bind strongly to the DNA minor groove, but despite strong bonding these compounds do not have high antiparasitic activity.Computer-assisted drug design (CADD) approachesAs compared to the last 15 years, there has been a revival of drug research and development regarding neglected parasitic diseases, and a number of drug development projects are currently ongoing.", [["parasitic diseases", "DISEASE", 320, 338], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["Computer-assisted drug design (CADD) approaches", "TREATMENT", 161, 208], ["drug research", "TREATMENT", 270, 283], ["neglected parasitic diseases", "PROBLEM", 310, 338], ["parasitic diseases", "OBSERVATION", 320, 338]]], ["However discovering lead compounds with anti-trypanosomal activity remains a crucial step to sustain the progress achieved till date.", [["discovering lead compounds", "PROBLEM", 8, 34], ["anti-trypanosomal activity", "TREATMENT", 40, 66]]], ["The use of Computer-assisted drug design (CADD), since their start, has become increasingly helpful in understanding many aspects of chemical-biological interactions in drug and other scientific research.", [["Computer-assisted drug design (CADD", "TREATMENT", 11, 46]]], ["The latest technological advances (QSAR, structure-based design, ligand-based design, cheminformatics & bioinformatics) are providing a much improved basis for the design of ligands and inhibitors with desired specificity.", [["inhibitors", "TREATMENT", 186, 196]]], ["Recently, computer-assisted drug design approaches based on ligand-based and structure- based drug design have been successfully employed to develop new drugs for the treatment of cancer, AIDS and other diseases [89\u201396].", [["cancer", "ANATOMY", 180, 186], ["cancer", "DISEASE", 180, 186], ["AIDS", "DISEASE", 188, 192], ["cancer", "CANCER", 180, 186], ["computer-assisted drug design approaches", "TREATMENT", 10, 50], ["new drugs", "TREATMENT", 149, 158], ["cancer", "PROBLEM", 180, 186], ["AIDS", "PROBLEM", 188, 192], ["other diseases", "PROBLEM", 197, 211], ["cancer", "OBSERVATION", 180, 186]]], ["Statistical methods are applied in QSAR modeling to establish correlations between chemical structures and their biological activities.", [["Statistical methods", "TREATMENT", 0, 19], ["QSAR modeling", "TEST", 35, 48]]], ["Though only countable but sustainable attempts has been made to build molecular model in the field of HAT, exemplified by the work of Prashanth A et al [98] who have performed 3D QSAR analysis on a library of heterocyclic diamidines derivatives with antiparasitic activity and Martin MB et at [99] who have performed CoMFA analysis on bisphosphonates against Trypanosoma brucei rhodesiense.Computer-assisted drug design (CADD) approachesPrashanth A et al have performed CoMFA and CoMSIA based 3D QSAR analysis on furamidine and a set of 25 other structurally related compounds.", [["diamidines", "CHEMICAL", 222, 232], ["bisphosphonates", "CHEMICAL", 335, 350], ["Trypanosoma brucei rhodesiense", "DISEASE", 359, 389], ["CoMFA", "CHEMICAL", 470, 475], ["furamidine", "CHEMICAL", 513, 523], ["heterocyclic diamidines", "CHEMICAL", 209, 232], ["bisphosphonates", "CHEMICAL", 335, 350], ["furamidine", "CHEMICAL", 513, 523], ["heterocyclic diamidines derivatives", "SIMPLE_CHEMICAL", 209, 244], ["bisphosphonates", "SIMPLE_CHEMICAL", 335, 350], ["Trypanosoma brucei rhodesiense", "ORGANISM", 359, 389], ["furamidine", "SIMPLE_CHEMICAL", 513, 523], ["Trypanosoma brucei", "SPECIES", 359, 377], ["rhodesiense", "SPECIES", 378, 389], ["Trypanosoma brucei rhodesiense", "SPECIES", 359, 389], ["3D QSAR analysis", "TEST", 176, 192], ["a library of heterocyclic diamidines derivatives", "TREATMENT", 196, 244], ["antiparasitic activity", "TREATMENT", 250, 272], ["CoMFA analysis", "TEST", 317, 331], ["bisphosphonates", "TREATMENT", 335, 350], ["Trypanosoma brucei rhodesiense", "PROBLEM", 359, 389], ["CoMFA", "TEST", 470, 475], ["CoMSIA based 3D QSAR analysis", "TEST", 480, 509], ["furamidine", "TREATMENT", 513, 523], ["brucei rhodesiense", "OBSERVATION", 371, 389]]], ["The main goal of this study has been to correlate the structural features of this class of compounds with their biological activity using the knowledge of the DNA minor groove bioreceptor in AT sequences.Computer-assisted drug design (CADD) approachesTwo different alignment strategies, based on a putative kinetoplast DNA minor groove target, have been used.", [["kinetoplast", "ANATOMY", 307, 318], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["kinetoplast", "CELLULAR_COMPONENT", 307, 318], ["DNA", "CELLULAR_COMPONENT", 319, 322], ["DNA minor groove bioreceptor", "PROTEIN", 159, 187], ["AT sequences", "DNA", 191, 203], ["putative kinetoplast DNA minor groove target", "DNA", 298, 342], ["this study", "TEST", 17, 27], ["Computer-assisted drug design (CADD)", "TREATMENT", 204, 240], ["Two different alignment strategies", "TREATMENT", 251, 285], ["a putative kinetoplast DNA minor groove target", "TREATMENT", 296, 342], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Due to conserved electrostatic properties across the compounds, models that used only steric and electronic properties have not performed well in predicting biological results.", [["steric and electronic properties", "TREATMENT", 86, 118], ["electrostatic properties", "OBSERVATION", 17, 41]]], ["An extended CoMSIA model with additional descriptors for hydrophobic, donor, and acceptor properties have had good predictive ability with a q2 = 0.699, r2 = 0.974, SEE, standard error of estimate = 0.1, and F = 120.04.", [["r2", "TEST", 153, 155], ["estimate", "TEST", 188, 196]]], ["The results have been used as a guide to design compounds that, potentially, have better activity against African trypanosomes.Computer-assisted drug design (CADD) approachesThese specifically derived chemical properties that are important to activity and in view of this, the developed model can be adopted as a rational approach toward the selection of substituents at various positions in the scaffold.", [["African trypanosomes", "PROBLEM", 106, 126], ["Computer-assisted drug design (CADD)", "TREATMENT", 127, 163], ["a rational approach", "TREATMENT", 311, 330], ["the selection of substituents", "TREATMENT", 338, 367], ["scaffold", "ANATOMY", 396, 404]]], ["The information can be used to predict new compounds for synthesis that have high probability of enhanced activity.Computer-assisted drug design (CADD) approachesMartin MB et at have been the first to provide evidence that the enzyme farnesyl pyrophosphate synthase is a principal site of action of the bisphosphonate risedronate in inhibiting the growth of bloodstream-form T. b. rhodesiense trypomastigotes, the causative agent of human East African trypanosomiasis.", [["trypomastigotes", "ANATOMY", 393, 408], ["farnesyl pyrophosphate", "CHEMICAL", 234, 256], ["bisphosphonate", "CHEMICAL", 303, 317], ["risedronate", "CHEMICAL", 318, 329], ["trypanosomiasis", "DISEASE", 452, 467], ["farnesyl pyrophosphate", "CHEMICAL", 234, 256], ["bisphosphonate risedronate", "CHEMICAL", 303, 329], ["farnesyl pyrophosphate synthase", "GENE_OR_GENE_PRODUCT", 234, 265], ["bisphosphonate", "SIMPLE_CHEMICAL", 303, 317], ["risedronate", "SIMPLE_CHEMICAL", 318, 329], ["T.", "ORGANISM", 375, 377], ["b. rhodesiense", "ORGANISM", 378, 392], ["trypomastigotes", "ORGANISM", 393, 408], ["human", "ORGANISM", 433, 438], ["enzyme farnesyl pyrophosphate synthase", "PROTEIN", 227, 265], ["T. b. rhodesiense", "SPECIES", 375, 392], ["human", "SPECIES", 433, 438], ["T. b. rhodesiense", "SPECIES", 375, 392], ["human", "SPECIES", 433, 438], ["synthesis", "PROBLEM", 57, 66], ["enhanced activity", "PROBLEM", 97, 114], ["Computer-assisted drug design (CADD)", "TREATMENT", 115, 151], ["the enzyme farnesyl pyrophosphate synthase", "PROBLEM", 223, 265], ["the bisphosphonate risedronate", "TREATMENT", 299, 329], ["the growth of bloodstream", "PROBLEM", 344, 369], ["T. b. rhodesiense trypomastigotes", "PROBLEM", 375, 408], ["enhanced activity", "OBSERVATION", 97, 114]]], ["They have also reported 3D-QSAR/CoMFA analysis of 26 bisphosphonates, yielding a theoretical-versus-experimental pIC50 correlation of R2 = 0.87 with a cross-validated R2 value of 0.79.", [["bisphosphonates", "CHEMICAL", 53, 68], ["bisphosphonates", "CHEMICAL", 53, 68], ["bisphosphonates", "SIMPLE_CHEMICAL", 53, 68], ["CoMFA analysis", "TEST", 32, 46], ["bisphosphonates", "TREATMENT", 53, 68], ["R2", "TEST", 134, 136], ["a cross-validated R2 value", "TEST", 149, 175]]], ["This has been the first report of a QSAR/CoMFA correlation for 1,1-bisphosphonates acting as antiparasitic agents.", [["1,1-bisphosphonates", "CHEMICAL", 63, 82], ["1,1-bisphosphonates", "CHEMICAL", 63, 82], ["1,1-bisphosphonates", "SIMPLE_CHEMICAL", 63, 82], ["a QSAR/CoMFA correlation", "TEST", 34, 58], ["bisphosphonates", "TREATMENT", 67, 82], ["antiparasitic agents", "TREATMENT", 93, 113]]], ["These results should be of use in the design and further development of bisphosphonates as antiparasitic agents.Computer-assisted drug design (CADD) approachesDaunes and D'Silva [100] have performed QSAR analysis in order to derive the contribution of Log P and Es to the in vitro antiprotozoal activity of glutathione derivatives.", [["bisphosphonates", "CHEMICAL", 72, 87], ["glutathione", "CHEMICAL", 307, 318], ["bisphosphonates", "CHEMICAL", 72, 87], ["glutathione", "CHEMICAL", 307, 318], ["bisphosphonates", "SIMPLE_CHEMICAL", 72, 87], ["Daunes", "SIMPLE_CHEMICAL", 159, 165], ["glutathione derivatives", "SIMPLE_CHEMICAL", 307, 330], ["bisphosphonates", "TREATMENT", 72, 87], ["antiparasitic agents", "TREATMENT", 91, 111], ["Computer-assisted drug design (CADD)", "TREATMENT", 112, 148], ["Daunes and D'Silva", "TREATMENT", 159, 177], ["QSAR analysis", "TEST", 199, 212], ["glutathione derivatives", "TREATMENT", 307, 330]]], ["Analysis of the inhibition data (ED50) vs calculated log P and Es values provided evidence to support membrane penetration and steric factors as the key component in the activity of these compounds.", [["membrane", "ANATOMY", 102, 110], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["steric factors", "PROTEIN", 127, 141], ["the inhibition data", "TEST", 12, 31], ["ED50", "TEST", 33, 37], ["calculated log P and Es values", "TEST", 42, 72], ["membrane penetration", "PROBLEM", 102, 122], ["steric factors", "PROBLEM", 127, 141]]], ["The optimum values for log P and Es determined have been 5.8 and \u22120.70, respectively.", [["The optimum values", "TEST", 0, 18], ["log P", "TEST", 23, 28]]], ["The best linear QSAR equation derived by a process of elimination, using a set of 17 compounds, excluding the outliers is eq 1 with an R2= 0.84 and F= 12.0(1)Log(1/ED50) = \u22122.57 logP + 1.87Es+0.20 MW\u2212 0.002 W \u2212 102Computer-assisted drug design (CADD) approachesEquation 1 indicates that the therapeutic activity of these compounds decreases with increasing values of log P and Es.Computer-assisted drug design (CADD) approachesOur core research group has also performed QSAR analysis of dicationic diphenylisoxazoles [10].", [["dicationic diphenylisoxazoles", "CHEMICAL", 487, 516], ["dicationic diphenylisoxazoles", "CHEMICAL", 487, 516], ["dicationic diphenylisoxazoles [10]", "SIMPLE_CHEMICAL", 487, 521], ["an R2", "TEST", 132, 137], ["F", "TEST", 148, 149], ["Log", "TEST", 158, 161], ["ED50", "TEST", 164, 168], ["logP", "TEST", 178, 182], ["Es", "TEST", 189, 191], ["W", "TEST", 207, 208], ["102Computer-assisted drug design (CADD", "TREATMENT", 211, 249], ["Equation", "TEST", 261, 269], ["these compounds", "PROBLEM", 315, 330], ["Computer-assisted drug design (CADD)", "TREATMENT", 380, 416], ["QSAR analysis", "TEST", 470, 483], ["dicationic diphenylisoxazoles", "TREATMENT", 487, 516], ["compounds", "OBSERVATION_MODIFIER", 321, 330], ["decreases", "OBSERVATION_MODIFIER", 331, 340]]], ["In this study, attempt has been to investigate the relationship between the various physiochemical parameters and anti-trypanosomal activity of dicationic 3,5-diphenylisoxazoles that may be helpful in development of potent anti-trypanosomal agents against sleeping sickness.Computer-assisted drug design (CADD) approachesSeveral statistical expressions have been developed using stepwise multiple linear regression analysis (MLR) and partial least squares (PLS).", [["anti-trypanosomal", "ANATOMY", 223, 240], ["3,5-diphenylisoxazoles", "CHEMICAL", 155, 177], ["sleeping sickness", "DISEASE", 256, 273], ["3,5-diphenylisoxazoles", "CHEMICAL", 155, 177], ["dicationic 3,5-diphenylisoxazoles", "SIMPLE_CHEMICAL", 144, 177], ["this study", "TEST", 3, 13], ["dicationic 3,5-diphenylisoxazoles", "TREATMENT", 144, 177], ["potent anti-trypanosomal agents", "TREATMENT", 216, 247], ["sleeping sickness", "PROBLEM", 256, 273], ["Computer-assisted drug design (CADD)", "TREATMENT", 274, 310], ["stepwise multiple linear regression analysis", "TREATMENT", 379, 423]]], ["The best MLR model showed good correlative and predictive ability as shown in following equationY = \u22120.023566637 X1 \u2212 0.32909143 X2 \u2212 0.090104289 X3 \u2212 1.0970852Computer-assisted drug design (CADD) approachesWhere X1=cosmic energy, X2=Log P, X3=total lipole.Computer-assisted drug design (CADD) approachess value=0.31, F value=79.01, r=0.94, r2=0.88, r2cv=0.84Computer-assisted drug design (CADD) approachesA comparable PLS model with r2cv=0.84 has also been obtained.", [["0.023566637 X1 \u2212 0.32909143 X2 \u2212 0.090104289 X3 \u2212 1.0970852Computer", "CHEMICAL", 101, 168], ["The best MLR model", "TEST", 0, 18], ["equationY", "TEST", 88, 97], ["cosmic energy", "TEST", 216, 229], ["value", "TEST", 306, 311], ["F value", "TEST", 318, 325], ["r", "TEST", 333, 334], ["r2", "TEST", 341, 343], ["r2cv", "TEST", 350, 354], ["Computer-assisted drug design (CADD)", "TREATMENT", 359, 395], ["r2cv", "TEST", 434, 438]]], ["The developed model has been validated by leave-one-out method of cross-validation and prediction of test set.", [["cross-validation", "TEST", 66, 82], ["prediction of test set", "TEST", 87, 109]]], ["The study indicates that the anti-trypanosomal activity is largely explained by cosmic energy, log P and total lipole descriptors.", [["The study", "TEST", 0, 9], ["total lipole descriptors", "TREATMENT", 105, 129]]], ["The QSAR study has reported in present study provides important structural insights, related to anti-trypanosomal activity.", [["anti-trypanosomal", "CANCER", 96, 113], ["The QSAR study", "TEST", 0, 14], ["present study", "TEST", 31, 44]]], ["Authors have developed a validated and highly predictive model sharing important structural requirement for effective binding of anti-trypanosomal compounds to minor groove of T. b. rhodesiense DNA.", [["b. rhodesiense", "ORGANISM", 179, 193], ["DNA", "CELLULAR_COMPONENT", 194, 197], ["T. b. rhodesiense", "SPECIES", 176, 193], ["T. b. rhodesiense", "SPECIES", 176, 193], ["anti-trypanosomal compounds", "TREATMENT", 129, 156], ["T. b. rhodesiense DNA", "PROBLEM", 176, 197], ["rhodesiense DNA", "OBSERVATION", 182, 197]]], ["The model reported in the study should be helpful in development of new compounds with improved efficacy and oral bioavailability.", [["oral", "ANATOMY", 109, 113], ["oral", "ORGANISM_SUBDIVISION", 109, 113], ["the study", "TEST", 22, 31], ["new compounds", "PROBLEM", 68, 81], ["new", "OBSERVATION_MODIFIER", 68, 71], ["compounds", "OBSERVATION", 72, 81]]], ["In line to the developed model authors have also designed some molecules which showed good activity in silico.", [["some molecules", "PROBLEM", 58, 72], ["good activity", "OBSERVATION", 86, 99]]], ["The further study of these compounds is in progress.ConclusionThe poor pharmacokinetic profile and toxicity produced by the drugs currently used to treat trypanosomiasis requires an immediate attention for the development of safe, economical and high affinity chemotherapeutic agents to meet the need for this class of drugs.", [["toxicity", "DISEASE", 99, 107], ["trypanosomiasis", "DISEASE", 154, 169], ["The further study", "TEST", 0, 17], ["The poor pharmacokinetic profile", "PROBLEM", 62, 94], ["toxicity", "PROBLEM", 99, 107], ["the drugs", "TREATMENT", 120, 129], ["trypanosomiasis", "PROBLEM", 154, 169], ["an immediate attention", "TREATMENT", 179, 201], ["safe, economical", "TREATMENT", 225, 241], ["high affinity chemotherapeutic agents", "TREATMENT", 246, 283], ["drugs", "TREATMENT", 319, 324]]], ["The unacceptable truth is the lack of attention of the government and less interest of pharmaceutical companies in light of less monitory gain in the area of protozoal infection since most of the affected people belong to poorer country.", [["protozoal infection", "DISEASE", 158, 177], ["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211], ["pharmaceutical companies", "TREATMENT", 87, 111], ["protozoal infection", "PROBLEM", 158, 177], ["unacceptable", "OBSERVATION_MODIFIER", 4, 16], ["truth", "OBSERVATION", 17, 22], ["protozoal", "OBSERVATION_MODIFIER", 158, 167], ["infection", "OBSERVATION", 168, 177]]], ["It is felt by the researchers that the treatment for HAT requires a combined approach by government organization, pharmaceutical companies and academic institutions.", [["HAT", "DISEASE", 53, 56], ["the treatment", "TREATMENT", 35, 48], ["HAT", "PROBLEM", 53, 56], ["a combined approach", "TREATMENT", 66, 85]]], ["The most promising fact is that in the last decade several synthetic approaches have been made in the field of development of anti-trypanosomal therapies.", [["anti-trypanosomal", "ANATOMY", 126, 143], ["anti-trypanosomal", "SIMPLE_CHEMICAL", 126, 143], ["anti-trypanosomal therapies", "TREATMENT", 126, 153]]], ["Several compounds are being synthesized that yield new compounds for the treatment of HAT, as a result of these synthetic approaches newer leads have been identified, which are under different phase of drug development.ConclusionThe promising in vitro and in vivo activities of dicationic molecules clearly indicate that aromatic diamidines are the most promising class of compounds for the development of newer drugs against HAT.", [["HAT", "DISEASE", 86, 89], ["aromatic diamidines", "CHEMICAL", 321, 340], ["HAT", "DISEASE", 426, 429], ["aromatic diamidines", "CHEMICAL", 321, 340], ["aromatic diamidines", "SIMPLE_CHEMICAL", 321, 340], ["HAT", "CANCER", 426, 429], ["HAT", "PROBLEM", 86, 89], ["these synthetic approaches", "TREATMENT", 106, 132], ["aromatic diamidines", "PROBLEM", 321, 340], ["newer drugs", "TREATMENT", 406, 417], ["aromatic diamidines", "OBSERVATION", 321, 340]]], ["The most important one is the newer analogous of existing drugs pentamidine (compounds 32, Figure 3e and 66, Figure 3b) which shows excellent in vivo and in vitro activity (0.004 and 0.001 \u03bcM respectively) and also has very good selectivity index against the parasite but is cytotoxic.", [["pentamidine", "CHEMICAL", 64, 75], ["compounds 32, Figure 3e", "CHEMICAL", 77, 100], ["pentamidine", "CHEMICAL", 64, 75], ["pentamidine", "SIMPLE_CHEMICAL", 64, 75], ["existing drugs pentamidine", "TREATMENT", 49, 75], ["cytotoxic", "PROBLEM", 275, 284], ["excellent", "OBSERVATION_MODIFIER", 132, 141], ["cytotoxic", "OBSERVATION_MODIFIER", 275, 284]]], ["In an attempt to synthesise newer compounds with reduced cytotoxicity than pentamidine molecules, several benzofuran derivatives have been synthesized.", [["pentamidine", "CHEMICAL", 75, 86], ["pentamidine", "CHEMICAL", 75, 86], ["benzofuran", "CHEMICAL", 106, 116], ["pentamidine molecules", "SIMPLE_CHEMICAL", 75, 96], ["benzofuran derivatives", "SIMPLE_CHEMICAL", 106, 128], ["reduced cytotoxicity", "PROBLEM", 49, 69], ["pentamidine molecules", "TREATMENT", 75, 96], ["several benzofuran derivatives", "TREATMENT", 98, 128]]], ["However the replacement of phenoxy fragement of pentamidine with a benzofuran motif has resulted in poor analogues with lower anti-trypanosomal activity but improved cytotoxic profile.", [["anti-trypanosomal", "ANATOMY", 126, 143], ["pentamidine", "CHEMICAL", 48, 59], ["benzofuran", "CHEMICAL", 67, 77], ["phenoxy", "CHEMICAL", 27, 34], ["pentamidine", "CHEMICAL", 48, 59], ["benzofuran", "CHEMICAL", 67, 77], ["pentamidine", "SIMPLE_CHEMICAL", 48, 59], ["benzofuran", "SIMPLE_CHEMICAL", 67, 77], ["the replacement of phenoxy fragement", "TREATMENT", 8, 44], ["pentamidine", "TREATMENT", 48, 59], ["a benzofuran motif", "TREATMENT", 65, 83], ["poor analogues", "PROBLEM", 100, 114], ["lower anti-trypanosomal activity", "PROBLEM", 120, 152], ["cytotoxic profile", "OBSERVATION", 166, 183]]], ["However the strong activity against T. b. rhodesiense isolates indicates that steps should be taken to initiate further studies of compound 66 and compound 32 which can be further evolved as new lead compound.", [["T. b. rhodesiense", "ORGANISM", 36, 53], ["isolates", "ORGANISM", 54, 62], ["compound 66", "SIMPLE_CHEMICAL", 131, 142], ["T. b. rhodesiense", "SPECIES", 36, 53], ["T. b. rhodesiense", "SPECIES", 36, 53], ["T. b. rhodesiense isolates", "PROBLEM", 36, 62], ["further studies", "TEST", 112, 127], ["new lead compound", "PROBLEM", 191, 208]]], ["The newer analogues of furamidine also show promising anti-trypanosomal activity along with lower cytotoxicity than furamidine.", [["furamidine", "CHEMICAL", 23, 33], ["furamidine", "CHEMICAL", 116, 126], ["furamidine", "CHEMICAL", 23, 33], ["furamidine", "CHEMICAL", 116, 126], ["furamidine", "SIMPLE_CHEMICAL", 23, 33], ["anti-trypanosomal", "CANCER", 54, 71], ["furamidine", "SIMPLE_CHEMICAL", 116, 126], ["furamidine", "TREATMENT", 23, 33], ["promising anti-trypanosomal activity", "PROBLEM", 44, 80], ["lower cytotoxicity", "PROBLEM", 92, 110], ["furamidine", "TREATMENT", 116, 126], ["lower cytotoxicity", "OBSERVATION_MODIFIER", 92, 110]]], ["Thus strong activity against T. b. rhodesiense and lower cytotoxicity of compound 3 (Figure 13b) indicates that these compounds should be further evaluated.", [["T. b. rhodesiense", "DISEASE", 29, 46], ["T. b. rhodesiense", "ORGANISM", 29, 46], ["T. b. rhodesiense", "SPECIES", 29, 46], ["T. b. rhodesiense", "SPECIES", 29, 46], ["rhodesiense", "PROBLEM", 35, 46], ["lower cytotoxicity of compound", "PROBLEM", 51, 81], ["lower cytotoxicity", "OBSERVATION_MODIFIER", 51, 69]]], ["Thus the DNA minor grove binders are still the most interesting and potential target for the development of newer anti-trypanosomal agents.ConclusionApart from diamidines, polyamines and guanidine also have the potential to give anti-trypanosomal compounds.", [["anti-trypanosomal", "ANATOMY", 114, 131], ["diamidines", "CHEMICAL", 160, 170], ["polyamines", "CHEMICAL", 172, 182], ["guanidine", "CHEMICAL", 187, 196], ["diamidines", "CHEMICAL", 160, 170], ["polyamines", "CHEMICAL", 172, 182], ["guanidine", "CHEMICAL", 187, 196], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["anti-trypanosomal agents", "SIMPLE_CHEMICAL", 114, 138], ["diamidines", "SIMPLE_CHEMICAL", 160, 170], ["polyamines", "SIMPLE_CHEMICAL", 172, 182], ["guanidine", "SIMPLE_CHEMICAL", 187, 196], ["anti-trypanosomal compounds", "SIMPLE_CHEMICAL", 229, 256], ["the DNA minor grove binders", "PROBLEM", 5, 32], ["newer anti-trypanosomal agents", "TREATMENT", 108, 138], ["diamidines", "TREATMENT", 160, 170], ["polyamines", "TREATMENT", 172, 182], ["guanidine", "TREATMENT", 187, 196], ["anti-trypanosomal compounds", "TREATMENT", 229, 256], ["grove binders", "OBSERVATION", 19, 32]]], ["The success of DMFO as polyamine inhibitors has attracted researchers for synthesis and development of agents targeting polyamine metabolism.", [["DMFO", "CHEMICAL", 15, 19], ["polyamine", "CHEMICAL", 23, 32], ["polyamine", "CHEMICAL", 120, 129], ["DMFO", "CHEMICAL", 15, 19], ["polyamine", "CHEMICAL", 23, 32], ["polyamine", "CHEMICAL", 120, 129], ["DMFO", "SIMPLE_CHEMICAL", 15, 19], ["polyamine", "SIMPLE_CHEMICAL", 23, 32], ["polyamine", "SIMPLE_CHEMICAL", 120, 129], ["DMFO", "TREATMENT", 15, 19], ["polyamine inhibitors", "TREATMENT", 23, 43], ["synthesis", "TREATMENT", 74, 83], ["agents targeting polyamine metabolism", "TREATMENT", 103, 140], ["polyamine metabolism", "OBSERVATION", 120, 140]]], ["Recently polyamines carrying 1,3,5-triazine units have been synthesized and evaluated against T. brucei.", [["polyamines", "CHEMICAL", 9, 19], ["1,3,5-triazine", "CHEMICAL", 29, 43], ["polyamines", "CHEMICAL", 9, 19], ["1,3,5-triazine", "CHEMICAL", 29, 43], ["polyamines", "SIMPLE_CHEMICAL", 9, 19], ["1,3,5-triazine units", "SIMPLE_CHEMICAL", 29, 49], ["T. brucei", "ORGANISM", 94, 103], ["T. brucei", "SPECIES", 94, 103], ["T. brucei", "SPECIES", 94, 103], ["Recently polyamines carrying", "TREATMENT", 0, 28], ["triazine units", "TREATMENT", 35, 49], ["T. brucei", "PROBLEM", 94, 103]]], ["These compound exhibited good activity but are cytotoxic.", [["cytotoxic", "PROBLEM", 47, 56], ["good activity", "OBSERVATION", 25, 38], ["cytotoxic", "OBSERVATION_MODIFIER", 47, 56]]], ["Morpholine and dihydroquinolines have also shown promising in vivo anti-trypanosomal activity.", [["Morpholine", "CHEMICAL", 0, 10], ["dihydroquinolines", "CHEMICAL", 15, 32], ["Morpholine", "CHEMICAL", 0, 10], ["dihydroquinolines", "CHEMICAL", 15, 32], ["Morpholine", "SIMPLE_CHEMICAL", 0, 10], ["dihydroquinolines", "SIMPLE_CHEMICAL", 15, 32], ["anti-trypanosomal", "CANCER", 67, 84], ["Morpholine", "TREATMENT", 0, 10], ["dihydroquinolines", "TREATMENT", 15, 32], ["anti-trypanosomal activity", "OBSERVATION", 67, 93]]], ["In addition to this development of prodrugs, the existing compounds also promise to address the pharmacokinetic related problems, in near future.ConclusionThus excellent in vitro and in vivo activities and high selectivity of aforementioned compounds merit further investigation in order to reduce the cytotoxicity that may result in development of newer anti-trypanosomal drug with reduced toxicity, improved efficacy and pharmacokinetic profile.", [["toxicity", "DISEASE", 391, 399], ["prodrugs", "TREATMENT", 35, 43], ["the existing compounds", "TREATMENT", 45, 67], ["the pharmacokinetic related problems", "PROBLEM", 92, 128], ["further investigation", "TEST", 257, 278], ["the cytotoxicity", "PROBLEM", 298, 314], ["newer anti-trypanosomal drug", "TREATMENT", 349, 377], ["reduced toxicity", "PROBLEM", 383, 399], ["excellent", "OBSERVATION_MODIFIER", 160, 169]]], ["As the drug discovery and development process is expensive in terms of time and money, the cross application of existing series of compounds with selective trypanocidal activity may be the best prospect to new anti-trypanosomal drugs in the short term.", [["anti-trypanosomal", "ANATOMY", 210, 227], ["existing series of compounds", "TREATMENT", 112, 140], ["selective trypanocidal activity", "TREATMENT", 146, 177], ["new anti-trypanosomal drugs", "TREATMENT", 206, 233]]], ["More emphasis has to be put in the field of CADD approaches for development of anti-trypanosomal agents as CADD study reduces the time and cost required for development of newer analogues.", [["anti-trypanosomal agents", "SIMPLE_CHEMICAL", 79, 103], ["anti-trypanosomal agents", "TREATMENT", 79, 103], ["CADD study", "TEST", 107, 117], ["newer analogues", "PROBLEM", 172, 187]]]], "20568f35e696788f916804d32068750857fc9d34": [["As of the 5th of September 2020, there are already almost one million deaths and the mortality rate is still fluctuating at high levels.", [["deaths", "DISEASE", 70, 76], ["the mortality rate", "TEST", 81, 99]]], ["3 In the Philippines, the practice of \"cremations, online funerals, and wakes with a limited number of attendees to maintain physical distancing will continue to be the 'new normal' in the mortuary industry.\" 4 Crematoriums, such as those in Arlington Memorial Chapels and Crematory (Quezon City, Philippines), have limited their cremations to 10 a day, even with those who had not died of COVID-19.", [["COVID-19", "CHEMICAL", 390, 398], ["COVID", "TEST", 390, 395]]], ["Considerations include: (1) the cremation of those who died due to COVID-19 within 12 hours; (2) a video viewing of the crematory process;", [["COVID", "TEST", 67, 72], ["the crematory process", "PROBLEM", 116, 137]]]], "PMC7510523": [["IntroductionThe novel Coronavirus (SARS-CoV-2) was first identified in December 2019 [1,2], and has spread rapidly around the globe, crippling health systems and significantly impacting front line health workers [3].", [["SARS-CoV-2", "ORGANISM", 35, 45], ["The novel Coronavirus", "PROBLEM", 12, 33], ["CoV", "TEST", 40, 43], ["spread", "OBSERVATION_MODIFIER", 100, 106], ["rapidly", "OBSERVATION_MODIFIER", 107, 114], ["globe", "ANATOMY", 126, 131]]], ["The World Health Organization (WHO) described COVID-19 as a public health emergency of international concern on 30 January 2020 and a pandemic on the 11 March 2020 [4].", [["COVID", "TEST", 46, 51]]], ["In Australia, the Commonwealth Government\u2019s coronavirus emergency response plan was triggered in late February and a suite of approaches, including travel restrictions, quarantine measures and physical distancing were announced to both suppress the spread of the virus and allow health systems to prepare [5].", [["coronavirus", "ORGANISM", 44, 55], ["coronavirus", "SPECIES", 44, 55], ["travel restrictions", "TREATMENT", 148, 167], ["quarantine measures", "TREATMENT", 169, 188]]], ["Maternity services in all countries have been impacted by the COVID-19 response including the implementation of telehealth, social distancing, use of personal protective equipment for clinical care and reduced visitors and support people [6].", [["people", "SPECIES", 231, 237], ["personal protective equipment", "TREATMENT", 150, 179], ["clinical care", "TREATMENT", 184, 197]]], ["In the middle of the focus on COVID-19, women and families are still having babies and having to navigate a complex health system [7].IntroductionThe most common reason for hospital admission in Australia is pregnancy and childbirth.", [["women", "ORGANISM", 40, 45], ["babies", "ORGANISM", 76, 82], ["women", "SPECIES", 40, 45], ["pregnancy and childbirth", "PROBLEM", 208, 232], ["middle", "ANATOMY_MODIFIER", 7, 13]]], ["More than 300,000 babies are born in Australia each year and women attend more than two million pregnancy care visits annually [8].", [["babies", "ORGANISM", 18, 24], ["women", "ORGANISM", 61, 66], ["women", "SPECIES", 61, 66]]], ["Maternity services underwent rapid transformation in the delivery of pregnancy care to reduce the risk of transmission in both women and maternity care workers in response to the COVID 19 pandemic.", [["women", "ORGANISM", 127, 132], ["women", "SPECIES", 127, 132], ["the delivery of pregnancy care", "TREATMENT", 53, 83]]], ["On both social and mainstream media, women expressed increasing anxiety about these changes including concerns around their risk of contracting COVID-19, changes to intrapartum care, not having support people around them and potential separation from their baby [9,10].", [["anxiety", "DISEASE", 64, 71], ["women", "ORGANISM", 37, 42], ["people", "ORGANISM", 202, 208], ["women", "SPECIES", 37, 42], ["people", "SPECIES", 202, 208], ["increasing anxiety", "PROBLEM", 53, 71], ["contracting COVID", "TEST", 132, 149], ["intrapartum care", "TREATMENT", 165, 181]]], ["In response to this, there seems to have been an increase in women interested in homebirth across the country, mirroring international observations [7,11,12].", [["women", "ORGANISM", 61, 66], ["women", "SPECIES", 61, 66], ["increase", "OBSERVATION_MODIFIER", 49, 57]]], ["The Australian College of Midwives reported many additional calls relating to home births since March and private midwives in Australia have reported increased numbers of women requesting homebirth [10,13].", [["women", "ORGANISM", 171, 176], ["women", "SPECIES", 171, 176]]], ["In Victoria, one publicly funded homebirth model has tripled the number of homebirths provided between March and May 2020 when compared to the same period in 2019 to meet the increasing demand [14].IntroductionWhile the majority of women in Australia give birth in hospital, 0.3% of Australian babies are born at home [8].", [["women", "ORGANISM", 232, 237], ["babies", "ORGANISM", 294, 300], ["women", "SPECIES", 232, 237]]], ["PPMs are registered as midwives with the Nursing and Midwifery Board of Australia with Endorsement for Scheduled Medicines and are all self-employed.", [["PPMs", "PROBLEM", 0, 4], ["Scheduled Medicines", "TREATMENT", 103, 122]]], ["They provide care predominantly in the home and some also have visiting rights to admit women to hospital if needed.", [["women", "ORGANISM", 88, 93], ["women", "SPECIES", 88, 93]]], ["Consequently, PPMs are often not seen as a mainstream service and so are potentially missed in planning when public health emergencies like the COVID-19 pandemic occur.", [["PPMs", "PROBLEM", 14, 18], ["the COVID", "TEST", 140, 149]]], ["In a similar way, GPs have also expressed concerns about patient access to care, their personal safety and individual wellbeing [15].IntroductionIt is not known how COVID-19 has impacted PPMs in Australia, a small but important group in terms of demand for services, ability to provide such services, access to personal protective equipment (PPE), training in PPE and infection control, as well as ongoing practical and psychological support from the health system.", [["PPMs", "DISEASE", 187, 191], ["infection", "DISEASE", 368, 377], ["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["personal protective equipment", "TREATMENT", 311, 340], ["training in PPE", "TREATMENT", 348, 363], ["infection control", "TREATMENT", 368, 385], ["psychological support", "TREATMENT", 420, 441], ["impacted", "OBSERVATION_MODIFIER", 178, 186], ["PPMs", "OBSERVATION", 187, 191], ["small", "OBSERVATION_MODIFIER", 208, 213], ["infection", "OBSERVATION", 368, 377]]], ["The specific changes PPMs have made to their practice in response to the pandemic are also unknown.", [["The specific changes PPMs", "PROBLEM", 0, 25]]], ["The aim of this study was to explore the experience of PPMs in relation to the COVID-19 pandemic.", [["PPMs", "DISEASE", 55, 59], ["this study", "TEST", 11, 21], ["PPMs", "PROBLEM", 55, 59], ["the COVID", "TEST", 75, 84], ["pandemic", "PROBLEM", 88, 96]]], ["The findings will provide critical insights to guide maternity service preparedness for future pandemics or emergency situations and shine a unique light on a specific cadre of maternity staff.MethodsA cross-sectional national online survey was conducted in the early days of the COVID-19 response in Australia.", [["the COVID", "TEST", 276, 285]]], ["Prior to commencement, the study was approved by the Human Research Ethics Committee of Alfred Health in Melbourne (Project 198/20).MethodsMidwives currently providing any type of private midwifery services for antenatal, labour and birth and/or postnatal services in Australia were eligible to participate.", [["Human", "ORGANISM", 53, 58], ["Human", "SPECIES", 53, 58], ["the study", "TEST", 23, 32]]], ["The number of PPMs providing services, especially during labour and birth, is largely unknown.", [["PPMs providing services", "TREATMENT", 14, 37]]], ["We estimated that at least 100 PPMs would participate in the study based on interest and concerns in relation to COVID-19 expressed on social media.MethodsA bespoke survey was developed for this study.", [["COVID-19", "DNA", 113, 121], ["the study", "TEST", 57, 66], ["COVID", "TEST", 113, 118], ["this study", "TEST", 190, 200]]], ["The questions related to preparedness to manage potential COVID-19 clients, availability of personal protection equipment (PPE) and access to information about caring for women with COVID-19.", [["women", "ORGANISM", 171, 176], ["women", "SPECIES", 171, 176], ["personal protection equipment", "TREATMENT", 92, 121]]], ["The survey used Survey Gizmo, an online survey platform, which is password protected.MethodsThe study was advertised on social media (Facebook, Twitter, homebirth, midwifery sites) and through personal networks in early April 2020.", [["an online survey platform", "TEST", 30, 55], ["The study", "TEST", 92, 101]]], ["When the person clicked on the link they were taken to the opening page of the online survey.", [["person", "SPECIES", 9, 15]]], ["Content analysis was used to explore the open-ended questions and comments.", [["Content analysis", "TEST", 0, 16]]], ["All aspects of the survey were optional.", [["the survey", "TEST", 15, 25]]], ["Not all respondents answered every question, which means the amount of missing data varies.Increased demand from women wanting homebirth ::: FindingsNinety-three percent of PPMs reported an increase in the number of enquiries relating to homebirth which ranged from 17% receiving an extra 1\u20134 calls to 28% receiving over 20 extra calls over the past month.", [["PPMs", "DISEASE", 173, 177], ["women", "ORGANISM", 113, 118], ["PPMs", "PATHOLOGICAL_FORMATION", 173, 177], ["women", "SPECIES", 113, 118], ["missing data varies", "PROBLEM", 71, 90], ["PPMs", "PROBLEM", 173, 177], ["PPMs", "OBSERVATION", 173, 177], ["increase", "OBSERVATION_MODIFIER", 190, 198]]], ["The PPMS reported that women gave reasons such as concerns about the hospitals limiting support people during labour, other restrictive practices in hospitals and increased exposure to COVID-19.", [["PPMS", "DISEASE", 4, 8], ["COVID-19", "CHEMICAL", 185, 193], ["women", "ORGANISM", 23, 28], ["people", "ORGANISM", 96, 102], ["women", "SPECIES", 23, 28], ["people", "SPECIES", 96, 102], ["COVID", "TEST", 185, 190]]], ["Many of these enquiries were made close to the women\u2019s due date even as late as 39 weeks of pregnancy.", [["women", "ORGANISM", 47, 52], ["women", "SPECIES", 47, 52], ["pregnancy", "PROBLEM", 92, 101]]], ["PPMs explained women\u2019s reasons with these examples:\u201cFear of going to hospital due to COVID.", [["PPMs", "DISEASE", 0, 4], ["COVID", "DISEASE", 85, 90], ["women", "ORGANISM", 15, 20], ["women", "SPECIES", 15, 20], ["PPMs", "PROBLEM", 0, 4]]], ["Fear of being unsupported in hospital due to support people restrictions.\u201d\u201cLast week I had more enquires than I've had in about 6 months!\u201d\u201cI have had more requests from women who are concerned about the increasingly restrictive practices in hospitals which has made them turn to homebirth as a personally safer option.\u201d", [["people", "ORGANISM", 53, 59], ["women", "ORGANISM", 169, 174], ["people", "SPECIES", 53, 59], ["women", "SPECIES", 169, 174], ["restrictive", "OBSERVATION", 216, 227]]]]}